

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number
WO 03/025146 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US02/29878

(22) International Filing Date:
18 September 2002 (18.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/322,969 18 September 2001 (18.09.2001) US
60/351,550 25 January 2002 (25.01.2002) US

(71) Applicant (for all designated States except US): AVIGEN-
ICS, INC. [US/US]; 111 Riverbend Road, Athens, GA
30605 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RAPP, Jeffrey, C.
[US/US]; 265 Pinewood Circle, Athens, GA 30606 (US).
CHRISTMANN, Leandro [BR/US]; 1311 Victoria Road,
Watkinsville, GA 30677 (US).

(74) Agents: ANTLER, Adriane, M. et al.; Pennie & Edmonds
LLP, 1155 Avenue of the Americas, New York, NY 10036
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PRODUCTION OF A TRANSGENIC AVIAN BY CYTOPLASMIC INJECTION

(57) Abstract: This invention provides methods for the stable introduction of heterologous coding sequences into the genome of a bird and expressing the coding sequences to produce desired proteins or to alter the phenotype of the bird. The present invention provides preferred methods for introducing a transgene into the cytoplasm of avian embryonic cells by cytoplasmic microinjection. The embryo then develops into a transgenic adult capable of expressing a heterologous protein and/or capable of generating a line of transgenic birds through breeding. Synthetic vectors and gene promoters useful in the methods are also provided by the present invention, as are transgenic birds that express heterologous protein and avian eggs containing heterologous protein.

WO 03/025146 A2

**PRODUCTION OF A TRANSGENIC AVIAN
BY CYTOPLASMIC INJECTION**

5

This application claims the benefit of United States Provisional Application No. 60/322,969, filed September 18, 2001, and United States Provisional Application No. 60/351,550, filed January 25, 2002, both of which are incorporated by reference herein in their entireties.

10

1. FIELD OF THE INVENTION

The present invention relates to methods of producing a transgenic avian by introducing a nucleic acid encoding a heterologous protein into an avian embryo preferably by cytoplasmic injection, but also by other methods of introducing nucleic acids into
15 embryonic cells, including but not limited to, nuclear transfer, retroviral vector infection, and fertilization with sperm containing the nucleic acid. The present invention further relates to a transgenic avian expressing a heterologous polypeptide, which, preferably, is deposited into the white of the avian egg. The invention further provides vectors containing coding sequences for heterologous proteins, the expression of which is under the control of
20 a promoter and other regulatory elements that cause expression of the heterologous protein and preferably, lead to deposition of the protein in the avian egg. Also included in the invention are avian eggs derived from the transgenic avians and the heterologous proteins isolated therefrom.

25

2. BACKGROUND

The field of transgenics was initially developed to understand the action of a single gene in the context of the whole animal and the phenomena of gene activation, expression, and interaction. This technology has also been used to produce models for various diseases in humans and other animals and is amongst the most powerful tools available for the study
30 of genetics, and the understanding of genetic mechanisms and function. From an economic perspective, the use of transgenic technology for the production of specific proteins or other substances of pharmaceutical interest (Gordon *et al.*, 1987, *Biotechnology* 5: 1183-1187; Wilmut *et al.*, 1990, *Theriogenology* 33: 113-123) offers significant advantages over more conventional methods of protein production by gene expression.

35

Heterologous nucleic acids have been engineered so that an expressed protein may be joined to a protein or peptide that will allow secretion of the transgenic expression product into milk or urine, from which the protein may then be recovered. These procedures have had limited success and may require lactating animals, with the attendant costs of maintaining individual animals or herds of large species, including cows, sheep, or goats.

The hen oviduct offers outstanding potential as a protein bioreactor because of the high levels of protein production, the promise of proper folding and post-translation modification of the target protein, the ease of product recovery, and the shorter developmental period of chickens compared to other potential animal species. The production of an avian egg begins with formation of a large yolk in the ovary of the hen. The unfertilized oocyte or ovum is positioned on top of the yolk sac. After ovulation, the ovum passes into the infundibulum of the oviduct where it is fertilized, if sperm are present, and then moves into the magnum of the oviduct, lined with tubular gland cells. These cells secrete the egg-white proteins, including ovalbumin, lysozyme, ovomucoid, conalbumin and ovomucin, into the lumen of the magnum where they are deposited onto the avian embryo and yolk.

2.1 Microinjection

Historically, transgenic animals have been produced almost exclusively by microinjection of the fertilized egg. Mammalian pronuclei from fertilized eggs are microinjected *in vitro* with foreign, *i.e.*, xenogeneic or allogeneic, heterologous DNA or hybrid DNA molecules. The microinjected fertilized eggs are then transferred to the genital tract of a pseudopregnant female (*e.g.*, Krimpenfort *et al.*, in U.S. Pat. No. 5,175,384). However, the production of a transgenic avian using microinjection techniques is more difficult than the production of a transgenic mammal. In avians, the opaque yolk is positioned such that visualization of the pronucleus, or nucleus of a single-cell embryo, is impaired thus preventing efficient injection of these structures with heterologous DNA. What is therefore needed is an efficient method of introducing a heterologous nucleic acid into a recipient avian embryonic cell.

Cytoplasmic DNA injection has previously been described for introduction of DNA directly into the germinal disk of a chick embryo by Sang and Perry, 1989, *Mol. Reprod. Dev.* 1: 98-106, Love *et al.*, 1994, *Biotechnology* 12: 60-3, and Naito *et al.*, 1994, *Mol. Reprod. Dev.* 37:167-171; incorporated herein by reference in their entireties. Sang and Perry described only episomal replication of the injected cloned DNA, while Love *et al.*

suggested that the injected DNA becomes integrated into the cell's genome and Naito *et al.* showed no direct evidence of integration. In all these cases, the germinal disk was not visualized during microinjection, *i.e.*, the DNA was injected "blind" into the germinal disk. Such prior efforts resulted in poor and unstable transgene integration. None of these
5 methods were reported to result in expression of the transgene in eggs and the level of mosaicism in the one transgenic chicken reported to be obtained was one copy per 10 genome equivalents.

2.2 Retroviral Vectors

10 Other techniques have been used in efforts to create transgenic chickens expressing heterologous proteins in the oviduct. Previously, this has been attempted by microinjection of replication defective retroviral vectors near the blastoderm (PCT Publication WO 97/47739, entitled Vectors and Methods for Tissue Specific Synthesis of Protein in Eggs of Transgenic Hens, by MacArthur). Bosselman *et al.* in U.S. Patent No. 5,162,215 also
15 describes a method for introducing a replication-defective retroviral vector into a pluripotent stem cell of an unincubated chick embryo, and further describes chimeric chickens whose cells express a heterologous vector nucleic acid sequence. However, the percentage of G₁ transgenic offspring (progeny from vector-positive male G₀ birds) was low and varied between 1% and approximately 8%. Such retroviral vectors have other significant
20 limitations, for example, only relatively small fragments of nucleic acid can be inserted into the vectors precluding, in most instances, the use of large portions of the regulatory regions and/or introns of a genomic locus which, as described herein, can be useful in obtaining significant levels of heterologous protein expression. Additionally, retroviral vectors are generally not appropriate for generating transgenics for the production of pharmaceuticals
25 due to safety and regulatory issues.

2.3 Transfection of Male Germ Cells, Followed by Transfer to Recipient Testis

Other methods include *in vitro* stable transfection of male germ cells, followed by transfer to a recipient testis. PCT Publication WO 87/05325 discloses a method of
30 transferring organic and/or inorganic material into sperm or egg cells by using liposomes. Bachiller *et al.* (1991, *Mol. Reprod. Develop.* 30: 194-200) used Lipofectin-based liposomes to transfer DNA into mice sperm, and provided evidence that the liposome transfected DNA was overwhelmingly contained within the sperm's nucleus although no transgenic mice could be produced by this technique. Nakanishi & Iritani (1993, *Mol. Reprod. Develop.* 36:
35 258-261) used Lipofectin-based liposomes to associate heterologous DNA with chicken

sperm, which were in turn used to artificially inseminate hens. There was no evidence of genomic integration of the heterologous DNA either in the DNA-liposome treated sperm or in the resultant chicks.

Several methods exist for transferring DNA into sperm cells. For example,
5 heterologous DNA may also be transferred into sperm cells by electroporation that creates temporary, short-lived pores in the cell membrane of living cells by exposing them to a sequence of brief electrical pulses of high field strength. The pores allow cells to take up heterologous material such as DNA, while only slightly compromising cell viability. Gagne
10 *et al.* (1991, *Mol. Reprod. Dev.* 29: 6-15) disclosed the use of electroporation to introduce heterologous DNA into bovine sperm subsequently used to fertilize ova. However, there was no evidence of integration of the electroporated DNA either in the sperm nucleus or in the nucleus of the egg subsequent to fertilization by the sperm.

Another method for transferring DNA into sperm cells was initially developed for integrating heterologous DNA into yeasts and slime molds, and later adapted to sperm, is
15 restriction enzyme mediated integration (REMI) (Shemesh *et al.*, PCT International Publication WO 99/42569). REMI utilizes a linear DNA derived from a plasmid DNA by cutting that plasmid with a restriction enzyme that generates single-stranded cohesive ends. The linear, cohesive-ended DNA together with the restriction enzyme used to produce the
20 cohesive ends is then introduced into the target cells by electroporation or liposome transfection. The restriction enzyme is then thought to cut the genomic DNA at sites that enable the heterologous DNA to integrate via its matching cohesive ends (Schiestl and Petes, 1991, *Proc. Natl. Acad. Sci. USA* 88: 7585-7589).

It is advantageous, before the implantation of the transgenic germ cells into a testis of a recipient male, to depopulate the testis of untransfected male germ cells. Depopulation
25 of the testis has commonly been by exposing the whole animal to gamma irradiation by localized irradiation of the testis. Gamma radiation-induced spermatogonial degeneration is probably related to the process of apoptosis. (Hasegawa *et al.*, 1998, *Radiat. Res.* 149:263-70). Alternatively, a composition containing an alkylating agent such as busulfan (MYLERAN™) can be used, as disclosed in Jiang F.X., 1998, *Anat. Embryol.* 198(1):53-
30 61; Russell and Brinster, 1996, *J. Androl.* 17(6):615-27; Boujrad *et al.*, *Andrologia* 27(4), 223-28 (1995); Linder *et al.*, 1992, *Reprod. Toxicol.* 6(6):491-505; Kasuga and Takahashi, 1986, *Endocrinol. Jpn* 33(1):105-15. These methods likewise have not resulted in efficient transgenesis or heterologous protein production in avian eggs.

2.5 Nuclear Transfer

Nuclear transfer from cultured cell populations provides an alternative method of genetic modification, whereby donor cells may be sexed, optionally genetically modified, and then selected in culture before their use. The resultant transgenic animal originates from a single transgenic nucleus and mosaics are avoided. The genetic modification is easily transmitted to the offspring. Nuclear transfer from cultured somatic cells also provides a route for directed genetic manipulation of animal species, including the addition or "knock-in" of genes, and the removal or inactivation or "knock-out" of genes or their associated control sequences (Polejaeva *et al.*, 2000, *Theriogenology*, 53: 117-26). Gene targeting techniques also promise the generation of transgenic animals in which specific genes coding for endogenous proteins have been replaced by exogenous genes such as those coding for human proteins.

The nuclei of donor cells are transferred to oocytes or zygotes and, once activated, result in a reconstructed embryo. After enucleation and introduction of donor genetic material, the reconstructed embryo is cultured to the morula or blastocyte stage, and transferred to a recipient animal, either *in vitro* or *in vivo* (Eyestone and Campbell, 1999, *J Reprod Fertil Suppl.* 54:489-97). Double nuclear transfer has also been reported in which an activated, previously transferred nucleus is removed from the host unfertilized egg and transferred again into an enucleated fertilized embryo.

The embryos are then transplanted into surrogate mothers and develop to term. In some mammalian species (mice, cattle and sheep) the reconstructed embryos can be grown in culture to the blastocyst stage before transfer to a recipient female. The total number of offspring produced from a single embryo, however, is limited by the number of available blastomeres (embryos at the 32-64 cell stage are the most widely used) and the efficiency of the nuclear transfer procedure. Cultured cells can also be frozen and stored indefinitely for future use.

Two types of recipient cells are commonly used in nuclear transfer procedures: oocytes arrested at the metaphase of the second meiotic division (MII) and which have a metaphase plate with the chromosomes arranged on the meiotic spindle, and pronuclear zygotes. Enucleated two-cell stage blastomeres of mice have also been used as recipients. In agricultural mammals, however, development does not always occur when pronuclear zygotes are used, and, therefore, MII-arrested oocytes are the preferred recipient cells.

Although gene targeting techniques combined with nuclear transfer hold tremendous promise for nutritional and medical applications, current approaches suffer from several limitations, including long generation times between the founder animal and production

transgenic herds, and extensive husbandry and veterinary costs. It is therefore desirable to use a system where cultured somatic cells for nuclear transfer are more efficiently employed.

What is needed, therefore, is an efficient method of generating transgenic avians that express a heterologous protein encoded by a transgene, particularly in the oviduct for deposition into egg whites.

3. SUMMARY OF THE INVENTION

This invention provides methods for the stable introduction of heterologous coding sequences into the genome of a bird and expressing those heterologous coding sequences to produce desired proteins. Synthetic vectors and gene promoters useful in the methods are also provided by the present invention, as are transgenic birds that express a heterologous protein and avian eggs containing a heterologous protein. In a preferred embodiment, the vectors useful in methods of the invention are not eukaryotic viral, more preferably not retroviral, vectors (although the vectors may contain transcriptional regulatory elements, such as promoters, from eukaryotic viruses). In other embodiments, however, the vectors are eukaryotic viral vectors or are retroviral vectors.

One aspect of the present invention is a method of producing a transgenic avian capable of expressing a heterologous protein. The method comprises isolating an early stage embryo from a fertilized hen, and microinjecting into the isolated embryo a selected nucleic acid that encodes the desired heterologous protein. The microinjected avian embryo is transferred to the oviduct of a recipient hen for *in vivo* development and to be laid as a shelled egg (or, alternatively, cultured *ex vivo*). The shelled egg is incubated to hatch a transgenic chick that has incorporated, preferably, integrated into its genome, the selected nucleic acid.

The present invention provides methods for introducing a transgene into the cytoplasm of avian embryonic cells by cytoplasmic microinjection. The cells may be embryonic cells as, for example, from a single cell embryo visualized through overlying yolk or tissue by using, for example, light microscopy, or a camera system such as a CCD camera with a microscopic lens (*e.g.*, as disclosed in PCT International Publication WO 02/064727 by Christmann, which is incorporated by reference herein in its entirety). Microelectroporation can optionally be used to enhance the uptake of exogenous DNA into the cell nucleus and improving the efficiency of DNA integration. The cytoplasmically microinjected embryo is then, preferably, returned to a female bird to be laid as a hard-shell egg or, as an alternative, cultured *ex vivo*. After hatching from the hard-shelled egg, a

transgenic chick is produced that expresses a heterologous protein and/or that can be bred to generate a line of transgenic birds expressing a heterologous protein.

In alternative embodiments, the nucleic acid is introduced by infection or injection of the nucleic acid contained within a retroviral vector, sperm-mediated transgenesis, or
5 nuclear transfer.

In one embodiment, the present invention provides methods for producing heterologous proteins in avians. Transgenes are introduced by, most preferably, cytoplasmic microinjection into one embryonic cell, preferably the germinal disk of an early stage embryo, that then develop into a transgenic bird. The protein of interest may be
10 expressed in the tubular gland cells of the magnum of the oviduct, secreted into the lumen, or deposited within the egg white onto the egg yolk or expressed, for example, in the serum of the bird. Such transgenic birds can also be bred to identify birds that carry the transgene in their germ line. The exogenous genes can therefore be transmitted to birds by both cytoplasmic microinjection of the exogenous gene into bird embryonic cells, and by
15 subsequent stable transmission of the exogenous gene to the bird's offspring in a Mendelian fashion.

The present invention provides for a method of producing a heterologous protein in an avian oviduct. The method comprises, as a first step, providing a vector containing a coding sequence and a promoter that functions in avians, preferably in the avian magnum,
20 operably linked to the coding sequence, so that the promoter can effect expression of the nucleic acid in the tubular gland cells of the magnum of an avian oviduct and/or in any other desired tissue of the avian. In a preferred embodiment, the vector containing the transgene is not a eukaryotic viral vector (preferably, not a retroviral vector, such as but not limited to reticuloendotheliosis virus (REV), ALV or MuLV) or derived from a eukaryotic virus (but,
25 in certain embodiments, may contain promoter and/or other gene expression regulatory sequences from a eukaryotic virus, such as, but not limited to, a Rous sarcoma virus viral promoter or a cytomegalovirus promoter). Next, the vector is introduced into avian embryonic cells by cytoplasmic microinjection so that the vector sequence may be randomly inserted into the avian genome. Finally, a mature transgenic avian that expresses the
30 exogenous protein in its oviduct is derived from the transgenic embryonic cells or by breeding a transgenic avian derived from the transgenic embryonic cells.

In particular embodiments, the level of mosaicism of the transgene (percentage of cells containing the transgene) in avians hatched from microinjected embryos (*i.e.*, the G_0 s) is greater than 5%, 10%, 25%, 50%, 75% or 90%, or is the equivalent of one copy per one
35 genome, two genomes, five genomes, seven genomes or eight genomes, as determined by

any number of techniques known in the art and described *infra*. In additional particular embodiments, the percentage of G₀s that transmit the transgene to progeny (G₁s) is greater than 5%, preferably, greater than 10%, 20%, 30%, 40%, and, most preferably, greater than 50%. In other embodiments, the efficiency of transgenesis (i.e., number of G₀s containing the transgene) is greater than 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 99%.

This method can also be used to produce an avian egg containing an exogenous protein when the exogenous protein, that is expressed for example, in the tubular gland cells or fibroblast cells, is also secreted into the oviduct lumen and deposited, *e.g.*, into the white of an egg. In other embodiments of the invention, the exogenous protein is expressed in the liver, or secreted into the blood, and deposited into the yolk. In preferred embodiments, the level of expression of the heterologous protein in the egg white of eggs laid by G₀ and/or G₁ chicks and/or their progeny is greater than 5 µg, 10 µg, 50 µg, 100 µg, 250 µg, 500 µg, or 750 µg, more preferably greater than 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 500 mg, 700 mg, 1 gram, 2 grams, 3 grams, 4 grams or 5 grams.

The present invention further provides promoters useful for expression of the heterologous protein in the egg. For example, the promoter comprises regions of at least two promoters derived from an avian including, but not limited to, an ovomucoid, ovalbumin, conalbumin, lysozyme, or ovotransferrin, or any other promoter that directs expression of a gene in an avian, particularly in a specific tissue of interest, such as the magnum. Alternatively, the promoter used in the expression vector may be derived from that of the *lysozyme* gene that is expressed in both the oviduct and macrophages. In other embodiments the promoter is a viral or non-avian promoter, *e.g.*, cytomegalovirus or Rous sarcoma virus promoter. In certain embodiments, the promoter is constitutive in avian cells. In other embodiments, the promoter is inducible. In particular embodiments, the gene regulatory sequences are flanked by matrix attachment regions (MARs), preferably, but not limited to those associated with the lysozyme gene in chickens or other avia. The nucleic acid encoding the polypeptide may be operably linked to a transcription promoter and/or a transcription terminator. In other embodiments, prior to microinjection, the vector is mixed with a nuclear localization signal peptide to facilitate targeting of the injected vector to the nucleus.

Other embodiments of the invention provide for transgenic avians, such as chickens or quail, carrying a transgene in the genetic material of their germ-line tissue, preferably where the transgene was not introduced into the avian genome using a eukaryotic viral promoter. The transgene incorporated into the genomic DNA of a recipient bird can encode

at least one polypeptide that may be, for example, but is not limited to, a cytokine, a growth factor, enzyme, structural protein, immunoglobulin, or any other polypeptide of interest that is capable of being expressed by an avian cell or tissue. Preferably, the heterologous protein is a mammalian, or preferably a human, protein or derived from a mammalian, or preferably a human, protein (*e.g.*, a derivative or variant thereof). In particular embodiments, the invention provides heterologous proteins isolated or purified from an avian tissue, preferably serum, more preferably eggs, most preferably egg whites, and pharmaceutical compositions comprising such heterologous proteins. In a more preferred embodiment, the heterologous protein is an antibody that is human (including antibodies produced from human immunoglobulin sequences in mice or in antibody libraries or synthetically produced but having variable domain framework regions that are the same as or homologous to human framework regions) or humanized.

The present invention further relates to nucleic acid vectors (preferably, not derived from eukaryotic viruses, except, in certain embodiments, for eukaryotic viral promoters and/or enhancers) and transgenes inserted therein that incorporate multiple polypeptide-encoding regions, wherein a first polypeptide-encoding region is operatively linked to a transcription promoter and a second polypeptide-encoding region is operatively linked to an Internal Ribosome Entry Sequence (IRES). For example, the vector may contain coding sequences for two different heterologous proteins (*e.g.*, the heavy and light chains of an immunoglobulin) or the coding sequences for all or a significant part of the genomic sequence for the gene from which the promoter driving expression of the transgene is derived, and the heterologous protein desired to be expressed (*e.g.*, a construct containing the genomic coding sequences, including introns, of the avian lysozyme gene when the avian lysozyme promoter is used to drive expression of the transgene, an IRES, and the coding sequence for the heterologous protein desired to be expressed downstream (*i.e.*, 3' on the RNA transcript of the IRES)). Thus, in certain embodiments, the nucleic acid encoding the heterologous protein is introduced into the 5' untranslated or 3' untranslated regions of an endogenous gene, such as but not limited to, lysozyme, ovalbumin, ovotransferrin, and ovomucoid, with an IRES sequence directing translation of the heterologous sequence.

Such nucleic acid constructs, when inserted into the genome of a bird and expressed therein, will generate individual polypeptides that may be post-translationally modified, for example, glycosylated or, in certain embodiments, be present as complexes, such as heterodimers with each other in the white of the avian egg. Alternatively, the expressed polypeptides may be isolated from an avian egg and combined *in vitro*, or expressed in a non-reproductive tissue such as serum. In other embodiments, for example, but not limited

to, when expression of both heavy and light chains of an antibody is desired, two separate constructs, each containing a coding sequence for one of the heterologous proteins operably linked to a promoter (either the same or different promoters), are introduced by microinjection into cytoplasm of one or more embryonic cells and transgenic avians
5 harboring both transgenes in their genomes and expressing both heterologous proteins are identified. Alternatively, two transgenic avians each containing one of the two heterologous proteins (*e.g.*, one transgenic avian having a transgene encoding the light chain of an antibody and a second transgenic avian having a transgene encoding the heavy chain of the antibody) can be bred to obtain an avian containing both transgenes in its germline and
10 expressing both transgene encoded proteins, preferably in eggs.

In other embodiments, the present invention further provides methods for the introduction to an avian genome of at least one transgene encoding at least one heterologous polypeptide including sperm-mediated transfer where nucleic acids are incorporated into avian sperm by liposomes, electroporation, restriction enzyme mediated integration (REMI),
15 or similar methods. The modified sperm may then be returned to the testis of a male bird which then may be mated with a female to generate transgenic offspring, or the modified sperm may be used directly to fertilize the female bird by artificial insemination to generate transgenic offspring.

The present invention further provides methods for incorporating a transgene into
20 the nucleus of an avian cell cultured *in vitro* including by transfection, cytoplasmic microinjection or pronuclear microinjection. The transgenic cell nucleus may then be transferred to a fertilized enucleated cell. The enucleated cell may be an embryonic cell of a bird egg visualized through overlying yolk or tissue by using two photon laser scanning microscopy.

25 For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

3.1 Definitions

The term "avian" as used herein is intended to refer to any species, subspecies or
30 race of organism of the taxonomic class *ava*, such as, but not limited to, such organisms as chicken, turkey, duck, goose, quail, pheasants, parrots, finches, hawks, crows and ratites including ostrich, emu and cassowary. The term includes the various known strains of *Gallus gallus*, or chickens, (for example, White Leghorn, Brown Leghorn, Barred-Rock, Sussex, New Hampshire, Rhode Island, Ausstralorp, Minorca, Amrox, California Gray,

35

Italian Partidge-colored), as well as strains of turkeys, pheasants, quails, duck, ostriches and other poultry commonly bred.

The term "embryonic cells" as used herein refers to cells that are typically single cell embryos, or the equivalent thereof, and is meant to encompass dividing embryos, such as two-cell, four-cell, or even later stages as described by Eyal-Giladi and Kochav (1976, *Dev. Biol.* 49:321-337) and ova 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 hours after the preceding lay. The embryonic cells may be isolated freshly, maintained in culture, or reside within an embryo. Although the present invention is generally described in terms of microinjection of a single-cell embryo, it should be recognized that other cells from an early stage embryo are suitable for cytoplasmic injection in the methods of the present invention. For example, cells obtained from a stage later than a stage I embryo, up to and including a stage X embryo, *i.e.*, stages II-X, may be useful in the present invention. Chick developmental stages are described in the following reference, Eyal-Giladi and Kochav, 1976, *Dev. Biol.* 49(2):321-37, which is hereby incorporated by reference in its entirety.

The term "nucleic acid" as used herein refers to any natural and synthetic linear and sequential arrays of nucleotides and nucleosides, for example cDNA, genomic DNA, mRNA, tRNA, oligonucleotides, oligonucleosides and derivatives thereof. Representative examples of the nucleic acids of the present invention include bacterial plasmid vectors including expression, cloning, cosmid and transformation vectors such as, but not limited to, pBR322, animal viral vectors such as, but not limited to, modified adenovirus, influenza virus, polio virus, pox virus, retrovirus, and the like, vectors derived from bacteriophage nucleic acid, *e.g.*, plasmids and cosmids, artificial chromosomes, such as but not limited to, Yeast Artificial Chromosomes (YACs) and Bacterial Artificial Chromosomes (BACs), and synthetic oligonucleotides like chemically synthesized DNA or RNA. The term "nucleic acid" further includes modified or derivatised nucleotides and nucleosides such as, but not limited to, halogenated nucleotides such as, but not only, 5-bromouracil, and derivatised nucleotides such as biotin-labeled nucleotides.

As used herein the terms "polypeptide" and "protein" refer to a polymer of amino acids of three or more amino acids in a serial array, linked through peptide bonds. The term "polypeptide" includes proteins, protein fragments, protein analogues, oligopeptides and the like. The term "polypeptides" contemplates polypeptides as defined above that are encoded by nucleic acids, produced through recombinant technology, isolated from an appropriate source such as a bird, or are synthesized. The term "polypeptides" further contemplates polypeptides as defined above that include chemically modified amino acids or amino acids covalently or noncovalently linked to labeling ligands.

The term "fragment" as used herein refers to an at least 10, 20, 50, 75, 100, 150, 200, 250, 300, 500, 1000, 2000 or 5000 nucleotide long portion of a nucleic acid (e.g., cDNA) that has been constructed artificially (e.g., by chemical synthesis) or by cleaving a natural product into multiple pieces, using restriction endonucleases or mechanical shearing, or enzymatically, for example, by PCR or any other polymerizing technique known in the art, or expressed in a host cell by recombinant nucleic acid technology known to one of skill in the art. The term "fragment" as used herein may also refer to an at least 5, 10, 20, 30, 40, 50, 75, 100, 150, 200, 250, 300, 400, 500, 1000, 2000, or 5000 amino acid portion of a polypeptide, which portion is cleaved from a naturally occurring polypeptide by proteolytic cleavage by at least one protease, or is a portion of the naturally occurring polypeptide synthesized by chemical methods or using recombinant DNA technology (e.g., expressed from a portion of the nucleotide sequence encoding the naturally occurring polypeptide) known to one of skill in the art.

The term "isolated nucleic acid" as used herein refers to a nucleic acid that has been removed from other components of the cell containing the nucleic acid or from other components of chemical/synthetic reaction used to generate the nucleic acid. In specific embodiments, the nucleic acid is 50%, 60%, 70%, 80%, 90%, 95%, 99% or 100% pure. The techniques used to isolate and characterize the nucleic acids and proteins of the present invention are well known to those of skill in the art and standard molecular biology and biochemical manuals may be consulted to select suitable protocols without undue experimentation. See, for example, *Sambrook et al*, 2001, *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Press; the content of which is herein incorporated by reference in its entirety.

By the use of the term "enriched" in reference to nucleic acid it is meant that the specific DNA or RNA sequence constitutes a significantly higher fraction of the total DNA or RNA present in the cells or solution of interest than in normal or diseased cells or in the cells from which the sequence was taken. Enriched does not imply that there are no other DNA or RNA sequences present, just that the relative amount of the sequence of interest has been significantly increased, for example, by 1 fold, 2 fold, 5 fold, 10 fold, 50 fold, 100 fold, 500 fold, 1000 fold, 10,000 fold, 100,000 fold, or 1,000,000 fold. The other DNA may, for example, be derived from a yeast or bacterial genome, or a cloning vector, such as a plasmid or a viral vector.

The terms "transcription regulatory sequences" and "gene expression control regions" as used herein refer to nucleotide sequences that are associated with a gene nucleic acid sequence and which regulate the transcriptional expression of the gene. Exemplary

transcription regulatory sequences include enhancer elements, hormone response elements, steroid response elements, negative regulatory elements, and the like. The "transcription regulatory sequences" may be isolated and incorporated into a vector nucleic acid to enable regulated transcription in appropriate cells of portions of the vector DNA. The

5 "transcription regulatory sequence" may precede, but is not limited to, the region of a nucleic acid sequence that is in the region 5' of the end of a protein coding sequence that may be transcribed into mRNA. Transcriptional regulatory sequences may also be located within a protein coding region, in regions of a gene that are identified as "intron" regions, or may be in regions of nucleic acid sequence that are in the region of nucleic acid.

10 The term "promoter" as used herein refers to the DNA sequence that determines the site of transcription initiation by an RNA polymerase. A "promoter-proximal element" may be a regulatory sequence within about 200 base pairs of the transcription start site. A "magnum-specific" promoter, as used herein, is a promoter that is primarily or exclusively active in the tubular gland cells of the avian magnum. Useful promoters also include
15 exogenously inducible promoters. These are promoters that can be "turned on" in response to an exogenously supplied agent or stimulus, which is generally not an endogenous metabolite or cytokine. Examples include an antibiotic-inducible promoter, such as a tetracycline-inducible promoter, a heat-inducible promoter, a light-inducible promoter, or a laser inducible promoter. (e.g., Halloran *et al.*, 2000, *Development* 127: 1953-1960; Gerner
20 *et al.*, 2000, *Int. J. Hyperthermia* 16: 171-81; Rang and Will, 2000, *Nucleic Acids Res.* 28: 1120-5; Hagihara *et al.*, 1999, *Cell Transplant* 8: 4314; Huang *et al.*, 1999, *Mol. Med.* 5: 129-37; Forster *et al.*, 1999, *Nucleic Acids Res.* 27: 708-10; Liu *et al.*, 1998, *Biotechniques* 24: 624-8, 630-2; the contents of which have been incorporated herein by reference in their entireties).

25 To facilitate manipulation and handling of the nucleic acid to be administered, the nucleic acid is preferably inserted into a cassette where it is operably linked to a promoter. The promoter should be capable of driving expression in the desired cells. The selection of appropriate promoters can be readily accomplished. For some applications, a high expression promoter is preferred such as the cytomegalovirus (CMV) promoter. Other
30 promoters useful in the present invention include the Rous Sarcoma Virus (RSV) promoter (Davis *et al.*, 1993, *Hum. Gene Therap.* 4:151). In other embodiments, all or a portion of the, for example, lysozyme, ovomucoid, ovalbumin, albumin, conalbumin or ovotransferrin promoters, which direct expression of proteins present in egg white, are used, as detailed *infra*, or synthetic promoters such as the MDOT promoter described *infra*.

35

The terms "operably" or "operatively linked" refer to the configuration of the coding and control sequences so as to perform the desired function. Thus, control sequences operably linked to a coding sequence are capable of effecting the expression of the coding sequence and regulating in which tissues, at what developmental timepoints, or in response to which signals, etc., a gene is expressed. A coding sequence is operably linked to or under the control of transcriptional regulatory regions in a cell when DNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA that can be translated into the encoded protein. The control sequences need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences, can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence. Such intervening sequences include but are not limited to enhancer sequences which are not transcribed or are not bound by polymerase.

The term "expressed" or "expression" as used herein refers to the transcription from a gene to give an RNA nucleic acid molecule complementary at least in part to a region of one of the two nucleic acid strands of the gene. The term "expressed" or "expression" as used herein also refers to the translation from said RNA nucleic acid molecule to give a protein or polypeptide or a portion thereof.

The term "matrix attachment region" or "MAR" as used herein refers to a DNA sequence having an affinity or intrinsic binding ability for the nuclear scaffold or matrix. The MAR elements of the chicken lysozyme locus are described by Phi-Van *et al.*, 1996, *E.M.B.O. J.* 76:665-664 and Phi-Van, L. and Stratling, W.H., 1996, *Biochem.* 35:10735-10742; incorporated herein by reference in their entireties.

The term "probe" as used herein, when referring to a nucleic acid, refers to a nucleotide sequence that can be used to hybridize with and thereby identify the presence of a complementary sequence, or a complementary sequence differing from the probe sequence but not to a degree that prevents hybridization under the hybridization stringency conditions used. The probe may be modified with labels such as, but not only, radioactive groups, biotin, and the like.

The term "nucleic acid vector" as used herein refers to a natural or synthetic single or double stranded plasmid or viral nucleic acid molecule, or any other nucleic acid molecule, such as but not limited to YACs, BACs, bacteriophage-derived artificial chromosome (BBPAC), cosmid or P1 derived artificial chromosome (PAC), that can be transfected or transformed into cells and replicate independently of, or within, the host cell genome. A circular double stranded vector can be linearized by treatment with an

appropriate restriction enzyme based on the nucleotide sequence of the vector. A nucleic acid can be inserted into a vector by cutting the vector with restriction enzymes and ligating the pieces together. The nucleic acid molecule can be RNA or DNA.

5 The term "expression vector" as used herein refers to a nucleic acid vector that comprises regulatory sequences operably linked to a nucleotide sequence coding at least one polypeptide. As used herein, the term "regulatory sequences" includes promoters, enhancers, and other elements that may control gene expression.

10 The term "recombinant cell" refers to a cell that has a new combination of nucleic acid segments that are not covalently linked to each other in nature in that particular configuration. A new configuration of nucleic acid segments can be introduced into an organism using a wide array of nucleic acid manipulation techniques available to those skilled in the art. A recombinant cell can be a single eukaryotic cell, such as a mammalian cell, or a single prokaryotic cell. The recombinant cell may harbor a vector that is extragenomic. An extragenomic nucleic acid vector does not insert into the cell's genome.

15 A recombinant cell may further harbor a vector or a portion thereof (*e.g.*, the portion containing the regulatory sequences and the coding sequence) that is intragenomic. The term intragenomic defines a nucleic acid construct incorporated within the recombinant cell's genome.

The terms "recombinant nucleic acid" and "recombinant DNA" as used herein refer

20 a combination of at least two nucleic acids that is not naturally found in a eukaryotic or prokaryotic cell in that particular configuration. The nucleic acids may include, but are not limited to, nucleic acid vectors, gene expression regulatory elements, origins of replication, suitable gene sequences that when expressed confer antibiotic resistance, protein-encoding sequences and the like. The term "recombinant polypeptide" is meant to include a

25 polypeptide produced by recombinant DNA techniques such that it is distinct from a naturally occurring polypeptide either in its location, purity or structure. Generally, such a recombinant polypeptide will be present in a cell in an amount different from that normally observed in nature.

As used herein, the term "transgene" means a nucleic acid sequence (encoding, for

30 example, a human interferon polypeptide) that is partly or entirely heterologous, *i.e.*, foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene of the transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome of the cell into which it is inserted (*e.g.*, it is inserted at a location that differs from

35 that of the natural gene or its insertion results in a knockout). A transgene also includes a

regulatory sequence designed to be inserted into the genome such that it regulates the expression of an endogenous coding sequence, e.g., to increase expression and or to change the timing and or tissue specificity of expression, etc. (e.g., to effect "gene activation").

As used herein, a "transgenic avian" is any avian species, including the chicken, in which one or more of the cells of the avian may contain heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques known in the art, and particularly, as described herein. The nucleic acid is introduced into a cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or *in vitro* fertilization (although it does include fertilization with sperm into which a transgene has been introduced, but rather is directed to the introduction of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA. In the typical transgenic avian, the transgene causes cells to express a recombinant form of the subject polypeptide, e.g. either agonistic or antagonistic forms, or a form in which the gene has been disrupted. The terms "chimeric avian" or "mosaic avian" are used herein to refer to avians in which the recombinant gene is found, or in which the recombinant is expressed in some but not all cells of the avian. The term "tissue-specific chimeric avian" indicates that the recombinant gene is present and/or expressed in some tissues but not others.

The term "chromosomal positional effect (CPE)" as used herein refers to the variation in the degree of gene transcription as a function of the location of the transcribed locus within the cell genome. Random transgenesis may result in a transgene being inserted at different locations in the genome so that individual cells of a population of transgenic cells may each have at least one transgene, each at a different location and therefore each in a different genetic environment. Each cell, therefore, may express the transgene at a level specific for that particular cell and dependant upon the immediate genetic environment of the transgene. In a transgenic avian, as a consequence, different tissues may exhibit different levels of transgene expression.

The term "cytokine" as used herein refers to any secreted polypeptide that affects the functions of cells and is a molecule that modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines,

such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epidermal keratinocytes and B-lymphocytes.

- Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6),
- 5 Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-alpha) and Tumor Necrosis Factor beta (TNF-beta).

- The term "antibody" as used herein refers to polyclonal and monoclonal antibodies and fragments thereof, and immunologic binding equivalents thereof. The term "antibody" refers to a homogeneous molecular entity, or a mixture such as a polyclonal serum product
- 10 made up of a plurality of different molecular entities, and may further comprise any modified or derivatised variant thereof that retains the ability to specifically bind an epitope. A monoclonal antibody is capable of selectively binding to a target antigen or epitope. Antibodies may include, but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, camelized single chain antibodies (scFvs), Fab
- 15 fragments, F(ab')₂ fragments, disulfide-linked Fvs (sdFv) fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, intrabodies, synthetic antibodies, and epitope-binding fragments of any of the above.

- The term "immunoglobulin polypeptide" as used herein refers to a polypeptide derived from a constituent polypeptide of an immunoglobulin. An "immunoglobulin
- 20 polypeptide" may be, but is not limited to, an immunoglobulin (preferably an antibody) heavy or light chain and may include a variable region, a diversity region, joining region and a constant region or any combination, variant or truncated form thereof. The term "immunoglobulin polypeptides" further includes single-chain antibodies comprised of, but not limited to, an immunoglobulin heavy chain variable region, an immunoglobulin light
- 25 chain variable region and optionally a peptide linker.

- The term "male germ cells" as used herein refers to spermatozoa (i.e., male gametes) and developmental precursors thereof. In fetal development, primordial germ cells are thought to arise from the embryonic ectoderm, and are first seen in the epithelium of the endodermal yolk sac at the E8 stage. From there they migrate through the hindgut
- 30 endoderm to the genital ridges. In the sexually mature male vertebrate animal, there are several types of cells that are precursors of spermatozoa, and which can be genetically modified, including the primitive spermatogonial stem cells, known as A0/As, which differentiate into type B spermatogonia. The latter further differentiate to form primary spermatocytes, and enter a prolonged meiotic prophase during which homologous
- 35 chromosomes pair and recombine. Useful precursor cells at several

morphological/developmental stages are also distinguishable: preleptotene spermatocytes, leptotene spermatocytes, zygotene spermatocytes, pachytene spermatocytes, secondary spermatocytes, and the haploid spermatids. The latter undergo further morphological changes during spermatogenesis, including the reshaping of their nucleus, the formation of aerosome, and assembly of the tail. The final changes in the spermatozoon (i.e., male gamete) take place in the genital tract of the female, prior to fertilization.

The terms "ovum" and "oocyte" are used interchangeably herein. Although only one ovum matures at a time, an animal is born with a finite number of ova. In avian species, such as a chicken, ovulation, which is the shedding of an egg from the ovarian follicle, occurs when the brain's pituitary gland releases a luteinizing hormone. Mature follicles form a stalk or pedicle of connective tissue and smooth muscle. Immediately after ovulation the follicle becomes a thin-walled sac, the post-ovulatory follicle. The mature ovum erupts from its sac and starts its journey through the oviduct. Eventually, the ovum enters the infundibulum where fertilization occurs. Fertilization must take place within 15 minutes of ovulation, before the ovum becomes covered by albumen. During fertilization, sperm (avians have polyspermic fertilization) penetrate the blastodisc. When the sperm lodges within this germinal disk, an embryo begins to form as a "blastoderm" or "zygote."

The term "donor cell" is used herein to describe the source of the nuclear structure that is transplanted to the recipient enucleated cytoplasm. All cells of normal karyotype, including embryonic, fetal, and adult somatic cells, preferably in a quiescent state, may be nuclear donors. The use of non-quiescent cells as nuclear donors has been described by Cibelli, *et al.*, 1998, *Science* 280: 1256-8.

This application uses gene nomenclature accepted by the Cucurbit Genetics Cooperative as it appears in the *Cucurbit Genetics Cooperative Report*, 1995, 18:85; herein incorporated by reference in its entirety. Using this gene nomenclature, genes are symbolized by italicized Roman letters. If a mutant gene is recessive to the normal type, then the symbol and name of the mutant gene appear in italicized lower case letters.

3.2 Abbreviations

Abbreviations used in the present specification include the following: aa, amino acid(s); bp, base pair(s); cDNA, DNA complementary to RNA; nt, nucleotide(s); SSC, sodium chloride-sodium citrate; MAR, matrix attachment region; DMSO, dimethyl sulfoxide; TPLSM, two photon laser scanning microscopy; REMI, restriction enzyme mediated integration; mAb, monoclonal antibody, WEFs, whole embryo fibroblasts.

4. BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-E illustrate the nucleotide sequence (SEQ ID NO: 6) comprising the chicken lysozyme gene expression control region (SEQ ID NO: 7), the nucleotide sequence encoding the chicken expression optimized human interferon $\alpha 2b$ (IFNMAGMAX; SEQ ID NO: 5) and a SV40 polyadenylation signal sequence (SEQ ID NO: 8).

FIG. 2 illustrates the nucleotide sequence SEQ ID NO: 5 encoding the chicken expression optimized human interferon $\alpha 2b$ (IFNMAGMAX).

FIGS. 3A-E illustrate the nucleotide sequence SEQ ID NO: 7 encoding the chicken lysozyme gene expression control region.

FIG. 4 illustrates the nucleotide sequence SEQ ID NO: 8 encoding the SV40 polyadenylation signal sequence.

FIGS. 5A-C illustrate the nucleotide sequence SEQ ID NO: 9 encoding the chicken lysozyme 3' domain.

FIGS. 6A-J illustrate the nucleotide sequence SEQ ID NO: 10 encoding the lysozyme gene expression control region (SEQ ID NO: 7) linked to the nucleic acid insert SEQ ID NO: 5 encoding the chicken expression-optimized human interferon $\alpha 2b$ (IFNMAGMAX) and the chicken lysozyme 3' domain SEQ ID NO: 9.

FIG. 7 illustrates the results of the PCR analysis of chick blood DNA. Lanes 4 and 5 and lanes 11 and 12 contain PCR products from blood DNA collected from bird #8305.

FIG. 8 illustrates the results of ELISA for human IFN $\alpha 2b$ in transgenic hen serum. 8307 and AA59 are serum samples collected from negative control birds. Numbers on top of the bars represent the number of days after hatching that the serum was collected.

FIG. 9 illustrates the results of ELISA for human IFN $\alpha 2b$ in transgenic hen egg white. Three eggs from each hen were assayed.

FIG. 10 illustrates the results of SDS-PAGE analysis of human IFN- $\alpha 2b$ purified from the pooled egg whites obtained from transgenic chicken AVI-029. 1, molecular

weight markers; 2, transferrin/avidin markers; 3, ovalbumin/lysozyme markers; 4, ovoglobulins; 5, pooled egg white; 6, solubilized egg white; 7, cation exchange Pool #1; 8, cation exchange Pool #2; 9, HIC pool.

5 FIG. 11 illustrates the results of a Western blot analysis of the protein contents of fractions from the purification of human IFN- α 2b purified from the pooled egg whites obtained from transgenic chicken AVI-029. 1, HIC pool (artifact); 2, HIC pool; 3, cation exchange Pool #2; 4, cation exchange Pool #1; 5, solubilized egg white; 6, pooled egg white; 7, ovoglobulins; 8, ovalbumin/lysozyme markers; 9, transferrin/avidin markers; 10, molecular weight markers.

FIG. 12 illustrates the glycosylation analysis of IFN- α 2b purified from the pooled egg whites obtained from transgenic chicken AVI-029.

15 FIG. 13 compares the identities and relative proportions of glycosylated side-chains of human and transgenic chicken human IFN- α 2b.

FIG. 14 illustrates the nucleic acid sequence SEQ ID NO: 11 of the combinatorial promoter MDOT.

20

FIGS. 15A-B illustrate the oligonucleotides and primers (SEQ ID NOS: 17-34) used in the formation of the chicken codon optimized human interferon α 2b-encoding nucleic acid.

25 FIG. 16 illustrates the levels of expression of human α 2b in eggs as determined by ELISA.

FIG. 17 illustrates the bioactivity versus the mass of human interferon α 2b in G₂ hen egg whites.

30

FIG. 18 illustrates interferon serum levels in chicks producing human interferon α 2b.

FIG. 19 illustrates the presence of a pLNHX-MDOT-IFN transgene in chicks.

35

FIG. 20 illustrates the presence of a pLNHX-MDOT-IFN transgene in chicks.

FIG. 21 illustrates the production of human interferon by quail oviduct cells transfected with pAVJCR-A115.93.1.2.

5

FIG. 22 illustrates the primers (SEQ ID NOS: 38-41) used in the synthesis of the MDOT promoter.

FIG. 23 illustrates the induction of human interferon $\alpha 2b$ by hormonally treated transfected cells.

10

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods of introducing nucleic acids into avian embryonic cells to produce a transgenic chicken, or other avian species, carrying the transgene in the genetic material in all or most of its tissue, including germ-line tissue. The methods and vectors of the present invention further generate transgenic avians that express heterologous genes in the serum of the avian and/or are deposited into an avian egg, preferably in the egg white. Vectors containing promoters that direct high level of expression of the heterologous protein in the avian, particularly in the magnum for deposition into the avian egg are provided. Additional regulatory elements, such as MAR's, IRES's, enhancers, polyadenylation signals, etc., may be included in the vectors of the invention to improve expression and efficiency.

Using the methods of the invention, transgenic avians that express significant quantities of useful heterologous proteins, e.g., therapeutic and diagnostic proteins, including immunoglobulins, industrially useful proteins and other biologics etc. in the avian egg white are produced. The heterologous protein can then be readily purified from the avian egg. The methods of the invention provide improved efficiencies of transgenesis, transmission of the transgene and/or level of heterologous protein expression.

The transgenic avians of the invention are most preferably generated using cytoplasmic microinjection of nucleic acid into avian embryonic cells. Other methods contemplated by the invention include sperm-mediated transgenesis, nuclear transfer and injection or infection with a retroviral vector. Once the nucleic acid has been introduced into the embryo (or ovum which is then fertilized *in vitro*), the embryo is preferably returned to the avian using ovum transfer or, alternatively, is cultured *ex vivo*.

35

5.1 METHODS OF TRANSGENESIS

5.1.1 CYTOPLASMIC INJECTION

5 The present invention provides methods of introducing nucleic acids containing a transgene, preferably, nucleic acid vectors of the invention as described in Section 5.2, *infra*, into an embryonic avian cell or an avian ovum by microinjection into the cell. In preferred embodiments, the nucleic acid is introduced by microinjection into the cytoplasm of the cell; however, in other embodiments of the invention, the nucleic acid is introduced into a nucleus or pronucleus, or is deposited in the perinuclear space.

10 In the method of the present invention, fertilized ova, and preferably stage I embryos, are isolated from euthanized hens between forty-five minutes and four hours after oviposition of the previous egg. It is, however, contemplated that the methods of the present invention may be applied to recipient cells of other stages of embryonic development such as stage I-X, as described by Eyal-Giladi and Kochav (1976, *Dev. Biol.* 49:321-337). Alternatively, eggs may be isolated from hens whose oviducts have been fistulated as described by Gilbert and Woodgush, 1963, *J. of Reprod. and Fertility* 5: 451-453 and Pander *et al.*, 1989, *Br. Poult. Sci.* 30: 953-7; incorporated herein in their entireties. Also, unfertilized eggs can be injected by in-vitro fertilization performed by any method known in the art, for example, but not limited to, the method of Tanaka *et al.*, 1994, *J. Reprod. Fertility* 100:447-449 (the content of which is incorporated herein in its entirety).

20 In particular, microinjection into the germinal disk can be accomplished as described in Example 6.1, *infra*. Briefly, once the fertilized ovum or embryo has been obtained, the albumen capsule is optionally removed and the ovum placed in a dish with the germinal disk facing upwards. Remnants of the albumen capsule may be removed from over the germinal disk if necessary and/or desired. Phosphate buffered saline (PBS) or any other appropriate physiological solution may be added to the dish to prevent drying of the ovum.

Preferably, prior to microinjection, the surface of the embryo is visualized using a lateral imaging system described previously (International Patent Publication WO 02/064,727), this system allows precise imaging of the injection site and facilitates accurate
30 needle placement and injection within the germinal disk of the recipient embryo.

In one embodiment, allowing the visualization of the embryo's pronuclear or nuclear structures, a dye such as MITOTRACKER® (300 nM, Molecular Probes catalog number M-7510), can be added to the cylinder. Other dyes, such as DAPI (4", 6"-diamidino-2-phenylindole hydrochloride), HOECHST® 33342 (bis-benzimide), or Syto 59,
35 can also be used in methods of the invention. Visualization generally is performed after

approximately 20 minutes of incubation. Imaging using the MITOTracker® dye shows intense labeling of the region around the nucleus while the nucleus itself does not take up the dye. This allows localization of the embryo's nuclear structures for injection while not causing excessive damage to its structure since the content of the pronuclei are not labeled and therefore are not bleached during imaging. The nucleic acid solution (generally 1-100 nanoliters) is then injected into the cytoplasm or, alternatively, into the pronucleus or perinuclear space.

Any suitable microinjection assembly and methods for microinjecting and reimplanting avian eggs are contemplated as useful in the method of cytoplasmic injection of the present invention. A particularly suitable apparatus and method for use in the present invention is fully described in U.S. Patent Application No: 09/919,143 by Christmann and PCT Publication WO 02/064727, incorporated herein by reference in their entireties. The microscope/micromanipulation unit may be an IM-16 microinjector and a MM-188NE micromanipulator, both from NIKON®/NARISHIGE, adapted to an upright Nikon Eclipse E800 microscope adapted to operate under both transmitted and reflected light conditions. This unique configuration allows the loading of a DNA solution into a micropipette while observing the pipette with a dry or water immersion lenses under diascopic illumination or transmitted light. Pipette loading is followed by the prompt localization and positioning of the germinal disk under the microscope and subsequent guided injection of DNA solution into the germinal disk using dry or water-immersion lenses under fiber optic, as well as episcopic, illumination (through the objectives and onto the embryo surface).

In certain embodiments, the microinjected cell will also be subjected to microelectroporation. The application of electrical current, *e.g.*, microelectroporation, enhances the uptake of exogenous DNA fragments by cultured cells and the uptake of nucleic acids in the cytoplasm of a cell into the nucleus. Enhancement of nuclear uptake of the heterologous DNA will promote earlier chromosomal integration of the exogenous DNA molecules, thus reducing the degree of genetic mosaicism observed in transgenic avian founders.

Accordingly, in specific embodiments, a sample of nucleic acid will be microinjected using the methods described immediately above, and then, delivered to a recipient cell nucleus by microelectroporation. In a system suitable for use in microelectroporating early stage avian cells, a cathode will be located within the lumen of the DNA delivery micropipette. Alternatively, the cathode electrode may be located on the exterior surface of the micropipette. For either option, the electrode is situated close or adjacent to the exit orifice of the pipette so that the electrode and the micropipette may be

introduced into the recipient cell together. Alternatively, the micropipette will be introduced into the cytoplasm and used to guide a cathode to make electrical contact with the cytoplasm of the targeted cell.

5 In one arrangement of the electrodes of the microelectroporation system, the anode is located on the micropipette and, therefore, will enter the cell or cells with the micropipette and the cathode. In another arrangement, an anode is in electrical contact with the solution that surrounds the targeted recipient early stage avian cell. In yet another version, the anode is individually positioned within the cytoplasm, or the nucleus, of the recipient cell. The anode and cathode are electrically connected to an electrical pulse
10 generator capable of delivering a timed electrical pulse to the electrodes. One suitable apparatus for generating a timed electrical pulse according to the present invention is a Kation Scientific Iontophoresis pump BAB-500 or ECM 830 manufactured by BTX®. After microinjection of the nucleic acid, the recipient cell will be pulsed at least once with about 0.1 to about 20.0 microamps for about 0.1 to about 60 secs.

15 After injection and, optionally, microelectroporation, the embryo is allowed to proceed through the natural *in vivo* cycle of albumen deposition and hard-shell formation. In preferred embodiments, the embryo is surgically transferred into the infundibulum of a recipient hen, where it is allowed to move into the infundibulum and into the anterior magnum by gravity feed, such that the recipient hen produces a hard shell egg that is
20 incubated to produce a transgenic chick. See, e.g., Olsen and Neher, 1948, *J. Exp. Zoo* 109: 355-366, which is incorporated by reference in its entirety. The transgenic embryo is then laid as a hard-shell egg and may be incubated to hatch a transgenic chick. In an alternate embodiment of the present invention, the injected embryo is transferred into the oviduct of a recipient hen, a soft-shell egg is collected between 12 and 24 hours after ovum transfer by
25 injecting the hen with sufficient oxytocin to induce ovipositioning. The soft shell egg can subsequently be incubated, and a chick hatched, using an in-vitro culture system as, for example, that described by Perry in U.S. Patent No. 5,011,780 (the contents of which is incorporated herein in its entirety). In either case, the hatched chick may be allowed to attain sexual maturity whereupon it can be used, for example, to breed new generations of
30 heterozygous or homozygous transgenic progeny. Sexually mature female transgenic avians are particularly useful for the expression of a heterologous nucleic acid to yield a heterologous polypeptide in the white of an egg.

The hatched chick can then be tested for presence of the transgene and/or expression of the heterologous protein encoded by the transgene using methods well known in the art.

35 In a particular embodiment, blood cells of the hatched chick are screened using methods

disclosed in United States Patent No. 6,423,488, issued July 3, 2002, which is hereby incorporated by reference in its entirety.

5.1.2 TRANSGENESIS OF BLASTODERMAL CELLS

5 In alternative embodiments, a transgene can be introduced into avian embryonic blastodermal cells, to produce a transgenic chicken, or other avian species, that carries the transgene in the genetic material of its germ-line tissue. The methods and vectors of the present invention further generate transgenic avians capable of expressing heterologous genes in the serum of the avian and /or deposited in an avian egg. The blastodermal cells
10 are typically stage VII-XII cells, or the equivalent thereof, and preferably are near stage X. The cells useful in the present invention include embryonic germ (EG) cells, embryonic stem (ES) cells & primordial germ cells (PGCs). The embryonic blastodermal cells may be isolated freshly, maintained in culture, or reside within an embryo.

A variety of vectors useful in carrying out the methods of the present invention are
15 described herein, in Section 5.2 *infra*. These vectors may be used for stable introduction of an exogenous coding sequence into the genome of a bird. In alternative embodiments, the vectors may be used to produce exogenous proteins in specific tissues of an avian, and in the oviduct in particular. In still further embodiments, the vectors are used in methods to produce avian eggs which contain exogenous protein.

20 In some cases, introduction of a vector of the present invention into the embryonic blastodermal cells is performed with embryonic blastodermal cells that are either freshly isolated or in culture. The transgenic cells are then typically injected into the subgerminal cavity beneath a recipient blastoderm in an egg. In some cases, however, the vector is delivered directly to the cells of a blastodermal embryo.

25 In one embodiment of the invention, vectors used for transfecting blastodermal cells and generating random, stable integration into the avian genome contain a coding sequence and a magnum-specific promoter in operational and positional relationship to express the coding sequence in the tubular gland cell of the magnum of the avian oviduct. The magnum-specific promoter may optionally be a segment of the *ovalbumin* promoter region
30 which is sufficiently large to direct expression of the coding sequence in the tubular gland cells. Other exemplary promoters include the promoter regions of the *ovalbumin*, *lysozyme*, *conalbumin*, *ovomucoid*, or *ovomucin* genes. Alternatively, the promoter may be a promoter that is largely, but not entirely, specific to the magnum, such as the *lysozyme* promoter. Other suitable promoters may be artificial constructs such as a combination of nucleic acid
35 regions derived from at least two avian gene promoters. One such embodiment of the

present invention is the MDOT construct comprising regions derived from the chicken ovomucin and ovotransferrin promoters

In an alternative embodiment of the invention, transgenes containing constitutive promoters are used, but the transgenes are engineered so that expression of the transgene effectively becomes magnum-specific. Thus, a method for producing an exogenous protein in an avian oviduct provided by the present invention involves generating a transgenic avian that bears two transgenes in its tubular gland cells. One transgene comprises a first coding sequence operably linked to a constitutive promoter. The second transgene comprises a second coding sequence that is operably linked to a magnum-specific promoter, where expression of the first coding sequence is either directly or indirectly dependent upon the cellular presence of the protein expressed by the second coding sequence.

Optionally, site-specific recombination systems, such as the Cre-*loxP* or FLP-FRT systems, are utilized to implement the magnum-specific activation of an engineered constitutive promoter. In one embodiment, the first transgene contains an FRT-bounded blocking sequence which blocks expression of the first coding sequence in the absence of FTP, and the second coding sequence encodes FTP. In another embodiment, the first transgene contains a *loxP*-bounded blocking sequence which blocks expression of the first coding sequence in the absence of the Cre enzyme, and the second coding sequence encodes Cre. The *loxP*-bounded blocking sequence may be positioned in the 5' untranslated region of the first coding sequence and the *loxP*-bounded sequence may optionally contain an open reading frame.

For instance, in one embodiment of the invention, magnum-specific expression is conferred on a constitutive transgene, by linking a cytomegalovirus (CMV) promoter to the coding sequence of the protein to be secreted (CDS). The 5' untranslated region (UTR) of the coding sequence contains a *loxP*-bounded blocking sequence. The *loxP*-bounded blocking sequence contains two *loxP* sites, between which is a start codon (ATG) followed by a stop codon, creating a short, nonsense open reading frame (ORF). Note that the *loxP* sequence contains two start codons in the same orientation. Therefore, to prevent them from interfering with translation of the coding sequence after *loxP* excision, the *loxP* sites must be orientated such that the ATGs are in the opposite strand.

In the absence of Cre enzyme, the cytomegalovirus promoter drives expression of a small open reading frame (ORF). Ribosomes will initiate at the first ATG, the start codon of the ORF, then terminate without being able to reinitiate translation at the start codon of the coding sequence. To be certain that the coding sequence is not translated, the first ATG is out of frame with the coding sequence's ATG. If the Cre enzyme is expressed in cells

containing the CMV-cDNA transgene, the Cre enzyme will recombine the *loxP* sites, excising the intervening ORF. Translation will begin at the start codon of the coding sequence, resulting in synthesis of the desired protein.

To make this system tissue specific, the Cre enzyme is expressed under the control of a tissue-specific promoter, such as the magnum-specific *ovalbumin* promoter, in the same cell as the CMV-*loxP*-coding sequence transgene. Although a truncated *ovalbumin* promoter may be fairly weak, it is still tissue-specific and will express sufficient amounts of the Cre enzyme to induce efficient excision of the interfering ORF. In fact, low levels of recombinase should allow higher expression of the recombinant protein since it does not compete against coding sequence transcripts for translation machinery.

Alternate methods of blocking translation of the coding sequence include inserting a transcription termination signal and/or a splicing signal between the *loxP* sites. These can be inserted along with the blocking ORF or alone. In another embodiment of the invention, a stop codon can be inserted between the *loxP* sites in the signal peptide of the coding sequence. Before recombinase is expressed, the peptide terminates before the coding sequence. After recombinase is expressed (under the direction of a tissue specific promoter), the stop codon is excised, allowing translation of the coding sequence. The *loxP* site and coding sequence are juxtaposed such that they are in frame and the *loxP* stop codons are out of frame. Since signal peptides are able to accept additional sequence (Brown *et al.*, *Mol. Gen. Genet.* 197:351-7 (1984)), insertion of *loxP* or other recombinase target sequences (i.e. FRT) is unlikely to interfere with secretion of the desired coding sequence. In one expression vector, the *loxP* site is present in the signal peptide such that the amino acids encoded by *loxP* are not present in the mature, secreted protein. Before Cre enzyme is expressed, translation terminates at the stop codon, preventing expression of β -lactamase. After recombinase is expressed (only in magnum cells), the *loxP* sites recombine and excise the first stop codon. Therefore, β -lactamase is expressed selectively only in magnum cells.

In the aforementioned embodiments, the blocking ORF can be any peptide that is not harmful to chickens. The blocking ORF can also be a gene that is useful for production of the ALV-transduction particles and/or transgenic birds. In one embodiment, the blocking ORF is a marker gene.

For instance, the blocking ORF could be the neomycin resistance gene, which is required for production of transduction particles. Once the transgene is integrated into the chicken genome, the neomycin resistance gene is not required and can be excised.

35

Alternatively, β -lactamase can be used as the blocking ORF as it is an useful marker for production of transgenic birds. (For specific examples of the use of β -lactamase as a marker in transgenic birds, see Example 22, below.) As an example, the blocking ORF is replaced by β -lactamase and the downstream coding sequence now encodes a secreted biopharmaceutical. β -Lactamase will be expressed in blood and other tissues; it will not be expressed in the magnum after magnum-specific expression of Cre and recombination-mediated excision of β -lactamase, allowing expression of the desired protein.

The Cre and loxP transgenes could be inserted into the chicken genome via mediated transgenesis either simultaneously or separately. Any method of transgenesis that results in stable integration into the chicken genome is suitable including, but not limited to, viral integration and sperm-mediated integration. Both the *ovalbumin* promoter-recombinase and CMV-loxP-CDS transgenes could be placed simultaneously into chickens. However, the efficiencies of transgenesis are low and therefore the efficiency of getting both transgenes into the chicken genome simultaneously is low. In an alternative and preferred method, one flock is produced that carries the magnum-specific promoter/recombinase transgene and a second is produced that carries the CMV-loxP-CDS transgene. The flocks would then be crossed to each other. Hens resulting from this outbreeding will express the coding sequence and only in their magnum.

As mentioned above, the vectors produced according to the methods of the invention may optionally be provided with a 3' UTR containing a polyadenylation site to confer stability to the RNA produced. In a preferred embodiment, the 3' UTR may be that of the exogenous gene, or selected from the group consisting of the *ovalbumin*, *lysozyme*, or *SV40* late region. However, the *ovalbumin* 3' UTR is not suitable in a PMGI vector that is to be inserted into the endogenous *ovalbumin* gene because the addition of *ovalbumin* sequences to the PMGI vector will interfere with proper targeting.

5.1.3 VIRAL HOST CELL TRANSFORMATION

In another embodiment, a method of introducing a nucleic acid comprising a nucleic acid sequence encoding one of the subject polypeptides and the associated gene expression control regions into a cell is using of a viral vector containing nucleic acid, e.g. a cDNA, encoding the gene product. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells that have taken up viral vector nucleic acid.

35

Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of heterologous genes *in vivo*. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. Recombinant retrovirus
5 can be constructed wherein the retroviral coding sequences (*gag*, *pol*, *env*) have been replaced by nucleic acid encoding a polypeptide, thereby rendering the retrovirus replication defective. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel *et al.*, (1989) (eds.) Greene Publishing Associates, Sections 9.10-9.14 and other
10 standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include psiCrip, psiCre, psi2 and psiAm.

Furthermore, it is possible to limit the infection spectrum of retroviruses and
15 consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO 93/25234, WO 94/06920, and WO 94/11524). For instance, strategies for the modification of the infection spectrum of retroviral vectors include coupling antibodies specific for cell surface antigens to the viral *env* protein (Roux *et al.*, 1989, *Proc. Natl. Acad. Sci.* 86: 9079-9083; Julian *et al.*,
20 *J. Gen. Virol.* 73: 3251-3255 (1992); and Goud *et al.*, 1993, *Virology* 163: 251-254); or coupling cell surface ligands to the viral *env* proteins (Neda *et al.*, 1991, *J. Biol. Chem.* 266, 14143-14146), and which are incorporated herein by reference in their entireties. Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well as by generating fusion proteins
25 (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, can also be used to convert an ecotropic vector into an amphotropic vector. Moreover, use of retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences that control expression of the nucleic acid encoding an immunoglobulin polypeptide of the
30 retroviral vector.

One retrovirus for randomly introducing a transgene into the avian genome is the replication-deficient ALV retrovirus. To produce an appropriate ALV retroviral vector, a pNLB vector is modified by inserting a region of the *ovalbumin* promoter and one or more exogenous genes between the 5' and 3' long terminal repeats (LTRs) of the retrovirus
35 genome. Any coding sequence placed downstream of the *ovalbumin* promoter will be

expressed at high levels and only in the tubular gland cells of the oviduct magnum because the *ovalbumin* promoter drives the high level of expression of the ovalbumin protein and is only active in the oviduct tubular gland cells. While a 7.4 kb *ovalbumin* promoter has been found to produce the most active construct when assayed in cultured oviduct tubular gland cells, the *ovalbumin* promoter must be shortened for use in the retroviral vector. In a preferred embodiment, the retroviral vector comprises a 1.4 kb segment of the *ovalbumin* promoter; a 0.88 kb segment would also suffice.

Any of the vectors of the present invention may also optionally include a coding sequence encoding a signal peptide that will direct secretion of the protein expressed by the vector's coding sequence from the tubular gland cells of the oviduct. This aspect of the invention effectively broadens the spectrum of exogenous proteins that may be deposited in avian eggs using the methods of the invention. Where an exogenous protein would not otherwise be secreted, the vector bearing the coding sequence is modified to comprise a DNA sequence comprising about 60 bp encoding a signal peptide from the *lysozyme* gene. The DNA sequence encoding the signal peptide is inserted in the vector such that it is located at the N-terminus of the protein encoded by the cDNA.

Construction of one vector is reported in Example 19, below. β -lactamase may be expressed from the CMV promoter and utilizes a poly adenylation signal (pA) in the 3' long terminal repeat (LTR). β -Lactamase has a natural signal peptide; thus, it is found in blood and in egg white.

Avian embryos have been successfully transduced with pNLB-CMV-BL transduction particles (see Examples 11 and 12, below). The egg whites of eggs from the resulting stably transduced hens were found to contain up to 20 mg of secreted, active β -lactamase per egg (see Examples 13 and 14, below).

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes a gene product of interest, but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle (see, for example, Berkner *et al.* BioTechniques 6, 616 (1988); Rosenfeld *et al.* Science 252, 43 1434 (1991); and Rosenfeld *et al.* Cell 68, 143-155 (1992)), incorporated herein by reference in their entireties. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. The virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains

episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material (see, for example, *Jones et al.*, (1979) *Cell* 16, 683; *Berkner et al.*, supra; and *Graham et al.*, in *Methods in Molecular Biology*, E. J. Murray, (1991) Ed. (Humana, Clifton, N.J.) vol. 7. pp. 109-127), and which are incorporated herein by reference in their entireties. Expression of an inserted nucleic acid encoding a polypeptide such as IFN γ , an immunoglobulin, EPO, GM-CSF, can be under control of, for example, the lysozyme promoter, the ovalbumin promoter, artificial promoter construct sequences and the like.

Yet another viral vector system useful for delivery of, for example, the subject nucleic acid encoding an immunoglobulin polypeptide, is the adeno-associated virus (AAV). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for heterologous DNA is limited to about 4.5 kb. An AAV vector such as that described in *Tratschin et al.*, *Mol. Cell. Biol.* 5, 3251-3260 (1985) can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see, for example, *Hermonat et al.*, *Proc. Natl. Acad. Sci.* 81, 6466-6470 (1984); *Tratschin et al.*, *Mol. Cell. Biol.* 4, 2072-2081 (1985); *Wondisford et al.*, *Mol. Endocrinol.* 2, 32-39 (1988); *Tratschin et al.*, *J. Virol.* 51, 611-619 (1984); and *Flotte et al.*, *J. Biol. Chem.* 268, 3781-3790 (1993)), incorporated herein by reference in their entireties.

Other viral vector systems that may have application in the methods according to the present invention have been derived from, but are not limited to, herpes virus, vaccinia virus, avian leucosis virus and several RNA viruses.

5.1.4 GENERATION OF TRANSGENIC AVIAN ZYGOTES BY NUCLEAR TRANSFER AND TPLSM

In another embodiment, transgenes may be introduced into the ovum of an animal, according to the present invention, by nuclear transfer via two-photon visualization and ablation, wherein the nuclear donor contains a desired heterologous DNA sequence in its genome. One of ordinary skill in the art will be able to readily adapt conventional methods to insert the desired transgene into the genome of the nuclear donor prior to injection of the nuclear donor into the recipient cytoplasm, or prior to fusion of the nuclear donor cell with the recipient cell. For example, a vector that contains one or more transgene(s) encoding at

least one polypeptide chain of an antibody, may be delivered into the nuclear donor cell through the use of a delivery vehicle. The transgene is then transferred along with the nuclear donor into the recipient ovum. Following zygote reconstruction, the ovum is transferred into the reproductive tract of a recipient hen. In one embodiment of the present invention, the ovum is transferred into the infundibulum of the recipient hen. After reconstruction, the embryo containing the transgene develops inside the recipient hen and travels through the oviduct thereof where it is encapsulated by natural egg white proteins and a natural egg shell. The egg is laid and can be incubated and hatched to produce a transgenic chick. The resulting transgenic chick will carry one or more desired transgene(s) in its germ line. Following maturation, the transgenic avian may lay eggs that contain one or more desired heterologous protein(s) that can be easily harvested.

In another embodiment of the present invention, a nuclear donor cell is transfected with a vector construct that contains a transgene encoding at least one polypeptide chain. Methods for transfection of somatic cell nuclei are well known in the art and include, by way of example, the use of retroviral vectors, retrotransposons, adenoviruses, adeno-associated viruses, naked DNA, lipid-mediated transfection, electroporation and direct injection into the nucleus. Such techniques, particularly as applied to avians, are disclosed in *Bosselman* (U.S. Patent No. 5,162,215), *Etches* (PCT Publication No. WO 99/10505), *Hodgson* (U.S. Patent No. 5,027,722), *Hughes* (U.S. Patent No. 4,997,763), *Ivarie* (PCT Publication No. WO 99/19472), *MacArthur* (PCT Publication No. WO 97/47739), *Perry* (U.S. Patent No. 5,011,780), *Petitte* (U.S. Patent Nos. 5,340,740 and 5,656,749), and *Simkiss* (PCT Publication No. WO 90/11355), the disclosures of which are incorporated by reference herein in their entireties.

Nuclear transfer allows the cloning of animal species, wherein individual steps are common to the procedures of embryonic, fetal and adult cell cloning. These steps include, but are not limited to, preparation of a cytoplasm, donor cell nucleus (nuclear donor) isolation and transfer to the cytoplasm to produce a reconstructed embryo, optional reconstructed embryo culture, and embryo transfer to a synchronized host animal.

The present invention may use this approach to nuclear transfer in animals by employing two-photon visualization. In embodiments of the invention, the recipient animal is an avian including, but not limited to, chickens, ducks, turkeys, quails, pheasants and ratites. In this method, a fertilized or unfertilized egg is removed from an animal and manipulated *in vitro*, wherein the genetic material of the egg is visualized and removed and the ablated nucleus replaced with a donor nucleus. Optionally, the donor nucleus may be genetically modified with, for example, a transgene encoding an immunoglobulin

polypeptide. Two-photon laser scanning microscopy (TPLSM) may be used to visualize the nuclear structures. Following visualization, the nucleus in the recipient cell, such as a fertilized or unfertilized egg, is removed or ablated, optionally using TPLSM.

5 TPLSM is based on two-photon excited fluorescence in which two photons collide simultaneously with a fluorescent molecule. Their combined energy is absorbed by the fluorophore, inducing fluorescent emission that is detected by a photomultiplier tube and converted into a digital image. See *Squirrell et al.*, *Nature Biotechnol.* 17, 763-7, (1999) and *Piston et al.*, *Trends Cell Biol.* 9, 66-9, (1999) incorporated herein by reference in their entireties. TPLSM generates images of living, optically dense structures for prolonged
10 periods of time, while not affecting their viability. TPLSM utilizes biologically innocuous pulsed near-infrared light, usually at a wavelength of about 700 nm to about 1000 nm, which is able to penetrate deep into light-scattering specimens. TPLSM may employ different lasers, such as a mode-locked laser, where the wavelength is fixed, or a tunable laser that can be tuned to wavelengths between about 700 nm and about 1000 nm,
15 depending upon the range of emission of the dye used. For DAPI and Hoescht 33342 dyes, 720-770 nm is preferred. New fluorophores are being produced with different ranges of emission and the invention is not limited to the presently available dyes and their respective emission ranges.

Furthermore, lasers used in TPLSM can be grouped into femtosecond and
20 picosecond lasers. These lasers are distinguished by their pulse duration. A femtosecond laser is preferred since it is particularly suitable for visualization without harming the specimen.

TPLSM produces noninvasive, three-dimensional, real-time images of the optically dense avian egg. Visualization of the metaphase plate or pronucleus in avian eggs during
25 nuclear transfer has been prevented by the yolk. Two-photon imaging with femtosecond lasers operating in the near infrared, however, allows visualization of nuclear structures without damaging cellular constituents. Prior to visualization, specimens may be incubated or injected with DNA-specific dyes such as DAPI (4', 6'-diamidino-2-phenylindole hydrochloride) or Hoescht 33342 (bis-benzimide), the albumen capsule is removed and the
30 ovum placed in a dish with the germinal disk facing the top. Remnants of the albumen capsule are removed from the top of the germinal disk.

An aqueous solution, for example phosphate-buffered saline (PBS), is added to prevent drying of the ovum. A cloning cylinder is placed around the germinal disk and DAPI in PBS is added to the cylinder. Alternatively, a DAPI-PBS solution may be injected
35 into the germinal disk with a glass pipette, whereupon the dye enters the nuclear structures.

For dye injection, removal of the albumen capsule is not necessary, whereas injection of nuclei into the disk is facilitated in the absence of the capsule.

5 Images of the inside of the early avian embryo can be generated through the use of TPLSM. Visualization may be performed after about 10 to 15 minutes of incubation or about 10 minutes after dye injection. During visualization, the germinal disk is placed under the microscope objective and the pronuclear structures are searched within the central area of the disk using relatively low laser powers of about 3-6 milliwatts. Once the structures are found they may be ablated by using higher laser power or mechanically removed, guided by TPLSM.

10 Nuclear transfer also requires the destruction or enucleation of the pronucleus before a nuclear donor can be introduced into the oocyte cytoplasm. Two-photon laser-mediated ablation of nuclear structures provides an alternative to microsurgery to visualize the pronucleus lying about 25 μ m beneath the ovum's vitelline membrane within the germinal disk. Higher laser powers than those used for imaging are used for enucleation, with minimal collateral damage to the cell. The wavelength for ablation generally ranges from 15 about 700 nm to 1000 nm, at about 30 to about 70 milliwatts. TPLSM and two-photon laser-mediated ablation are more efficient than alternative methods because they are less operator dependent and less invasive, which results in improved viability of the recipient cell.

20 A nucleus from a cultured somatic cell (nuclear donor) may then be injected into the enucleated recipient cytoplasm by a micromanipulation unit comprising a microinjector and a micromanipulator. The donor nucleus is introduced into the germinal disk through guided injection using episcopic illumination (i.e., light coming through the objective onto the sample). Alternatively, a donor cell may be fused to the recipient cell using methods well known in the art, e.g. by means of fusion-promoting chemicals, such as polyethylene glycol, 25 inactivated viruses, such as Sendai virus, or electrical stimulation. The reconstructed zygote may then be surgically transferred to the oviduct of a recipient hen to produce a hard shell egg. Alternatively, the reconstructed embryo may be cultured for 24 hours and screened for development prior to surgical transfer.

30 The egg can be harvested after laying and before hatching of a chick, or further incubated to generate a cloned chick, optionally genetically modified. The cloned chick may carry a transgene in all or most of its cells. After maturation, the transgenic avian may lay eggs that contain one or more desired, heterologous protein(s). The cloned chick may also be a knock-in chick expressing an alternative phenotype or capable of laying eggs

35

having an heterologous protein therein. The reconstructed egg may also be cultured to term using the *ex ovo* method described by Perry *et al.* (*supra*).

5.1.5 ZYGOTE RECONSTRUCTION BY OVUM TRANSFER

5 Another embodiment of the invention provides for a method of producing a cloned animal comprising nuclear transfer in combination with ovum transfer. Two-photon visualization and ablation may be used to perform nuclear transfer, as described above. Accordingly, the replacement of the recipient cell's nucleus with the donor cell's nucleus results in a reconstructed zygote. Preferably, pronuclear stage eggs are used as recipient
10 cytoplasts already activated by fertilization. Alternatively, unactivated metaphase II eggs may serve as recipient cytoplasm and activation induced after renucleation. The ovum may be cultured via ovum transfer, wherein the ovum containing the reconstructed zygote is transferred to a recipient hen. The ovum is surgically transferred into the oviduct of the recipient hen shortly after oviposition. This is accomplished according to normal husbandry
15 procedures (oviposition, incubation, and hatching; see Tanaka *et al.*, *supra*).

Alternatively, the ovum may be cultured to stage X prior to transfer into a recipient hen. More specifically, reconstructed stage I embryos are cultured for 24-48 hours to stage X. This allows for developmental screening of the reconstructed embryo prior to surgical transfer. Stage I embryos are enclosed within a thick albumen capsule. In this novel
20 procedure, the albumen capsule is removed, after which the nuclear donor is injected into the germinal disk. Subsequently, the capsule and germinal disk are recombined by placing the thick capsule in contact with the germinal disk on top of the yolk. Embryos develop to stage X at similar rates as those cultured with their capsules intact. At stage X, the embryo is transferred to the oviduct of a recipient hen.

25 Once transferred, the embryo develops inside the recipient hen and travels through the oviduct of the hen where it is encapsulated by natural egg white proteins and a natural egg shell. The egg which contains endogenous yolk and an embryo from another hen, is laid and can then be incubated and hatched like a normal chick. The resulting chick may carry a transgene in all or most of its cells. Preferably, the transgene is at least in the
30 oviduct cells of the recipient chick. Following maturation, the cloned avian may express a desired phenotype or may be able to lay eggs that contain one or more desired, heterologous protein(s).

5.1.6 SPERM-MEDIATED INTEGRATION OF HETEROLOGOUS TRANSGENES

Detailed descriptions of methods of sperm-mediated transfer of nucleic acid suitable for use in the present invention are described in the PCT Publication WO 00/697257, incorporated herein by reference in its entirety. The first method of incorporating heterologous genetic material into the genome of an avian delivers a nucleic acid using known gene delivery systems to male germ cells *in situ* in the testis of the male avian (e.g., by *in vivo* transfection or transduction). The second, *in vitro*, method of incorporating heterologous genetic material into the genome of an avian involves isolating male germ cells *ex corpora*, delivering a polynucleotide thereto and then returning the transfected cells to the testes of a recipient male bird.

In vivo method

The *in vivo* method employs injection of the gene delivery mixture, preferably into the seminiferous tubules, or into the pte testis, and most preferably into the vas efferens or vasa efferentia, using, for example, a micropipette and a picopump delivering a precise measured volume under controlled amounts of pressure. A small amount of a suitable, non-toxic dye can be added to the gene delivery mixture (fluid) to confirm delivery and dissemination to the seminiferous tubules of the testis. The genetically modified germ cells differentiate in their own milieu. Progeny animals exhibiting the nucleic acid's integration into its germ cells (transgenic animals) are selected. The selected progeny can then be mated, or their sperm utilized for insemination or *in vitro* fertilization to produce further generations of transgenic progeny.

In vitro method

Male germ cells are obtained or collected from the donor male bird by any means known in the art such as, for example, transection of the testes. The germ cells are then exposed to a gene delivery mixture, preferably within several hours, or cryopreserved for later use. When the male germ cells are obtained from the donor vertebrate by transection of the testes, the cells can be incubated in an enzyme mixture known for gently breaking up the tissue matrix and releasing undamaged cells such as, for example, pancreatic trypsin, collagenase type I, pancreatic DNase type I, as well as bovine serum albumin and a modified DMEM medium. After washing the cells, they can be placed in an incubation medium such as DMEM, and the like, and plated on a culture dish for genetic modification by exposure to a gene delivery mixture.

Whether employed in the *in vivo* method or *in vitro* method, the gene delivery mixture, once in contact with the male germ cells, facilitates the uptake and transport of

heterologous genetic material into the appropriate cell location for integration into the genome and expression. A number of known gene delivery methods can be used for the uptake of nucleic acid sequences into the cell. Such methods include, but are not limited to viral vectors, liposomes, electroporation and Restriction Enzyme Mediated Integration (REMI) (discussed below). In both the *in vivo* or *in vitro* method, a gene delivery mixture typically comprises a polynucleotide encoding the desired trait or product (for example, immunoglobulin polypeptides) and a suitable promoter sequence such as, for example, a tissue-specific promoter, an IRES or the like and optionally agents that increase the uptake of or comprise the polynucleotide sequence, such as liposomes, retroviral vectors, adenoviral vectors, adenovirus enhanced gene delivery systems and the like, or combinations thereof. A reporter construct, including a genetic selection marker, such as the gene encoding for Green Fluorescent Protein, can further be added to the gene delivery mixture. Targeting molecules, such as the c-kit ligand, can be added to the gene delivery mixture to enhance the transfer of genetic material into the male germ cell. An immunosuppressing agent, such as cyclosporin or a corticosteroid may also be added to the gene delivery mixture as known in the art.

Any of a number of commercially available gene delivery mixtures can be used, to which the polynucleotide encoding a desired trait or product is further admixed. The final gene delivery mixture comprising the polynucleotide can then be admixed with the cells and allowed to interact for a period of between about 2 hours to about 16 hours, at a temperature of between about 33 °C to about 37 °C. After this period, the cells are preferably placed at a lower temperature of about 33 °C to about 34 °C, for about 4 hours to about 20 hours, preferably about 16 to 18 hrs.

Isolating and/or selecting genetically transgenic germ cells (and transgenic somatic cells, and of transgenic vertebrates) is by any suitable means, such as, but not limited to, physiological and/or morphological phenotypes of interest using any suitable means, such as biochemical, enzymatic, immunochemical, histologic, electrophysiologic, biometric or like methods, and analysis of cellular nucleic acids, for example the presence or absence of specific DNAs or RNAs of interest using conventional molecular biological techniques, including hybridization analysis, nucleic acid amplification including, but not limited to, polymerase chain reaction, transcription-mediated amplification, reverse transcriptase-mediated ligase chain reaction, and/or electrophoretic technologies.

A preferred method of isolating or selecting male germ cell populations comprises obtaining specific male germ cell populations, such as spermatogonia, from a mixed population of testicular cells by extrusion of the cells from the seminiferous tubules and enzyme digestion. The spermatogonia, or other male germ cell populations, can be isolated

from a mixed cell population by methods such as the utilization of a promoter sequence that is specifically or selectively active in cycling male germ line stem cell populations. Suitable promoters include B-Myb or a specific promoter, such as the c-kit promoter region, c-raf-1 promoter, ATM (ataxia-telangiectasia) promoter, vasa promoter, RBM (ribosome binding motif) promoter, DAZ (deleted in azoospermia) promoter, XRCC- 1 promoter, HSP 90 (heat shock gene) promoter, cyclin A1 promoter, or FRMI (from Fragile X site) promoter and the like. A selected promoter may be linked to a reporter construct, for example, a construct comprising a gene encoding Green Fluorescent Protein (or EGFP), Yellow Fluorescent Protein, Blue Fluorescent Protein, a phycobiliprotein, such as phycoerythrin or phycocyanin, or any other protein which fluoresces under suitable wave-lengths of light, or encoding a light-emitting protein, such as luciferase or apoaquorin. The unique promoter sequences drive the expression of the reporter construct only during specific stages of male germ cell development (e.g., *Mailer et al.*, J. Biol. Chem. 276(16), 11220-28 (1999); *Schrans-Stassen et al.*, Endocrinology 140, 5894-5900 (1999)) incorporated herein by reference in their entireties. In the case of a fluorescent reporter construct, the cells can be sorted with the aid of, for example, a FACS set at the appropriate wavelength(s), or they can be selected by chemical methods.

Male germ cells that have the DNA modified in the desired manner are isolated or selected, and transferred to the testis of a suitable recipient animal. Further selection can be attempted after biopsy of one or both of the recipient male's testes, or after examination of the animal's ejaculate amplified by the polymerase chain reaction to confirm that the desired nucleic acid sequence had been incorporated.

The genetically modified germ cells isolated or selected as described above are preferably transferred to a testis of a recipient male avian, preferably a chicken, that can be, but need not be, the same donor animal. Before transferring the genetically modified male germ cells to the recipient animal, the testes of the recipient can be depopulated of endogenous germ cells, thereby facilitating the colonization of the recipient testis by the genetically modified germ cells, by any suitable means, including by gamma irradiation, by chemical treatment, by means of infectious agents such as viruses, or by autoimmune depletion or by combinations thereof, preferably by a combined treatment of the vertebrate with an alkylating agent and gamma irradiation.

The basic rigid architecture of the gonad should not be destroyed, nor significantly damaged. Disruption of tubules may lead to impaired transport of testicular sperm and result in infertility. Sertoli cells should not be irreversibly damaged, as they provide a base for development of the germ cells during maturation, and for preventing the host immune defense system from destroying grafted foreign spermatogonia.

In a preferred method, a cytotoxic alkylating agent, such as, but not limited to, bisulfan (1,4-butanediol dimethanesulphonate), chlorambucil, cyclophosphamide, melphalan, or ethyl ethanesulfonic acid, is combined with gamma irradiation, to be administered in either sequence. The dose of the alkylating agent and the dose of gamma radiation are in an amount sufficient to substantially depopulate the testis. The alkylating agent can be administered by any pharmaceutically acceptable delivery system, including but not limited to, intraperitoneal, intravenous, or intramuscular injection, intravenous drip, implant, transdermal or transmucosal delivery systems.

The isolated or selected genetically modified germ cells are transferred into the recipient testis by direct injection using a suitable micropipette. Support cells, such as Leydig or Sertoli cells, that can be unmodified or genetically modified, can be transferred to a recipient testis along with the modified germ cells.

A union of male and female gametes to form a transgenic zygote is brought about by copulation of the male and female vertebrates of the same species, or by *in vitro* or *in vivo* artificial means. If artificial means are chosen, then incorporating into the genome a genetic selection marker that is expressed in male germ cells is particularly useful.

Suitable artificial means include, but are not limited to, artificial insemination, *in vitro* fertilization (IVF) and/or other artificial reproductive technologies, such as intracytoplasmic sperm injection (ICSI), subzonal insemination (SUZI), or partial zona dissection (PZD). Also others, such as cloning and embryo transfer, cloning and embryo splitting, and the like, can be employed.

The transgenic vertebrate progeny can, in turn, be bred by natural mating, artificial insemination, or by *in vitro* fertilization (IVF) and/or other artificial reproductive technologies, such as intracytoplasmic sperm injection (ICSI) and chicken intracytoplasmic sperm injection (CHICSI™), subzonal insemination (SUZI), or partial zona dissection (PZD), to obtain further generations of transgenic progeny. Although the genetic material is originally inserted solely into the germ cells of a parent animal, it will ultimately be present in the germ cells of future progeny and subsequent generations thereof. In addition, the genetic material will also be present in cells of the progeny other than germ cells, i.e., somatic cells.

5.1.7 GENERATION OF TRANSGENIC AVIAN ZYGOTES BY RESTRICTION ENZYME-MEDIATED INTEGRATION (REMI)

The REMI method for stably integrating heterologous DNA into the genomic DNA of a recipient cell is described by Shemesh *et al.* in PCT Publication No. WO 99/42569 and incorporated herein by reference in its entirety. This REMI method comprises in part an

adaptation of the REMI technique disclosed by Schiest and Petes (Proc. Nat. Acad. Sci. U.S.A. 88, 7585-7589 (1991)) and Kuspa and Loomis (Proc. Nat. Acad. Sci. U.S.A., 89, 8803-8807 (1992)) both incorporated herein by reference in their entireties.

5 The REMI method is suitable for introducing heterologous DNA into the genome nucleic acid of sperm and sperm precursor cells, or ovum, embryonic cell, or somatic cell of an animal, preferably an avian, more preferably a chicken.

The heterologous nucleic acid to be integrated into, for example, the sperm nuclear DNA is converted to a linear double stranded DNA possessing single-stranded cohesive ends by contacting the heterologous DNA with a type II restriction enzyme that upon
10 scission, generates such ends. The nucleic acid to be cut can be a circular nucleic acid such as in a plasmid or a viral vector or a linear nucleic acid that possesses at least one recognition and cutting site outside of the genes or regulatory regions critical to the desired post-integration function of the nucleic acid, and no recognition and cutting sites within the critical regions.

15 Alternatively the heterologous DNA to be integrated into the sperm nuclear DNA can be prepared by chemically and/or enzymatically adding cohesive ends to a linear DNA (see, for example *Sambrook et al., Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (2001) incorporated herein by reference in its entirety). The added cohesive ends must be able to hybridize to the cohesive
20 ends characteristic of a nucleic acid cleaved by a type II restriction endonuclease. Alternatively the cohesive ends can be added by combining the methods based on type II restriction enzyme cutting and chemical and / or enzymatic addition.

According to the present invention, a heterologous nucleic acid encoding at least one polypeptide, and the appropriate restriction enzyme can be introduced into sperm cells
25 together or sequentially by way of, for example, electroporation, or lipofection. Preferably electroporation may be used, and most preferably lipofection is used. However, the present invention contemplates that any technique capable of transferring heterologous material into sperm could be used so long as the technique preserves enough of the sperm's motility and fertilization functions, such that the resultant sperm will be able to fertilize the appropriate
30 oocytes. It is understood that the heterologous nucleic acid may be integrated into the genome of a recipient cell such as a spermatogonial cell or a spermatogonial precursor cell for subsequent transfer to an embryo or the testicular material of the recipient male animal, preferably a chicken. It is further understood that the heterologous nucleic acid may not be integrated into the genome of the recipient cell.

35 The combination of REMI as described in the present application, plus a relatively benign method of transferring heterologous material into a cell may result in heterologous

nucleic acid being stably integrated into genomic DNA of a high fraction of the treated sperm, while not diminishing to any great extent, the viability of the sperm or their ability to fertilize oocytes. Examples of suitable methods for the introduction of the genetically modified sperm, spermatogonial cells or precursor spermatogonial cells into a recipient avian, preferably a chicken, are as described above.

5.1.8 BREEDING AND MAINTENANCE OF TRANSGENIC AVIANS

A union of male and female gametes from transgenic birds generated by the cytoplasmically microinjected embryos, thereby forming a transgenic zygote, is brought about by copulation of the male and female vertebrates of the same species, or by *in vitro* or *in vivo* artificial means. Suitable artificial means include, but are not limited to, artificial insemination, *in vitro* fertilization (IVF) and/or other artificial reproductive technologies, such as intracytoplasmic sperm injection (ICSI), subzonal insemination (SUZI), or partial zona dissection (PZD). Also others, such as cloning and embryo transfer, cloning and embryo splitting, and the like, can be employed.

The transgenic avian progeny can, in turn, be bred by natural mating, artificial insemination, or by *in vitro* fertilization (IVF) and/or other artificial reproductive technologies, such as intracytoplasmic sperm injection (ICSI) and chicken intracytoplasmic sperm injection (CHICSI™), subzonal insemination (SUZI), or partial zona dissection (PZD), to obtain further generations of transgenic progeny.

Using the methods of the invention for producing transgenic avians, particularly methods using vectors that are not derived from eukaryotic viruses, and, preferably, the methods of cytoplasmic micro-injection described herein, the level of mosaicism of the transgene (percentage of cells containing the transgene) in avians hatched from microinjected embryos (*i.e.*, the G_0 s) is greater than 5%, 10%, 25%, 50%, 75% or 90%, or is the equivalent of one copy per one genome, two genomes, five genomes, seven genomes or eight genomes, as determined by any number of techniques known in the art and described *infra*. In additional particular embodiments, the percentage of G_0 s that transmit the transgene to progeny (G_1 s) is greater than 5%, preferably, greater than 10%, 20%, 30%, 40%, and, most preferably, greater than 50%, 60%, 70%, 80%, 90%. In other embodiments, the transgene is detected in 10%, 20%, 30%, 40%, and most preferably, greater than 50%, 60%, 70%, 80%, 90% of chicks hatching from embryos into which nucleic acids have been introduced using methods of the invention.

35

5.2 VECTORS

A variety of vectors useful in carrying out the methods of the present invention are described herein. These vectors may be used for stable introduction of a selected heterologous polypeptide-coding sequence (and/or regulatory sequences) into the genome of an avian, in particular, to generate transgenic avians that produce exogenous proteins in specific tissues of an avian, and in the oviduct in particular, or in the serum of an avian. In still further embodiments, the vectors are used in methods to produce avian eggs containing exogenous protein.

In particular embodiments, preferably for use in the microinjection, sperm-mediated transgenesis, and nuclear transfer methods described herein, the vectors of the invention are not derived from eukaryotic viral vectors or retroviral vectors (except in certain embodiments for containing eukaryotic viral regulatory elements such as promoters, origins of replication, etc). In particular embodiments, the vector is not an REV, ALV or MuLV vector. In particular, useful vectors include, bacteriophages such as lambda derivatives, such as λ gt11, λ gt WES.tB, Charon 4, and plasmid vectors such as pBR322, pBR325, pACYC177, pACYC184, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKC101, SV40, PBLUESCRIPT® II SK +/- or KS +/- (see "Stratagene Cloning Systems" Catalog (1993) from STRATAGENE®, La Jolla, Calif., which is hereby incorporated by reference), pQE, pIH821, pGEX, pET series (see Studier, F.W. *et al.*, 1990, "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes" *Gene Expression Technology* 185, which is hereby incorporated by reference) and any derivatives thereof, cosmid vectors and, in preferred embodiments, artificial chromosomes, such as, but not limited to, YACs, BACs, BBPACs or PACs. Such artificial chromosomes are useful in that a large nucleic acid insert can be propagated and introduced into the avian cell.

In other particular embodiments, as detailed above in section 5.2, *infra*, the vectors of the invention are derived from eukaryotic viruses, preferably avian viruses, and can be replication competent or, preferably, replication deficient. In particular embodiments, the vectors are derived from REV, ALV or MuLV. Nucleic acid sequences or derivative or truncated variants thereof, may be introduced into viruses such as vaccinia virus. Methods for making a viral recombinant vector useful for expressing a protein under the control of the lysozyme promoter are analogous to the methods disclosed in U.S. Patent Nos. 4,603,112; 4,769,330; 5,174,993; 5,505,941; 5,338,683; 5,494,807; 4,722,848; Paoletti, E., 1996, *Proc. Natl. Acad. Sci.* 93: 11349-11353; Moss, 1996, *Proc. Natl. Acad. Sci.* 93: 11341-11348; Roizman, 1996, *Proc. Natl. Acad. Sci.* 93: 11307-11302; Frolov *et al.*, 1996, *Proc. Natl. Acad. Sci.* 93: 11371-11377; Grunhaus *et al.*, 1993, *Seminars in Virology* 3: 237-252 and U.S. Patent Nos. 5,591,639; 5,589,466; and 5,580,859 relating to DNA

expression vectors, *inter alia*; the contents of which are incorporated herein by reference in their entireties.

Recombinant viruses can also be generated by transfection of plasmids into cells infected with virus.

5 Preferably, vectors can replicate (*i.e.*, have a bacterial origin of replication) and be manipulated in bacteria (or yeast) and can then be introduced into avian cells. Preferably, the vector comprises a marker that is selectable and/or detectable in bacteria or yeast cells and, preferably, also in avian cells, such markers include, but are not limited to, Amp^r, tet^r, LacZ, etc. Preferably, such vectors can accommodate (*i.e.*, can be used to introduce into
10 cells and replicate) large pieces of DNA such as genomic sequences, for example, large pieces of DNA consisting of at least 25 kb, 50 kb, 75 kb, 100 kb, 150 kb, 200 kb or 250 kb, such as BACs, YACs, cosmids, etc.

The insertion of a DNA fragment into a vector can, for example, be accomplished by ligating the DNA fragment into a vector that has complementary cohesive termini.

15 However, if the complementary restriction sites used to fragment the DNA are not present in the vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative
20 method, the cleaved vector and the transgene may be modified by homopolymeric tailing.

The vector can be cloned using methods known in the art, *e.g.*, by the methods disclosed in Sambrook *et al.*, 2001, Molecular Cloning, A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, N.Y.; Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.,
25 both of which are hereby incorporated by reference in their entireties. Preferably, the vectors contain cloning sites, for example, restriction enzyme sites that are unique in the sequence of the vector and insertion of a sequence at that site would not disrupt an essential vector function, such as replication.

As discussed above, vectors used in certain methods of the invention preferably can
30 accommodate, and in certain embodiments comprise, large pieces of heterologous DNA such as genomic sequences, particularly avian genomic sequences. Such vectors can contain an entire genomic locus, or at least sufficient sequence to confer endogenous regulatory expression pattern, *e.g.*, high level of expression in the magnum characteristic of lysozyme, ovalbumin, ovomucoid, ovotransferrin, etc, and to insulate the expression of the
35 transgene sequences from the effect of regulatory sequences surrounding the site of integration of the transgene in the genome. Accordingly, as detailed below, in preferred

embodiments, the transgene is inserted in an entire genomic loci or significant portion thereof.

To manipulate large genomic sequences contained in, for example, a BAC, nucleotide sequences coding for the heterologous protein to be expressed and/or other regulatory elements may be inserted into the BAC by directed homologous recombination in bacteria, e.g., the methods of Heintz WO 98/59060; Heintz *et al.*, WO 01/05962; Yang *et al.*, 1997, *Nature Biotechnol.* 15: 859-865; Yang *et al.*, 1999, *Nature Genetics* 22: 327-35; which are incorporated herein by reference in their entireties.

Alternatively, the BAC can also be engineered or modified by "E-T cloning," as described by Muyrers *et al.* (1999, *Nucleic Acids Res.* 27(6): 1555-57, incorporated herein by reference in its entirety). Using these methods, specific DNA may be engineered into a BAC independently of the presence of suitable restriction sites. This method is based on homologous recombination mediated by the recE and recT proteins ("ET-cloning") (Zhang *et al.*, 1998, *Nat. Genet.* 20(2): 123-28; incorporated herein by reference in its entirety). Homologous recombination can be performed between a PCR fragment flanked by short homology arms and an endogenous intact recipient such as a BAC. Using this method, homologous recombination is not limited by the disposition of restriction endonuclease cleavage sites or the size of the target DNA. A BAC can be modified in its host strain using a plasmid, e.g., pBAD- $\alpha\beta\gamma$, in which recE and recT have been replaced by their respective functional counterparts of phage lambda (Muyrers *et al.*, 1999, *Nucleic Acids Res.* 27(6): 1555-57). Preferably, a BAC is modified by recombination with a PCR product containing homology arms ranging from 27-60 bp. In a specific embodiment, homology arms are 50 bp in length.

In another embodiment, a transgene is inserted into a yeast artificial chromosome (YAC) (Burke *et al.*, 1987, *Science* 236: 806-12; and Peterson *et al.*, 1997, *Trends Genet.* 13:61, both of which are incorporated by reference herein in their entireties).

In other embodiments, the transgene is inserted into another vector developed for the cloning of large segments of genomic DNA, such as a cosmid or bacteriophage P1 (Sternberg *et al.*, 1990, *Proc. Natl. Acad. Sci. USA* 87: 103-07). The approximate maximum insert size is 30-35 kb for cosmids and 100 kb for bacteriophage P1. In another embodiment, the transgene is inserted into a P-1 derived artificial chromosome (PAC) (Mejia *et al.*, 1997, *Genome Res* 7:179-186). The maximum insert size is 300 kb.

Vectors containing the appropriate heterologous sequences may be identified by any method well known in the art, for example, by sequencing, restriction mapping, hybridization, PCR amplification, etc.

The vectors of the invention comprise one or more nucleotide sequences encoding a heterologous protein desired to be expressed in the transgenic avian, as well as regulatory elements such as promoters, enhancers, MARs, IRES's and other translation control elements, transcriptional termination elements, polyadenylation sequences, etc, as discussed
5 *infra*. In particular embodiments, the vector of the invention contains at least two nucleotide sequences coding for heterologous proteins, for example, but not limited to, the heavy and light chains of an immunoglobulin.

In a preferred embodiment, the nucleotide sequence encoding the heterologous protein is inserted into all or a significant portion of a nucleic acid containing the genomic
10 sequence of an endogenous avian gene, preferably an avian gene that is expressed in the magnum, *e.g.*, lysozyme, ovalbumin, ovomucoid, conalbumin, ovotransferrin, etc. For example, the heterologous gene sequence may be inserted into or replace a portion of the 3' untranslated region (UTR) or 5' untranslated region (UTR) or an intron sequence of the endogenous gene genomic sequence. Preferably, the heterologous gene coding sequence
15 has its own IRES. For descriptions of IRESes, *see, e.g.*, Jackson *et al.*, 1990, *Trends Biochem Sci.* 15(12):477-83; Jang *et al.*, 1988, *J. Virol.* 62(8):2636-43; Jang *et al.*, 1990, *Enzyme* 44(1-4):292-309; and Martinez-Salas, 1999, *Curr. Opin. Biotechnol.* 10(5):458-64; Palmenberg *et al.*, United States Patent No. 4,937,190, which are incorporated by reference herein in their entireties. In another embodiment, the heterologous protein coding sequence
20 is inserted at the 3' end of the endogenous gene coding sequence. In another preferred embodiment, the heterologous gene coding sequences are inserted using 5' direct fusion wherein the heterologous gene coding sequences are inserted in-frame adjacent to the initial ATG sequence (or adjacent the nucleotide sequence encoding the first two, three, four, five, six, seven or eight amino acids) of the endogenous gene or replacing some or all of the
25 sequence of the endogenous gene coding sequence. In yet another specific embodiment, the heterologous gene coding sequence is inserted into a separate cistron in the 5' region of the endogenous gene genomic sequence and has an independent IRES sequence.

The present invention further relates to nucleic acid vectors (preferably, not derived from eukaryotic viruses, except, in certain embodiments, for eukaryotic viral promoters and/
30 or enhancers) and transgenes inserted therein that incorporate multiple polypeptide-encoding regions, wherein a first polypeptide-encoding region is operatively linked to a transcription promoter and a second polypeptide-encoding region is operatively linked to an IRES. For example, the vector may contain coding sequences for two different heterologous proteins (*e.g.*, the heavy and light chains of an immunoglobulin) or the coding
35 sequences for all or a significant part of the genomic sequence for the gene from which the promoter driving expression of the transgene is derived, and the heterologous protein

desired to be expressed (e.g., a construct containing the genomic coding sequences, including introns, of the avian lysozyme gene when the avian lysozyme promoter is used to drive expression of the transgene, an IRES, and the coding sequence for the heterologous protein desired to be expressed downstream (i.e., 3' on the RNA transcript of the IRES)).

- 5 Thus, in certain embodiments, the nucleic acid encoding the heterologous protein is introduced into the 5' untranslated or 3' untranslated regions of an endogenous gene, such as but not limited to, lysozyme, ovalbumin, ovotransferrin, and ovomucoid, with an IRES sequence directing translation of the heterologous sequence.

- Such nucleic acid constructs, when inserted into the genome of a bird and expressed
10 therein, will generate individual polypeptides that may be post-translationally modified, for example, glycosylated or, in certain embodiments, form complexes, such as heterodimers with each other in the white of the avian egg. Alternatively, the expressed polypeptides may be isolated from an avian egg and combined *in vitro*, or expressed in a non-reproductive tissue such as serum. In other embodiments, for example, but not limited to, when
15 expression of both heavy and light chains of an antibody is desired, two separate constructs, each containing a coding sequence for one of the heterologous proteins operably linked to a promoter (either the same or different promoters), are introduced by microinjection into cytoplasm of one or more embryonic cells and transgenic avians harboring both transgenes. In their genomes and expressing both heterologous proteins are identified. Alternatively,
20 two transgenic avians each containing one of the two heterologous proteins (e.g., one transgenic avian having a transgene encoding the light chain of an antibody and a second transgenic avian having a transgene encoding the heavy chain of the antibody) can be bred to obtain an avian containing both transgenes in its germline and expressing both transgene encoded proteins, preferably in eggs.

- 25 Recombinant expression vectors can be designed for the expression of the encoded proteins in eukaryotic cells. Useful vectors may comprise constitutive or inducible promoters to direct expression of either fusion or non-fusion proteins. With fusion vectors, a number of amino acids are usually added to the expressed target gene sequence such as, but not limited to, a protein sequence for thioredoxin, a polyhistidine, or any other amino
30 acid sequence that facilitates purification of the expressed protein. A proteolytic cleavage site may further be introduced at a site between the target recombinant protein and the fusion sequence. Additionally, a region of amino acids such as a polymeric histidine region may be introduced to allow binding of the fusion protein to metallic ions such as nickel bonded to a solid support, and thereby allow purification of the fusion protein. Once the
35 fusion protein has been purified, the cleavage site allows the target recombinant protein to be separated from the fusion sequence. Enzymes suitable for use in cleaving the proteolytic

cleavage site include, but are not limited to, Factor Xa and thrombin. Fusion expression vectors that may be useful in the present invention include pGex (AMRAD® Corp., Melbourne, Australia), pRIT5 (PHARMACIA®, Piscataway, NJ) and pMAL (NEW ENGLAND BIOLABS®, Beverly, MA), fusing glutathione S-transferase, protein A, or maltose E binding protein, respectively, to the target recombinant protein.

Once a promoter and a nucleic acid encoding a heterologous protein of the present invention have been cloned into a vector system, it is ready to be incorporated into a host cell. Such incorporation can be carried out by the various forms of transformation noted above, depending upon the vector/host cell system. It is contemplated that the incorporation of the DNA of the present invention into a recipient cell may be by any suitable method such as, but not limited to, viral transfer, electroporation, gene gun insertion, sperm-mediated transfer to an ovum, microinjection and the like. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, and the like. In particular, the present invention contemplates the use of recipient avian cells, such as chicken cells or quail cells.

Another aspect of the present invention, therefore, is a method of expressing a heterologous polypeptide in a eukaryotic cell by transfecting an avian cell with a recombinant DNA comprising an avian tissue-specific promoter operably linked to a nucleic acid insert encoding a polypeptide and, optionally, a polyadenylation signal sequence, and culturing the transfected cell in a medium suitable for expression of the heterologous polypeptide under the control of the avian lysozyme gene expression control region.

Yet another aspect of the present invention is a eukaryotic cell transformed with an expression vector according to the present invention and described above. In one embodiment of the present invention, the transformed cell is a chicken oviduct cell and the nucleic acid insert comprises the chicken lysozyme gene expression control region, a nucleic acid insert encoding a human interferon $\alpha 2b$ and codon optimized for expression in an avian cell, and an SV40 polyadenylation sequence.

In another embodiment, the transformed cell is a quail oviduct cell and the nucleic acid insert comprises the artificial avian promoter construct MDOT (SEQ ID NO.:11) operably linked to an interferon-encoding sequence, as described in Example 34 below.

In yet another embodiment of the present invention, a quail oviduct cell is transfected with the nucleic acid insert comprising the MDOT artificial promoter construct operably linked to an erythropoietin (EPO)-encoding nucleic acid, wherein the transfected quail produces heterologous erythropoietin.

35

5.2.1 PROMOTERS

The vectors of the invention contain promoters that function in avian cells, preferably, that are tissue-specific and, in preferred embodiments, direct expression in the magnum or serum or other tissue such that expressed proteins are deposited in eggs, more preferably, that are specific for expression in the magnum. Alternatively, the promoter directs expression of the protein in the serum of the transgenic avian. Introduction of the vectors of the invention, preferably, generate transgenics that express the heterologous protein in tubular gland cells where it is secreted into the oviduct lumen and deposited, e.g., into the white of an egg. In preferred embodiments, the promoter directs a level of expression of the heterologous protein in the egg white of eggs laid by G₀ and/or G₁ chicks and/or their progeny that is greater than 5 µg, 10 µg, 50 µg, 100 µg, 250 µg, 500 µg, or 750 µg, more preferably greater than 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 500 mg, 700 mg, 1 gram, 2 grams, 3 grams, 4 grams or 5 grams. Such levels of expression can be obtained using the promoters of the invention.

In preferred embodiments, the promoters of the invention are derived from genes that express proteins present in significant levels in the egg white and/or the serum. For example, the promoter comprises regions of an ovomucoid, ovalbumin, conalbumin, lysozyme or ovotransferrin promoter or any other promoter that directs expression of a gene in an avian, particularly in a specific tissue of interest, such as the magnum or in the serum. Alternatively, the promoter used in the expression vector may be derived from that of the lysozyme gene that is expressed in both the oviduct and macrophages. Portions of two or more of these, and other promoters that function in avians, may be combined to produce effective synthetic promoter.

The promoter may optionally be a segment of the *ovalbumin* promoter region that is sufficiently large to direct expression of the coding sequence in the tubular gland cells. Other exemplary promoters include the promoter regions of the *ovalbumin*, *lysozyme*, *ovomucoid*, *ovotransferrin* or *ovomucin* genes (for example, but not limited to, as disclosed in co-pending United States Patent Application Nos. 09/922,549, filed August 3, 2001 and 10/114,739, filed April 1, 2002, both entitled "Avian Lysozyme Promoter", by Rapp, and United States Patent Application No. 09/998,716, filed November 30, 2001, entitled "Ovomucoid Promoter and Methods of Use," by Harvey *et al.*, all of which are incorporated by reference herein in their entireties). Alternatively, the promoter may be a promoter that is largely, but not entirely, specific to the magnum, such as the *lysozyme* promoter. Other suitable promoters may be artificial constructs such as a combination of nucleic acid regions derived from at least two avian gene promoters. One such embodiment of the present invention is the MDOT construct (SEQ ID NO: 11) comprising regions derived from the

chicken ovomucin and ovotransferrin promoters, including but not limited to promoters altered, *e.g.*, to increase expression, and inducible promoters, *e.g.*, the *tet*^r system.

The *ovalbumin* gene encodes a 45 kD protein that is also specifically expressed in the tubular gland cells of the magnum of the oviduct (Beato, 1989, *Cell* 56:335-344).

- 5 Ovalbumin is the most abundant egg white protein, comprising over 50 percent of the total protein produced by the tubular gland cells, or about 4 grams of protein per large Grade A egg (Gilbert, "Egg albumen and its formation" in *Physiology and Biochemistry of the Domestic Fowl*, Bell and Freeman, eds., Academic Press, London, New York, pp. 1291-1329). The *ovalbumin* gene and over 20 kb of each flanking region have been cloned and
10 analyzed (Lai *et al.*, 1978, *Proc. Natl. Acad. Sci. USA* 75:2205-2209; Gannon *et al.*, 1979, *Nature* 278:428-424; Roop *et al.*, 1980, *Cell* 19:63-68; and Royal *et al.*, 1975, *Nature* 279:125-132).

- The *ovalbumin* gene responds to steroid hormones such as estrogen, glucocorticoids, and progesterone, which induce the accumulation of about 70,000 *ovalbumin* mRNA
15 transcripts per tubular gland cell in immature chicks and 100,000 *ovalbumin* mRNA transcripts per tubular gland cell in the mature laying hen (Palmiter, 1973, *J. Biol. Chem.* 248:8260-8270; Palmiter, 1975, *Cell* 4:189-197). The 5' flanking region contains four DNase I-hypersensitive sites centered at -0.25, -0.8, -3.2, and -6.0 kb from the transcription start site. These sites are called HS-I, II, -III, and -IV, respectively. Promoters of the
20 invention may contain one, all, or a combination of HS-I, HS-II, HS-III and HS-IV. Hypersensitivity of HS-II and -III are estrogen-induced, supporting a role for these regions in hormone-induction of *ovalbumin* gene expression.

- HS-I and HS-II are both required for steroid induction of *ovalbumin* gene transcription, and a 1.4 kb portion of the 5' region that includes these elements is sufficient
25 to drive steroid-dependent *ovalbumin* expression in explanted tubular gland cells (Sanders and McKnight, 1988, *Biochemistry* 27: 6550-6557). HS-I is termed the negative-response element ("NRE") because it contains several negative regulatory elements which repress *ovalbumin* expression in the absence of hormone (Haekers *et al.*, 1995, *Mol. Endo.* 9:1113-1126). Protein factors bind these elements, including some factors only found in oviduct
30 nuclei suggesting a role in tissue-specific expression. HS-II is termed the steroid-dependent response element ("SDRE") because it is required to promote steroid induction of transcription. It binds a protein or protein complex known as Chirp-I. Chirp-I is induced by estrogen and turns over rapidly in the presence of cyclohexamide (Dean *et al.*, 1996, *Mol. Cell. Biol.* 16:2015-2024). Experiments using an explanted tubular gland cell culture
35 system defined an additional set of factors that bind SDRE in a steroid-dependent manner,

including a NF κ B-like factor (Nordstrom *et al.*, 1993, *J. Biol. Chem.* 268:13193-13202; Schweers and Sanders, 1991, *J. Biol. Chem.* 266: 10490-10497).

Less is known about the function of HS-III and HS-IV. HS-III contains a functional estrogen response element, and confers estrogen inducibility to either the *ovalbumin* proximal promoter or a heterologous promoter when co-transfected into HeLa cells with an estrogen receptor cDNA. These data imply that HS-III may play a functional role in the overall regulation of the *ovalbumin* gene. Little is known about the function of HS-IV, except that it does not contain a functional estrogen-response element (Kato *et al.*, 1992, *Cell* 68: 731-742).

In an alternative embodiment of the invention, transgenes containing constitutive promoters are used, but the transgenes are engineered so that expression of the transgene effectively becomes magnum-specific. Thus, a method for producing an exogenous protein in an avian oviduct provided by the present invention involves generating a transgenic avian having two transgenes in its tubular gland cells. One transgene comprises a first coding sequence operably linked to a constitutive promoter. The second transgene comprises a second coding sequence that is operably linked to a magnum-specific promoter, where expression of the first coding sequence is either directly or indirectly dependent upon the cellular presence of the protein expressed by the second coding sequence.

Additional promoters useful in the present invention include inducible promoters, such as the tet operator and the metallothionein promoter which can be induced by treatment with tetracycline and zinc ions, respectively (Gossen *et al.*, 1992, *Proc. Natl. Acad. Sci.* 89: 5547-5551 and Walden *et al.*, 1987, *Gene* 61: 317-327; incorporated herein by reference in their entireties).

Chicken lysozyme gene expression control region nucleic acid sequences:

The chicken lysozyme gene is highly expressed in the myeloid lineage of hematopoietic cells, and in the tubular glands of the mature hen oviduct (Hauser *et al.*, 1981, *Hematol. and Blood Transfusion* 26: 175-178; Schutz *et al.*, 1978, Cold Spring Harbor Symp. Quart. Biol. 42: 617-624) and is therefore a suitable candidate for an efficient promoter for heterologous protein production in transgenic animals. The regulatory region of the lysozyme locus extends over at least 12 kb of DNA 5' upstream of the transcription start site, and comprises a number of elements that have been individually isolated and characterized. The known elements include three enhancer sequences at about -6.1 kb, -3.9 kb, and -2.7 kb (Grewal *et al.*, 1992, *Mol. Cell Biol.* 12: 2339-2350; Bonifer *et al.*, 1996, *J. Mol. Med.* 74: 663-671), a hormone responsive element (Hecht *et al.*, 1988, *E.M.B.O.J.* 7: 2063-2073), a silencer element and a complex proximal promoter. The constituent

elements of the lysozyme gene expression control region are identifiable as DNAase 1 hypersensitive chromatin sites (DHS). They may be differentially exposed to nuclease digestion depending upon the differentiation stage of the cell. For example, in the multipotent progenitor stage of myelomonocytic cell development, or in erythroblasts, the silencer element is a DHS. At the myeloblast stage, a transcription enhancer located -6.1 kb upstream from the gene transcription start site is a DHS, while at the later monocytic stage another enhancer, at -2.7 kb becomes DNAase sensitive (Huber *et al.*, 1995, *DNA and Cell Biol.* 14: 397-402).

This invention also envisions the use of promoters other than the lysozyme promoter, including but not limited to, a cytomegalovirus promoter, an ovomucoid, conalbumin or ovotransferrin promoter or any other promoter that directs expression of a gene in an avian, particularly in a specific tissue of interest, such as the magnum.

Another aspect of the methods of the present invention is the use of combinational promoters comprising an artificial nucleic acid construct having at least two regions wherein the regions are derived from at least two gene promoters, including but not limited to a lysozyme, ovomucoid, conalbumin or ovotransferrin promoter. In one embodiment of the present invention, the promoter may comprise a region of an avian ovomucoid promoter and a region of an avian oxotransferrin promoter, thereby generating the MDOT avian artificial promoter construct as described in Example 12, below. The avian MDOT promoter construct of the present invention has the nucleic acid sequence SEQ ID NO: 11 and is illustrated in FIG. 14. This promoter is useful for allowing expression of a heterologous protein in chicken oviduct cells and may be operably linked to any nucleic acid encoding a heterologous polypeptide of interest including, for example, a cytokine, growth hormone, growth factor, enzyme, structural protein or the like.

25

5.2.2 MATRIX ATTACHMENT REGIONS

In preferred embodiments of the invention, the vectors contain matrix attachment regions (MARs) that preferably flank the transgene sequences to reduce position effects on expression when integrated into the avian genome. In fact, 5' MARs and 3' MARs (also referred to as "scaffold attachment regions" or SARs) have been identified in the outer boundaries of the chicken lysozyme locus (Phi-Van *et al.*, 1988, *E.M.B.O.J.* 7: 655-664; Phi-Van, L. and Stratling, W.H., 1996, *Biochem.* 35: 10735-10742). Deletion of a 1.32 kb or a 1.45 kb halves region, each comprising half of a 5' MAR, reduces positional variation in the level of transgene expression (Phi-Van and Stratling, *supra*).

The 5' matrix-associated region (5' MAR), located about -11.7 kb upstream of the chicken lysozyme transcription start site, can increase the level of gene expression by

limiting the positional effects exerted against a transgene (Phi-Van *et al.*, 1988, *supra*). At least one other MAR is located 3' downstream of the protein encoding region. Although MAR nucleic acid sequences are conserved, little cross-hybridization is seen, indicating significant overall sequence variation. However, MARs of different species can interact with the nucleomatrixes of heterologous species, to the extent that the chicken lysozyme MAR can associate with the plant tobacco nucleomatrix as well as that of the chicken oviduct cells (Mlynarona *et al.*, 1994, *Cell* 6: 417-426; von Kries *et al.*, 1990, *Nucleic Acids Res.* 18: 3881-3885).

Gene expression must be considered not only from the perspective of cis-regulatory elements associated with a gene, and their interactions with trans-acting elements, but also with regard to the genetic environment in which they are located. Chromosomal positioning effects (CPEs), therefore, are the variations in levels of transgene expression associated with different locations of the transgene within the recipient genome. An important factor governing CPE upon the level of transgene expression is the chromatin structure around a transgene, and how it cooperates with the cis-regulatory elements. The cis-elements of the lysozyme locus are confined within a single chromatin domain (Bonifer *et al.*, 1996, *supra*; Sippel *et al.*, pgs. 133-147 in Eckstein F. & Lilley D.M.J. (eds), "Nucleic Acids and Molecular Biology", Vol. 3, 1989, Springer).

The lysozyme promoter region of chicken is active when transfected into mouse fibroblast cells and linked to a reporter gene such as the bacterial chloramphenicol acetyltransferase (CAT) gene. The promoter element is also effective when transiently transfected into chicken promacrophage cells. In each case, however, the presence of a 5' MAR element increased positional independency of the level of transcription (Stief *et al.*, 1989, *Nature* 341: 343-345; Sippel *et al.*, pgs. 257 - 265 in Houdebine L.M. (ed), "Transgenic Animals: Generation and Use").

The ability to direct the insertion of a transgene into a site in the genome of an animal where the positional effect is limited offers predictability of results during the development of a desired transgenic animal, and increased yields of the expressed product. Sippel and Steif disclose, in U.S. Patent No. 5,731,178, which is incorporated by reference herein in its entirety, methods to increase the expression of genes introduced into eukaryotic cells by flanking a transcription unit with scaffold attachment elements, in particular the 5' MAR isolated from the chicken lysozyme gene. The transcription unit disclosed by Sippel and Steif was an artificial construct that combined only the -6.1 kb enhancer element and the proximal promoter element (base position -579 to +15) from the lysozyme gene. Other promoter associated elements were not included. However, although individual cis-regulatory elements have been isolated and sequenced, together with short regions flanking

DNA, the entire nucleic acid sequence comprising the functional 5' upstream region of the lysozyme gene has not been determined in its entirety and therefore not employed as a functional promoter to allow expression of a heterologous transgene.

Accordingly, vectors of the invention comprise MARs, preferably both 5' and 3' MARs that flank the transgene, including the heterologous protein coding sequences and the regulatory sequences.

5.2.3 NUCLEAR LOCALIZATION SIGNAL PEPTIDES

Targeting of the nucleic acids introduced into embryonic cells using methods of the invention may be enhanced by mixing the nucleic acid to be introduced with a nuclear localization signal (NLS) peptide prior to introduction, *e.g.*, microinjection, of the nucleic acid. Nuclear localization signal (NLS) sequences are a class of short amino acid sequences which may be exploited for cellular import of linked cargo into a nucleus. The present invention envisions the use of any NLS peptide, including but not limited to, the NLS peptide of SV40 virus T-antigen.

An NLS sequence of the invention is an amino acid sequence which mediates nuclear transport into the nucleus, wherein deletion of the NLS prevents nuclear transport. In particular embodiments, a NLS is a highly cationic peptide. The present invention envisions the use of any NLS sequence, including but not limited to, SV40 virus T-antigen. NLSs known in the art include, but are not limited to those discussed in Cokol *et al.*, 2000, *EMBO Reports*, 1(5):411-415, Boulikas, T., 1993, *Crit. Rev. Eukaryot. Gene Expr.*, 3:193-227, Collas, P. *et al.*, 1996, *Transgenic Research*, 5: 451-458, Collas and Alestrom, 1997, *Biochem. Cell Biol.* 75: 633-640, Collas and Alestrom, 1998, *Transgenic Research*, 7: 303-309, Collas and Alestrom, *Mol. Reprod. Devel.*, 1996, 45:431-438, all of which are incorporated by reference in their entireties.

5.2.4 CODON-OPTIMIZED GENE EXPRESSION

Another aspect of the present invention provides nucleic acid sequences encoding heterologous polypeptides that are codon-optimized for expression in avian cells, and derivatives and fragments thereof. When a heterologous nucleic acid is to be delivered to a recipient cell for expression therein, the sequence of the nucleic acid sequence may be modified so that the codons are optimized for the codon usage of the recipient species. For example, if the heterologous nucleic acid is transfected into a recipient chicken cell, the sequence of the expressed nucleic acid insert is optimized for chicken codon usage. This may be determined from the codon usage of at least one, and preferably more than one, protein expressed in a chicken cell. For example, the codon usage may be determined from

the nucleic acid sequences encoding the proteins ovalbumin, lysozyme, ovomucin and ovotransferrin of chicken. Briefly, the DNA sequence for the target protein may be optimized using the BACKTRANSLATE® program of the Wisconsin Package, version 9.1 (Genetics Computer Group, Inc., Madison, WI) with a codon usage table compiled from the chicken (*Gallus gallus*) ovalbumin, lysozyme, ovomucoid, and ovotransferrin proteins. The template and primer oligonucleotides are then amplified, by any means known in the art, including but not limited to PCR with *Pfu* polymerase (STRATAGENE®, La Jolla CA).

In one exemplary embodiment of a heterologous nucleic acid for use by the methods of the present invention, a nucleic acid insert encoding the human interferon $\alpha 2b$ polypeptide optimized for codon-usage by the chicken is microinjected into the cytoplasm of a stage 1 embryo. Optimization of the sequence for codon usage is useful in elevating the level of translation in avian eggs.

It is contemplated to be within the scope of the present invention for any nucleic acid encoding a polypeptide to be optimized for expression in avian cells. It is further contemplated that the codon usage may be optimized for a particular avian species used as a source of the host cells. In one embodiment of the present invention, the heterologous polypeptide is encoded using the codon-usage of a chicken.

5.2.5 SPECIFIC VECTORS OF THE INVENTION

In a preferred embodiment, a transgene of the invention comprises a chicken, or other avian, lysozyme control region sequence which directs expression of the coding sequence within the transgene. A series of PCR amplifications of template chicken genomic DNA are used to isolate the gene expression control region of the chicken lysozyme locus. Two amplification reactions used the PCR primer sets 5pLMAR2 (5'-TGCCGCCTTCTTTGATATTC-3') (SEQ ID NO: 1) and LE-6.1kbrev1 (5'-TTGGTGGTAAGGCCTTTTGTG-3') (SEQ ID NO: 2) (Set 1) and lys-6.1 (5'-CTGGCAAGCTGTCAAAAACA-3') (SEQ ID NO: 3) and LysE1Rev (5'-CAGCTCACATCGTCCAAAGA-3') (SEQ ID NO: 4) (Set 2). The amplified PCR products were united as a contiguous isolated nucleic acid by a third PCR amplification step with the primers SEQ ID NOS: 1 and 4, as described in Example 9 below.

The isolated PCR-amplified product, comprising about 12 kb of the nucleic acid region 5' upstream of the native chicken lysozyme gene locus, was cloned into the plasmid pCMV-LysSPIFNMM. pCMV-LysSPIFNMM comprises a modified nucleic acid insert encoding a human interferon $\alpha 2b$ sequence and an SV40 polyadenylation signal sequence (SEQ ID NO: 8) 3' downstream of the interferon encoding nucleic acid. The sequence SEQ ID NO: 5 of the nucleic acid insert encoding human interferon $\alpha 2b$ was in accordance with

avian cell codon usage, as determined from the nucleotide sequences encoding chicken ovomucin, ovalbumin, ovotransferrin and lysozyme.

The nucleic acid sequence (SEQ ID NO: 6) (GenBank Accession No. AF405538) of the insert in pAVIJCR-A115.93.1.2 is shown in FIG. 1A-E. The modified human interferon $\alpha 2b$ encoding nucleotide sequence SEQ ID NO: 5 (GenBank Accession No. AF405539) and the novel chicken lysozyme gene expression control region SEQ ID NO: 7 (GenBank Accession No. AF405540), shown in FIGS. 2 and 3A-E respectively. A polyadenylation signal sequence that is suitable for operably linking to the polypeptide-encoding nucleic acid insert is the SV40 signal sequence SEQ ID NO: 8, as shown in FIG. 4.

The plasmid pAVIJCR-A115.93.1.2 was restriction digested with enzyme *FseI* to isolate a 15.4 kb DNA containing the lysozyme 5' matrix attachment region (MAR) and the -12.0 kb lysozyme promoter during the expression of the interferon-encoding insert, as described in Example 10, below. Plasmid pIIIlys was restriction digested with *MluI* and *XhoI* to isolate an approximately 6 kb nucleic acids, comprising the 3' lysozyme domain, the sequence of which (SEQ ID NO: 9) is shown in FIG. 5A-C. The 15.4 kb and 6 kb nucleic acids were ligated and the 21.4 kb nucleic acid comprising the nucleic acid sequence SEQ ID NO: 10 as shown in FIG. 6A-J was transformed into recipient STBL4 cells as described in Example 10, below.

The inclusion of the novel isolated avian lysozyme gene expression control region of the present invention upstream of a codon-optimized interferon-encoding sequence in pAVIJCR-A115.93.1.2 allowed expression of the interferon polypeptide in avian cells transfected by cytoplasmic microinjection, as described in Examples 3 and 4, below. The 3' lysozyme domain SEQ ID NO: 9, when operably linked downstream of a heterologous nucleic acid insert, also allows expression of the nucleic acid insert as described in Example 11, below. For example, the nucleic acid insert may encode a heterologous polypeptide such as the $\alpha 2b$ interferon encoded by the sequence SEQ ID NO: 5.

It is further contemplated that any nucleic acid sequence encoding a polypeptide may be operably linked to the novel isolated avian lysozyme gene expression control region (SEQ ID NO: 7) and optionally operably linked to the 3' lysozyme domain SEQ ID NO. 9 so as to be expressed in a transfected avian cell. The plasmid construct pAVIJCR-A115.93.1.2 when transfected into cultured quail oviduct cells, which were then incubated for about 72 hours. ELISA assays of the cultured media showed that the transfected cells synthesized a polypeptide detectable with anti-human interferon $\alpha 2b$ antibodies. Plasmid construct pAVIJCR-A212.89.2.1 and pAVIJCR-A212.89.2.3 transfected into chicken myelomonocytic HD11 cells yield detectable human $\alpha 2b$ interferon, as described in Example 3 and 4 below, and shown in FIGS. 8-12.

The isolated chicken lysozyme gene expression control region (SEQ ID NO: 7) for use in the methods of the present invention comprises the nucleotide elements that are positioned 5' upstream of the lysozyme-encoding region of the native chicken lysozyme locus and which are necessary for the regulated expression of a downstream polypeptide-
5 encoding nucleic acid. While not wishing to be bound by any one theory, the inclusion of at least one 5' MAR sequence of or reference element in the isolated control region may confer positional independence to a transfected gene operably linked to the novel lysozyme gene expression control region.

The isolated lysozyme gene expression control region (SEQ ID NO: 7) of the present
10 invention is useful for reducing the chromosomal positional effect of a transgene operably linked to the lysozyme gene expression control region and transfected into a recipient avian cell. By isolating a region of the avian genome extending from a point 5' upstream of a 5' MAR of the lysozyme locus to the junction between the signal peptide sequence and a polypeptide-encoding region, cis-regulatory elements are also included that may allow gene
15 expression in a tissue-specific manner. The lysozyme promoter region of the present invention, therefore, will allow expression of an operably linked heterologous nucleic acid insert in a transfected avian cell such as, for example, an oviduct cell.

It is further contemplated that a recombinant DNA of the present invention may further comprise the chicken lysozyme 3' domain (SEQ. ID NO: 9) linked downstream of
20 the nucleic acid insert encoding a heterologous polypeptide. The lysozyme 3' domain (SEQ ID NO: 9) includes a nucleic acid sequence encoding a 3' MAR domain that may cooperate with a 5' MAR to direct the insertion of the construct of the present invention into the chromosome of a transgenic avian, or may act independently of the 5' MAR.

Fragments of a nucleic acid encoding a portion of the subject lysozyme gene
25 expression control region may also be useful as an autonomous gene regulatory element that may itself be operably linked to a polypeptide-encoding nucleic acid. Alternatively, the fragment may be combined with fragments derived from other gene promoters, such as an avian ovalbumin or ovomucoid promoter, thereby generating novel promoters having new properties or a combination of properties. As used herein, a fragment of the nucleic acid
30 encoding an active portion of a lysozyme gene expression control region refers to a nucleotide sequence having fewer nucleotides than the nucleotide sequence encoding the entire nucleic acid sequence of the lysozyme gene expression control region, but at least 200 nucleotides.

The present invention also contemplates the use of antisense nucleic acid molecules
35 that are designed to be complementary to a coding strand of a nucleic acid (*i.e.*, complementary to an endogenous DNA or an mRNA sequence) or, alternatively,

complimentary to a 5' or 3' untranslated region of the mRNA and therefore useful for regulating the expression of a gene by the lysozyme promoter.

Synthesized oligonucleotides can be produced in variable lengths when for example, non-naturally occurring polypeptide sequences are desired. The number of bases synthesized will depend upon a variety of factors, including the desired use for the probes or primers. Additionally, sense or anti-sense nucleic acids or oligonucleotides can be chemically synthesized using modified nucleotides to increase the biological stability of the molecule or of the binding complex formed between the anti-sense and sense nucleic acids. For example, acridine substituted nucleotides can be synthesized. Protocols for designing isolated nucleotides, nucleotide probes, and/or nucleotide primers are well-known to those of ordinary skill, and can be purchased commercially from a variety of sources (e.g., SIGMA GENOSYS®, The Woodlands, TX or The Great American Gene Co., Ramona, CA).

5.2.6 RECOMBINANT EXPRESSION VECTORS

A useful application of the novel promoters of the present invention, such as the avian lysozyme gene expression control region (SEQ ID NO: 7) or the MDOT promoter construct (SEQ ID NO: 11, Example 12, below) is the possibility of increasing the amount of a heterologous protein present in a bird, especially a chicken, by gene transfer. In most instances, a heterologous polypeptide-encoding nucleic acid insert transferred into the recipient animal host will be operably linked with a gene expression control region to allow the cell to initiate and continue production of the genetic product protein. A recombinant DNA molecule of the present invention can be transferred into the extra-chromosomal or genomic DNA of the host.

Expression of a foreign gene in an avian cell permits partial or complete post-translational modification such as, but not only, glycosylation, as shown, for example, in FIGS. 10-12, and/or the formation of the relevant inter- or intra-chain disulfide bonds. Examples of vectors useful for expression in the chicken *Gallus gallus* include pYepSec1 (Baldari *et al.*, 1987, *E.M.B.O.J.*, 6: 229-234; incorporated herein by reference in its entirety) and pYES2 (INVITROGEN® Corp., San Diego, CA).

The present invention contemplates that the injected cell may transiently contain the injected DNA, whereby the recombinant DNA or expression vector may not be integrated into the genomic nucleic acid. It is further contemplated that the injected recombinant DNA or expression vector may be stably integrated into the genomic DNA of the recipient cell, thereby replicating with the cell so that each daughter cell receives a copy of the injected

nucleic acid. It is still further contemplated for the scope of the present invention to include a transgenic animal producing a heterologous protein expressed from an injected nucleic acid according to the present invention.

Heterologous nucleic acid molecules can be delivered to cells using the cytoplasmic microinjection method or any other method of the present invention. The nucleic acid molecule may be inserted into a cell to which the nucleic acid molecule (or promoter coding region) is heterologous (*i.e.*, not normally present). Alternatively, the recombinant DNA molecule may be introduced into cells which normally contain the recombinant DNA molecule or the particular coding region, as, for example, to correct a deficiency in the expression of a polypeptide, or where over-expression of the polypeptide is desired.

Another aspect of the present invention, therefore, is a method of expressing a heterologous polypeptide in an avian cell by transfecting the avian cell with a selected heterologous nucleic acid comprising an avian promoter operably linked to a nucleic acid insert encoding a polypeptide and, optionally, a polyadenylation signal sequence. The transfected cell, which may be an avian embryonic cell microinjected with a heterologous nucleic acid, will generate a transgenic embryo that after introduction into a recipient hen will be laid as a hard-shell egg and develop into a transgenic chick.

In another embodiment of the present invention, the nucleic acid insert comprises the chicken lysozyme gene expression control region, a nucleic acid insert encoding a human interferon $\alpha 2b$ and codon optimized for expression in an avian cell, and a chicken 3' domain, *i.e.*, downstream enhancer elements.

In one embodiment of the present invention, the transgenic animal is an avian selected from a turkey, duck, goose, quail, pheasant, ratite, and ornamental bird or a feral bird. In another embodiment, the avian is a chicken and the heterologous polypeptide produced under the transcriptional control of the avian promoter is produced in the white of an egg. In yet another embodiment of the present invention, the heterologous polypeptide is produced in the serum of a bird.

5.3 HETEROLOGOUS PROTEINS PRODUCED BY TRANSGENIC AVIANS

Methods of the present invention, providing for the production of heterologous protein in the avian oviduct (or other tissue leading to deposition of the protein into the egg) and the production of eggs containing heterologous protein, involve providing a suitable vector coding for the heterologous protein and introducing the vector into embryonic cells such as a single cell embryo such that the vector is integrated into the avian genome. A subsequent step involves deriving a mature transgenic avian from the transgenic embryonic

cells produced in the previous steps by transferring the injected cell or cells into the infundibulum of a recipient hen; producing a hard shell egg from that hen; and allowing the egg to develop and hatch to produce a transgenic bird.

A transgenic avian so produced from transgenic embryonic cells is known as a founder. Such founders may be mosaic for the transgene (in certain embodiments, the founder has 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100% of the cells containing the transgene. The invention further provides production of heterologous proteins in other tissues of the transgenic avians. Some founders will carry the transgene in the tubular gland cells in the magnum of their oviducts. These birds will express the exogenous protein encoded by the transgene in their oviducts. If the exogenous protein contains the appropriate signal sequences, it will be secreted into the lumen of the oviduct and into the white of an egg.

Some founders are germ-line founders. A germ-line founder is a founder that carries the transgene in genetic material of its germ-line tissue, and may also carry the transgene in oviduct magnum tubular gland cells that express the exogenous protein. Therefore, in accordance with the invention, the transgenic bird may have tubular gland cells expressing the exogenous protein and the offspring of the transgenic bird will also have oviduct magnum tubular gland cells that express the exogenous protein. Alternatively, the offspring express a phenotype determined by expression of the exogenous gene in a specific tissue of the avian. In preferred embodiments, the heterologous proteins are produced from transgenic avians that were not (or the founder ancestors were not) using a eukaryotic viral vector, or a retroviral vector.

The present invention can be used to express, in large yields and at low cost, a wide range of desired proteins including those used as human and animal pharmaceuticals, diagnostics, and livestock feed additives. Proteins such as growth hormones, cytokines, structural proteins and enzymes, including human growth hormone, interferon, lysozyme, and β -casein, are examples of proteins that are desirably expressed in the oviduct and deposited in eggs according to the invention. Other possible proteins to be produced include, but are not limited to, albumin, α -1 antitrypsin, antithrombin III, collagen, factors VIII, IX, X (and the like), fibrinogen, hyaluronic acid, insulin, lactoferrin, protein C, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), tissue-type plasminogen activator (tPA), feed additive enzymes, somatotropin, and chymotrypsin. Immunoglobulins and genetically engineered antibodies, including immunotoxins that bind to surface antigens on human tumor cells and destroy them, can also be expressed for use as pharmaceuticals or diagnostics. It is contemplated that immunoglobulin polypeptides expressed in avian cells

following transfection by the methods of the present invention may include monomeric heavy and light chains, single-chain antibodies or multimeric immunoglobulins comprising variable heavy and light chain regions, *i.e.*, antigen-binding domains, or intact heavy and light immunoglobulin chains.

5

5.3.1 PROTEIN RECOVERY

The protein of the present invention may be produced in purified form by any known conventional technique. For example, chicken cells may be homogenized and centrifuged. The supernatant can then be subjected to sequential ammonium sulfate precipitation and
10 heat treatment. The fraction containing the protein of the present invention is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the proteins. If necessary, the protein fraction may be further purified by HPLC. In another embodiment, an affinity column is used, wherein the protein is expressed with a tag.

Accordingly, the invention provides proteins that are produced by transgenic avians
15 of the invention. In a preferred embodiment, the protein is produced and isolated from an avian egg. In another embodiment, the protein is produced and isolated from avian serum.

5.3.2 MULTIMERIC PROTEINS

The invention, in preferred embodiments, provides methods for producing
20 multimeric proteins, preferably immunoglobulins, such as antibodies, and antigen binding fragments thereof.

In one embodiment of the present invention, the multimeric protein is an immunoglobulin, wherein the first and second heterologous polypeptides are an immunoglobulin heavy and light chains respectively. Illustrative examples of this and other
25 aspects and embodiments of the present invention for the production of heterologous multimeric polypeptides in avian cells are fully disclosed in U.S. Patent Application No. 09/877,374, filed June 8, 2001, by Rapp, which is incorporated herein by reference in its entirety. In one embodiment of the present invention, therefore, the multimeric protein is an immunoglobulin wherein the first and second heterologous polypeptides are an
30 immunoglobulin heavy and light chain respectively. Accordingly, the invention provides immunoglobulin and other multimeric proteins that have been produced by transgenic avians of the invention.

In the various embodiments of this aspect of the present invention, an immunoglobulin polypeptide encoded by the transcriptional unit of at least one expression
35 vector may be an immunoglobulin heavy chain polypeptide comprising a variable region or a variant thereof, and may further comprise a D region, a J region, a C region, or a

combination thereof. An immunoglobulin polypeptide encoded by the transcriptional unit of an expression vector may also be an immunoglobulin light chain polypeptide comprising a variable region or a variant thereof, and may further comprise a J region and a C region. It is also contemplated to be within the scope of the present invention for the immunoglobulin regions to be derived from the same animal species, or a mixture of species including, but not only, human, mouse, rat, rabbit and chicken. In preferred embodiments, the antibodies are human or humanized.

In other embodiments of the present invention, the immunoglobulin polypeptide encoded by the transcriptional unit of at least one expression vector comprises an immunoglobulin heavy chain variable region, an immunoglobulin light chain variable region, and a linker peptide thereby forming a single-chain antibody capable of selectively binding an antigen.

Another aspect of the present invention provides a method for the production in an avian of an heterologous protein capable of forming an antibody suitable for selectively binding an antigen comprising the step of producing a transgenic avian incorporating at least one transgene, wherein the transgene encodes at least one heterologous polypeptide selected from an immunoglobulin heavy chain variable region, an immunoglobulin heavy chain comprising a variable region and a constant region, an immunoglobulin light chain variable region, an immunoglobulin light chain comprising a variable region and a constant region, and a single-chain antibody comprising two peptide-linked immunoglobulin variable regions. Preferably, the antibody is expressed such that it is deposited in the white of the developing eggs of the avian. The hard shell avian eggs thus produced can be harvested and the heterologous polypeptide capable of forming or which formed an antibody can be isolated from the harvested egg. It is also understood that the heterologous polypeptides may also be expressed under the transcriptional control of promoters that allow for release of the polypeptides into the serum of the transgenic animal. Exemplary promoters for non-tissue specific production of a heterologous protein are the CMV promoter and the RSV promoter.

In one embodiment of this method of the present invention, the transgene comprises a transcription unit encoding a first and a second immunoglobulin polypeptide operatively linked to a transcription promoter, a transcription terminator and, optionally, an internal ribosome entry site (IRES)(*see*, for example, U.S. Patent No. 4,937,190 to Palmenberg *et al.*, the contents of which is incorporated herein by reference in its entirety).

In an embodiment of this method of the present invention, the isolated heterologous protein is an antibody capable of selectively binding to an antigen. In this embodiment, the antibody may be generated within the serum of an avian or within the white of the avian egg

by combining at least one immunoglobulin heavy chain variable region and at least one immunoglobulin light chain variable region, preferably cross-linked by at least one disulfide bridge. The combination of the two variable regions will generate a binding site capable of binding an antigen using methods for antibody reconstitution that are well known in the art.

It is, however, contemplated to be within the scope of the present invention for immunoglobulin heavy and light chains, or variants or derivatives thereof, to be expressed in separate transgenic avians, and therefore isolated from separate media including serum or eggs, each isolate comprising a single species of immunoglobulin polypeptide. The method may further comprise the step of combining a plurality of isolated heterologous immunoglobulin polypeptides, thereby producing an antibody capable of selectively binding to an antigen. In this embodiment, two individual transgenic avians may be generated wherein one transgenic produces serum or eggs having an immunoglobulin heavy chain variable region, or a polypeptide comprising such, expressed therein. A second transgenic animal, having a second transgene, produces serum or eggs having an immunoglobulin light chain variable region, or a polypeptide comprising such, expressed therein. The polypeptides may be isolated from their respective sera and eggs and combined *in vitro* to generate a binding site capable of binding an antigen.

Examples of therapeutic antibodies that can be used in methods of the invention include but are not limited to HERCEPTIN® (Trastuzumab) (Genentech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; REOPRO® (abciximab) (Centocor) which is an anti-glycoprotein IIb/IIIa receptor on the platelets for the prevention of clot formation; ZENAPAX® (daclizumab) (Roche Pharmaceuticals, Switzerland) which is an immunosuppressive, humanized anti-CD25 monoclonal antibody for the prevention of acute renal allograft rejection; PANOREX™ which is a murine anti-17-1A cell surface antigen IgG2a antibody (Glaxo Wellcome/Centocor); BEC2 which is a murine anti-idiotypic (GD3 epitope) IgG antibody (ImClone System); IMC-C225 which is a chimeric anti-EGFR IgG antibody (ImClone System); VITAXIN™ which is a humanized anti- α V β 3 integrin antibody (Applied Molecular Evolution/MedImmune); Campath 1H/LDP-03 which is a humanized anti CD52 IgG1 antibody (Leukosite); Smart M195 which is a humanized anti-CD33 IgG antibody (Protein Design Lab/Kanebo); RITUXAN™ which is a chimeric anti-CD20 IgG1 antibody (IDEC Pharm/Genentech, Roche/Zetkyaku); LYMPHOCIDE™ which is a humanized anti-CD22 IgG antibody (Immunomedics); ICM3 is a humanized anti-ICAM3 antibody (ICOS Pharm); IDEC-114 is a primatized anti-CD80 antibody (IDEC Pharm/Mitsubishi); ZEVALIN™ is a radiolabelled murine anti-CD20 antibody (IDEC/Schering AG); IDEC-

131 is a humanized anti-CD40L antibody (IDEC/Eisai); IDEC-151 is a primatized anti-CD4 antibody (IDEC); IDEC-152 is a primatized anti-CD23 antibody (IDEC/Seikagaku); SMART anti-CD3 is a humanized anti-CD3 IgG (Protein Design Lab); 5G1.1 is a humanized anti-complement factor 5 (C5) antibody (Alexion Pharm); D2E7 is a humanized anti-TNF- α antibody (CAT/BASF); CDP870 is a humanized anti-TNF- α Fab fragment (Celltech); IDEC-151 is a primatized anti-CD4 IgG1 antibody (IDEC Pharm/SmithKline Beecham); MDX-CD4 is a human anti-CD4 IgG antibody (Medarex/Eisai/Genmab); CDP571 is a humanized anti-TNF- α IgG4 antibody (Celltech); LDP-02 is a humanized anti- α 4 β 7 antibody (LeukoSite/Genentech); OrthoClone OKT4A is a humanized anti-CD4 IgG antibody (Ortho Biotech); ANTOVATM is a humanized anti-CD40L IgG antibody (Biogen); ANTEGRENTM is a humanized anti-VLA-4 IgG antibody (Elan); and CAT-152 is a human anti-TGF- β ₂ antibody (Cambridge Ab Tech).

5.4 PHARMACEUTICAL COMPOSITIONS

15 The present invention further provides pharmaceutical compositions, formulations, dosage units and methods of administration comprising the heterologous proteins produced by the transgenic avians using methods of the invention. Preferably, compositions of the invention comprise a prophylactically or therapeutically effective amount of a the heterologous protein, and a pharmaceutically acceptable carrier.

20 The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which a compound of the invention is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, 25 and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. When administered to a patient, the compounds of the invention and pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, 30 particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propyleneglycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

35 The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release

formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (see *e.g.*, U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.

5 In a preferred embodiment, the heterologous proteins are formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compounds of the invention for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the compositions may also include a solubilizing agent. Compositions for intravenous
10 administration may optionally include a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the heterologous protein of the invention is to be
15 administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition of the invention is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

Compositions for oral delivery may be in the form of tablets, lozenges, aqueous or
20 oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions may contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the
25 compositions may be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compounds of the invention. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which
30 swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose,
35 magnesium carbonate, *etc.* Such vehicles are preferably of pharmaceutical grade.

Further, the effect of the heterologous proteins may be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets.

- 5 Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.

10 5.5 TRANSGENIC AVIANS

Another aspect of the present invention concerns transgenic avians, preferably chicken or quail, produced by methods of the invention described in section 5.1 *infra*, preferably by microinjecting a nucleic acid comprising a transgene into an avian embryo by the cytoplasmic microinjection methods of the present invention. Following introduction of
15 the selected nucleic acid into an early stage avian embryo by the methods of the present invention, the embryo is transferred into the reproductive tract of a recipient hen. The embryo containing the transgene then develops inside the recipient hen and travels through the oviduct thereof, where it is encapsulated by natural egg white proteins and a natural egg shell. The egg is laid and can be incubated and hatched to produce a transgenic chick. The
20 resulting transgenic avian chick (*i.e.*, the G0) will carry one or more desired transgene(s) some or all of its cells, preferably in its germ line. These G0 transgenic avians can be bred using methods well known in the art to generate second generation (*i.e.*, G1s) transgenic avians that carry the transgene, *i.e.*, achieve germline transmission of the transgene. In preferred embodiments, the methods of the invention result in germline transmission, *i.e.*,
25 percentage of G0s that transmit the transgene to progeny (G1s), that is greater than 5%, preferably, greater than 10%, 20%, 30%, 40%, and, most preferably, greater than 50%, 60%, 70%, 80%, 90% or even 100%. In other embodiments, the efficiency of transgenesis (*i.e.*, number of G0s containing the transgene) is greater than 2%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 99%.

30 Following maturation, the transgenic avian and/or transgenic progeny thereof, may lay eggs containing one or more desired heterologous protein(s) expressed therein and that can be easily harvested therefrom. The G1 chicks, when sexually mature, can then be bred to produce progeny that are homozygous or heterozygous for the transgene.

A transgenic avian of the invention may contain at least one transgene, at least two
35 transgenes, at least 3 transgenes, at least 4 transgenes, at least 5 transgenes, and preferably, though optionally, may express the subject nucleic acid encoding a polypeptide in one or

more cells in the animal, such as the oviduct cells of the chicken. In embodiments of the present invention, the expression of the transgene may be restricted to specific subsets of cells, tissues, or developmental stages utilizing, for example, cis-acting sequences that control expression in the desired pattern. Toward this end, it is contemplated that tissue-specific regulatory sequences, or tissue-specific promoters, and conditional regulatory sequences may be used to control expression of the transgene in certain spatial patterns. Moreover, temporal patterns of expression can be provided by, for example, conditional recombination systems or prokaryotic transcriptional regulatory sequences. The inclusion of a 5' MAR region, and optionally the 3' MAR on either end of the sequence, in the expression cassettes suitable for use in the methods of the present invention may allow the heterologous expression unit to escape the chromosomal positional effect (CPE) and therefore be expressed at a more uniform level in transgenic tissues that received the transgene by a route other than through germ line cells.

The transgenes may, in certain embodiments, be expressed conditionally, *e.g.*, the heterologous protein coding sequence is under the control of an inducible promoter, such as a prokaryotic promoter or operator that requires a prokaryotic inducer protein to be activated. Operators present in prokaryotic cells have been extensively characterized *in vivo* and *in vitro* and can be readily manipulated to place them in any position upstream from or within a gene by standard techniques. Such operators comprise promoter regions and regions that specifically bind proteins such as activators and repressors. One example is the operator region of the *lexA* gene of *E. coli* to which the LexA polypeptide binds. Other exemplary prokaryotic regulatory sequences and the corresponding trans-activating prokaryotic proteins are disclosed by Brent and Ptashne in U.S. Patent No. 4,833,080 (the contents of which is herein incorporated by reference in its entirety). Transgenic animals can be created which harbor the subject transgene under transcriptional control of a prokaryotic sequence or other activator sequence that is not appreciably activated by avian proteins. Breeding of this transgenic animal with another animal that is transgenic for the corresponding trans-activator can be used to activate of the expression of the transgene. Moreover, expression of the conditional transgenes can also be induced by gene therapy-like methods wherein a gene encoding the trans-activating protein, *e.g.*, a recombinase or a prokaryotic protein, is delivered to the tissue and caused to be expressed, such as in a cell-type specific manner.

Transactivators in these inducible or repressible transcriptional regulation systems are designed to interact specifically with sequences engineered into the transgene. Such systems include those regulated by tetracycline ("tet systems"), interferon, estrogen, ecdysone, Lac operator, progesterone antagonist RU486, and rapamycin (FK506) with tet

systems being particularly preferred (see, e.g., Gingrich and Roder, 1998, *Annu. Rev. Neurosci.* 21: 377-405; incorporated herein by reference in its entirety). These drugs or hormones (or their analogs) act on modular transactivators composed of natural or mutant ligand-binding domains and intrinsic or extrinsic DNA binding and transcriptional activation domains. In certain embodiments, expression of the heterologous peptide can be regulated by varying the concentration of the drug or hormone in medium *in vitro* or in the diet of the transgenic animal *in vivo*.

In a preferred embodiment, the control elements of the tetracycline-resistance operon of *E. coli* is used as an inducible or repressible transactivator or transcriptional regulation system ("tet system") for conditional expression of the transgene. A tetracycline-controlled transactivator can require either the presence or absence of the antibiotic tetracycline, or one of its derivatives, e.g., doxycycline (dox), for binding to the tet operator of the tet system, and thus for the activation of the tet system promoter (Ptet).

In a specific embodiment, a tetracycline-repressed regulatable system (TrRS) is used (Agha-Mohammadi and Lotze, 2000, *J. Clin. Invest.* 105(9): 1177-83; Shockett *et al.*, 1995, *Proc. Natl. Acad. Sci. USA* 92: 6522-26 and Gossen and Bujard, 1992, *Proc. Natl. Acad. Sci. USA* 89: 5547-51; incorporated herein by reference in their entireties).

In another embodiment, a reverse tetracycline-controlled transactivator, e.g., rtTA2 S-M2, is used. rtTA2 S-M2 transactivator has reduced basal activity in the absence of doxycycline, increased stability in eukaryotic cells, and increased doxycycline sensitivity (Urlinger *et al.*, 2000, *Proc. Natl. Acad. Sci. USA* 97(14): 7963-68; incorporated herein by reference in its entirety). In another embodiment, the tet-repressible system described by Wells *et al.* (1999, *Transgenic Res.* 8(5): 371-81; incorporated herein by reference in its entirety) is used. In one aspect of the embodiment, a single plasmid Tet-repressible system is used. In another embodiment, the GAL4-UAS system (Ornitz *et al.*, 1991, *Proc. Natl. Acad. Sci. USA* 88:698-702; Rowitch *et al.*, 1999, *J. Neuroscience* 19(20):8954-8965; Wang *et al.*, 1999, *Proc. Natl. Acad. Sci. USA* 96:8483-8488; Lewandoski, 2001, *Nature Reviews (Genetics)* 2:743-755) or a GAL4-VP16 fusion protein system (Wang *et al.*, 1999, *Proc. Natl. Acad. Sci. USA* 96:8483-8488) is used.

In other embodiments, conditional expression of a transgene is regulated by using a recombinase system that is used to turn on or off the gene's expression by recombination in the appropriate region of the genome in which the potential drug target gene is inserted. The transgene is flanked by recombinase sites, e.g., FRT sites. Such a recombinase system can be used to turn on or off expression a transgene (for review of temporal genetic switches and "tissue scissors" using recombinases, see Hennighausen & Furth, 1999, *Nature Biotechnol.* 17: 1062-63). Exclusive recombination in a selected cell type may be mediated

by use of a site-specific recombinase such as Cre, FLP-wild type (wt), FLP-L or FLPe. Recombination may be effected by any art-known method, *e.g.*, the method of Doetschman *et al.* (1987, Nature 330: 576-78; incorporated herein by reference in its entirety); the method of Thomas *et al.*, (1986, Cell 44: 419-28; incorporated herein by reference in its entirety); the Cre-loxP recombination system (Sternberg and Hamilton, 1981, J. Mol. Biol. 150: 467-86; Lakso *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89: 6232-36; which are both incorporated herein by reference in their entireties); the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.*, 1991, Science 251: 1351-55); the Cre-loxP-tetracycline control switch (Gossen and Bujard, 1992, Proc. Natl. Acad. Sci. USA 89: 5547-51, incorporated herein by reference in its entirety); and ligand-regulated recombinase system (Kellendonk *et al.*, 1999, J. Mol. Biol. 285: 175-82; incorporated herein by reference in its entirety). Preferably, the recombinase is highly active, *e.g.*, the Cre-loxP or the FLPe system, and has enhanced thermostability (Rodríguez *et al.*, 2000, Nature Genetics 25: 139-40; incorporated herein by reference in its entirety).

In a specific embodiment, the ligand-regulated recombinase system of Kellendonk *et al.* (1999, J. Mol. Biol. 285: 175-82; incorporated herein by reference in its entirety) can be used. In this system, the ligand-binding domain (LBD) of a receptor, *e.g.*, the progesterone or estrogen receptor, is fused to the Cre recombinase to increase specificity of the recombinase.

In the case of an avian, a heterologous polypeptide or polypeptides encoded by the transgenic nucleic acid may be secreted into the oviduct lumen of the mature animal and deposited as a constituent component of the egg white into eggs laid by the animal. It is also contemplated to be within the scope of the present invention for the heterologous polypeptides to be produced in the serum of a transgenic avian.

A leaky promoter such as the CMV promoter may be operably linked to a transgene, resulting in expression of the transgene in all tissues of the transgenic avian, resulting in production of, for example, immunoglobulin polypeptides in the serum. Alternatively, the transgene may be operably linked to an avian promoter that may express the transgene in a restricted range of tissues such as, for example, oviduct cells and macrophages so that the heterologous protein may be identified in the egg white or the serum of a transgenic avian. Transgenic avians produced by the cytoplasmic microinjection method of the present invention will have the ability to lay eggs that contain one or more desired heterologous protein(s) or variant thereof.

One embodiment of the present invention, therefore, is a transgenic avian produced by the cytoplasmic microinjection methods of the present invention and having a heterologous polynucleotide sequence comprising a nucleic acid insert encoding a

heterologous polypeptide and operably linked to an avian lysozyme gene expression control region, the gene expression control region comprising at least one 5' matrix attachment region, an intrinsically curved DNA region, at least one transcription enhancer, a negative regulatory element, at least one hormone responsive element, at least one avian CR1 repeat element, and a proximal lysozyme promoter and signal peptide-encoding region.

Another embodiment of the present invention provides a transgenic avian further comprising a transgene with a lysozyme 3' domain.

Accordingly, the invention provides transgenic avians produced by methods of the invention, preferably by cytoplasmic microinjection as described *infra*. In preferred embodiments, the transgenic avian contains a transgene comprising a heterologous peptide coding sequence operably linked to a promoter and, in certain embodiments, other regulatory elements. In more preferred embodiments, the transgenic avians of the invention produce heterologous proteins, preferably in a tissue specific manner, more preferably such that they are deposited in the serum and, most preferably, such that the heterologous protein is deposited into the egg, particularly in the egg white. In preferred embodiments, the transgenic avians produce eggs containing greater than 5 µg, 10 µg, 50 µg, 100 µg, 250 µg, 500 µg, or 750 µg, more preferably greater than 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 500 mg, 700 mg, 1 gram, 2 grams, 3 grams, 4 grams or 5 grams of the heterologous protein. In preferred embodiments, the transgenic avians produce an immunoglobulin molecule and deposit the immunoglobulin in the egg or serum of the avian, and preferably, the immunoglobulin isolated from the egg or serum specifically binds its cognate antigen. The antibody so produced may bind the antigen with the same, greater or lesser affinity than the antibody produced in a mammalian cell, such as a myeloma or CHO cell.

In specific embodiments, the transgenic avians of the invention were not produced or are not progeny of a transgenic ancestor produced using a eukaryotic viral vector, more particularly, not a retroviral vector (although, in certain embodiments, the vector may contain sequences derived from a eukaryotic viral vector, such as promoters, origins of replication, etc.). The transgenic avians of the invention include G0 avians, founder transgenic avians, G1 transgenic avians, avians containing the transgene in the sperm or ova, avians mosaic for the transgene and avians containing copies of the transgene in most or all of the cells. Contemplated by the invention are transgenic avians in which the transgene is episomal. In more preferred embodiments, the transgenic avians have the transgene integrated into one or more chromosomes. Chromosomal integration can be detected using a variety of methods well known in the art, such as, but not limited to, Southern blotting, PCR, etc.

6. EXAMPLES

The present invention is further illustrated by the following examples. Each example is provided by way of explanation of the invention, and is not intended to be a limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications, combination, additions, deletions and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be used in another embodiment to yield a still further embodiment. It is intended that the present invention covers such modifications, combinations, additions, deletions and variations as come within the scope of the appended claims and their equivalents.

The contents of all references, published patent applications, and patents cited throughout the present application are hereby incorporated by reference in their entirety.

6.1 Example 1: Cytoplasmic Microinjections

(a) *Preparation of DNA for microinjection:* The plasmid pAVICR-A115.93.1.2 (containing the -12.0 kb lysozyme promoter controlling expression of human interferon $\alpha 2b$) was purified with a QIAGEN® Plasmid Maxi Kit (QIAGEN®, Valencia, CA), and 100 μ g of the plasmid were restriction digested with *Not*I restriction enzyme. The digested DNA was phenol/ CHCl_3 extracted and ethanol precipitated. Recovered DNA was resuspended in 1mM Tris-HCl (pH 8.0) and 0.1mM EDTA, then placed overnight at 4°C. DNA was quantified by spectrophotometry and diluted to the appropriate concentration. DNA samples which were bound with the SV40 T antigen nuclear localization signal peptide (NLS peptide, amino acid sequence CGGPKKKRKVG (SEQ ID NO: 12)) were first resuspended in 0.25 M KCl, and NLS peptide was added to achieve a peptide DNA molar ratio of 100:1 (Collas and Alestrom, 1996, *Mol. Reprod. Develop.* 45: 431-438, the contents of which are incorporated by reference in its entirety). The DNA samples were bound to the SV40 T antigen NLS peptide by incubation for 15 minutes.

(b) *Cytoplasmic microinjections:* The germinal disc of the avian egg was positioned in, and illuminated by the incident light beam, then the micropipette was moved to a position whereby the tip of the micropipette was over the area of the germinal disc and therefore optimally placed for the insertion of the micropipette into the germinal disc. The tip of the micropipette was then pressed onto the vitelline membrane of the avian egg, to a depth of about 20 microns below the general plane of the membrane. The vitelline membrane resisted penetration by the micropipette and therefore the tip indented the vitelline membrane without piercing the membrane. The depth of the indentation formed by the pressure of the tip of the micropipette on the vitelline membrane can be determined by

two methods. The micropipette may be pre-marked about 20 microns from the tip. When the mark is about level with the general plane of the membrane, the tip will enter the germinal disc once the vitelline membrane is penetrated. The distance for the micropipette to be depressed may also be controlled by using the micropipette bevel as reference. In this method, the injection needle penetrates the vitelline membrane up to a point where only the apical end of the opening of the bevel is visible above the vitelline membrane, while the remaining of the opening is located inside the germinal disk. The movement of the micropipette relative to an avian germinal disc is monitored by the obliquely angled macro monitoring unit, comprising a focusable macro lens capable of delivering a focused magnified image of the avian germinal disc to an electronic camera for display by a monitor. The oblique angle of the macro lens shows the depth of movement of the micropipette relative to the vitelline membrane and the degree of indentation thereof, more distinctly than if a vertical microscope objective is used to monitor the microinjection. Pulses of piezo-electric induced oscillations were applied to the micropipette once it was in contact with the indented vitelline membrane. The vibrating tip of the micropipette drills through the vitelline membrane. The fluid contents of the micropipette are then injected into the germinal disc by positive hydraulic pressure exerted on the lumen and the contents therein, by the pressure-regulating system.

Approximately 100 nanoliters of DNA were injected into a germinal disc of stage 1 White Leghorn embryos obtained two hours after oviposition of the previous egg. DNA amounts per injection ranged from 1 nanoliter to 100 nanoliters.

Injected embryos were surgically transferred to recipient hens via ovum transfer according to the method of Christmann *et al.* (PCT/US01/26723, the contents of which are incorporated by reference in its entirety), and hard shell eggs were incubated and hatched (Olsen and Neher, 1948, *J. Exp. Zoo.* 109: 355-366).

6.2 Example 2: PCR Analysis of Chick Blood DNA

(a) *DNA extraction.* Whole blood from one-week old chicks was collected with heparinized capillary tubes. Red blood cell (RBC) nuclei were released and washed with lysis buffer solution. DNA's from RBC nuclei were extracted by digestion with proteinase K (1mg/ml) and precipitated with ethanol. Purified DNA was resuspended in 1mM Tris-HCl (pH 8.0) and 0.1mM EDTA and quantitated.

(b) *PCR analysis of chick blood DNA.* Genomic DNA samples from one-week old chicks were analyzed by PCR using primers LYS051 for (5'-TGCATCCTTCAGCACTTGAG-3')(SEQ ID NO: 13) and IFN-3 (5'-AACTCCTCTTGAGGAAAGCC-3')(SEQ ID NO: 14). This primer set amplifies a 584 bp region of the transgene carried by the pAVIJC-

A115.93.1.2 plasmid. Three hundred nanograms of genomic DNA were added to a 50 μ l reaction mixture (1 X Promega PCR Buffer with 1.5mM MgCl₂, 200 μ M of each dNTP, 5 μ M primers) and 1.25 units of Taq DNA polymerase (Promega). The reaction mixtures were heated for 4 minutes at 94°C, and then amplified for 34 cycles at 94°C for 1 min, 60°C for 1 min and 72°C for 1 min. The samples were heated in a final cycle for 4 minutes at 72°C. PCR products were detected on a 0.8% agarose gel with ethidium bromide staining, as shown in FIG. 7.

6.3 Example 3: Human Interferon α 2b Expression In Chick Serum

One week after hatching, blood was collected from chicks using heparinized capillary tubes. Blood was then added to an equal volume of phosphate buffered saline, centrifuged at 200 x g, and 100 microliters of the supernatant were assayed by human IFN ELISA (PBL Biomedical Laboratories, New Brunswick, New Jersey), as shown in FIGS. 8 and 9.

6.4 Example 4: Human Interferon α 2b Expression In Egg White of Transgenic Hens

Once hens have reached sexual maturity and began to lay (approximately 22-24 weeks of age), eggs were collected and the egg whites were assayed by ELISA using human IFN ELISA (PBL Biomedical Laboratories, New Brunswick, New Jersey) according to the manufacturer's instructions. The results of PCR and ELISA analysis of blood and egg white are given in Table 1 below that summarizes results of PCR and ELISA analysis.

Table 1: Analysis of Transgene Presence and Interferon Expression

Bird #	Nuclear Localization Signal	Sex	PCR (Blood)	ELISA (Blood)	ELISA (egg white)
8305	- NLS	M	+	+	NA
8331		F	-	-	+
8340	- NLS	F	-	-	+
AA123	+ NLS	F	+	+	NA
AA61	+ NLS	M	+	+	
AA105	+ NLS	F	-	+	
AA115	+ NLS	M	+	-	NA

-NLS: DNA injected without NLS peptide; + NLS: DNA injected with NLS peptide; NA: not applicable.

As shown in Table 1, one bird (#8305) of 69 produced using microinjection of DNA without the NLS peptide was positive for both the presence of the transgene and the

expression of interferon in the blood. Because this bird is a male, he can be bred to a non-transgenic hen to establish germline transmission of the transgene.

Figs. 8 and 9 demonstrate the expression of human interferon in the blood of #8305, as compared to standards. FIG. 7 illustrates the PCR results from the serum of for several birds, including bird 8305, obtained at different intervals after hatching. As can be seen in lanes 4, 5, 11, and 12 of FIG. 7, positive signal indicated the presence of the transgene at two different collection periods. Other PCR positive bands were seen in birds produced by microinjection of DNA covalently linked to the NLS peptide as described above. Table 1 shows that 4 birds, AA123, AA61, AA105 and AA115, of 43 tested were PCR positive, ELISA positive or both. Expression levels of human IFN in bird AA61, as compared to standards, are also illustrated in FIGS. 8 and 9. PCR-positive male birds can be bred to determine germline transmission, and eggs collected from transgenic females to assay for IFN expression, as described above, as chicks reach sexual maturity

6.5 Example 5: Purification and Identification of Human Interferon- α 2b from Transgenic Eggs

15

One hundred eggs were cracked and the egg whites separated from the yolks by manual manipulation and pooled. The pooled egg white was solubilized by adding 3 volumes of deionized water per volume of egg white, followed by adjusting the pH to 5.0 with the drop-wise addition of 1N HCl. The solubilized egg white was clarified by centrifugation at 3750 g for 20 minutes at 4 °C.

The solubilized egg white was fractionated by cation exchange chromatography using SP-Sepharose HP. Two chromatographic runs were performed, the first in 50 mM sodium acetate at pH 5.0, the second in 50 mM sodium acetate at pH 4.0. A commercially available ELISA kit specific for human interferon- α was used to identify interferon-containing fractions.

The cation-exchange purified material was further purified by hydrophobic interaction chromatography on Phenyl-Sepharose, with the interferon fraction eluting after the addition of 1M acetic acid, pH 4.5, containing 0.5% triton X-100.

The results of SDS-PAGE and Western Blot analyses of the products at each step of the purification procedure are shown in FIGS. 10 and 11 respectively. A peak of interferon with a molecular weight of approximately 22,000 daltons was seen following the hydrophobic interaction chromatography step. The purity of the interferon at this stage was estimated to be approximately 50%, based on the intensity of staining.

An analysis of the carbohydrate content of the human IFN- α 2b purified from the transgenic chicken AVI-029 is shown in FIG. 12. Bands 1, 2 and 3 are the unsialylated, mono- and disialylated saccharides. Sialic acid linkage is alpha 2-3 to galactose and alpha

2-6 to N-acetylgalactosamine. The glycosylation of the human IFN- α 2b produced by human cells is compared to that produced in chicken cells, as shown in FIG. 13.

6.6 Example 6: Construction of Lysozyme Promoter Plasmids

- The chicken lysozyme gene expression control region was isolated by PCR
- 5 amplification. Ligation and reamplification of the fragments thereby obtained yielded a contiguous nucleic acid construct comprising the chicken lysozyme gene expression control region operably linked to a nucleic acid sequence optimized for codon usage in the chicken (SEQ ID NO: 5) and encoding a human interferon α 2b polypeptide optimized for expression in an avian cell.
 - 10 White Leghorn Chicken (*Gallus gallus*) genomic DNA was PCR amplified using the primers 5pLMAR2 (SEQ ID NO: 1) and LE-6.1kbrev1 (SEQ ID NO: 2) in a first reaction, and Lys-6.1 (SEQ ID NO: 3) and LysE1rev (SEQ ID NO: 4) as primers in a second reaction. PCR cycling steps were: denaturation at 94°C for 1 minute; annealing at 60°C for 1 minute; extension at 72°C for 6 minutes, for 30 cycles using TAQ PLUS PRECISION DNA
 - 15 polymerase (STRATAGENE®, LaJolla, CA). The PCR products from these two reactions were gel purified, and then united in a third PCR reaction using only 5pLMAR2 (SEQ ID NO: 1) and LysE1rev (SEQ ID NO: 4) as primers and a 10-minute extension period. The resulting DNA product was phosphorylated, gel-purified, and cloned into the *EcoR* V restriction site of the vector PBLUESCRIPT® KS, resulting in the plasmid p12.0-lys.
 - 20 p12.0-lys was used as a template in a PCR reaction with primers 5pLMAR2 (SEQ ID NO: 1) and LYSBSU (5'-CCCCCCCCTAAGGCAGCCAGGGGCAGGAAGCAAA-3') (SEQ ID NO: 5) and a 10 minute extension time. The resulting DNA was phosphorylated, gel-purified, and cloned into the *EcoR* V restriction site of PBLUESCRIPT® KS, forming plasmid p12.0lys-B.
 - 25 p12.0lys-B was restriction digested with *Not* I and *Bsu*36 I, gel-purified, and cloned into *Not* I and *Bsu*36 I digested pCMV-LysSPIFNMM, resulting in p12.0-lys-LSPIFNMM. p12.0-lys-LSPIFNMM was digested with *Sal* I and the SalItoNotI primer (5'-TCGAGCGGCCGC-3') (SEQ ID NO: 16) was annealed to the digested plasmid, followed by *Not* I digestion. The resulting 12.5 kb *Not* I fragment, comprising the lysozyme promoter
 - 30 region linked to IFNMAGMAX-encoding region and an SV40 polyadenylation signal sequence, was gel-purified and ligated to *Not* I cleaved and dephosphorylated PBLUESCRIPT® KS, thereby forming the plasmid pAVIICR-A115.93.1.2, which was then sequenced.

6.7 Example 7: Construction of Plasmids Which Contain the 3' Lysozyme Domain

The plasmid pAVIJCR-A115.93.1.2 was restriction digested with *FseI* and blunt-ended with T4 DNA polymerase. The linearized, blunt-ended pAVIJCR-A115.93.1.2
5 plasmid was then digested with *XhoI* restriction enzyme, followed by treatment with alkaline phosphatase. The resulting 15.4 kb DNA band containing the lysozyme 5' matrix attachment region (MAR) and -12.0 kb lysozyme promoter driving expression of a human interferon was gel purified by electroelution.

The plasmid pIIIilys was restriction digested with *MluI*, then blunt-ended with the
10 Klenow fragment of DNA polymerase. The linearized, blunt-ended pIIIilys plasmid was digested with *XhoI* restriction enzyme and the resulting 6 kb band containing the 3' lysozyme domain from exon 3 to the 3' end of the 3' MAR was gel purified by electroelution. The 15.4 kb band from pAVIJCR-A115.93.1.2 and the 6 kb band from pIIIilys were ligated with T4 DNA ligase and transformed into STBL4 cells (Invitrogen Life
15 Technologies, Carlsbad, CA) by electroporation. The resulting 21.3 kb plasmids from two different bacterial colonies were named pAVIJCR-A212.89.2.1 and pAVIJCR-A212.89.2.3 respectively.

6.8 Example 8: Transfection of Chicken HD11 Cells with pAVIJCR-A212.89.2.1 and pAVIJCR-A212.89.2.3

20 Chicken cells transfected with plasmids having the 3' lysozyme domain linked to a nucleic acid expressing human $\alpha 2b$ interferon express the heterologous polypeptide. Chicken myelomonocytic HD11 cells were transfected with plasmid pAVIJCR-A212.89.2.1 and pAVIJCR-A212.89.2.3 to test the functionality of the plasmids. One million HD11 cells were plated per each well of a 24-well dish. The next day, HD11 cells were transfected
25 with 1 μ g of plasmid DNA per 4 μ l of LIPOFECTAMINE 2000 (Invitrogen Life Technologies). For comparison, independent wells were also transfected with the parent vector pAVIJCR-A115.93.1.2. After 5 hours of transfection, the cell medium was changed with fresh medium. 48 hours later, cell medium was harvested by centrifugation at 110 x g for 5 min and assayed for human interferon by ELISA (PBL Biomedicals, Flanders, NJ).

30 The transfected cells expressed the heterologous human $\alpha 2b$ interferon at least to the level seen with a plasmid not having the 3' lysozyme domain operably linked to the human $\alpha 2b$ interferon encoding nucleic acid.

6.9 Example 9: Cytoplasmic Microelectroporation

The application of electrical current has been shown to enhance the uptake of
35 exogenous DNA fragments by cultured cells. The DNA fragments will be injected into the germinal disk according to the above-described methods. Enhancement of nuclear uptake

of the heterologous DNA will promote earlier chromosomal integration of the exogenous DNA molecules, thus reducing the degree of genetic mosaicism observed in transgenic avian founders.

5 A sample of nucleic acid will be microinjected into the cytoplasm of a recipient stage 1 avian cell, and delivered to a recipient cell nucleus by microelectroporation. In a system suitable for use in microelectroporating early stage avian cells, a cathode will be located within the lumen of the DNA delivery micropipette. Another possible location for the electrode is on the exterior surface of the micropipette. For either option, the electrode is situated close or adjacent to the exit orifice of the pipette so that the electrode and the
10 micropipette may be introduced into the recipient cell together. Alternatively, the micropipette will be introduced into the cytoplasm and used to guide a cathode to make electrical contact with the cytoplasm of the targeted cell.

The placement of the anode is optional. In one arrangement of the electrodes of the microelectroporation system, the anode is located on the micropipette and, therefore, will
15 enter the cell or cells with the micropipette and the cathode. In another arrangement, an anode is in electrical contact with the Ringers solution that will surround the targeted recipient early stage avian cell. In yet another version, the anode is individually positioned within the cytoplasm, or the nucleus, of the recipient stage 1 cell. The anode and cathode are electrically connected to an electrical impulse generator capable of delivering a timed
20 electrical pulse to the electrodes. One suitable apparatus for generating a timed electrical pulse according to the present invention is a Kation Scientific Iontophoresis pump BAB-500.

A solution of a selected nucleic acid will be microinjected through the inserted micropipette into the recipient cell according to the protocols described in the examples above. The recipient cell will be pulsed at least once with about 0.1 to about 20.0
25 microamps for about 0.1 to about 60 secs.

This novel intracellular DNA microelectroporation method will enhance the efficiency of transgenesis, increase the efficiency of chromosomal integration of heterologous transgenic DNA, and reduce mosaicism of the transgenic founder animal by ensuring that more recipient cells receive and incorporate the nucleic acid at each delivery
30 to a cell than is the case with non-electroporated microinjection.

6.10 Example 10: Construction of an ALV-based Vector Having β -lactamase Encoding Sequences

The *lacZ* gene of pNLB, a replication-deficient avian leukosis virus (ALV)-based
35 vector (Cosset *et al.*, *J. Virol.* 65: 3388-94 (1991)), was replaced with an expression cassette

consisting of a cytomegalovirus (CMV) promoter and the reporter gene β -lactamase (β -La or BL).

To efficiently replace the *lacZ* gene of pNLB with a transgene, an intermediate adaptor plasmid was first created, pNLB-Adapter. pNLB-Adapter was created by inserting
5 the chewed back *ApaI/ApaI* fragment of pNLB (Cosset *et al.*, 1991, *J. Virol.* 65:3388-94) (in pNLB, the 5' *ApaI* sites reside 289 bp upstream of *lacZ* and the 3' *ApaI* sites reside 3' of the 3' LTR and Gag segments) into the chewed-back *KpnI/SacI* sites of PBLUESCRIPT®KS(-). The filled-in *MluI/XbaI* fragment of pCMV-BL (Moore *et al.*, *Anal. Biochem.* 247: 203-9 (1997)) was inserted into the chewed-back *KpnI/NdeI* sites of pNLB-Adapter, replacing
10 *lacZ* with the CMV promoter and the *BL* gene (in pNLB, *KpnI* resides 67 bp upstream of *lacZ* and *NdeI* resides 100 bp upstream of the *lacZ* stop codon), thereby creating pNLB-Adapter-CMV-BL. To create pNLB-CMV-BL, the *HindIII/BlpI* insert of pNLB (containing *lacZ*) was replaced with the *HindIII/BlpI* insert of pNLB-Adapter-CMV-BL. This two step
cloning was necessary because direct ligation of blunt-ended fragments into the *HindIII/BlpI*
15 sites of pNLB yielded mostly rearranged subclones, for unknown reasons.

6.11 Example 11: Production of Transduction Particles Having an ALV-based Vector Having β -lactamase Encoding Sequences

Sentas and Isoldes were cultured in F10 (GIBCO®), 5% newborn calf serum
20 (GIBCO®), 1% chicken serum (GIBCO®), 50 μ g/ml phleomycin (Cayla Laboratories) and 50 μ g/ml hygromycin (SIGMA®). Transduction particles were produced as described in Cosset *et al.*, 1991, herein incorporated by reference, with the following exceptions. Two days after transfection of the retroviral vector pNLB-CMV-BL (from Example 10, above) into 9×10^5 Sentas, virus was harvested in fresh media for 6-16 hours and filtered. All of
25 the media was used to transduce 3×10^6 Isoldes in three 100 mm plates with polybrene added to a final concentration of 4 μ g/ml. The following day the media was replaced with media containing 50 μ g/ml phleomycin, 50 μ g/ml hygromycin and 200 μ g/ml G418 (SIGMA®). After 10-12 days, single G418^r colonies were isolated and transferred to 24-well plates. After 7-10 days, titers from each colony was determined by transduction of
30 Sentas followed by G418 selection. Typically 2 out of 60 colonies gave titers at $1-3 \times 10^5$. Those colonies were expanded and the virus concentrated to $2-7 \times 10^7$ as described in Allilioli *et al.*, 1994, *Dev. Biol.* 165:30-7, herein incorporated by reference. The integrity of the CMV-BL expression cassette was confirmed by assaying for β -lactamase in the media of cells transduced with NLB-CMV-BL transduction particles.

35

6.12 Example 12: Production of Chickens Transgenic for β -lactamase

Stage X embryos in freshly laid eggs were transduced with NLB-CMV-BL transduction particles (from Example 11, above) as described in Thoraval *et al.*, 1995, *Transgenic Res.* 4:369-377, herein incorporated by reference, except that the eggshell hole
5 was covered with 1-2 layers of eggshell membrane and, once dry, DUCO® model cement.

Approximately 120 White Leghorns were produced by transduction of the stage X embryos with NLB-CMV-BL transduction particles. These birds constitute chimeric founders, not fully transgenic birds. Extensive analysis of DNA in the blood and sperm from the transduced chickens indicates that 10-20% of the birds had detectable levels of the
10 transgene in any given tissue. Of those birds carrying the transgene, approximately 2-15% of the cells in any given tissue were actually transgenic.

6.13 Example 13: β -lactamase Activity Assay in Blood and Egg White

When hens produced in Example 12, above, began to lay eggs, the egg whites of
15 those eggs were assayed for the presence of β -lactamase. The β -lactamase assay was carried out as described in Moore *et al.*, 1997, *Anal. Biochem.* 247:203-9, herein incorporated by reference, with the following modifications.

To assay blood from two to ten day old chicks, the leg vein was pricked with a scalpel. 50 μ l of blood was collected in a heparinized capillary tube (Fisher), of which 25
20 μ l was transferred to 100 μ l phosphate-buffered saline (PBS) in a 96-well plate. Various dilutions of purified β -lactamase (CALBIOCHEM®) was added to some wells prior to addition of blood from control (non-transduced) chicks to establish a β -lactamase standard curve. After one day at 4°C, the plate was centrifuged for 10 minutes at 730 x g. 25 μ l of the supernatant was added to 75 μ l of PBS. 100 μ l of 20 μ M 7-(thienyl-2-acetamido)-3-[2-
25 (4-N,N-dimethylaminophenylazo)pyridinium-methyl]-3-cephem-4-carboxylic acid (PADAC, from CALBIOCHEM®) in PBS was added, and the wells were read immediately on a plate reader in a 10 minute kinetic read at 560 nm or left overnight in the dark at room temperature. Wells were scored positive if the well had turned from purple to yellow. To assay blood from older birds, the same procedure was followed except that 200-300 μ l
30 blood was drawn from the wing vein using a syringe primed with 50 μ l of heparin (SIGMA®).

Analysis of the NLB-CMV-BL transduced flock revealed nine chickens that had significant levels of β -lactamase in their blood. Three of these chickens were males and these were the only three males that had significant levels of the NLB-CMV-BL transgene
35 in their sperm as determined by PCR analysis. Thus, these are the males to be outbred to obtain fully transgenic G₁ offspring. The other six chickens were the hens that expressed β -

lactamase in their magnum tissue (see below). Other birds had low levels of β -lactamase (just above the level of detection) in their blood but did not have transgenic sperm or eggs containing β -lactamase. Thus β -lactamase expression in blood is a strong indicator of whether a chicken was successfully transduced.

5 To assay β -lactamase in egg white, freshly laid eggs were transferred that day to a 4°C cooler, at which point the β -lactamase is stable for at least one month. (Bacterially-expressed, purified β -lactamase added to egg white was determined to lose minimal activity over several weeks at 4°C, confirming the stability of β -lactamase in egg white.) To collect egg white samples, eggs were cracked onto plastic wrap. The egg white was pipetted up
10 and down several times to mix the thick and thin egg whites. A sample of the egg white was transferred to a 96-well plate. 10 μ l of the egg white sample was transferred to a 96-well plate containing 100 μ l of PBS supplemented with 1.5 μ l of 1 M NaH_2PO_4 , pH 5.5 per well. After addition of 100 μ l of 20 μ M PADAC, the wells were read immediately on a plate reader in a 10 minute or 12 hour kinetic read at 560 nm. Various dilutions of purified
15 β -lactamase was added to some wells along with 10 μ l of egg white from control (non-transduced) hens to establish a β -lactamase standard curve. Egg white from both untreated and NLB-CMV-BL transduced hens were assayed for the presence of β -lactamase.

Significant levels of β -lactamase were detected in the egg white of six hens, as shown in Table 2, below. Eggs laid by Hen 1522, the first hen to demonstrate expression in
20 eggs, have 0.3 mg or higher of active β -lactamase per egg. Also shown is β -lactamase production from three other NLB-CMV-BL transduced hens (Hen 1549, Hen 1790 and Hen 1593). Every hen that laid eggs containing β -lactamase also had significant levels of β -lactamase in its blood.

Table 2: Expression of β -lactamase in eggs of NLB-CMV-BL treated hens.

25		Hen #	Average mg of β -lactamase per egg	# of eggs assayed
		Control	0.1 \pm 0.07	29
		1522	0.31 \pm 0.07	20
		1549	0.96 \pm 0.15	22
		1581	1.26 \pm 0.19	12
30		1587	1.13 \pm 0.13	15
		1790	0.68 \pm 0.15	13
		1793	1.26 \pm 0.18	12

Controls were eggs from untreated hens. The low level of BL in these eggs was due
35 to spontaneous breakdown of PADAC during the course of the kinetic assay. The other

hens were transduced with NLB-CMV-BL as described in Example 3. Egg white from each egg was assayed in triplicate.

Based on the β -lactamase activity assay, the expression levels of β -lactamase appeared to range from 0.1 to 1.3 mg per egg (assuming 40 milliliters of egg white per egg). However, these assay quantities were significantly less than the quantities obtained by western blot assay and were determined to be deceptively lower than the true values. The difference in results between the enzymatic activity assay and a western blot analysis was due to a β -lactamase inhibitor in egg white. The activity of purified β -lactamase was inhibited by egg white such that 50 μ l of egg white in a 200 μ l reaction resulted in nearly 100% inhibition, whereas 10 μ l of egg white in a 200 μ l reaction resulted in only moderate inhibition. Furthermore, spontaneous breakdown of the enzymatic substrate, PADAC, during the course of the assay also contributed to the erroneously low calculation of β -lactamase concentration.

6.14 Example 14: Isolation and *Ex Vivo* Transfection of Blastodermal Cells

Donor blastodermal cells are isolated from fertilized eggs of Barred Plymouth Rock hens using a sterile annular ring of Whatman filter paper which is placed over a blastoderm and lifted after cutting through the yolk membrane of the ring. The ring bearing the attached blastoderm is transferred to phosphate-buffered saline (PBS) in a petri dish ventral side up, and adhering yolk is removed by gentle pipetting. The area opaca is dissected away with a hair loop and the translucent stage X blastoderm is transferred via a large-bore pipette tip to a microfuge tube. About 30,000-40,000 cells are isolated per blastoderm and for a typical experiment 10 blastoderms are collected.

Cells are dispersed by brief trypsin (0.2%) digestion, washed once by low speed centrifugation in Dulbecco's modified Eagle's medium (DMEM) and then transfected with linearized plasmids via lipofectin (16 mg/200 ml, BRL) for 3 hours at room temperature. Cells are washed free of lipofectin with medium and then 400-600 cells are injected into g-irradiated (650 rads) recipient stage X embryos from the Athens-Canadian randombred line (AC line). Injection is through a small window (~0.5 cm) into the subgerminal cavity beneath the recipient blastoderms. Windows are sealed with fresh egg shell membrane and DUCO® plastic cement. Eggs are then incubated at 39.1°C in a humidified incubator with 90° rotation every 2 hr.

6.15 Example 15: Identification of Transgenic Mosaics by PCR Assay

Among the chicks which hatch from embryos containing transfected or transduced blastodermal cells, only those exhibiting Barred Plymouth Rock feather mosaicism are

retained. Even if no reporter gene is present in the transgene, transgenic mosaics can be identified by PCR assay.

To identify transgenic mosaics, DNA blood and black feather pulp of individual chicks are assayed by PCR for the presence of the transgene using a primer pair specific to the transgene as described by Love *et al.*, 1994, *Bio/Technology* 12:60-63. Transgene chimeras are induced, withdrawn and re-induced with diethylstilbestrol (DES) pellets and excised magnums analyzed for expression of reporter activity. Blood and liver are assayed to monitor tissue specificity.

Male and female blood DNA was collected at 10 to 20 days post-hatch. Blood is drawn from a wing vein into a heparinized syringe and one drop is immediately dispensed into one well of a flat-bottom 96-well dish containing a buffer which lyses cytoplasmic membranes exclusively. The plate is then briefly centrifuged, which pellets the nuclei. The supernatant is removed and a second lysis buffer is added which releases genomic DNA from nuclei and degrades nucleases. The DNA is ethanol precipitated in the plate, washed with 70% ethanol, dried and resuspended in 100 μ l of water per well. As much as 80 μ g of DNA suitable for PCR and TAQMAN™ (Perkin Elmer/Applied Biosystems) analysis can be obtained from one drop (8 μ l) of chick blood.

The isolated DNA is tested for the presence of the transgenes using the TAQMAN® sequence detection assay to evaluate the efficiency of the embryo transduction process. The TAQMAN® sequence detection system allows the direct detection of a specific sequence. A fluorescently-labeled oligonucleotide probe complementary to an internal region of a desired PCR product only fluoresces when annealed to the desired PCR product, which in this case is complementary to the transgene. Because all of the detection occurs in the PCR tube during the cycling process, the TAQMAN® system allows high-throughput PCR (no gel electrophoresis is need) as well as sequence detection analogous to and as sensitive as Southern analysis. 1 μ l of the isolated DNA, which contains 600-800 ng of DNA, is used for the TAQMAN® reaction. Each reaction contains two sets of primer pairs and TAQMAN® probes. The first set detects the chicken glyceraldehyde 3-phosphate dehydrogenase gene (*GAPDH*) and is used as an internal control for the quality of the genomic DNA and also serves as a standard for quantitation of the transgene dosage. The second set is specific for the desired transgene. Fluorescence is detected in a dissecting stereomicroscope equipped with epifluorescence detection. The two TAQMAN® probes are attached to different dyes that fluoresce at unique wavelengths: thus both PCR products are detected simultaneously in an ABI/PE 7700 Sequence Detector. It is estimated that up to 180 birds will hatch, and 20% (36 birds) will contain the transgene in their blood.

6.16 Example 16: Production of Fully Transgenic G₁ Chickens Expressing β -Lactamase

Males are selected for breeding as a single male can give rise to 20 to 30 G₁ offspring per week as opposed to 6 G₁ offspring per female per week, thereby speeding the expansion of G₁ transgenics. The feed of G₀ males is supplemented with sulfamethazine, which accelerates the sexual maturation of males such that they can start producing sperm at 10-12 weeks of age instead of 20-22 weeks without influencing their health or fertility.

Sperm DNA of all males are screened for the presence of the transgene. Sperm are collected and the DNA extracted using Chelex-100. Briefly, 3 μ l of sperm and 200 μ l of 5% Chelex-100 are mixed, followed by addition of 2 μ l of 10 mg/ml proteinase K and 7 μ l of 2 M DTT. Samples are incubated at 56°C for 30-60 minutes. Samples are boiled for 8 minutes and vortexed vigorously for 10 seconds. After centrifugation at 10 to 15 kG for 2-3 minutes, the supernatant is ready for PCR or TAQMAN® analysis. The DNAs are analyzed by the TAQMAN® assay using a TAQMAN® probe and primers complementary to the transgene. Of the 90 G₀ males, it is estimated that 5%, or 4 to 5, will have the transgene in their sperm DNA.

As noted above in Example 13, the NLB-CMV-BL transduced flock included three males that had significant levels of the NLB-CMV-BL transgene in their sperm as determined by PCR analysis. Thus, these males are chosen for further breeding to obtain fully transgenic G₁ offspring.

By breeding germline transgenic males to 90 non-transgenic White Leghorn females per week, about 16 G₁ offspring per week will be obtained. Hatched chicks are vent-sexed and screened for the presence of the transgene in their blood DNA by the TAQMAN® assay. Twenty male and female G₁ transgenics will be obtained or 40 total, which will take up to 3 weeks.

Males will be kept for further breeding and females tested for expression of transgenes in the egg.

6.17 Example 17: pNLB-CMV-IFN Vector Having an IFN Encoding Sequence

The DNA sequence for human interferon α 2b based on hen oviduct optimized codon usage was created using the BACKTRANSLATE program of the Wisconsin Package, version 9.1 (Genetics Computer Group, Inc., Madison, WI) with a codon usage table compiled from the chicken (*Gallus gallus*) ovalbumin, lysozyme, ovomucoid, and ovotransferrin proteins. The template and primer oligonucleotides (SEQ ID NOS: 17-34) shown in Fig. 15A-B were amplified by PCR with *Pfu* polymerase (STRATAGENE®, La

Jolla, CA) using 20 cycles of 94°C for 1 min., 50°C for 30 sec., and 72°C for 1 min. and 10 sec.

PCR products were purified from a 12% polyacrylamide-TBE gel by the "crush and soak" method (Maniatis *et al.* 1982), then combined as templates in an amplification
5 reaction using only IFN-1 (SEQ ID NO: 24) and IFN-8 (SEQ ID NO: 34) as primers. The resulting PCR product was digested with *Hind* III and *Xba* I and gel purified from a 2% agarose-TAE gel, then ligated into *Hind* III and *Xba* I digested, alkaline phosphatase-treated, PBLUESCRIPT® KS (STRATAGENE®), resulting in the plasmid pBluKSP-IFNMagMax. Both strands were sequenced by cycle sequencing on an ABI PRISM 377 DNA Sequencer
10 (Perkin-Elmer, Foster City, CA) using universal T7 or T3 primers. Mutations in pBluKSP-IFN derived from the original oligonucleotide templates were corrected by site-directed mutagenesis with the Transformer Site-Directed Mutagenesis Kit (Clontech, Palo Alto, CA). The interferon coding sequence was then removed from the corrected pBluKSP-IFN with *Hind* III and *Xba* I, purified from a 0.8% agarose-TAE Gel, and ligated to *Hind* III and
15 *Xba* I digested, alkaline phosphatase-treated pCMV-BetaLa-3B-dH. The resulting plasmid was pCMV-IFN which contained IFN coding sequence controlled by the cytomegalovirus immediate early promoter/enhancer and SV40 polyA site.

To clone the IFN coding sequence controlled by the CMV promoter/enhancer into the NLB retroviral plasmid, pCMV-IFN was first digested with *Cla*I and *Xba*I, then both
20 ends were filled in with Klenow fragment of DNA polymerase (New England BioLabs, Beverly, MA). pNLB-adapter was digested with *Nde* I and *Kpn* I, and both ends were made blunt by T4 DNA polymerase (New England BioLabs). Appropriate DNA fragments were purified on a 0.8% agarose-TAE gel, then ligated and transformed into DH5α cells. The resulting plasmid was pNLB-adapter-CMV-IFN.

25 This plasmid was then digested with *Mlu* I and partially digested with *Blp* I and the appropriate fragment was gel purified. pNLB-CMV-EGFP was digested with *Mlu* I and *Blp* I, then alkaline-phosphatase treated and gel purified. The *Mlu* I/*Blp* I partial fragment of pNLB-adapter-CMV-IFN was ligated to the large fragment derived from the *Mlu* I/*Blp* I digest of pNLB-CMV-EGFP, creating pNLB-CMV-IFN.

30

6.18 Example 18: Production of pNLB-CMV-IFN Transduction Particles

Senta packaging cells (Cosset *et al.*, 1991) were plated at a density of 3×10^5 cells/35 mm tissue culture dish in F-10 medium (Life Technologies) supplemented with 50% calf serum (Atlanta Biologicals), 1% chicken serum (Life Technologies), 50 µg/ml
35 hygromycin (SIGMA®), and 50 µg/ml phleomycin (CAYLA, Toulouse, France). These cells were transfected 24h after plating with 2 µg of CsCl-purified pNLB-CMV-IFN DNA

and 6 μ l of Lipofectin liposomes (Life Technologies) in a final volume of 500 μ l Optimem (Life Technologies). The plates were gently rocked for four hours at 37° C in a 5% CO₂ incubator. For each well, the media was removed, washed once with 1 ml of Optimem and re-fed with 2 mls of F-10 medium supplemented with 50% calf serum, 1% chicken serum, 50 μ g/ml hygromycin, and 50 μ g/ml phleomycin. The next day, medium from transfected Sentas was recovered and filtered through a 0.45 micron filter.

This medium was then used to transduce Isolde cells. 0.3 ml of the filtered medium recovered from Senta cells was added to 9.6 ml of F-10 (Life Technologies) supplemented as described above, in addition to polybrene (SIGMA®) at a final concentration of 4 μ g/ml. This mixture was added to 10⁶ Isolde packaging cells (Cosset *et al.*, 1991) plated on a 100mm dish the previous day, then replaced with fresh F-10 medium (as described for Senta growth) 4 hours later.

The next day, the medium was replaced with fresh medium which also contained 200 μ g/ml neomycin (G418, SIGMA®). Every other day, the medium was replaced with fresh F-10 medium supplemented with 50% calf serum, 1% chicken serum, 50 μ g/ml hygromycin, 50 μ g/ml phleomycin, and 200 μ g/ml neomycin. Eleven to twelve days later, single colonies were visible by eye, and these were picked and placed into 24 well dishes. When some of the 24 well dishes became confluent, medium was harvested and titered to determine the cell lines with the highest production of retrovirus.

Titering was performed by plating 7.5 x 10⁴ Senta cells per well in 24 well plates on the day prior to viral harvest and transduction. The next day 1 ml of fresh F-10 medium supplemented with 50% calf serum, 1% chicken serum, 50 μ g/ml hygromycin, and 50 μ g/ml phleomycin was added to each well of the isolated Isolde colonies. Virus was harvested for 8-10 hours. The relative density of each well of Isoldes was noted. After 8-10 hours, 2 and 20 μ l of media from each well of Isoldes was added directly to the media of duplicate wells of the Sentas. Harvested medium was also tested for the presence of interferon by IFN ELISA and for interferon bioreactivity. The next day the media was replaced with F-10 medium supplemented with 50% calf serum, 1% chicken serum, 50 μ g/ml hygromycin, 50 μ g/ml phleomycin, and 200 μ g/ml neomycin. When obvious neomycin-resistant colonies were evident in the wells of transduced Sentas, the number of colonies was counted for each well.

The Isolde colony producing the highest titer was determined by taking into account the number of colonies and correcting for the density of the Isolde cells when the viral particles were harvested (i.e., if two Isolde colonies gave rise to media with the same titer, but one was at a 5% density and the other was at a 50% density at the time of viral harvest,

the one at the 5% density was chosen for further work, as was the case in the present example).

The Isolde cell line producing the highest titer of IFN-encoding transducing particles was scaled up to six T-75 tissue culture flasks. When flasks were confluent, cells were washed with F-10 medium (unsupplemented) and transducing particles were then harvested for 16 hours in 14 ml/flask of F-10 containing 1% calf serum (Atlanta Biologicals) and 0.2% chicken serum (Life Technologies). Medium was harvested, filtered through a 0.45 micron syringe filter, then centrifuged at 195,000xg in a Beckman 60Ti rotor for 35 min. Liquid was removed except for 1 ml, and this was incubated with the pellet at 37°C with gentle shaking for one hour. Aliquots were frozen at -70°C. Transducing particles were then titered on Senta cells to determine concentrations used to inject embryos.

6.19 Example 19: Production of Chimeric Transgenic Chickens

Approximately 300 White Leghorn (strain Line 0) eggs were windowed according to the Speksnijder procedure described in U.S. Patent No. 5,897,998, incorporated herein by reference in its entirety, then injected with about 7×10^4 transducing particles per egg. Eggs hatched 21 days after injection and human interferon levels were measured by IFN ELISA from serum samples collected from chicks one week after hatch.

6.20 Example 20: Production of Fully Transgenic G₁ Chickens for Selective Breeding From Males Expressing Human Interferon

To screen for G₀ roosters which contained the interferon transgene in their sperm, DNA was extracted from rooster sperm samples by Chelex-100 extraction (Walsh *et al.*, 1991). DNA samples were then subjected to TAQMAN® analysis on a 7700 Sequence Detector (Perkin Elmer) using the "neo for-1" (5'-TGGATTGCACGCAGGTTCT-3') (SEQ ID NO: 35) and "neo rev-1" (5'-GTGCCAGTCATAGCCGAAT-3') (SEQ ID NO: 36) primers and FAM labeled NEO-PROBE1 (5'-CCTCTCCACCCAAGCGGCCG-3') (SEQ ID NO: 37) to detect the transgene. Three G₀ roosters with the highest levels of the transgene in their sperm samples were bred to nontransgenic SPAFAS (White Leghorn) hens by artificial insemination.

Blood DNA samples were screened for the presence of the transgene by TAQMAN® analysis as described in Example 14, above. Out of 1,597 offspring, one rooster was found to be transgenic (a.k.a. "Alphie"). Alphie's serum was tested for the presence of human interferon by hIFN ELISA. hIFN was present at 200 nanograms/ml.

Alphie's sperm was used for artificial insemination of nontransgenic SPAFAS (White Leghorn) hens. To date, 106 out of 202 (about 52%) offspring contain the transgene

as detected by TAQMAN® analysis. These breeding results follow a Mendelian inheritance pattern and indicate that Alphonse is transgenic.

6.21 Example 21: Production of Human Interferon $\alpha 2b$ in the Egg White of G_2 Transgenic Hens

5

Human lung carcinoma cells were incubated with diluted egg white samples, then washed and challenged with mengovirus. After incubation, cells were stained with crystal violet to assess viral interference.

Expression levels of human IFN $\alpha 2b$ in egg white produced by G_2 hens as determined by ELISA are shown in Fig. 16. The bioactivity versus the mass of human IFN $\alpha 2b$ produced in G_2 hen egg white is shown in Fig. 17. Bioactivity was determined by a viral inhibition assay, and mass was determined by IFN ELISA. Bird number 53 was a control bird and represented egg white from a non-transgenic hen.

6.22 Example 22: Transfection of Cultured Quail Oviduct Cells

The oviduct was removed from a Japanese quail (*Coturnix coturnix japonica*) and the magnum portion was minced and enzymatically dissociated with 0.8 mg/ml collagenase (SIGMA® Chemical Co., St. Louis, MO) and 1.0 mg/ml dispase (ROCHE® Molecular Biochemicals, Indianapolis, IN) by shaking and titrating for 30 min at 37°C. The cell suspension was then filtered through sterile surgical gauze, washed three times with F-12 medium (Life Technologies, Grand Island, NY) by centrifugation at 200 x g, and resuspended in OPTIMEM™ (Life Technologies) such that the OD₆₀₀ was approximately 2. 300 μ l of cell suspension was plated per well of a 24-well dish. For each transfection, 2.5 μ l of DMRIE-C liposomes (Life Technologies) and 1 μ g of DNA were preincubated 15 minutes at room temperature in 100 μ l of OPTIMEM™, then added to the oviduct cells. Cells with DNA/liposomes were incubated for 5 hours at 37°C in 5% CO₂. Next, 0.75 ml of DMEM (Life Technologies) supplemented with 15% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA), 2X penicillin/streptomycin (Life Technologies), 10⁻⁶ M insulin (SIGMA®), 10⁻⁸ M β -estradiol (SIGMA®), and 10⁻⁷ M corticosterone (SIGMA®) was added to each well, and incubation continued for 72 hours. Medium was then harvested and centrifuged at 110 x g for 5 minutes.

35

6.23 Example 23: Transfection of Cultured Chicken Whole Embryo Fibroblasts

To obtain whole embryo fibroblasts (WEFs), fertile chicken eggs were incubated for approximately 65 hours. Embryos were collected using filter paper rings, then washed three times in phosphate buffered saline with glucose (PBS-G) followed by a wash in calcium- and magnesium-free EDTA (CMF-EDTA). Embryos were then incubated in fresh CMF-EDTA at 4°C with gentle shaking for 30 minutes. CMF-EDTA was removed, and replaced with 0.5% trypsin solution (no EDTA) at 37°C for 3 minutes. Cells were titrated 10 times, then 5% chicken serum was added to inhibit the trypsin reaction. The cell suspension was then added to α -MEM (Life Technologies) supplemented with 2.2 g/l NaHCO₃, 2.52 g/L EPPS, 0.18 g/l D-glucose, 5% FBS, 5% chick serum (heat inactivated at 55°C for 1 hour), 5x10⁻⁵M β -mercaptoethanol, 0.2 mM L-glutamine, 2X penicillin/streptomycin and centrifuged. Cells were resuspended in α -MEM supplemented as described above, and plated on 6-well dishes at a density of 2 x 10⁵ cells per well.

For each transfection, 6 μ l of FuGene 6 liposomes (ROCHE® Molecular Biochemicals) and 2 μ g of DNA were preincubated 15 min at room temperature in 100 μ l of OPTIMEM™, then added to the WEFs. WEFs with DNA/liposomes were incubated 5 hours at 37°C in 5% CO₂. The transfection medium was then removed and replaced with 2 ml of α -MEM supplemented as described above. Medium was removed 72 hours after transfection and centrifuged at 110 x g for 5 minutes.

WEFs were transfected either with the heavy and light immunoglobulin polypeptides encoded by separate plasmids (p1083 and p1086 respectively) each under the control of the CMV promoter or encoded on the same reactor under the transcriptional control of a CMV promoter and including an IRES translational element as described in U.S. Patent Application No. 09/977,374, filed 08 June 2001 and incorporated herein by reference in its entirety. The supernatants were analyzed for antibody content by ELISA and FACs.

6.24 Example 24: Generation of Transgenic Chickens Expressing Antibodies

A retroviral vector, based on either avian leukosis virus (ALV) or Moloney murine leukemia virus (MoMLV), will be constructed such that the light (L) and heavy (H) chains of a monoclonal antibody (MAb) will be linked by an internal ribosome entry site (IRES) element. Both genes will then be transcriptionally regulated by a promoter such as the cytomegalovirus (CMV) immediate early promoter/enhancer or a promoter that demonstrates tissue specificity for the hen oviduct (for example, the lysozyme promoter, ovalbumin promoter, an artificial promoter construct such as MDOT, and the like). The promoter-L chain-IRES-H chain DNA expression cassette will be flanked by the long

terminal repeats (LTRs) of the retrovirus. Stage X chicken embryos will be injected with transducing particles containing the above construct to generate transgenic chickens.

Alternatively, the heavy and light chains will be included in separate retroviral vectors and separate lines of transgenic chickens will be generated. Each line will either
5 express the heavy or light chain of the MAb. Once germline transmission of the transgene is established in the two lines, they will be bred to each other to express heavy and light chains together to make functional MAbs in the offspring.

The above DNA constructs can also be integrated into a chicken genome by sperm-mediated transgenesis (SMT). SMT may involve transfection, electroporation, or
10 incubation of sperm with the desired DNA construct (for example, the lysozyme promoter controlling expression of heavy and light chains of the MAb) and fertilization of ovum with the treated sperm by artificial insemination or by chicken intracytoplasmic sperm injection (ChICSI™).

15 6.25 Example 25: Preparation of Recipient Avian Cytoplasts by TPLSM

Incubation

Ova were isolated from euthanized hens between 2-4 hours after oviposition of the previous egg. Alternatively, eggs were isolated from hens whose oviducts have been fistulated (Gilbert & Woodgush, 1963, *J. Reprod. & Fertility* 5: 451-453) and (Pander et
20 al., 1989, *Br. Poult. Sci.* 30: 953-7). Before generating images of the avian early embryo, DNA was incubated with a specific dye according to the following protocol.

The albumen capsule was removed and the ovum placed in a dish with the germinal disk facing the top. Remnants of the albumen capsule were removed from the top of the germinal disk. Phosphate buffered saline was added to the dish to prevent drying of the
25 ovum. A cloning cylinder was placed around the germinal disk and 1.0 µg/ml of DAPI in PBS was added to the cylinder. Visualization was performed after approximately 15 minutes of incubation.

Injection

Preparation of the egg was done as described for incubation. Following removal of
30 the capsule, 10-50 nanoliters of a 0.1 µg/ml solution of DAPI in PBS was injected into the germinal disk using a glass pipette. Visualization was performed approximately 15 minutes after injection.

Visualization

Following incubation, images of the inside of the avian early embryo were generated
35 through the use of TPLSM. The germinal disk was placed under the microscope objective, and the pronuclear structures were searched within the central area of the disk, to a depth of

60 μ m using low laser power of 3-6 milliwatts at a wavelength of 750 nm. Once the structures were found they were subsequently ablated.

Nuclear Ablation and Enucleation

Pronuclear structures were subjected to laser-mediated ablation. In these experiments, an Olympus 20x/0.5NA (Numerical Aperture) water immersion lens was used. The x and y planes to be ablated were defined with the two photon software, while the z plane (depth) was just under 10 μ m for this type of objective. Since the pronuclear structure was about 20 μ m in diameter, the ablation comprised two steps (2 times 10 μ m). The focal point was lowered to visualize the remaining of the pronucleus, which was subsequently ablated. The laser power used to ablate the pronuclei was between 30 to 70 milliwatts at a wavelength of 750 nm. For the ablation experiments, the image was zoomed by a factor of 4 to 5, giving an area compression of 16-25 fold. Then the power was increased 10-12 fold for a total intensity increase of 160-300 fold compared to the visualization intensity of 3-6 milliwatts. The ablation intensity (power density) is the functional parameter, i.e. the power increase of 10-12 fold results in ablation power of 30-70 milliwatts, but the zoom factor compressed this power into an area 16-25x smaller giving a power density increase of 160-300 fold.

6.26 Example 26: Preparation of the Nuclear Donor Cell and Isolation of the Donor Nucleus

Avian fibroblast cells in culture were trypsinized (0.25% Trypsin and 1 μ M EDTA), centrifuged twice in PBS containing 5% of fetal calf serum (FCS) and placed in a 60 mm plastic dish in PBS containing 5% of FCS. Using the microscope/micromanipulation unit described in Example 27 below, under transmission light, the nuclear donors were then isolated by repeated pipetting of the cells, which disrupted the cytoplasmic membrane and released the nucleus from inside the cell.

6.27 Example 27: Preparation of the Reconstructed Zygote

A micromanipulation unit, comprising an IM-16 microinjector and a MM-188NE micromanipulator, both from NIKON®/MARISHIGE, were adapted to an upright NIKON® Eclipse E800. This microscope was adapted to operate under both transmission and reflective light conditions. This unique configuration has allowed us to morphologically examine and prepare (isolate the nuclei, as described above) somatic cells in suspension and to load the injection pipette using dry or water immersion lenses under diascopic illumination or transmitted light. This was followed by prompt localization and positioning of the germinal disk under the microscope and subsequent guided injection of

the somatic cells, using dry and long distance lenses under fiber optic as well as episcopic illumination (light coming from the side and through the objectives onto the sample respectively).

5 **6.28 Example 28: Production of Transgenic Chickens by Direct Pronuclear DNA Injection**

Production of transgenic chickens by direct DNA injection can be by two methods:
(a) injection of a DNA directly into the germinal disk, commonly described as cytoplasmic injection, as described for avian species by Sang & Perry, 1989, *Mol. Reprod. Dev.* 1: 98-
10 106, and Love *et al.*, 1994, *Biotechnology* (N.Y.) 12: 60-3, incorporated herein by reference in their entireties. Sang & Perry described only episomal replication of the injected cloned DNA. Love *et al.* suggested that the injected DNA becomes integrated into the cell's genome. In both cases, injection was into pronuclear stage eggs. This procedure, therefore, is cytoplasmic injection of pronuclear stage eggs, not pronuclear injection; and (b) imaging
15 of the egg using multiphoton microscopy to allow localization of the pronuclear structures. The DNA solution is then injected directly into the pronucleus.

DNA preparation

The plasmid pAVIUCR-A115.93.1.2 containing the chicken lysozyme promoter region, and controlling expression of human interferon $\alpha 2b$, was purified with a QIAGEN®
20 Plasmid Maxi Kit (QIAGEN®, Valencia, CA), and 5 μ g of the plasmid DNA were restriction digested with the restriction enzyme *Not I*. A 12.7 kb fragment was purified by gel electrophoresis and electroelution, phenol/chloroform extraction, and ethanol precipitation. The DNA was resuspended in 1mM Tris-HCl, pH8.0 and 0.1mM EDTA (0.1X TE) to a final concentration of 5pg/ μ l and then used for microinjections.

25 *Pronuclear injection*

(i) *Preparation of ova*. Ova were isolated from euthanized hens between two and four hours after oviposition of the previous egg. Alternatively, eggs were isolated from hens whose oviducts have been fistulated as described by Gilbert & Woodgush, 1963, *J. of Reprod. and Fertility* 5: 451-453 and Pander *et al.*, 1989, *Br. Poult. Sci.* 30: 953-7 and
30 incorporated herein in their entireties.

The albumen capsule was removed and the ovum placed in a dish with the germinal disk facing upwards. Remnants of the albumen capsule were removed from over the germinal disk. Phosphate buffered saline (PBS) was added to the dish to prevent drying of the ovum. A cloning cylinder could be placed around the germinal disk to reduce the
35 depression of the ooplasmic membrane formed during subsequent pipette penetration, thereby facilitating the injection.

(ii) *Injection.* Between about 1-100 nanoliters of DNA solution was injected into a germinal disk using a glass pipette after removal of the capsule. The microinjection assembly and methods for microinjecting and reimplanting avian eggs are fully described in U.S. Patent Application No. 09/919,143, filed 31 July 2001.

5 Briefly, the microscope/micromanipulation unit is an IM-16 microinjector and a MM-188NE micromanipulator, both from NIKON®/MARISHIGE, adapted to an upright NIKON® Eclipse E800 microscope adapted to operate under both transmitted and reflected light conditions. This unique configuration allows the loading of a DNA solution into a micropipette while observed with a pipette dry or water immersion lenses under diascopic
10 illumination or transmitted light. Pipette loading is followed by the prompt localization and positioning of the germinal disk under the microscope and subsequent guided injection of DNA solution into the germinal disk using dry and long working distance lenses under fiber optic as well as episcopic illumination (side illumination and directly through the objectives and onto the sample, respectively).

15 (iii) *Localization of the Avian Embryo.* A cloning cylinder is placed around the germinal disk and MITOTRACKER® (300 nM) in PBS was added to the cylinder. Visualization is performed after approximately 20 minutes of incubation. Imaging using this dye shows intense labeling of the region around the nucleus while the nucleus itself does not take up the dye. This will allow localization of the pronucleus for injection while not causing
20 excessive damage to its structure, since the content of the pronuclei are not labeled and therefore are bleached during imaging. Once the pronucleus is localized, the DNA solution can be delivered into it using a microinjector. Cytoplasmic or pronuclear injected eggs can then be surgically transferred to a recipient hen.

(iv) *Ovum transfer.* At the time of laying, recipient hens are gas anesthetized using
25 Isofluorine. At this time, the infundibulum is receptive to receiving a donor ovum but has not yet ovulated. Feathers are removed from the abdominal area, and the area is scrubbed with betadine, and rinsed with 70% ethanol. The bird is placed in a supine position and a surgical drape is placed over the bird with the surgical area exposed. An incision approximately 2 inches long is made beginning at the junction of the sternal rib to the
30 breastbone and running parallel to the breastbone and through the smooth muscle layers and the peritoneum, to locate the infundibulum. The infundibulum is externalized and opened using gloved hands and the donor ovum is gently applied to the open infundibulum. The ovum is allowed to move into the infundibulum and into the anterior magnum by gravity feed. The infundibulum is returned to the body cavity and the incision closed using
35 interlocking stitches both for the smooth muscle layer and the skin. The recipient hen is returned to her cage and allowed to recover with free access to both feed and water.

Recovery time for the bird to be up, moving and feeding is usually within 45 minutes. Eggs laid by the recipient hens are collected the next day, set, and incubated. They will hatch 21 days later.

The procedure described by Love *et al.*, 1994, in *Biotechnology* (N.Y.) 12: 60-63, resulted in 5.5% survival to sexual maturity using the Perry *ex ovo* procedure. Following injection and surgical transfer by the methods described herein, however, a survival rate between about 50% and about 70% is expected, i.e., hatching, and most of the hatched birds should reach maturity.

6.29 Example 29:MuLV and VSV Viral Transfection of Avian Eggs

Preparation of MuLV/VSVg viral stocks. GP-293 cells at 70-80% confluence were transfected with 10 µg of the plasmid pVSVg or pLNHX-CMVE-MDOT-IFN. Sixty hours after transfection, the supernatant was collected and centrifuged at 1000 rpm for 5 minutes to remove cells. The supernatant was filtered through a 0.45 micron filter and the filtrate was centrifuged at 20,000 rpm to pellet the virus. The viral pellet was resuspended in 400 ml of STE buffer. To determine the viral titer, a 100-fold dilution of the viral stock was made and 5 µl of the serially diluted stock was used to infect Sentas cells. Forty-eight hours after infection, the cells were grown in medium containing 100 µg/ml G418. Colonies that were formed after two weeks in the selection medium were counted to determine the viral titer.

Isolation of blastodermal cells from stage X Barred Plymouth Rock (BPR) embryos. Freshly laid eggs were collected. The embryo at this stage consists of about 50,000-60,000 cells in a small circular area called the blastodermal disc. The discs from about 30 embryos were dissected from the eggs and the cells dissociated using 1XPBS (phosphate buffer saline) containing 0.05% trypsin. The cells were centrifuged at 500 rpm for 5 minutes. The pellet was gently washed with 1 x PBS and pelleted again and counted using a hemocytometer.

Interferon (IFN) assay. Blood samples were collected from 6 wk old chicks and the interferon levels in the serum were measured using the hu-IFN-α ELISA Kit (PBL Biomedical Lab., New Brunswick, NJ).

119 WL stage X eggs were injected with 5 µl of pLNHX-MDOT-IFN/VSVg virus with a titer 6×10^4 /ml). 53 injected eggs survived, of which 20 hatched. Sperm samples were tested from the males at sexual maturity. Two males, # A 24 and A 34, showed the presence of the transgene and therefore were used for further breeding for testing the germ-line transmission.

Freshly isolated 2×10^5 BRD cells from stage X embryos were infected with 1.5×10^4 pLNHX-MDOT-IFN/VSVg virus at 37°C for 1 hour. The cells were gently stirred every 10-15 minutes. While the blastodermal cells were being thus processed, 150 freshly laid WL (stage X) eggs were irradiated at 600 rads and set aside for the injections. A $5 \mu\text{l}$ cell suspension containing about 4000-5000 blastodermal cells were injected into each of 85 irradiated stage X WL eggs through a hole drilled in the shell. The eggs were sealed and incubated to hatch. Out of 85 stage X WL eggs that were injected with the BRD cells infected with pLNHX-MDOT-IFN/VSVg virus, 47 survived and 15 of these hatched. The feather chimerism in these birds was between 5-85%.

In an alternative experiment, freshly isolated 6×10^5 BRD cells from stage X embryos were mixed with 4×10^5 pLNHX-CMVE-MDOT-IFN viral particle and incubated at 37°C for 1 hour. The cells were gently stirred every 10-15 minutes. While the blastodermal cells were being processed, 150 freshly laid WL (stage X) eggs were collected and irradiated at 600 rads and set aside for the injections. A $5 \mu\text{l}$ cell suspension containing about 4000-5000 cells was injected into each of 107 irradiated stage X WL eggs through a small hole drilled in the shell. The eggs were sealed and incubated to hatch.

Out of 107 stage X WL eggs injected with the BPR cells infected with the pLNHX-CMVE-MDOT-IFN virus, 53 of these survived, of which 17 hatched. These birds showed varying degree of feather chimerism that ranged from 2-85%, as shown in Table 3 below.

Table 3: Chimera distribution of chicks transgenic for pLNHX-CMVE-MDOT-IFN virus

Bird #	Chimerism % Black	Status	Sex
457	75%		Male
458	15%	DEAD	
459			Female
460			
461	85%	DEAD	
462			Female
463	45%		Male
464	20%		Male
465	30%	DEAD	
466			Male
467			Female
468			
469	30%	DEAD	
470	2%	DEAD	
471		DEAD	
472		DEAD	
473		DEAD	

Blood samples were collected from these chicks when they were 6wk old. Interferon levels in 100µl serum sample was analyzed using the h-IFN-ELISA Kit. Results of the assay are shown in Fig 18. The successful detection of the transgene-encoded product (i.e. interferon) indicates that the BPR-injected cells were stably integrated into different tissues and thereby demonstrating that Moloney leukemia viruses pseudotyped with VSVg
5 can be used for generating transgenic birds.

In a parallel experiment with a different MuLV/VSVg pseudotyped virus (pLNHX-MDOT-IFN), feather chimeric chicks that did not hatch (i.e. died during the incubation period) were collected. Three tissues, skin heart and lung, from these birds were analyzed
10 for the presence of the transgene by TAQMAN® analysis. In three chicks, all three tissues showed the presence of the transgene. In the fourth chick, as shown in Figs. 19 and 20, the transgene was detected in two of the tissues. These results show that the injected BPR cells infected with Moloney viruses pseudotyped with VSVg are stably integrated into different tissues of the chick.

15

6.30 Example 30: Construction of Lysozyme Promoter Plasmids

The chicken lysozyme gene expression control region isolated by PCR amplification is fully disclosed in U.S. Patent Application No. 09/922,549, filed 03 August 2001 and incorporated herein by reference in its entirety. Ligation and reamplification of the
20 fragments thereby obtained yielded a functionally contiguous nucleic acid construct comprising the chicken lysozyme gene expression control region operably linked to a nucleic acid sequence encoding a human interferon α2b polypeptide and optimized for codon usage in the chicken. Briefly, chicken (*Gallus gallus* (White Leghorn)) genomic DNA was PCR amplified using the primers 5pLMAR2 and LE-6.1kbrev1 in a first
25 reaction, and Lys-6.1 and LysE1rev as primers in a second reaction. PCR cycling steps were: denaturation at 94°C for 1 minute; annealing at 60°C for 1 minute; extension at 72°C for 6 minutes, for 30 cycles using TAQ PLUS PRECISION™ DNA polymerase (STRATAGENE®, LaJolla, CA). The PCR products from these two reactions were gel purified, and then united in a third PCR reaction using only 5pLMAR2 and LysE1rev
30 primers and a 10 minute extension period. The resulting DNA product was phosphorylated, gel-purified, and cloned into the *EcoR* V restriction site of the vector PBLUESCRIPT® KS, resulting in the plasmid p12.0-lys.

p12.0-lys was used as a template in a PCR reaction with primers 5pLMAR2 and LYSBSU and a 10 minute extension time. The resulting DNA was phosphorylated, gel-
35 purified, and cloned into the *EcoR* V restriction site of PBLUESCRIPT® KS, forming plasmid p12.0lys-B.

p12.0lys-B was restriction digested with *Not* I and *Bsu*36 I, gel-purified, and cloned into *Not* I and *Bsu*36 I digested pCMV-LysSPIFNMM, resulting in p12.0-lys-LSPIFNMM. p12.0-lys-LSPIFNMM was digested with *Sal* I and the *Sal*Ito*Not*I primer was annealed to the digested plasmid, followed by *Not* I digestion. The resulting 12.5 kb *Not* I fragment, comprising the lysozyme promoter region linked to IFNMAGMAX-encoding region and an SV40 polyadenylation signal sequence, was gel-purified and ligated to *Not* I cleaved and dephosphorylated pBLUESCRIPT® KS, thereby forming the plasmid pAVIJCR-A115.93.1.2.

6.31 Example 31: Complete Lysozyme Promoter and IFNMAGMAX Sequences

The complete sequences of the lysozyme gene promoter and the codon-optimized human interferon α 2b nucleic acid are fully disclosed in U.S. Patent Application No. 09/922,549, filed 03 August 2001 and incorporated herein by reference in its entirety. The complete nucleotide sequence of the approximately 12.5 kb chicken lysozyme promoter region/IFNMAGMAX construct spans the 5' matrix attachment region (5' MAR), through the lysozyme signal peptide, to the sequence encoding the gene IFNMAGMAX and the subsequent polyadenylation signal sequence. The IFNMAGMAX nucleic acid sequence had been synthesized as described in Example 17 above. The expressed IFN α 2b sequence within plasmid pAVIJCR-A115.93.1.2 functioned as a reporter gene for lysozyme promoter activity. This plasmid construct may also be used for production of interferon α 2b in the egg white of transgenic chickens.

6.32 Example 32: Expression in Transfected Cultured Avian Oviduct Cells of Human Interferon α 2b Regulated by the 12kb Lysozyme Promoter

The oviduct was removed from a Japanese quail (*Coturnix coturnix japonica*) and the oviduct cells transfected with the lysozyme promoter-IFNMAGMAX as described in Example 21, above. The supernatant was analyzed by ELISA for human interferon α 2b content.

The human interferon α 2b contents of medium derived from cultured oviduct cells transfected with either pAVIJCR-A115.93.1.2 or the negative control plasmid pCMV-EGFP, as shown in Fig. 16. Bars to the right of the figure represent the standards for the IFN ELISA.

6.33 Example 33: Production of Heterologous GM-CSF in Serum of Transgenic Chickens

Seventy-three birds were injected with CMV-GMCSF (ALV) wherein a nucleic acid encoding GM-CSF was functionally linked to the cytomegalovirus promoter. All were subsequently tested. Three control birds that had nothing injected were also included. For each bird tested, approximately 100µl of blood was collected with heparinized tubes then diluted into 100µl of PBS solution and spun to remove red blood cells. 100µl of the plasma was then assayed.

As shown in Table 2 (below), three of the experimental birds had GM-CSF plasma levels that were higher than the highest available standard of 500 pg/ml used in the ELISAs.

Table 2: production of heterologous GM-CSF by heterologous chickens

Band #	Diluted sample 100µl diluent/ 100µl blood ng/ml	corrected results ng/ml	M/F	Transgene in sperm	Sperm Transgene +/- evaluation	Conformation	Egg Weight sample 1 (g)	Protein in egg sample 1 (pg/ml)	Egg Weight sample 2 (g)	Protein in egg sample 2 (pg/ml)
1210	0.002	0.004	F							
1212	0	0	M	0						
4545	0	0	M	NT						
5488	0.031	0.062	M	NT						
8371	0	0	M	0						
8374	0.03	0.06	M	0						
8375	0	0	M	0						
8376	0.003	0.006	F				53.40	0.00	53.90	0.00
8380	0	0	M	0						
8387	0	0	M	NT						
8389	0	0	F				45.70	0.00	41.90	0.00
8391	0	0	F				47.20	0.00	48.90	0.00
8392	0.007	0.014	M	0						
8397	0	0	M	NT						

	8400	0	0	M	0						
	8401	0	0	M	NT	-					
	8402	0.674	1.348	M	50 copies						
5	8403	0	0	M	50 copies						
	8406	0	0	F							
	8410	0	0	F				45.90	0.00	47.40	0.00
	8413	0.003	0.006	F				41.50	0.00	43.70	0.00
10	8415	0	0	M	0						
	8416	0.039	0.078	M	50 copies						
	8417	0	0	M	NT	-					
	8424	0	0	M	NT	+	+				
15	8425	0	0	F				44.80	0.00	44.10	0.00
	8426	0	0	M	50 copies						
	8429	0	0	M	500 copies	-					
	8430	0.091	0.182	M	NT						
	8432	0	0	M	0	+					
20	8433	0	0	M	>500 copies	-	-				
	8440	0	0	M	NT	-					
	8444	0	0	M	0	-					
	8447	0	0	F				35.60	0.00	58.90	0.00
25	8448	0	0	M	NT	-					
	8449	0	0	F				49.60	0.00	46.80	0.00
	8452	0.706	1.412	F				41.70	4117.25	39.80	4051.31
	8454	0	0	M	0	-					
30	8455	0	0	M	NT						
	8456	0	0	F							
	8460	0.027	0.054	M	500 copies	-	-				
	8461	0	0	M	500 copies	-	-				
35	8462	0.063	0.126	F				45.80	0.00	54.40	0.00

5

10

15

20

25

30

35

8463	0	0	M	0	-					
8464	0.057	0.114	M	0	-					
8467	0	0	F				53.90	0.00	51.50	0.00
8468	0	0	M	0	-					
8470	0	0	M	0	-					
8473	0	0	F				40.70	0.02	56.80	0.00
8475	0	0	F				41.50	0.00	41.00	0.00
8478	0	0	M	500 copies	-	-				
8482	0	0	F				38.10	0.00		
8483	0	0	M	50 copies						
8485	0	0	M	NT						
8489	0	0	M	500 copies	+	+				
8490	0	0	M	0	-					
8497	0	0	M	NT	-					
8499	0	0	M	500 copies	-	-				
8500	0	0	M	0	-					
8501	0	0	F				38.10	0.00	37.60	0.00
8502	0	0	F				44.10	0.01	47.10	0.00
8508	0.086	0.172	M	NT	+	+				
8509	1.068	2.136	F				72.30	0.00	48.50	0.00
8514	0	0	F				45.30	0.00	44.70	0.00
8518	0	0	F				48.70	0.00	47.30	0.00
8521	0	0	F				49.00	0.00	47.70	0.00
8525	0.016	0.032	F				54.10	0.00	49.10	0.01
8526	0	0	M	500 copies	+	++				
8528	0.013	0.026	M	500 copies	+	++				
8531	0	0	M	0	-					
8650	0.001	0.002	F				45.60	16.55	46.50	0.04
8653	0.045	0.09	F				44.60	0.00	44.30	0.00

8720	0	0	M	NT						
S8484(c)	0	0	F							
S8507(c)	0	0	F							
S8508 (c)	0	0	F							

5

When the dilution is factored in, three birds had greater than approximately 1 ng/ml. Eleven additional birds had GM-CSF levels within the range detectable by ELISA, from 26 pg/ml to 182 pg/ml (with the dilution factored in). Control birds S8484, S8507 and S8508 were negative.

10

6.34 Example 34: Synthesis of the MDOT promoter construct

Amplification of the ovomucoid and ovotransferrin promoter sequences

Oligonucleotide primers 1 (SEQ ID NO: 38) and 2 (SEQ ID NO: 39), as shown in Fig. 22 were used to amplify the ovomucoid sequences. Oligonucleotide primers 3 (SEQ ID NO: 40) and 4 (SEQ ID NO: 41) were used to amplify the ovotransferrin sequence by PCR. The primers were designed such that the PCR-amplified ovomucoid sequences contained an *Xho* I restriction cleavage site at the 5' end and a *Cla* I site at the 3' end. Similarly, the PCR-amplified ovotransferrin product had a *Cla* I restriction site at the 5' end and a *Hind* III site at the 3' end. The overlapping *Cla* I site was used to splice the two-PCR products to create the MDOT promoter construct. The nucleic acid sequence SEQ ID NO: 11 of the MDOT promoter construct is shown in Fig. 14. The final product was cloned in a bluescript vector between the *Xho* I and *Hind* III sites. From the bluescript vector the promoter region was released by *Kpn* I/*Hind* III restriction digestion and cloned into the pre-CMV-IFN vector to replace the CMV promoter to create MDOT-IFN (clone #10). This plasmid was tested *in vitro*.

20

Interferon synthesis directed by the MDOT promoter in transfected oviduct cells.

The promoter activity was tested *in vitro* by transfecting the plasmid construct into tubular gland cells isolated from the quail oviduct. The transfected cells were treated with hormones (progesterone, estrogen and insulin). At 72 hrs after transfection, the supernatant media of the transfected cells were collected and the interferon levels analyzed using an ELISA assay. The results, as shown in Fig. 23 show a significant induction of interferon $\alpha 2b$ expression in hormonally treated cells.

30

35

6.35 Example 35: Production of Erythropoietin in the Serum of Transgenic Chickens

Sixty birds were injected with a nucleic acid construct comprising a nucleic acid region encoding erythropoietin (EPO) 3' of, and operably linked to, the MDOT artificial promoter in the ALV vector (MDOT-EPO (ALV)) described in Example 34, above. All birds were subsequently tested. Two control birds that had nothing injected were also tested. Approximately 100µl of blood from each bird was diluted into 100µl of PBS/EDTA solution and spun to remove red blood cells. 100µl of the plasma was then assayed.

As shown in Table 4 below, twenty-three of the experimental birds had EPO levels in their plasma higher than the highest available ELISA standard of 1540 pg/ml.

Table 4: Production of erythropoietin under the control of promoter MDOT

	ELISA		Taqman®		ELISA		EGG ELISA		EGG ELISA	
	Diluted sample (100ul diluent 100ul blood) ng/ml	corrected results ng/ml	M/F	Sperm Transgene +/- evaluation	Confirmation	Protein in egg (pg/ml)	Protein in egg (pg/ml)	Protein in egg (pg/ml)	Protein in egg (pg/ml)	Protein in egg (pg/ml)
15	Band #									
	300	6.067	12.134	F		1011.403	697.186	2792.153	1848.942	2529.037
20	301	0.45	0.9	M	+					
	302	6.187	12.374	M	++	++				
	303	0.771	1.542	M	+++	+++				
	304	0.56	1.12	M	-					
25	305	0.545	1.09	F		1562.893		1859.896	2405.046	1702.548
	306	0.682	1.364	M	+					
	307	6.245	12.49	M	+					
	308	6.24	12.48	F		NT		17918.84	24599.5	17378.85
30	309	6.211	12.422	M	-	-				
	310	6.25	12.5	M	-	-				
	311	6.245	12.49	M	++	++				
	312	2.239	4.478	M	+					
	314	4.545	9.09	F		691.466		1979.496	2203.295	2128.271
35	316	4.738	9.476	M	-					1869.904

	317	1.841	3.682	F			0		149.161	0			
	320	1.028	2.056	M	++								
	321	0.029	0.058	M	-								
	322	0	0	M	-								
5	323	6.148	12.296	M	++	++							
	324	0	0	F			NT		0	0			
	325	1.683	3.366	F			NT						
	327	0	0	M	NT								
10	328	0	0	M	-								
	329	0.975	1.95	M	NT								
	330	6.263	12.526	F			4118.945	2592.05	7515.93	5638.896			
	331	0.533	1.066	M	+								
	332	0.319	0.638	M	+								
15	333	1.969	3.938	M	redo	-							
	334	0	0	F					0	0			
	335	0	0	F			NT		0	0			
	336	0.356	0.712	F			NT		1800.975	2360.708		1536.928	2551.83
	337	0.437	0.874	M	-								
	338	0.306	0.612	F			NT		0	0	0		
20	339	6.255	12.51	M	++	++							
	340	0.009	0.018	M	-								
	341	0.436	0.872	M	++	++							
	342	2.314	4.628	M	++	++							
	343	0.083	0.166	M	-								
25	344	0.219	0.438	M	++	+							
	345	0.195	0.39	F			0		375.962	1465.575		349.881	1936.851
	346	0.429	0.858	F			NT						
	348	0.422	0.844	M	+								
	349	1.199	2.398	M	-								
30	350	0.1	0.2	M	+++	+++							
	352	0.29	0.58	F			NT		141.163	296.148			
	353	0.572	1.144	F			NT		802.981	747.527			
	354	6.243	12.486	F			NT		0				
	356	1.225	2.45	M	+								
	357	0.038	0.076	F			NT		118.717	0			
35	359	0.002	0.004	F			NT		52.913	38.691			

360	2.318	4.636	M	+							
362	1.055	2.11	F			NT		0	0		
363	6.242	12.484	F			517.406		1005.69	2033.381	747.537	1980.494
365	0.446	0.892	M	++	++						
367								0	92.454		
368								0	69.274		
369			M	-							
608	6.191	12.382	M	NT	++						
609	0	0	M	NT				0	0		
1173	0	0	M	NT	-						
1174	1.614	3.228	M	NT	++						
1175	6.252	12.504	M	NT	-						
1204	0	0	F			NT					
367	0	0	F			NT					

When the dilution is factored in, 23 birds have greater than approximately 3080 pg/ml. An additional 27 birds had EPO levels within the range detectable by ELISA, from 58 pg/ml to 2450 pg/ml (with the dilution factored in). Control birds were negative.

Although preferred embodiments of the invention have been described using specific terms, devices, and methods, such description is for illustrative purposes only. The words used are words of description rather than of limitation. It is to be understood that changes and variations may be made by those of ordinary skill in the art without departing from the spirit or the scope of the present invention, which is set forth in the following claims. In addition, it should be understood that aspects of the various embodiments may be interchanged both in whole or in part.

All references cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to

be limited only by the terms of the appended claims along with the full scope of equivalents to which such claims are entitled.

5

10

15

20

25

30

35

What is claimed is:

1. A method of producing a transgenic avian, said method comprising:
 - (a) microinjecting into a cell of an avian embryo a nucleic acid comprising a transgene comprising a nucleotide sequence encoding a heterologous polypeptide;
 - (b) introducing the microinjected avian embryo into an oviduct of a recipient hen, such that the recipient hen lays a shelled egg containing the microinjected avian embryo; and
 - (c) incubating the shelled egg containing the microinjected avian embryo until said shelled egg hatches,thereby producing a transgenic avian containing the transgene.
2. The method of Claim 1, wherein the avian embryo is an early stage embryo having a germinal disk and said nucleic acid is microinjected into said germinal disk.
3. The method of Claim 2, wherein the early stage embryo is a stage I embryo.
4. The method of Claim 1, wherein the heterologous polypeptide is expressed in one or more cells of said transgenic avian.
5. The method of Claim 4, wherein the heterologous polypeptide is expressed in the serum of said transgenic avian.
6. The method of Claim 4, wherein the heterologous polypeptide is expressed in the magnum of said transgenic avian.
7. The method of Claim 1 further comprising the step of allowing the transgenic avian to develop to sexual maturity.
8. The method of Claim 7, wherein the heterologous polypeptide is delivered to the white of a developing avian egg produced by the transgenic avian.
9. The method of Claim 1, wherein the avian is a chicken.

10. The method of Claim 1, wherein the nucleotide sequence encoding said heterologous polypeptide is operably linked to a transcriptional regulatory element that can direct gene expression in one or more cells of said transgenic avian.

5 11. The method of Claim 10, wherein the transcriptional regulatory element is selected from the group consisting of the promoter regions of the avian genes encoding ovalbumin, lysozyme, ovomucoid, ovomucin, conalbumin and ovotransferrin.

12. The method of Claim 11, wherein the selected nucleic acid further comprises
10 a chicken lysozyme gene expression controlling region comprising the nucleic acid sequence SEQ ID NO: 7.

13. The method of Claim 10, wherein the transcriptional regulatory element is a tissue specific promoter.

15 14. The method of Claim 13, wherein the tissue specific promoter is specific for the magnum.

15. The method of Claim 1, wherein the transgene comprises at least one
20 cytomegalovirus promoter.

16. The method of Claim 10, wherein the transcriptional regulatory element comprises at least two regions derived from the promoter of an avian gene, said regions being from a different promoter.

25 17. The method of Claim 16, wherein the transcriptional regulatory element has a nucleotide sequence comprising the sequence SEQ ID NO: 11.

18. The method of Claim 1, wherein the transgene comprises at least one matrix
30 attachment region (MAR).

19. The method of Claim 18, wherein the transgene comprises a 5' MAR and a 3' MAR which flank said nucleotide sequence.

35 20. The method of Claim 1, wherein the nucleic acid is combined with a nuclear localization signal (NLS) peptide prior to said microinjection.

21. The method of Claim 1, wherein the nucleotide sequence encoding a heterologous polypeptide is optimized for codon usage by an avian.

22. The method of Claim 1, wherein the nucleotide sequence encoding a polypeptide is optimized for codon usage by a chicken.

23. The method of Claim 1, wherein the heterologous polypeptide is selected from the group consisting of a cytokine, a hormone, an enzyme, a structural polypeptide and an immunoglobulin polypeptide.

24. The method of Claim 23, wherein the cytokine is selected from the group consisting of interferon, interleukin, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, stem cell factor, erythropoietin, thrombopoietin and stem cell factor.

25. The method of Claim 23, wherein the cytokine is an interferon.

26. The method of Claim 1, wherein the transgene comprises an internal ribosome entry site (IRES).

27. The method of Claim 26, wherein the transgene comprises at least two nucleotide sequences each encoding a heterologous polypeptide.

28. The method of Claim 27, wherein the at least two nucleotide sequences encode at least two heterologous peptides that form a multimeric protein.

29. The method of Claim 28, wherein the multimeric protein specifically binds a selected ligand.

30. The method of Claim 29, wherein the multimeric protein is an antibody.

31. The method of Claim 1, wherein the heterologous polypeptide comprises a peptide region suitable for the isolation of the heterologous polypeptide.

32. The method of Claim 1, wherein the nucleic acid is a eukaryotic viral vector.

33. The method of Claim 32, wherein the eukaryotic viral vector is derived from any of the group consisting of avian leukosis virus, adenovirus, transferrin-polylysine enhanced adenoviral vectors, human immunodeficiency virus vectors, lentiviral vectors, and Moloney murine leukemia virus-derived vectors.

5

34. The method of Claim 1, wherein the nucleic acid is a plasmid vector.

35. The method of Claim 1, wherein the nucleic acid is a bacterial artificial chromosome (BAC).

10

36. The method of Claim 1, wherein the nucleic acid is not a eukaryotic viral vector.

37. The method of Claim 10, wherein the transcriptional regulatory element is a regulatable promoter.

20

38. The method of Claim 12, wherein the selected nucleic acid further comprises a region encoding the 3' region of the chicken lysozyme gene and having the nucleotide sequence SEQ ID NO: 9.

39. The method of Claim 4 or 8 further comprising isolating said heterologous peptide from said transgenic avian or an egg laid by said transgenic avian.

40. A transgenic avian that produces at least one heterologous polypeptide in egg white, wherein the transgenic avian or founder ancestor of said transgenic avian was not produced using a eukaryotic viral vector.

30

41. A transgenic avian produced by the method of Claim 1.

42. The transgenic avian of Claim 40 or 41, wherein the avian is a chicken.

43. The transgenic avian of Claim 42, wherein the heterologous polypeptide is selected from the group consisting of a cytokine, a hormone, an enzyme, a structural protein, and an immunoglobulin polypeptide.

35

44. The transgenic avian of Claim 42, wherein the cytokine is an interferon.

45. The transgenic avian of Claim 40 or 41, wherein the transgenic avian produces a heterologous multimeric protein.

46. The transgenic avian of Claim 45, wherein the heterologous multimeric protein specifically binds a selected ligand.

47. The transgenic avian of Claim 45, wherein the heterologous multimeric protein is an antibody.

48. An avian egg produced by the transgenic avian of Claim 40 or 41.

49. An avian egg produced by the transgenic avian of any of Claims 42-47.

50. A heterologous protein produced by the transgenic avian of Claim 40 or 41, wherein the heterologous protein comprises a heterologous polypeptide selected from the group consisting of a cytokine, a hormone, an enzyme, a structural protein, and an immunoglobulin polypeptide.

51. The heterologous polypeptide of Claim 50, wherein the cytokine is an interferon.

52. The heterologous protein of Claim 50, wherein the heterologous protein is a multimeric protein.

53. The heterologous protein of Claim 50, wherein the heterologous protein is an antibody.

30

35

1/43

SEQ ID NO: 6

TGCCGCCTTC TTTGATATTC ACTCTGTTGT ATTTTCATCTC TTCTTGCCGA TGAAAGGATA 60
TAACAGTCTG TATAACAGTC TGTGAGGAAA TACTTGGTAT TTCTTCTGAT CAGTGTTTTT 120
ATAAGTAATG TTGAATATTG GATAAGGCTG TGTGTCCTTT GTCTTGGGAG ACAAGGCCCA 180
CAGCAGGTGG TGGTTGGGGT GGTGGCAGCT CAGTGACAGG AGAGGTTTTT TTGCCTGTTT 240
TTTTTTTTTT TTTTTTTTTT AAGTAAGGTG TTCTTTTTTC TTAGTAAATT TTCTACTGGA 300
CTGTATGTTT TGACAGGTCA GAAACATTTT TCAAAAGAA GAACCTTTTG GAAACTGTAC 360
AGCCCTTTTC TTTTATTCCC TTTTGTCTT CTGTGCCAAT GCCTTTGGTT CTGATTGCAT 420
TATGGAAAAC GTTGATCGGA ACTTGAGGTT TTTATTTATA GTGTGGCTTG AAAGCTTGGA 480
TAGCTGTTGT TACACGAGAT ACCTTATTAA GTTTAGGCCA GCTTGATGCT TTATTTTTTC 540
CCTTTGAAGT AGTGAGCGTT CTCTGGTTTT TTTCTTTTGA AACTGGTGAG GCTTAGATTT 600
TTCTAATGGG ATTTTTTACC TGATGATCTA GTTGCATACC CAAATGCTTG TAAATGTTTT 660
CCTAGTTAAC ATGTTGATAA CTTCCGATTT ACATGTTGTA TATACTTGTC ATCTGTGTTT 720
CTAGTAAAAA TATATGGCAT TTATAGAAAT ACGTAATTCC TGATTTCTTT TTTTTTATC 780
TCTATGCTCT GTGTGTACAG GTCAAACAGA CTTCACTCCT ATTTTTATTT ATAGAATTTT 840
ATATGCAGTC TGTCGTTGGT TCTTGTGTTG TAAGGATACA GCCTTAAATT TCCTAGAGCG 900
ATGCTCAGTA AGGCGGGTTG TCACATGGGT TCAAATGTAA AACGGGCACG TTTGGCTGCT 960
GCCTTCCCGA GATCCAGGAC ACTAAACTGC TTCTGCACTG AGGTATAAAT CGCTTCAGAT 1020
CCCAGGGAAG TGCAGATCCA CGTGCATATT CTTAAAGAAG AATGAATACT TTCTAAAATA 1080
TTTTGGCATA GGAAGCAAGC TGCATGGATT TGTTTGGGAC TTAAATTATT TTGGTAACGG 1140
AGTGCATAGG TTTTAAACAC AGTTGCAGCA TGCTAACGAG TCACAGCGTT TATGCAGAAG 1200
TGATGCCTGG ATGCCTGTTG CAGCTGTTTA CGGCACTGCC TTGCAGTGAG CATTGCAGAT 1260
AGGGGTGGGG TGCTTTGTGT CGTGTTCCTA CACGCTGCCA CACAGCCACC TCCCGGAACA 1320
CATCTCACCT GCTGGGTACT TTTCAAACCA TCTTAGCAGT AGTAGATGAG TTAATATGAA 1380
ACAGAGAAGT TCCTCAGTTG GATATTCTCA TGGGATGTCT TTTTCCCAT GTTGGGCAAA 1440
GTATGATAAA GCATCTCTAT TTGTAAATTA TGCATTGTT AGTTCCTGAA TCCTTTCTAT 1500
AGCACCATT ATTGCAGCAG GTGTAGGCTC TGGTGTGGCC TGTGTCTGTG CTTCATCTT 1560
TTAAAGCTTC TTTGGAAATA CACTGACTTG ATTGAAGTCT CTTGAAGATA GTAAACAGTA 1620
CTTACCTTTG ATCCCAATGA AATCGAGCAT TTCAGTTGTA AAAGAATTCC GCCTATTCTAT 1680
ACCATGTAAT GTAATTTTAC ACCCCAGTG CTGACACTTT GGAATATATT CAAGTAATAG 1740
ACTTTGGCCT CACCCTCTTG TGTACTGTAT TTTGTAATAG AAAATATTTT AAATGTGCA 1800
TATGATTATT ACATTATGAA AGAGACATTC TGCTGATCTT CAAATGTAAG AAAATGAGGA 1860
GTGCGTGTGC TTTTATAAAT ACAAGTGATT GCAAATTAGT GCAGGTGTCC TTAACAAAAA 1920
AAAAAAAAG TAATATAAAA AGGACCAGGT GTTTTACAAG TGAAATACAT TCCTATTTGG 1980
TAAACAGTTA CATTTTTATG AAGATTACCA GCGCTGCTGA CTTTCTAAAC ATAAGGCTGT 2040
ATTGTCTTCC TGTACCATTT CATTTCTCTA TTCCCAATT GCACAAGGAT GTCTGGGTAA 2100
ACTATTCAAG AAATGGCTTT GAAATACAGC ATGGGAGCTT GTCTGAGTTG GAATGCAGAG 2160
TTGCACTGCA AAATGTCAGG AAATGGATGT CTCTCAGAAT GCCCAACTCC AAAGGATTTT 2220
ATATGTGTAT ATAGTAAGCA GTTTCCTGAT TCCAGCAGGC CAAAGAGTCT GCTGAATGTT 2280
GTGTTGCCGG AGACCTGTAT TTCTCAACAA GGTAAGATGG TATCCTAGCA ACTGCGGATT 2340
TTAATACATT TTCAGCAGAA GTACTTAGTT AATCTCTACC TTTAGGGATC GTTTCATCAT 2400
TTTTAGATGT TATACTTGAA ATACTGCATA ACTTTTAGCT TTCATGGGTT CCTTTTTTTC 2460
AGCCTTTAGG AGACTGTAA GCAATTTGCT GTCCAACCTT TGTGTTGGTC TTAAACTGCA 2520
ATAGTAGTTT ACCTTGATT GAAGAAATAA AGACCATTTT TATATTAATA AATACTTTTG 2580
TCTGTCTTCA TTTTGACTTG TCTGATATCC TTGCAGTGCC CATTATGTCA GTTCTGTCAG 2640
ATATTGAGAC ATCAAACTT AACGTGAGCT CAGTGGAGTT ACAGCTGCGG TTTTGATGCT 2700

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/43

GTTATTATTT CTGAAACTAG AAATGATGTT GTCTTCATCT GCTCATCAAA CACTTCATGC 2760
 AGAGTGTAAG GCTAGTGAGA AATGCATACA TTTATTGATA CTTTTTTAAA GTCAACTTTT 2820
 TATCAGATTT TTTTTCATT TGGAAATATA TTGTTTTCTA GACTGCATAG CTTCTGAATC 2880
 TGAAATGCAG TCTGATTGGC ATGAAGAAGC ACAGCACTCT TCATCTTACT TAAACTTCAT 2940
 TTTGGAATGA AGGAAGTTAA GCAAGGGCAC AGGTCCATGA AATAGAGACA GTGCGCTCAG 3000
 GAGAAAGTGA ACCTGGATTT CTTTGGCTAG TGTTCCTAAAT CTGTAGTGAG GAAAGTAACA 3060
 CCCGATTCTT TGAAAGGGCT CCAGCTTTAA TGCTTCCAAA TTGAAGGTGG CAGGCAACTT 3120
 GGCCACTGGT TATTTACTGC ATTATGTCTC AGTTTCGCAG CTAACCTGGC TTCTCCACTA 3180
 TTGAGCATGG ACTATAGCCT GGCTTCAGAG GCCAGGTGAA GGTGGGGATG GGTGGAAGGA 3240
 GTGCTGGGCT GTGGCTGGGG GGAAGTGGG GACTCCAAGC TGAGCTTGGG GTGGGCAGCA 3300
 CAGGGAAG TGTGGGTAAC TATTTTAAAG TACTGTGTTG CAAACGTCTC ATCTGCAAAT 3360
 ACGTAGGGTG TGTACTCTCG AAGATTAACA GTGTGGGTTT AGTAATATAT GGATGAATTC 3420
 ACAGTGGAAG CATTCAAGGG TAGATCATCT AACGACACCA GATCATCAAG CTATGATTGG 3480
 AAGCGGTATC AGAAGAGCGA GGAAGGTAAG CAGTCTTCAT ATGTTTTCCC TCCACGTAAA 3540
 GCAGTCTGGG AAAGTAGCAC CCCTTGAGCA GAGACAAGGA AATAATTCAG GAGCATGTGC 3600
 TAGGAGAACT TTCTTGCTGA ATTCTACTTG CAAGAGCTTT GATGCCTGGC TTCTGGTGCC 3660
 TTCTGCAGCA CCTGCAAGGC CCAGAGCCTG TGGTGAGCTG GAGGGAAGA TTCTGCTCAA 3720
 GTCCAAGCTT CAGCAGGTCA TTGTCTTTCG TTCTTCCCC AGCACTGTGC AGCAGAGTGG 3780
 AACTGATGTC GAAGCCTCCT GTCCACTACC TGTTGCTGCA GGCAGACTGC TCTCAGAAAA 3840
 AGAGAGCTAA CTCTATGCCA TAGTCTGAAG GTAAAATGGG TTTTAAAAAA GAAAACACAA 3900
 AGGCAAAACC GGCTGCCCCA TGAGAAGAAA GCAGTGGTAA ACATGGTAGA AAAGGTGCAG 3960
 AAGCCCCCAG GCAGTGTGAC AGGCCCTCC TGCCACCTAG AGGCGGGAAC AAGCTTCCCT 4020
 GCCTAGGGCT CTGCCCGCGA AGTGCGTGTT TCTTTGGTGG GTTTTGTGTT GCGTTTGGTT 4080
 TTGAGATTTA GACACAAGGG AAGCCTGAAA GGAGGTGTTG GGCATATTT TGGTTTGTAA 4140
 AGCCTGTACT TCAAATATAT ATTTTGTGAG GGAGTGTAGC GAATTGGCCA ATTTAAATA 4200
 AAGTTGCAAG AGATTGAAGG CTGAGTAGTT GAGAGGGTAA CACGTTTAAAT GAGATCTTCT 4260
 GAAACTACTG CTTCTAAACA CTTGTTTGGG TGGTGAGACC TTGGATAGGT GAGTGCTCTT 4320
 GTTACATGTC TGATGCACTT GCTTGTCTTT TTCCATCCAC ATCCATGCAT TCCACATCCA 4380
 CGCATTTGTC ACTTATCCCA TATCTGTCAT ATCTGACATA CCTGTCTCTT CGTCACTTGG 4440
 TCAGAAGAAA CAGATGTGAT AATCCCCAGC CGCCCCAAGT TTGAGAAGAT GGCAGTTGCT 4500
 TCTTTCCCTT TTTCTGCTA AGTAAGGATT TTCTCCTGGC TTTGACACCT CACGAAATAG 4560
 TCTTCTGCTT TTACATTCTG GGCATTATTT CAAATATCTT TGGAGTGCGC TGCTCTCAAG 4620
 TTTGTGCTTT CTTACTCTTA GAGTGAATGC TCTTAGAGTG AAAGAGAAGG AAGAGAAGAT 4680
 GTTGGCCGCA GTTCTCTGAT GAACACACCT CTGAATAATG GCCAAAGGTG GGTGGGTTTC 4740
 TCTGAGGAAC GGGCAGCGTT TGCCTCTGAA AGCAAGGAGC TCTGCGGAGT TGCAGTTATT 4800
 TTGCAACTGA TGGTGGAACT GGTGCTTAAA GCAGATTCCC TAGGTTCCCT GCTACTTCTT 4860
 TTCTTCTTGG GCAGTCAGTT TATTTCTGAC AGACAAACAG CCACCCCCAC TGCAGGCTTA 4920
 GAAAGTATGT GGCTCTGCCT GGGTGTGTTA CAGCTCTGCC CTGGTGAAAG GGGATTAAAA 4980
 CGGGCACCAT TCATCCCAAA CAGGATCCTC ATTCATGGAT CAAGCTGTAA GGAAGTTGGG 5040
 CTCCAACCTC AAAACATTAA TTGGAGTACG AATGTAATTA AAAGTGCATT CTCGCATTCC 5100
 TAAGTCATTT AGTCTGGACT CTGCAGCATG TAGGTCGGCA GCTCCCACTT TCTCAAAGAC 5160
 CACTGATGGA GGAGTAGTAA AAATGGAGAC CGATTGAGAA CAACCAACGG AGTGTTGCCG 5220
 AAGAACTGA TGGAAATAAT GCATGAATTG TGTGGTGGAC ATTTTTTTTA AATACATAAA 5280
 CTACTTCAAA TGAGGTCGGA GAAGGTGAGT GTTTTATTAG CAGCCATAAA ACCAGGTGAG 5340
 CGAGTACCAT TTTTCTCTAC AAGAAAAACG ATTCTGAGCT CTGCGTAAGT ATAAGTTCTC 5400

FIG.1B

3/43

CATAGCGGCT GAAGCTCCCC CCTGGCTGCC TGCCATCTCA GCTGGAGTGC AGTGCCATTT 5460
CCTTGGGGTT TCTCTACAG CAGTAATGGG ACAACTTTC AAAAAATTC TTTCTTTTCC 5520
TGTCATGTGG GATCCCTACT GTGCCCTCCT GGTTTTACGT TACCCCTGA CTGTTCCATT 5580
CAGCGGTTTG GAAAGAGAAA AAGAATTTGG AAATAAAACA TGTCTACGT ATCACCTCCT 5640
CCAGCATTTT GGTTTTAAAT TATGTCAATA ACTGGCTTAG ATTTGGAAAT GAGAGGGGGT 5700
TGGGTGTATT ACCGAGGAAC AAAGGAAGGC TTATATAAAC TCAAGTCTTT TATTTAGAGA 5760
ACTGGCAAGC TGTCAAAAAC AAAAAGGCCT TACCACCAAA TTAAGTGAAT AGCCGCTATA 5820
GCCAGCAGGG CCAGCACGAG GGATGGTGCA CTGCTGGCAC TATGCCACGG CCTGCTTGTG 5880
ACTCTGAGAG CAACTGCTTT GGAAATGACA GCACTTGGTG CAATTTCTTT TGTTCAGAA 5940
TGCCTAGAGC GTGTGCTTGG CGACAGTTTT TCTAGTTAGG CCACTTCTTT TTTCTTCTC 6000
TCCTCATTCT CCTAAGCATG TCTCCATGCT GGTAATCCCA GTCAAGTGAA CGTTCAAACA 6060
ATGAATCCAT CACTGTAGGA TTCTCGTGGT GATCAAATCT TTGTGTGAGG TCTATAAAAT 6120
ATGGAAGCTT ATTTATTTTT CGTTCTTCCA TATCAGTCTT CTCTATGACA ATTCACATCC 6180
ACCACAGCAA ATTTAAAGGTG AAGGAGGCTG GTGGGATGAA GAGGGTCTTC TAGCTTTACG 6240
TTCTTCTTG CAAGGCCACA GGAAAATGCT GAGAGCTGTA GAATACAGCC TGGGGTAAGA 6300
AGTTCACTCT CCTGCTGGGA CAGCTAACCG CATCTTATAA CCCCTTCTGA GACTCATCTT 6360
AGGACCAAT AGGGTCTATC TGGGGTTTTT GTTCTGCTG TTCCTCTGG AAGGCTATCT 6420
CACTATTTCA CTGCTCCAC GGTTACAAAC CAAAGATACA GCCTGAATTT TTTCTAGGCC 6480
ACATTACATA AATTTGACCT GGTACCAATA TTGTTCTCTA TATAGTTATT TCCTTCCCA 6540
CTGTGTTTAA CCCCTTAAGG CATTGAGAAC AACTAGAATC ATAGAATGGT TTGGATTGGA 6600
AGGGGCTTA AACATCATCC ATTTCCAACC CTCTGCCATG GGCTGCTTGC CACCCACTGG 6660
CTCAGGCTGC CCAGGGCCCC ATCCAGCCTG GCCTTGAGCA CCTCCAGGGA TGGGGCACCC 6720
ACAGCTTCTC TGGGCAGCCT GTGCCAACAC CTCACCACTC TCTGGGTAAG GAATTCTCTT 6780
TTAACATCTA ATCTAAATCT CTTCTCTTTT AGTTTAAAGC CATTCTCTT TTTCCCGTTG 6840
CTATCTGTCC AAGAAATGTG TATTGGTCTC CCTCCTGCTT ATAAGCAGGA AGTACTGGAA 6900
GGCTGCAGTG AGGTCTCCCC ACAGCCTTCT CTTCTCCAGG CTGAACAAGC CCAGCTCCTT 6960
CAGCCTGTCT TCGTAGGAGA TCATCTTAGT GGCCCTCTC TGGACCCATT CCAACAGTTC 7020
CACGGCTTTC TTGTGGAGCC CCAGGTCTGG ATGCAGTACT TCAGATGGGG CTTTACAAAG 7080
GCAGAGCAGA TGGGGACAAT CGCTTACCCC TCCCTGCTGG CTGCCCCTGT TTTGATGCAG 7140
CCCAGGGTAC TGTTGGCCTT TCAGGCTCCC AGACCCCTTG CTGATTTGTG TCAAGCTTTT 7200
CATCCACCAG AACCCACGCT TCCTGGTTAA TACTTCTGCC CTCACTTCTG TAAGCTTGTT 7260
TCAGGAGACT TCCATTCTTT AGGACAGACT GTGTTACACC TACCTGCCCT ATTCTTGCAT 7320
ATATACATTT CAGTTTCATGT TTCCTGTAAC AGGACAGAAT ATGTATTCTT CTAACAAAAA 7380
TACATGCAGA ATTCCTAGTG CCATCTCAGT AGGGTTTTCA TGGCAGTATT AGCACATAGT 7440
CAATTTGCTG CAAGTACCTT CCAAGCTGCG GCCTCCATA AATCCTGTAT TTGGGATCAG 7500
TTACCTTTTG GGGTAAGCTT TTGTATCTGC AGAGACCCTG GGGGTTCTGA TGTGCTTCAG 7560
CTCTGCTCTG TTCTGACTGC ACCATTTTCT AGATCACCCA GTTGTTCTCTG TACAATTCC 7620
TTGTCTCTCA TCCTTTCCCA GCTTGTATCT TTGACAAATA CAGGCCTATT TTTGTGTTTG 7680
CTTCAGCAGC CATTTAATTC TTCAGTGTC TCTTGTCTG TTGATGCCAC TGGAACAGGA 7740
TTTTCAGCAG TCTTGCAAAG AACATCTAGC TGAAAATTT CTGCCATTCA ATATTCTTAC 7800
CAGTTCTTCT TGTTTGAGGT GAGCCATAAA TTAAGTAGAAC TTCGTCCTG ACAAGTTTAT 7860
GCATTTTATT ACTTCTATTA TGTACTTACT TTGACATAAC ACAGACACGC ACATATTTTG 7920
CTGGGATTTT CACAGTGTCT CTGTGTCCTT CACATGGTTT TACTGTCATA CTTCCGTTAT 7980
AACCTTGGCA ATCTGCCAG CTGCCATCA CAAGAAAAGA GATTCTTTT TTATTACTTC 8040

FIG.1C

4/43

TCTTCAGCCA	ATAAACAAAA	TGTGAGAAGC	CCAAACAAGA	ACTTGTGGGG	CAGGCTGCCA	8100
TCAAGGGAGA	GACAGCTGAA	GGGTTGTGTA	GCTCAATAGA	ATTAAGAAAT	AATAAAGCTG	8160
TGTCAGACAG	TTTTGCCTGA	TTTATACAGG	CACGCCCCAA	GCCAGAGAGG	CTGTCTGCCA	8220
AGGCCACCTT	GCAGTCCTTG	GTTTGTAAAG	TAAGTCATAG	GTAACTTTTT	TGGTGAATTG	8280
CGTGGAGAAT	CATGATGGCA	GTTCTTGCTG	TTTACTATGG	TAAGATGCTA	AAATAGGAGA	8340
CAGCAAAGTA	ACACTTGCTG	CTGTAGGTGC	TCTGCTATCC	AGACAGCGAT	GGCACTCGCA	8400
CACCAAGATG	AGGGATGCTC	CCAGCTGACG	GATGCTGGGG	CAGTAACAGT	GGGTCCCATG	8460
CTGCCTGCTC	ATTAGCATCA	CCTCAGCCCT	CACCAGCCCA	TCAGAAGGAT	CATCCCAAGC	8520
TGAGGAAAGT	TGCTCATCTT	CTTCACATCA	TCAAACCTTT	GGCCTGACTG	ATGCCTCCCG	8580
GATGCTTAAA	TGTGGTCACT	GACATCTTTA	TTTTTCTATG	ATTTCAAGTC	AGAACCTCCG	8640
GATCAGGAGG	GAACACATAG	TGGGAATGTA	CCCTCAGCTC	CAAGGCCAGA	TCTTCCTTCA	8700
ATGATCATGC	ATGCTACTTA	GGAAGGTGTG	TGTGTGTGAA	TGTAGAATTG	CCTTTGTTAT	8760
TTTTTCTTCC	TGCTGTCAGG	AACATTTTGA	ATACCAGAGA	AAAAGAAAAG	TGCTCTTCTT	8820
GGCATGGGAG	GAGTTGTCAC	ACTTGCAAAA	TAAAGGATGC	AGTCCCAAAT	GTTCCATAATC	8880
TCAGGGTCTG	AAGGAGGATC	AGAAACTGTG	TATACAATTT	CAGGCTTCTC	TGAATGCAGC	8940
TTTTGAAAGC	TGTTCTGGC	CGAGGCAGTA	CTAGTCAGAA	CCCTCGGAAA	CAGGAACAAA	9000
TGTCTTCAAG	GTGCAGCAGG	AGGAAACACC	TTGCCCATCA	TGAAAGTGAA	TAACCACTGC	9060
CGCTGAAGGA	ATCCAGCTCC	TGTTTGAGCA	GGTGCTGCAC	ACTCCACAC	TGAAACAACA	9120
GTTCATTTTT	ATAGGACTTC	CAGGAAGGAT	CTTCTTCTTA	AGCTTCTTAA	TTATGGTACA	9180
TCTCCAGTTG	GCAGATGACT	ATGACTACTG	ACAGGAGAAT	GAGGAACTAG	CTGGGAATAT	9240
TTCTGTTTGA	CCACCATGGA	GTCACCCATT	TCTTTACTGG	TATTTGAAA	TAATAATTCT	9300
GAATTGCAAA	GCAGGAGTTA	GCGAAGATCT	TCATTTCTTC	CATGTTGGTG	ACAGCACAGT	9360
TCTGGCTATG	AAAGTCTGCT	TACAAGGAAG	AGGATAAAAA	TCATAGGGAT	AATAAATCTA	9420
AGTTTGAAGA	CAATGAGGTT	TTAGCTGCAT	TTGACATGAA	GAAATTGAGA	CCTCTACTGG	9480
ATAGCTATGG	TATTTACGTG	TCTTTTGGCT	TAGTTACTTA	TTGACCCAG	CTGAGGTCAA	9540
GTATGAACTC	AGGTCTCTCG	GGCTACTGGC	ATGGATTGAT	TACATACAAC	TGTAATTTTA	9600
GCAGTGATTT	AGGGTTTATG	AGTACTTTTG	CAGTAAATCA	TAGGGTTAGT	AATGTTAATC	9660
TCAGGGAAAA	AAAAAAAAAG	CCAACCCTGA	CAGACATCCC	AGCTCAGGTG	GAAATCAAGG	9720
ATCACAGCTC	AGTGCGGTCC	CAGAGAACAC	AGGGACTCTT	CTCTTAGGAC	CTTTATGTAC	9780
AGGGCCTCAA	GATAACTGAT	GTTAGTCAGA	AGACTTTCCA	TTCTGGCCAC	AGTTCAGCTG	9840
AGGCAATCCT	GGAATTTTCT	CTCCGCTGCA	CAGTTCCAGT	CATCCCAGTT	TGTACAGTTC	9900
TGGCACTTTT	TGGGTCAGGC	CGTGATCCAA	GGAGCAGAAG	TTCCAGCTAT	GGTCAGGGAG	9960
TGCCTGACCG	TCCCAACTCA	CTGCACTCAA	ACAAAGGCGA	AACCACAAGA	GTGGCTTTTG	10020
TTGAAATTGC	AGTGTGGCCC	AGAGGGGCTG	CACCAGTACT	GGATTGACCA	CGAGGCAACA	10080
TTAATCCTCA	GCAAGTGCAA	TTTGCAGCCA	TTAAATTGAA	CTAACTGATA	CTACAATGCA	10140
ATCAGTATCA	ACAAGTGGTT	TGGCTTGGAA	GATGGAGTCT	AGGGGCTCTA	CAGGAGTAGC	10200
TACTCTCTAA	TGGAGTTGCA	TTTTGAAGCA	GGACACTGTG	AAAAGCTGGC	CTCCTAAAGA	10260
GGCTGCTAAA	CATTAGGGTC	AATTTTCCAG	TGCACTTTCT	GAAGTGTCTG	CAGTCCCA	10320
TGCAAAGCTG	CCCAACATA	GCACTTCCAA	TTGAATACAA	TTATATGCAG	CGTACTGCT	10380
TCTTGCCAGC	ACTGTCCTTC	TCAAATGAAC	TCAACAAACA	ATTTCAAAGT	CTAGTAGAAA	10440
GTAACAAGCT	TTGAATGTCA	TTAAAAAGTA	TATCTGCTTT	CAGTAGTTCA	GCTTATTTAT	10500
GCCCACTAGA	AACATCTTGT	ACAAGCTGAA	CACTGGGGCT	CCAGATTAGT	GGTAAACCT	10560
ACTTTATACA	ATCATAGAAT	CATAGAATGG	CCTGGGTTGG	AAGGGACCCC	AAGGATCATG	10620
AAGATCCAAC	ACCCCGCCA	CAGGCAGGGC	CACCAACCTC	CAGATCTGGT	ACTAGACCAG	10680
GCAGCCCAGG	GCTCCATCCA	ACCTGGCCAT	GAACACCTCC	AGGGATGGAG	CATCCACAAC	10740

FIG.1D

SUBSTITUTE SHEET (RULE 26)

5/43

CTCTCTGGGC	AGCCTGTGCC	AGCACCTCAC	CACCCCTCTCT	GTGAAGAACT	TTTCCCTGAC	10800
ATCCAATCTA	AGCCTTCCCT	CCTTGAGGTT	AGATCCACTC	CCCCTTGTGC	TATCACTGTC	10860
TACTCTTGTA	AAAAGTTGAT	TCTCCTCCTT	TTTGGAAAGGT	TGCAATGAGG	TCTCCTTGCA	10920
GCCTTCTTCT	CTTCTGCAGG	ATGAACAAGC	CCAGCTCCCT	CAGCCTGTCT	TTATAGGAGA	10980
GGTGCTCCAG	CCCTCTGATC	ATCTTTGTGG	CCCTCCTCTG	GACCCGCTCC	AAGAGCTCCA	11040
CATCTTTCCT	GTA CTGGGGG	CCCCAGGCCT	GAATGCAGTA	CTCCAGATGG	GGCCTCAAAA	11100
GAGCAGAGTA	AAGAGGGACA	ATCACCTTCC	TCACCCTGCT	GGCCAGCCCT	CTTCTGATGG	11160
AGCCCTGGAT	ACA ACTGGCT	TTCTGAGCTG	CAACTTCTCC	TTATCAGTTC	CACTATTAAA	11220
ACAGGAACAA	TACAACAGGT	GCTGATGGCC	AGTGCAGAGT	TTTTCACACT	TCTTCATTTT	11280
GGTAGATCTT	AGATGAGGAA	CGTTGAAGTT	GTGTTCTGTC	GTGTGCTTCT	TCCTCCTCAA	11340
ATACTCTGTC	CTGATACCTC	ACCCACCTG	CCACTGAATG	GCTCCATGGC	CCCCTGCAGC	11400
CAGGGCCCTG	ATGAACCCGG	CACTGCTTCA	GATGCTGTTT	AATAGCACAG	TATGACCAAG	11460
TTGCACCTAT	GAATACACAA	ACAATGTGTT	GCATCCTTCA	GCACCTGAGA	AGAAGAGCCA	11520
AATTTGCATT	GTCAGGAAAT	GGTTTAGTAA	TTCTGCCAAT	TAAACTTGT	TTATCTACCA	11580
TGGCTGTTTT	TATGGCTGTT	AGTAGTGGTA	CACTGATGAT	GAACAATGGC	TATGCAGTAA	11640
AATCAAGACT	GTAGATATTG	CAACAGACTA	TAAATTCCT	CTGTGGCTTA	GCCAATGTGG	11700
TACTTCCAC	ATTGTATAAG	AAATTTGGCA	AGTTTAGAGC	AATGTTTGAA	GTGTTGGGAA	11760
ATTTCTGTAT	ACTCAAGAGG	GCGTTTTTGA	CAACTGTAGA	ACAGAGGAAT	CAAAAGGGGG	11820
TGGGAGGAAG	TAAAAGAAG	AGGCAGGTGC	AAGAGAGCTT	GCAGTCCCGC	TGTGTGTACG	11880
ACACTGGCAA	CATGAGGTCT	TTGCTAATCT	TGGTGCTTTG	CTTCCTGCCC	CTGGCTGCCT	11940
TAGGGTGCGA	TCTGCCTCAG	ACCCACAGCC	TGGGCAGCAG	GAGGACCCTG	ATGCTGCTGG	12000
CTCAGATGAG	GAGAATCAGC	CTGTTTAGCT	GCCTGAAGGA	TAGGCACGAT	TTTGGCTTTC	12060
CTCAAGAGGA	GTTTGGCAAC	CAGTTTCAGA	AGGCTGAGAC	CATCCCTGTG	CTGCACGAGA	12120
TGATCCAGCA	GATCTTTAAC	CTGTTTAGCA	CCAAGGATAG	CAGCGCTGCT	TGGGATGAGA	12180
CCCTGCTGGA	TAAGTTTTAC	ACCGAGCTGT	ACCAGCAGCT	GAACGATCTG	GAGGCTTGCG	12240
TGATCCAGGG	CGTGGGCGTG	ACCGAGACCC	CTCTGATGAA	GGAGGATAGC	ATCCTGGCTG	12300
TGAGGAAGTA	CTTTCAGAGG	ATCACCTGT	ACCTGAAGGA	GAAGAAGTAC	AGCCCCTGCG	12360
CTTGGGAAGT	CGTGAGGGCT	GAGATCATGA	GGAGCTTTAG	CCTGAGCACC	AACCTGCAAG	12420
AGAGCTTGAG	GTCTAAGGAG	TAAAAAGTCT	AGAGTCGGGG	CGGCCGGCCG	CTTCGAGCAG	12480
ACATGATAAG	ATACATTGAT	GAGTTTGGAC	AAACCACAAC	TAGAATGCAG	TGAAAAAAT	12540
GCTTTATTTG	TGAAATTTGT	GATGCTATTG	CTTTATTTGT	AACCATTATA	AGCTGCAATA	12600
AACAAGTTAA	CAACAACAAT	TGCATTCATT	TTATGTTTCA	GGTTCAGGGG	GAGGTGTGGG	12660
AGGTTTTTTA	AAGCAAGTAA	AACCTCTACA	AATGTGGTAA	AATCGATAAG	GATCCGTCGA	12720
GCGGCCGC	12728					

FIG.1E

6/43

SEQ ID NO: 5

TGCGATCTGC	CTCAGACCCA	CAGCCTGGGC	AGCAGGAGGA	CCCTGATGCT	GCTGGCTCAG	60
ATGAGGAGAA	TCAGCCTGTT	TAGCTGCCTG	AAGGATAGGC	ACGATTTTGG	CTTTCCTCAA	120
GAGGAGTTTG	GCAACCAGTT	TCAGAAGGCT	GAGACCATCC	CTGTGCTGCA	CGAGATGATC	180
CAGCAGATCT	TTAACCTGTT	TAGCACCAAG	GATAGCAGCG	CTGCTTGGGA	TGAGACCCTG	240
CTGGATAAGT	TTTACACCGA	GCTGTACCAG	CAGCTGAACG	ATCTGGAGGC	TTGCGTGATC	300
CAGGGCGTGG	GCGTGACCGA	GACCCCTCTG	ATGAAGGAGG	ATAGCATCCT	GGCTGTGAGG	360
AAGTACTTTC	AGAGGATCAC	CCTGTACCTG	AAGGAGAAGA	AGTACAGCCC	CTGCGCTTGG	420
GAAGTCGTGA	GGGCTGAGAT	CATGAGGAGC	TTTAGCCTGA	GCACCAACCT	GCAAGAGAGC	480
TTGAGGTCTA	AGGAGTAA	498				

FIG.2

7/43

SEQ ID NO: 7

TGCCGCCTTC TTTGATATTC ACTCTGTTGT ATTTTCATCTC TTCTTGCCGA TGAAAGGATA 60
TAACAGTCTG TATAACAGTC TGTGAGGAAA TACTTGGTAT TTCTTCTGAT CAGTGTTTTT 120
ATAAGTAATG TTGAATATTG GATAAGGCTG TGTGTCCTTT GTCTTGGGAG ACAAAGCCCA 180
CAGCAGGTGG TGGTTGGGGT GGTGGCAGCT CAGTGACAGG AGAGGTTTTT TTGCTGTGTT 240
TTTTTTTTTT TTTTTTTTTT AAGTAAGGTG TTCTTTTTTC TTAGTAAATT TTCTACTGGA 300
CTGTATGTTT TGACAGGTCA GAAACATTTT TCACAAAGAA GAACCTTTTG GAAACTGTAC 360
AGCCCTTTTC TTTTCATTCCC TTTTGTCTT CTGTGCCAAT GCCTTTGGTT CTGATTGCAT 420
TATGGAAAAC GTTGATCGGA ACTTGAGGT TTTATTTATA GTGTGGCTTG AAAGCTTGGA 480
TAGCTGTTGT TACACGAGAT ACCTTATTAA GTTTAGGCCA GCTTGATGCT TTTATTTTTC 540
CCTTTGAAGT AGTGAGCGTT CTCTGGTTTT TTTCTTTTGA AACTGGTGAG GCTTAGATTT 600
TTCTAATGGG ATTTTTTACC TGATGATCTA GTTGCATACC CAAATGCTTG TAAATGTTTT 660
CCTAGTTAAC ATGTTGATAA CTTCGGATT ACATGTTGTA TATACTTGT ATCTGTGTTT 720
CTAGTAAAAA TATATGGCAT TTATAGAAAT ACGTAATTCC TGATTTCTT TTTTTTATC 780
TCTATGCTCT GTGTGTACAG GTCAAACAGA CTTCACTCCT ATTTTATTT ATAGAATTTT 840
ATATGCAGTC TGTCGTTGGT TCTTGTGTTG TAAGGATACA GCCTTAAATT TCCTAGAGCG 900
ATGCTCAGTA AGGCGGGTTG TCACATGGGT TCAAATGTAA AACGGGCACG TTTGGCTGCT 960
GCCTTCCCGA GATCCAGGAC ACTAACTGC TTCTGCACTG AGGTATAAAT CGCTTCAGAT 1020
CCCAGGGAAG TGCAGATCCA CGTGCAATTT CTTAAAGAAG AATGAATACT TTCTAAAATA 1080
TTTTGGCATA GGAAGCAAGC TGCATGGATT TGTTTGGGAC TTAAATTATT TTGGTAACGG 1140
AGTGCATAGG TTTTAAACAC AGTTGCAGCA TGCTAACGAG TCACAGCGTT TATGCAGAAG 1200
TGATGCCTGG ATGCCTGTTG CAGCTGTTT CCGCACTGCC TTGCAGTGAG CATTGCAGAT 1260
AGGGGTGGGG TGCTTTGTGT CGTGTTCCTA CACGCTGCCA CACAGCCACC TCCCAGAAC 1320
CATCTCACCT GCTGGGTACT TTTCAAACCA TCTTAGCAGT AGTAGATGAG TTAGTATGAA 1380
ACAGAGAAGT TCCTCAGTTG GATATTCTCA TGGGATGTCT TTTTCCCAT GTTGGGCAAA 1440
GTATGATAAA GCATCTCTAT TTGTAAATTA TGCATTGTT AGTTCCTGAA TCCTTCTAT 1500
AGCACCATT ATTGCAGCAG GTGTAGGCTC TGGTGTGGCC TGTGTCTGTG CTTCATCTT 1560
TTAAAGCTTC TTTGGAAATA CACTGACTTG ATTGAAGTCT CTTGAAGATA GTAAACAGTA 1620
CTTACCTTTG ATCCCAATGA AATCGAGCAT TTCAGTTGTA AAAGAATTCC GCCTATTAT 1680
ACCATGTAAT GTAATTTTAC ACCCCAGTG CTGACACTTT GGAATATATT CAAGTAATAG 1740
ACTTTGGCCT CACCCTCTTG TGTACTGTAT TTTGTAATAG AAAATATTTT AAAGTGTGCA 1800
TATGATTATT ACATTATGAA AGAGACATTC TGCTGATCTT CAAATGTAAG AAAATGAGGA 1860
GTGCGTGTGC TTTTATAAAT ACAAGTGATT GCAAATTAGT GCAGGTGTCC TTAACAAAAA 1920
AAAAAAAAG TAATATAAAA AGGACCAGGT GTTTTACAAG TGAAATACAT TCCTATTTGG 1980
TAAACAGTTA CATTTTTATG AAGATTACCA GCGCTGCTGA CTTTCTAAAC ATAAGGCTGT 2040
ATTGTCTTCC TGTACCATTG CATTTCTCA TTCCCAATTT GCACAAGGAT GTCTGGGTAA 2100
ACTATTCAAG AAATGGCTTT GAAATACAGC ATGGGAGCTT GTCTGAGTTG GAATGCAGAG 2160
TTGCACTGCA AAATGTCAGG AAATGGATGT CTCTCAGAAT GCCCACTCC AAAGGATTTT 2220
ATATGTGTAT ATAGTAAGCA GTTTCCTGAT TCCAGCAGGC CAAAGAGTCT GCTGAATGTT 2280
GTGTTGCCGG AGACCTGTAT TTCTCAACAA GGTAAGATGG TATCCTAGCA ACTGCGGATT 2340
TTAATACATT TTCAGCAGAA GACTTAGTT AATCTCTACC TTTAGGGATC GTTTCATCAT 2400
TTTTAGATGT TATACTTGAA ATACTGCATA ACTTTTAGCT TTCATGGGTT CCTTTTTTTC 2460
AGCCTTTAGG AGACTGTAA GCAATTTGCT GTCCAACTTT TGTGTTGGTC TTAAGTGTCA 2520
ATAGTAGTTT ACCTTGATT GAAGAAATAA AGACCATTTT TATATTAAAA AATACTTTTG 2580
TCTGTCTTCA TTTTGACTTG TCTGATATCC TTGCAGTGCC CATTATGTCA GTTCTGTGAG 2640
ATATTGAGAC ATCAAACTT AACGTGAGCT CAGTGGAGTT ACAGCTGCGG TTTTGATGCT 2700

FIG.3A

SUBSTITUTE SHEET (RULE 26)

8/43

GTTATTATTT CTGAAACTAG AAATGATGTT GTCTTCATCT GCTCATCAAA CACTTCATGC 2760
AGAGTGTAAG GCTAGTGAGA AATGCATACA TTTATTGATA CTTTTTTAAA GTCAACTTTT 2820
TATCAGATTT TTTTTTCATT TGGAAATATA TTGTTTTCTA GACTGCATAG CTTCTGAATC 2880
TGAAATGCAG TCTGATTGGC ATGAAGAAGC ACAGCACTCT TCATCTTACT TAAACTTCAT 2940
TTTGAATGA AGGAAGTTAA GCAAGGGCAC AGGTCCATGA AATAGAGACA GTGCGCTCAG 3000
GAGAAAGTGA ACCTGGATTT CTTTGGCTAG TGTTCTAAAT CTGTAGTGAG GAAAGTAACA 3060
CCCGATTCTT TGAAAGGGCT CCAGCTTTAA TGCTTCCAAA TTGAAGGTGG CAGGCAACTT 3120
GGCCACTGGT TATTTACTGC ATTATGTCTC AGTTTCGCAG CTAACCTGGC TTCTCCACTA 3180
TTGAGCATGG ACTATAGCCT GGCTTCAGAG GCCAGGTGAA GGTTGGGATG GGTGGAAGGA 3240
GTGCTGGGCT GTGGCTGGGG GGACTGTGGG GACTCCAAGC TGAGCTTGGG GTGGGCAGCA 3300
CAGGGAAAAG TGTGGGTAAC TATTTTTAAG TACTGTGTTG CAAACGTCTC ATCTGCAAT 3360
ACGTAGGGTG TGTACTCTCG AAGATTAACA GTGTGGGTTT AGTAATATAT GGATGAATTC 3420
ACAGTGGAAG CATTCAAGGG TAGATCATCT AACGACACCA GATCATCAAG CTATGATTGG 3480
AAGCGGTATC AGAAGAGCGA GGAAGGTAAG CAGTCTTCAT ATGTTTTCCC TCCACGTAAA 3540
GCAGTCTGGG AAAGTAGCAC CCCTTGAGCA GAGACAAGGA AATAATTCAG GAGCATGTGC 3600
TAGGAGAACT TTCTTGCTGA ATTCTACTTG CAAGAGCTTT GATGCCTGGC TTCTGGTGCC 3660
TTCTGCAGCA CCTGCAAGGC CCAGAGCCTG TGGTGAGCTG GAGGGAAAGA TTCTGCTCAA 3720
GTCCAAGCTT CAGCAGGTCA TTGTCTTTGC TTCTTCCCC AGCACTGTGC AGCAGAGTGG 3780
AACTGATGTC GAAGCCTCCT GTCCACTACC TGTTGCTGCA GGCAGACTGC TCTCAGAAAA 3840
AGAGAGCTAA CTCTATGCCA TAGTCTGAAG GTAAAAATGGG TTTTAAAAAA GAAAACACAA 3900
AGGCAAAACC GGCTGCCCCA TGAGAAGAAA GCAGTGGTAA ACATGGTAGA AAAGGTGCAG 3960
AAGCCCCCAG GCAGTGTGAC AGGCCCCCTC TGCCACCTAG AGGCGGGAAC AAGCTTCCCT 4020
GCCTAGGGCT CTGCCCAGCA AGTGCGTGTT TCTTTGGTGG GTTTTGTGTT GCGTTTGGTT 4080
TTGAGATTTA GACACAAGGG AAGCCTGAAA GGAGGTGTTG GGCCTATTT TGGTTTGTAA 4140
AGCCTGTACT TCAAATATAT ATTTTGTGAG GGAGTGTAGC GAATTGGCCA ATTTAAATA 4200
AAGTTGCAAG AGATTGAAGG CTGAGTAGTT GAGAGGGTAA CACGTTTAAAT GAGATCTTCT 4260
GAAACTACTG CTTCTAAACA CTTGTTTGAG TGGTGAGACC TTGGATAGGT GAGTGCTCTT 4320
GTTACATGTC TGATGCACTT GCTTGTCTT TTCCATCCAC ATCCATGCAT TCCACATCCA 4380
CGCATTTGTC ACTTATCCCA TATCTGTCAT ATCTGACATA CCTGTCTCTT CGTCACTTGG 4440
TCAGAAGAAA CAGATGTGAT AATCCCCAGC CGCCCCAAGT TTGAGAAGAT GGCAGTTGCT 4500
TCTTTCCCTT TTTCTGCTA AGTAAGGATT TTCTCCTGGC TTTGACACCT CACGAAATAG 4560
TCTTCCTGCC TTACATTCTG GGCATTATTT CAAATATCTT TGGAGTGCGC TGCTCTCAAG 4620
TTTGTGTCTT CTTACTCTTA GAGTGAATGC TCTTAGAGTG AAAGAGAAGG AAGAGAAGAT 4680
GTTGGCCGCA GTTCTCTGAT GAACACACCT CTGAATAATG GCCAAAGGTG GGTGGGTTTC 4740
TCTGAGGAAC GGGCAGCGTT TGCCTCTGAA AGCAAGGAGC TCTGCGGAGT TGCAGTTATT 4800
TTGCAACTGA TGGTGGAAC GGTGCTTAAA GCAGATTCCC TAGGTTCCCT GCTACTTCTT 4860
TTCTTCTTG GCAGTCAGTT TATTTCTGAC AGACAAACAG CCACCCCCAC TGCAGGCTTA 4920
GAAAGTATGT GGCTCTGCCT GGGTGTGTTA CAGCTCTGCC CTGGTGAAAG GGGATTAAAA 4980
CGGGCACCAT TCATCCCAA CAGGATCCTC ATTCATGGAT CAAGCTGTAA GGAAGTTGGG 5040
CTCCAACCTC AAAACATTAA TTGGAGTAGC AATGTAATTA AAAGTGCATT CTCGCATTCC 5100
TAAGTCATTT AGTCTGGACT CTGCAGCATG TAGGTCCGCA GCTCCCACTT TCTCAAAGAC 5160
CACTGATGGA GGAGTAGTAA AAATGGAGAC CGATTGAGAA CAACCAACGG AGTGTTGCCG 5220
AAGAACTGA TGGAAATAAT GCATGAATTG TGTGGTGGAC ATTTTTTTTA AATACATAAA 5280
CTACTTCAAA TGAGGTGCGA GAAGGTCAGT GTTTTATTAG CAGCCATAAA ACCAGGTGAG 5340
CGAGTACCAT TTTTCTCTAC AAGAAAAACG ATTCTGAGCT CTGCGTAAGT ATAAGTTCTC 5400

FIG.3B

9/43

CATAGCGGCT GAAGCTCCCC CCTGGCTGCC TGCCATCTCA GCTGGAGTGC AGTGCCATTT 5460
 CCTTGGGGTT TCTCTCACAG CAGTAATGGG ACAATACTTC ACAAAAATTC TTTCTTTTCC 5520
 TGTCTGTGG GATCCCTACT GTGCCCTCCT GGTTTTACGT TACCCCTGA CTGTTCCATT 5580
 CAGCGGTTTG GAAAGAGAAA AAGAATTTGG AAATAAAACA TGTCTACGT ATCACCTCCT 5640
 CCAGCATTTT GGTTTTAAAT TATGTCAATA ACTGGCTTAG ATTTGGAAAT GAGAGGGGGT 5700
 TGGGTGTATT ACCGAGGAAC AAAGGAAGGC TTATATAAAC TCAAGTCTTT TATTAGAGA 5760
 ACTGGCAAGC TGTCAAAAAC AAAAAGGCC TACCACCAA TTAAGTGAAT AGCCGCTATA 5820
 GCCAGCAGGG CCAGCACGAG GGATGGTGCA CTGCTGGCAC TATGCCACGG CCTGCTTGTG 5880
 ACTCTGAGAG CAACTGCTTT GGAAATGACA GCACTTGGTG CAATTTCTTT TGTTCAGAA 5940
 TGGCTAGAGC GTGTGCTTGG CGACAGTTTT TCTAGTTAGG CCACTTCTTT TTTCTTCTC 6000
 TCCTCATTCT CCTAAGCATG TCTCCATGCT GGTAAATCCA GTCAAGTGA CGTTCAAACA 6060
 ATGAATCCAT CACTGTAGGA TTCTCGTGGT GATCAAATCT TTGTGTGAGG TCTATAAAAT 6120
 ATGGAAGCTT ATTTATTTTT CGTTCTTCCA TATCAGTCTT CTCTATGACA ATTCACATCC 6180
 ACCACAGCAA ATTAAGGTG AAGGAGGCTG GTGGGATGAA GAGGGTCTTC TAGCTTTACG 6240
 TTCTTCCTTG CAAGGCCACA GGAAAATGCT GAGAGCTGTA GAATACAGCC TGGGGTAAGA 6300
 AGTTCAAGTCT CCTGCTGGGA CAGCTAACCG CATCTTATAA CCCCTTCTGA GACTCATCTT 6360
 AGGACCAAAT AGGGTCTATC TGGGGTTTTT GTTCTGCTG TTCCTCCTGG AAGGCTATCT 6420
 CACTATTTCA CTGCTCCAC GGTACAAAC CAAAGATACA GCCTGAATTT TTTCTAGGCC 6480
 ACATTACATA AATTTGACCT GGTACCAATA TTGTTCTCTA TATAGTTATT TCCTTCCCA 6540
 CTGTGTTTAA CCCCTTAAGG CATTAGAATC AACTAGAATC ATAGAATGGT TTGGATTGGA 6600
 AGGGGCTTA AACATCATCC ATTTCCAACC CTCTGCCATG GGCTGCTTGC CACCCACTGG 6660
 CTCAGGCTGC CCAGGGCCCC ATCCAGCCTG GCCTTGAGCA CCTCCAGGGA TGGGGCACCC 6720
 ACAGCTTCTC TGGGCAGCCT GTGCCAACAC CTCACCACTC TCTGGGTAAA GAATTCCTTT 6780
 TTAACATCTA ATCTAAATCT CTTCTTTTTT AGTTTAAAGC CATTCCTCTT TTTCCCGTTG 6840
 CTATCTGTCC AAGAAATGTG TATTGGTCTC CCTCTGCTT ATAAGCAGGA AGTACTGGAA 6900
 GGCTGCAGTG AGGTCTCCCC ACAGCCTTCT CTTCTCCAGG CTGAACAAGC CCAGCTCCTT 6960
 CAGCCTGTCT TCGTAGGAGA TCATCTTAGT GGCCCTCCTC TGGACCCATT CCAACAGTTC 7020
 CACGGCTTTC TTGTGGAGCC CCAGGTCTGG ATGCAGTACT TCAGATGGGG CCTTACAAAG 7080
 GCAGAGCAGA TGGGGACAAT CGCTTACCCC TCCCTGCTGG CTGCCCCTGT TTTGATGCAG 7140
 CCCAGGGTAC TGTTGGCCTT TCAGGCTCCC AGACCCCTTG CTGATTTGTG TCAAGCTTTT 7200
 CATCCACCAG AACCCACGCT TCCTGGTTAA TACTTCTGCC CTCACCTCTG TAAGCTTGT 7260
 TCAGGAGACT TCCATTCTTT AGGACAGACT GTGTTACACC TACCTGCCCT ATTCTTGCAT 7320
 ATATACATTT CAGTTCATGT TTCCTGTAAC AGGACAGAAT ATGTATTCCT CTAACAAAAA 7380
 TACATGCAGA ATTCCTAGTG CCATCTCAGT AGGGTTTTCA TGGCAGTATT AGCACATAGT 7440
 CAATTTGCTG CAAGTACCTT CCAAGCTGCG GCCTCCCAT AATCCTGTAT TTGGGATCAG 7500
 TTACCTTTTG GGGTAAGCTT TTGTATCTGC AGAGACCCTG GGGGTCTGA TGTGCTTCAG 7560
 CTCTGCTCTG TTCTGACTGC ACCATTTTCT AGATCACCCA GTTGTCTCTG TACAATTCC 7620
 TTGTCTCCA TCCTTTCCCA GCTTGTATCT TTGACAAATA CAGGCCTATT TTTGTGTTG 7680
 CTTCAGCAGC CATTTAATTC TTCAGTGTCA TCTTGTCTG TTGATGCCAC TGAACAGGA 7740
 TTTTCAGCAG TCTTGCAAAG AACATCTAGC TGAAAACTT CTGCCATTCA ATATTCTTAC 7800
 CAGTTCTTCT TGTTTGAGGT GAGCCATAAA TTAGTAGAAC TTCGTCACTG ACAAGTTTAT 7860
 GCATTTTATT ACTTCTATTA TGTACTTACT TTGACATAAC ACAGACACGC ACATATTTTG 7920
 CTGGGATTTT CACAGTGTCT CTGTGCTCTT CACATGGTTT TACTGTCATA CTTCCGTTAT 7980
 AACCTTGGCA ATCTGCCAG CTGCCATCA CAAGAAAAGA GATTCCTTTT TTATTACTTC 8040
 TCTTCAGCCA ATAAACAAA TGTGAGAAGC CCAAACAAGA ACTTGTGGGG CAGGCTGCCA 8100

FIG.3C

SUBSTITUTE SHEET (RULE 26)

10/43

TCAAGGGAGA	GACAGCTGAA	GGGTTGTGTA	GCTCAATAGA	ATTAAGAAAT	AATAAAGCTG	8160
TGTCAGACAG	TTTTGCCTGA	TTTATACAGG	CACGCCCAA	GCCAGAGAGG	CTGTCTGCCA	8220
AGGCCACCTT	GCAGTCCTTG	GTTTGTAAAG	TAAGTCATAG	GTAACCTTTC	TGGTGAATTG	8280
CGTGGAGAAT	CATGATGGCA	GTTCTTGCTG	TTTACTATGG	TAAGATGCTA	AAATAGGAGA	8340
CAGCAAAGTA	ACACTTGCTG	CTGTAGGTGC	TCTGCTATCC	AGACAGCGAT	GGCACTCGCA	8400
CACCAAGATG	AGGGATGCTC	CCAGCTGACG	GATGCTGGGG	CAGTAACAGT	GGGTCCCATG	8460
CTGCCGTGCTC	ATTAGCATCA	CCTCAGCCCT	CACCAGCCCA	TCAGAAGGAT	CATCCCAAGC	8520
TGAGGAAAGT	TGCTCATCTT	CTTCACATCA	TCAAACCTTT	GGCCTGACTG	ATGCCTCCCG	8580
GATGCTTAAA	TGTGGTCACT	GACATCTTTA	TTTTTCTATG	ATTTCAAGTC	AGAACCTCCG	8640
GATCAGGAGG	GAACACATAG	TGGGAATGTA	CCCTCAGCTC	CAAGGCCAGA	TCTTCCTTCA	8700
ATGATCATGC	ATGCTACTTA	GGAAGGTGTG	TGTGTGTGAA	TGTAGAATTG	CCTTTGTTAT	8760
TTTTTCTTCC	TGCTGTCAGG	AACATTTTGA	ATACCAGAGA	AAAAGAAAAG	TGCTCTTCTT	8820
GGCATGGGAG	GAGTTGTAC	ACTTGCAAAA	TAAAGGATGC	AGTCCCAAAT	GTTCCATAATC	8880
TCAGGGTCTG	AAGGAGGATC	AGAACTGTG	TATACAATTT	CAGGCTTCTC	TGAATGCAGC	8940
TTTTGAAAGC	TGTTCTGGC	CGAGGCAGTA	CTAGTCAGAA	CCCTCGGAAA	CAGGAACAAA	9000
TGCTTCAAG	GTGCAGCAGG	AGGAAACACC	TTGCCCATCA	TGAAAGTGAA	TAACCACTGC	9060
CGCTGAAGGA	ATCCAGCTCC	TGTTTGAGCA	GGTGTGCAC	ACTCCACAC	TGAAACAACA	9120
GTTTCATTTT	ATAGGACTTC	CAGGAAGGAT	CTTCTTCTTA	AGCTTCTTAA	TTATGGTACA	9180
TCTCCAGTTG	GCAGATGACT	ATGACTACTG	ACAGGAGAAT	GAGGAACTAG	CTGGGAATAT	9240
TTCTGTTTGA	CCACCATGGA	GTCACCCATT	TCTTTACTGG	TATTTGGAAA	TAATAATTCT	9300
GAATTGCAAA	GCAGGAGTTA	GCGAAGATCT	TCATTTCTTC	CATGTTGGTG	ACAGCACAGT	9360
TCTGGCTATG	AAAGTCTGCT	TACAAGGAAG	AGGATAAAAA	TCATAGGGAT	AATAAATCTA	9420
AGTTTGAAGA	CAATGAGGTT	TTAGCTGCAT	TTGACATGAA	GAAATTGAGA	CCTCTACTGG	9480
ATAGCTATGG	TATTTACGTG	TCTTTTTGCT	TAGTTACTTA	TTGACCCAG	CTGAGGTCAA	9540
GTATGAACTC	AGGTCTCTCG	GGCTACTGGC	ATGGATTGAT	TACATACAAC	TGTAATTTTA	9600
GCAGTGATTT	AGGGTTTATG	AGTACTTTTG	CAGTAAATCA	TAGGGTTAGT	AATGTTAATC	9660
TCAGGGAAAA	AAAAAAAAAAG	CCAACCTGA	CAGACATCCC	AGCTCAGGTG	GAAATCAAGG	9720
ATCACAGCTC	AGTGCGGTCC	CAGAGAACAC	AGGGACTCTT	CTCTTAGGAC	CTTTATGTAC	9780
AGGGCCTCAA	GATAACTGAT	GTTAGTCAGA	AGACTTTCCA	TTCTGGCCAC	AGTTCAGCTG	9840
AGGCAATCCT	GGAATTTTCT	CTCCGCTGCA	CAGTTCAGT	CATCCCAGTT	TGTACAGTTC	9900
TGGCACTTTT	TGGGTCAGGC	CGTGATCCAA	GGAGCAGAAG	TTCCAGCTAT	GGTCAGGGAG	9960
TGCCTGACCG	TCCCAACTCA	CTGCACTCAA	ACAAAGGCGA	AACCACAAGA	GTGGCTTTTG	10020
TTGAAATTGC	AGTGTGGCCC	AGAGGGGCTG	CACCAGTACT	GGATTGACCA	CGAGGCAACA	10080
TTAATCCTCA	GCAAGTGCAA	TTTGCAGCCA	TTAAATTGAA	CTAACTGATA	CTACAATGCA	10140
ATCAGTATCA	ACAAGTGGTT	TGGCTTGGAA	GATGGAGTCT	AGGGGCTCTA	CAGGAGTAGC	10200
TACTCTCTAA	TGGAGTTGCA	TTTTGAAGCA	GGCACTGTG	AAAAGCTGGC	CTCCTAAAGA	10260
GGCTGCTAAA	CATTAGGGTC	AATTTTCCAG	TGCACTTTCT	GAAGTGTCTG	CAGTTCCCCA	10320
TGCAAAGCTG	CCCAAACATA	GCACTTCCAA	TTGAATACAA	TTATATGCAG	GCGTACTGCT	10380
TCTTGCCAGC	ACTGTCCTTC	TCAAATGAAC	TCAACAAACA	ATTTCAAAGT	CTAGTAGAAA	10440
GTAACAAGCT	TTGAATGTCA	TTAAAAAGTA	TATCTGCTTT	CAGTAGTTCA	GCTTATTTAT	10500
GCCCACTAGA	AACATCTTGT	ACAAGCTGAA	CACTGGGGCT	CCAGATTAGT	GGTAAAACCT	10560
ACTTTATACA	ATCATAGAAT	CATAGAATGG	CCTGGGTTGG	AAGGGACCCC	AAGGATCATG	10620
AAGATCCAAC	ACCCCGCCA	CAGGCAGGGC	CACCAACCTC	CAGATCTGGT	ACTAGACCAG	10680
GCAGCCCAGG	GCTCCATCCA	ACCTGGCCAT	GAACACCTCC	AGGGATGGAG	CATCCACAAC	10740
CTCTCTGGGC	AGCCTGTGCC	AGCACCTCAC	CACCCTCTCT	GTGAAGAACT	TTTCCCTGAC	10800
ATCCAATCTA	AGCCTTCCT	CCTTGAGGTT	AGATCCACTC	CCCCTTGTGC	TATCACTGTC	10860

FIG.3D

SUBSTITUTE SHEET (RULE 26)

11/43

TACTCTTGTA AAAAGTTGAT TCTCCTCCTT TTTGGAAGGT TGCAATGAGG TCTCCTTGCA 10920
GCCTTCTTCT CTTCTGCAGG ATGAACAAGC CCAGCTCCCT CAGCCTGTCT TTATAGGAGA 10980
GGTGCTCCAG CCCTCTGATC ATCTTTGTGG CCCTCCTCTG GACCCGCTCC AAGAGCTCCA 11040
CATCTTTCCT GTACTGGGGG CCCCAGGCCT GAATGCAGTA CTCCAGATGG GGCCTCAAAA 11100
GAGCAGAGTA AAGAGGGACA ATCACCTTCC TCACCCTGCT GGCCAGCCCT CTTCTGATGG 11160
AGCCCTGGAT ACAACTGGCT TTCTGAGCTG CAACTTCTCC TTATCAGTTC CACTATTAAA 11220
ACAGGAACAA TACAACAGGT GCTGATGGCC AGTGCAGAGT TTTTCACACT TCTTCATTTT 11280
GGTAGATCTT AGATGAGGAA CGTTGAAGTT GTGCTTCTGC GTGTGCTTCT TCCTCCTCAA 11340
ATACTCCTGC CTGATACCTC ACCCCACCTG CCACTGAATG GCTCCATGGC CCCCTGCAGC 11400
CAGGGCCCTG ATGAACCCGG CACTGCTTCA GATGCTGTTT AATAGCACAG TATGACCAAG 11460
TTGCACCTAT GAATACACAA ACAATGTGTT GCATCCTTCA GCACTTGAGA AGAAGAGCCA 11520
AATTTGCATT GTCAGGAAAT GGTTTAGTAA TTCTGCCAAT TAAAACTTGT TTATCTACCA 11580
TGGCTGTTTT TATGGCTGTT AGTAGTGGTA CACTGATGAT GAACAATGGC TATGCAGTAA 11640
AATCAAGACT GTAGATATTG CAACAGACTA TAAAATTCCT CTGTGGCTTA GCCAATGTGG 11700
TACTTCCCAC ATTGTATAAG AAATTTGGCA AGTTTAGAGC AATGTTTGAA GTGTTGGGAA 11760
ATTTCTGTAT ACTCAAGAGG GCGTTTTGA CAACTGTAGA ACAGAGGAAT CAAAAGGGGG 11820
TGGGAGGAAG TTAAGAAG AGGCAGGTGC AAGAGAGCTT GCAGTCCCGC TGTGTGTACG 11880
ACACTGGCAA CATGAGGTCT TTGCTAATCT TGGTGCTTTG CTTCTGCCC CTGGCTGCCT 11940
TAGGG 11945

FIG.3E

12/43

SEQ ID NO: 8

```
AAAGTCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGATAAGATACATTGATGAG 60
TTTGGACAAACCACAAC TAGAATGCAGTGAATAAATGCTTTATTTGTGAAATTTGTGAT 120
GCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGC 180
ATTCATTTTATGTTTCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAC 240
CTCTACAAATGTGGTAAATCGATAAGGATCCGTCGAGCGGCCGC 285
```

FIG.4

13/43

SEQ ID NO: 9

1 CGCGTGGTAGGTGGCGGGGGTTCCCAGGAGAGCCCCAGCGCGGACGGC
AGCGCCGTCACTACCGCTCCGTCTCCCTCCGCCCAGGGTCGCCTGGCGC
AACCGCTGCAAGGGACCGACGTCCAGGCGTGATCAGAGGCTGCCGGCT
GTGAGGAGCTGCCGCGCCCGGCCCGCCGCTGCACAGCCGGCCGCTTTGC
200 GAGCGCGACGCTACCCGCTTGGCAGTTTTAAACGCATCCCTCATTAAAC
GACTATACGCAAACGCTTCCCGTCGGTCCGCGTCTCTTTCCGCCGCCAG
GGCGACACTCGCGGGGAGGGCGGGAAGGGGGCCGGGCGGGAGCCCCGGGC
CAACCGTCGCCCCGTGACGGCACCGCCCCGCCCGCCGTGACGCGGTGCGGG
400 CGCCGGGGCCGTGGGGTGAGCGCTGCGGGGGGGCCGGGCGGGCCGGGG
CGGGAGCTGAGCGCGGCGGGCTGCGGGCGGCGCCCCCTCCGGTGCAATA
TGTTCAAGAGAATGGCTGAGTTCGGGCTGACTCCGGGGGCAGGGTGAAG
GTGCGGCGCGGGCGGAGGGACGGGGCGGGCGCGGGGCGCCCGGCGGGTG
600 CCGGGGCTCTGCCGCGCCGCGGCTCGGGCTGCTGCGGCGCTTACGGG
CGCGCTTCTCGCCGCTGCCGCTTCTCTTCTCTCCGCGCAAGGGCGTCAC
CATCGTGAAGCCGGTAGTGACGGGAACGTGGCGCGGTACTTCGGGAAGA
AGAGGGAGGAGGACGGGCACACGCATCAGTGGACGGTTTACGTGAAGCCC
800 TACAGGAACGAGGTAGGGCCCAGCGCGTCGGCCGCCGTTCTCGGAGCGC
CGGAGCCGTGAGCGCGCGCTGGGTGCGCTGTGGGACACAGCGAGCTTC
TCTCGTAGGACATGTCCGCTACGTGAAAAAATCCAGTTCAAGCTGCAC
GAGAGCTACGGGAATCCTCTCCGAGGTGGGTGTTGCGTCGGGGGGTTTGC
1000 TCCGCTCGGTCCGCTGAGGCTCGTCGCCCTCATCTTTCTTTCGTGCCGC
AGTCGTTACCAAACCGCGTACGAGATCACCGAAACGGGTGGGGCGAAT
TTGAAATCATCATCAAGATATTTTCATTGATCCAAACGAGCGACCCGTA
AGTACGCTCAGCTTCTCGTAGTGCTTCCCCGTCCTGGCGGCCCGGGCT
1200 GGGCTGCTCGCTGCTGCCGGTCACAGTCCCGCCAGCCGCGGAGCTGACTG
AGCTCCCTTTCCCGGACGTGTGCTCTGTGTTGCGTCAGCGAGGCTATCG
GGAGGGCTTTGGCTGCATTTGGCTTCTCTGGCGCTTAGCGCAGGAGCACG
TTGTGCTACGCCTGAACCTACAGCTGTGAGAAGCCGTGGAACCGCTCTC
1400 AAACGTATTTATTGGCGAAATGGCTCTAAACTAAATCGTCTCCTCTCTT
GGAAATGCTTTAGAGAAGGTCTCTGTGGTAGTTCTTATGCATCTATCCTA
AAGCACTTGGCCAGACAATTTAAAGACATCAAGCAGCATTTATAGCAGGC
ACGTTTAATAACGAATACTGAATTTAAGTAACTCTGCTCACGTTGTATGA
1600 CGTTTATTTTCGTATTCTGAAAGCCATTAAATCCTGTGCAGTTGTTTA
GTAAGAACAGCTGCCACTGTTTTGTATCTAGGAGATAACTGGTGTTCCTC
TACAGTTCTCAAGCTGATAAACTCTGTCTTTGTATCTAGGTAACCTGT
ATCACTTGCTGAAGCTTTTTCAGTCTGACACCAATGCAATCCTGGGAAAG
1800 AAACTGTAGTTTCTGAATTCTATGATGAAATGGTATGAAAATTTTAATG
TCAACCGAGCCTGACTTTATTTAAAAAAATTTATGATGGTGTGTGTAT
TTTGGTCCTTCTTAGATATTTCAAGATCCTACTGCCATGATGCAGCAAC
TGCTAACGACGTCCCGTCAGCTGACACTTGGTGTCTACAAGCATGAAACA

FIG.5A

14/43

2000 GAGTGTAAAGTGCAAAATGAGGATACCTTCGCCGACCGTCATTCACACTACTA
ATGTTTTCTGTGGGATGTGATCGTACAGTGAGTTTGGCTGTGTGAAATTT
GAATAGCTTGGTATTGGCAGTGATGACGTGATCGATGCCTTGCTTATCAT
GTTTGAAATGAAGTAGAATAAATGCAGCCTGCTTTATTTGAGATAGTTTG
2200 GTTCATTTTATGGAATGCAAGCAAAGATTATACTTCCTCACTGAATTGCA
CTGTCCAAAGGTGTGAAATGTGTGGGGATCTGGAGGACCGTGACCGAGGG
ACATTGGATCGCTATCTCCATTTCTTTTGCTGTTACCAGTTCAGATTTT
CTTTTCACCTAGTCTTTAATTCCAGGGTTTTGTTTTTCTTGGTCATA
2400 GTTTTTGTTTTTCACTCTGGCAAATGATGTTGTGAATTACACTGCTTCAG
CCACAAACTGATGGACTGAATGAGGTCATCAAACAACTTTTTCTTCTTC
CGTATTTCTTTTTTTTCCCCACTTATCATTTTTACTGCTGTTGTTGAG
TCTGTAAGGCTAAAAGTAACTGTTTTGTGCTTTTTCAGGACGTGTGCTTT
2600 CCAAATTACTGCCACATATATAAAGAAAGGTTGGAATTTTAAAGATAATT
CATGTTTCTTCTTTTTTTGCCACCACAGTTGCAGATCTTGAAGTAAAA
ACCAGGGAAAAGCTGGAAGCTGCCAAAAGAAAACCAGTTTTGAAATTGC
TGAGCTTAAAGAAAGGTTAAAAGCAAGTCGTGAAACCATCAACTGCTTAA
2800 AGAGTGAAATCAGAAAACCTCGAAGAGGATGATCAGTCTAAAGATATGTGA
TGAGTGTTGACTTGGCAGGGAGCCTATAATGAGAATGAAAGGACTTCAGT
CGTGGAGTTGTATGCGTTCTCTCCAATTCTGTAACGGGAGACTGTATGAAT
TTCATTTGCAAATCACTGCAGTGTGTGACAACTGACTTTTTATAAATGGC
3000 AGAAAACAAGAATGAATGTATCCTCATTTTATAGTTAAAATCTATGGGTA
TGTA CTGGTTTATTTCAAGGAGAAATGGATCGTAGAGACTTGGAGGCCAGA
TTGCTGCTTGTATTGACTGCATTTGAGTGGTGTAGGAACATTTTGTCTAT
GGTCCCGTGTAGTTTACAGAATGCCACTGTTCACTGTTTTGTTTTGTAT
3200 TTTACTTTTTTCTACTGCAACGTCAAGGTTTTAAAAGTTGAAAATAAAACA
TGCAGGTTTTTTTTTAAATATTTTTTTGTCTCTATCCAGTTTGGGCTTCAA
GTATTATTGTTAACAGCAAGTCCTGATTTAAGTCAGAGGCTGAAGTGTAA
TGGTATTCAAGATGCTTAAGTCTGTTGTGTCAGCAAAACAAAAGAGAAAAC
3400 TCATAAAATCAGGAAGTTGGCATTCTAATAACTTCTTTATCAACAGATA
AGAGTTTCTAGCCCTGCATCTACTTTCACTTATGTAGTTGATGCCTTTAT
ATTTTGTGTGTTTGGATGCAGGAAGTGATTCTACTCTGTTATGTAGATA
TTCTATTTAACACTTGTACTCTGCTGTGCTTAGCCTTTCCCATGAAAAT
3600 TCAGCGGCTGTAAATCCCCCTCTCTTTGTAGCCTCATACAGATGGCAG
ACCCTCAGGCTTATAAAGGCTTGGGCATCTTCTTTACTGCTTTGAGATTCT
TGTGTTGCAGTAACCTCTGCCAGAGAGGAGAAAAGCCCCACAAACCTCAT
CCCCTTCTTCTATAGCAATCAGTATTACTAATGCTTTGAGAACAGAGCAC
3800 TGGTTTGAAACGTTTGATAATTAGCATTTAACATGGCTTGGTAAAGATGC
AGAACTGAAACAGCTGTGACAGTATGAACTCAGTATGGAGACTTCATTAA
GACAAACAGCTGTTAAAATCAGGCATGTTTCATTGAGGAGGACGGGGCAA
CTTGCAACCAAGTGGTGCCACACAAATCCTTCCTGGCGCTGCAGACCAATT

FIG.5B

15/43

4000 TTTCTGGCATTCTGACTGCCGTTGCTGCTGGTCACAGAGAGCAACTATTT
TTATCAGCCACAGGCAATTTGCTTGTAGTATTTTCCAAGTGTGTAGGTA
AGTATAAATGCATCGGCTCCAGAGCACTTTGAGTATACTTATTAACAAACA
TAAATGAAAGACAAATTAGCTTTGCTTGGGTGCACAGAACATTTTGTGTT
4200 CCAGCCTGCTTTTTGGTAGAAGCCCTCTTCTGAGGCTAGAACTGACTTTG
ACAAGTAGAGAACTGGCAACGGAGCTATTGCTATCGAAGGATCCTTGTT
AACAAAGTTAATCGTCTTTTAAGGTTTGGTTTATTCATTAATTTGCTTT
TAAGCTGTAGCTGAAAAAGAACGTGCTGTCTTCCATGCACCAGGTGGCAG
4400 CTCTGTGCAAAGTCTCTCTGGTCTCACCAGCCTTTTAATTGCCGGGATT
CTGGCACGTCTGAGAGGGCTCAGACTGGCTTCGTTTGTGTAACAGCGTG
TACTGCTTTCTGTAGACATGGCCGGTTTCTCTCCTGCAGCTTATGAACT
GTTTCACTGAACACACTGGAACAGGTTGCCAAGGAGGCCGTGGATGCC
4600 CCATCCCTGGAGGCATTCAAGGCCAGGCTGGATGTGGCTCTGGGCAGCCT
GGTCTGGTGGTTGGCGATCCTGCACATAGCAGCGGGTTGAACTCGATG
ATCACTGTGGTCCTTTTCAACCCAGGCTATTCTATGATTCTATGATTCAA
CAGCAAATCATATGTACTGAGAGAGGAAACAAACACAAGTGCTACTGTTT
4800 GCAAGTTTTGTTCAATTTGGTAAAAGAGTCAGGTTTTAAATTCAAAATCT
GTCTGGTTTTGGTGTTTTTTTTTTTTATTTATTTCTTTGGGGTTCT
TTTTGATGCTTTATCTTCTCTGCCAGGACTGTGTGACAATGGGAACGAA
AAAGAACATGCCAGGCACTGTCTGGATTGCACACGCTGGTTGCACTCAG
5000 TAGCAGGCTCAGAACTGCCAGTCTTTCCACAGTATTACTTTCTAACCTA
ATTTTAATAGCGTTAGTAGACTTCCATCACTGGGCAGTGCTTAGTGAATG
CTCTGTGTGAACGTTTTACTTATAAGCATGTTGGAAGTTTTGATGTTCT
GGATGCAGTAGGGAAGGACAGATTAGCTATGTGAAAAGTAGATTCTGAGT
5200 ATCGGGGTTACAAAAAGTATAGAAACGATGAGAAATCTTGTTGTAAC
ATTGGAATTTCTTTAAGCGTTCACTTATGCTACATTCATAGTATTTCCAT
TTAAAAGTAGGAAAAGGTAAAACGTGAAATCGTGTGATTTTCGGATGGAA
CACCGCCTTCCTATGCACCTGACCAACTTCCAGAGGAAAAGCCTATTGAA
5400 AGCCGAGATTAAGCCACCAAAGAACTCATTTGCATTGGAATATGTAGTA
TTTGCCCTCTTCTCCCGGTAATTACTATACTTTATAGGGTGCTTATAT
GTTAAATGAGTGGCTGGCACTTTTTATTCTCACAGCTGTGGGGAATCTG
TCCTCTAGGACAGAAACAATTTAATCTGTTCCACTGGTGACTGCTTTGT
5600 CAGCACTTCCACCTGAAGAGATCAATACACTCTTCAATGTCTAGTTCTGC
AACACTTGGCAAACCTCACATCTTATTTCACTCTCTTCATGCCTATGC
TTATTAAGCAATAATCTGGGTAATTTTTGTTTTAATCACTGTCCTGACC
CCAGTGATGACCGTGCCACCTAAAGCTCAATTCAGGTCCTGAATCTCT
5800 TCAACTCTCTATAGCTAACATGAAGAATCTTCAAAGTTAGGTCTGAGGG
ACTTAAGGCTAACTGTAGATGTTGTTGCCTGGTTTCTGTGCTGAAGGCCG
TGTAAGTAGTTAGAGCATTCAACCTCTAG

FIG.5C

16/43

SEQ ID NO: 10

1 TGCCGCCCTTCTTTGATATTCACTCTGTTGTATTTTCATCTCTTCTTGCCGA
TGAAAGGATATAACAGTCTGTATAACAGTCTGTGAGGAAATACTTGGTAT
TTCTTCTGATCAGTGTATTTATAAGTAATGTTGAATATTGGATAAGGCTG
151 TGTGTCTTTGTCTTGGGAGACAAAGCCCACAGCAGGTGGTGGTTGGGGT
GGTGGCAGCTCAGTGACAGGAGAGGTTTTTTTGCCTGTTTTTTTTTTTT
TTTTTTTTTAAAGTAAGGTGTTCTTTTTCTTAGTAAATTTCTACTGGA
301 CTGTATGTTTTGACAGGTCAGAAACATTTCTTCAAAGAAGAACCTTTTG
GAAACTGTACAGCCCTTTTCTTTCATTCCCTTTTGTCTTCTGTGCCAAT
GCCTTTGGTTCTGATTGCATTATGGAACCGTTGATCGGAACCTTGAGGT
451 TTTATTTATAGTGTGGCTTGAAAGCTTGATAGCTGTTGTTACACGAGAT
ACCTTATTAAGTTTAGGCCAGCTTGATGCTTATTTTTCCCTTTGAAGT
AGTGAGCGTTCTCTGGTTTTTTTCTTTGAAACTGGTGAGGCTTAGATT
601 TTCTAATGGGATTTTTTACCTGATGATCTAGTTGCATACCCAAATGCTG
TAAATGTTTTCTAGTTAACATGTTGATAACTTCGGATTTACATGTTGTA
TATACTTGTCATCTGTGTTTCTAGTAAAAATATATGGCATTATAGAAAT
751 ACGTAATTCCTGATTTCTTTTTTTTTATCTCTATGCTCTGTGTGTACAG
GTCAAACAGACTTCACTCCTATTTTTATTTATAGAATTTTATATGCAGTC
TGTCGTTGGTTCTTGTGTTGTAAGGATACAGCCTTAAATTTCTAGAGCG
901 ATGCTCAGTAAGGCGGGTGTACATGGGTTCAAATGTAAACGGGCACG
TTTGGCTGCTGCCTTCCCGAGATCCAGGACACTAAACTGCTTCTGCACTG
AGGTATAAATCGCTTCAGATCCAGGGAAGTGCAGATCCACGTGCATATT
1051 CTTAAAGAAGAATGAATACTTTCTAAAATATTTTGGCATAGGAAGCAAGC
TGCATGGATTTGTTTGGGACTTAAATTATTTTGGTAACGGAGTGCATAGG
TTTTAAACACAGTTGCAGCATGCTAACGAGTCACAGCGTTTATGCAGAAG
1201 TGATGCCTGGATGCCTGTTGCAGCTGTTTACGGCACTGCCTTGCAGTGAG
CATTGCAGATAGGGGTGGGGTGTCTTGTGTGCTGTTCCACACGCTGCCA
CACAGCCACCTCCCGAACACATCTCACCTGCTGGGTACTTTTCAAACCA
1351 TCTTAGCAGTAGTAGATGAGTTACTATGAAACAGAGAAGTTCCTCAGTTG
GATATTCTCATGGGATGTCTTTTTTCCCATGTTGGGCAAAGTATGATAAA
GCATCTCTATTTGTAAATTATGCACTTGTTAGTTCTGAATCCTTTCTAT
1501 AGCACCACTTATTGCAGCAGGTGTAGGCTCTGGTGTGGCCTGTGTCTGTG
CTTCAATCTTTTAAAGCTTCTTTGAAATACACTGACTTGATTGAAGTCT
CTTGAAGATAGTAAACAGTACTTACCTTTGATCCCAATGAAATCGAGCAT
1651 TTCAGTTGTAAAAGAATTCCGCCTATTCATACCATGTAATGTAATTTTAC
ACCCCAAGTGCTGACACTTTGGAATATATTCAAGTAATAGACTTTGGCCT
CACCTCTTGTGTACTGTATTTGTAATAGAAAATATTTTAAACTGTGCA
1801 TATGATTATTACATTATGAAAGAGACATTCTGCTGATCTTCAAATGTAAG
AAAATGAGGAGTGCGTGTGCTTTTATAAATACAAGTGATTGCAAATTAGT
GCAGGTGTCCTTAAAAAAAAAAAAAAAAAGTAATATAAAAAGGACCAGGT
1951 GTTTTACAAGTGAAATACATTCTATTTGGTAAACAGTTACATTTTTATG
AAGATTACCAGCGCTGCTGACTTTCTAAACATAAGGCTGTATTGTCTTCC
TGTACCATTGCATTTCTCATTCCAATTTGCACAAGGATGTCTGGGTAA
2101 ACTATTCAAGAAATGGCTTTGAAATACAGCATGGGAGCTTGTCTGAGTTG
GAATGCAGAGTTGCACTGCAAAATGTGAGGAAATGGATGTCTCTCAGAAAT
GCCCAACTCCAAAGGATTTTATATGTGTATATAGTAAGCAGTTTCTGAT

FIG. 6A

SUBSTITUTE SHEET (RULE 26)

17/43

2251 TCCAGCAGGCCAAAGAGTCTGCTGAATGTTGTGTTGCCGGAGACCTGTAT
TTCTCAACAAGGTAAGATGGTATCCTAGCAACTGCCGATTTTAATACATT
TTCAGCAGAAGTACTTAGTTAATCTCTACCTTTAGGGATCGTTTCATCAT
2401 TTTTAGATGTTATACTTGAAATACTGCATAACTTTTAGCTTTCATGGGT
CCTTTTTTTCAGCCTTTAGGAGACTGTTAAGCAATTTGCTGTCCAACCTT
TGTGTTGGTCTTAACTGCAATAGTAGTTTACCTTGTATTGAAGAAATAA
2551 AGACCATTTTTATATTAATAAATACTTTTGTCTGTCTTCATTTTGACTTG
TCTGATATCCTTGCAGTGCCCATATGTCACTTCTGTCAGATATTCAGAC
ATCAAACTTAACGTGAGCTCAGTGGAGTTACAGCTGCCGTTTTGATGCT
2701 GTTATTATTTCTGAACTAGAAATGATGTTGTCTTCATCTGCTCATCAAA
CACTTCATGCAGAGTGTAAGGCTAGTGAGAAATGCATACATTTATTGATA
CTTTTTTAAAGTCAACTTTTTATCAGATTTTTTTTTTCATTTGGAAATATA
2851 TTGTTTTCTAGACTGCATAGCTTCTGAATCTGAAATGCAGTCTGATTGGC
ATGAAGAAGCACAGCACTCTTCATCTTACTTAACTTCATTTTGAATGA
AGGAAGTTAAGCAAGGGCACAGGTCCATGAAATAGAGACAGTGGCTCAG
3001 GAGAAAGTGAACCTGGATTTCTTTGGCTAGTGTTCTAAATCTGTAGTGAG
GAAAGTAACACCCGATTCCTTGAAAGGGCTCCAGCTTTAATGCTTCCAAA
TTGAAGGTGGCAGGCAACTTGGCCACTGGTTATTTACTGCATTATGTCTC
3151 AGTTTCGCAGCTAACCTGGCTTCTCCACTATTGAGCATGGACTATAGCCT
GGCTTCAGAGGCCAGGTGAAGGTTGGGATGGGTGGAAGGAGTGCTGGGCT
GTGGCTGGGGGACTGTGGGGACTCCAAGCTGAGCTTGGGGTGGGCAGCA
3301 CAGGGAAAAGTGTGGGTAACATTTTTAAGTACTGTGTTGCAACGTCTC
ATCTGCAAATACGTAGGGTGTGTACTCTCGAAGATTAACAGTGTGGGTTC
AGTAATATATGGATGAATTCACAGTGAAGCATTCAAGGGTAGATCATCT
3451 AACGACACCAGATCATCAAGCTATGATTGGAAGCGGTATCAGAAGAGCGA
GGAAGGTAAGCAGTCTTCATATGTTTTCCCTCCACGTAAAGCAGTCTGGG
AAAGTAGCACCCCTTGAGCAGAGACAAGGAAATAATTCAGGAGCATGTGC
3601 TAGGAGAACTTTCTTGCTGAATTCTACTTGCAAGAGCTTTGATGCCTGGC
TTCTGGTGCCTTCTGCAGCACCTGCAAGGCCAGAGCTGTGGTGAGCTG
GAGGGAAAGATTCTGCTCAAGTCCAAGCTTCAGCAGGTCATTGTCTTTGC
3751 TTCTTCCCCAGCACTGTGCAGCAGAGTGGAAGTGTGTCGAAGCCTCCT
GTCCACTACCTGTTGCTGCAGGCAGACTGCTCTCAGAAAAAGAGAGTAA
CTCTATGCCATAGTCTGAAGGTAAATGGGTTTTAAAAAGAAAACACAA
3901 AGGCAAAACCGCTGCCCATGAGAAGAAAGCAGTGGTAAACATGGTAGA
AAAGGTGCAGAAGCCCCAGGCAGTGTGACAGGCCCTCCTGCCACCTAG
AGGCGGGAACAAGCTTCCCTGCCTAGGGCTCTGCCCGGAAGTGCGTGT
4051 TCTTTGGTGGGTTTTGTTTGGCGTTTGGTTTTGAGATTTAGACACAAGGG
AAGCCTGAAAGGAGGTGTTGGGCACTATTTTGGTTTTGTAAAGCCTGTACT
TCAAATATATATTTTGTGAGGGAGTGTAGCGAATTGGCCAATTTAAATA
4201 AAGTTGCAAGAGATTGAAGGCTGAGTAGTTGAGAGGGTAACACGTTTAA
GAGATCTTCTGAACTACTGCTTCTAAACACTTGTGTTGAGTGGTGAGACC
TTGGATAGGTGAGTGCTTGTGTACATGTCTGATGCACTTGCTTGTCTT
4351 TTCCATCCACATCCATGCATTCCACATCCAGCATTTGTCACTTATCCCA
TATCTGTCATATCTGACATACCTGTCTCTCGTCACTTGGTCAGAAGAAA
CAGATGTGATAATCCCCAGCCGCCCAAGTTTGAGAAGATGGCAGTTGCT
4501 TCTTTCCCTTTTCCCTGCTAAGTAAGGATTTCTCCTGGCTTTGACACCT
CACGAAATAGTCTTCTGCTTACATTCTGGGCATTATTTCAAATATCTT

FIG.6B

18/43

TGGAGTGGCTGCTCTCAAGTTTGTGTCTTCCTACTCTTAGAGTGAATGC
4651 TCTTAGAGTGAAAGAGAAGGAAGAGAAGATGTTGGCCGCAGTTCTCTGAT
GAACACACCTCTGAATAATGGCCAAAGGTGGGTGGGTTTCTCTGAGGAAC
GGGCAGCGTTTGCCTCTGAAAGCAAGGAGCTCTGCGGAGTTGCAGTTATT
4801 TTGCAACTGATGGTGGAACGGTGCTTAAAGCAGATTCCCTAGGTTCCCT
GCTACTTCTTTTCTTCTTGGCAGTCAGTTTATTTCTGACAGACAAACAG
CCACCCCACTGCAGGCTTAGAAAGTATGTGGCTCTGCCTGGGTGTGTTA
4951 CAGCTCTGCCCTGGTGAAAGGGGATTAAAACGGGCACCATTTCATCCCAA
CAGGATCCTCATTTCATGGATCAAGCTGTAAGGAACCTGGGCTCCAACCTC
AAAACATTAATTGGAGTACGAATGTAATTAAGGAACCTGCATTCTCGCATTCC
5101 TAAGTCATTTAGTCTGGACTCTGCAGCATGTAGGTCGGCAGCTCCCACTT
TCTCAAAGACCACTGATGGAGGAGTAGTAAAAATGGAGACCGATTTCAGAA
CAACCAACGGAGTGTTGCCGAAGAACTGATGGAAATAATGCATGAATTG
5251 TGTGGTGGACATTTTTTTAAATACATAAACTACTTCAAATGAGGTCGGA
GAAGGTCAAGTGTATTATAGCAGCCATAAAACCAGGTGAGCGAGTACCAT
TTTTCTCTACAAGAAAAACGATTCTGAGCTCTGCGTAAGTATAAGTTCTC
5401 CATAGCGGCTGAAGCTCCCCCTGGCTGCCTGCCATCTCAGCTGGAGTGC
AGTGCCATTTCTTGGGGTTTCTCTCACAGCAGTAATGGGACAATACTTC
ACAAAAATTCCTTCTTCTTCTGTGATGTGGGATCCCTACTGTGCCCTCCT
5551 GGTTTTACGTTACCCCTGACTGTTCCATTACGCGGTTTGAAAGAGAAA
AAGAAATTTGAAATAAAACATGTCTACGTTATCACCTCCTCCAGCATTTT
GGTTTTTAATTATGTCAATAACTGGCTTAGATTGAAATGAGAGGGGGT
5701 TGGGTGTATTACCGAGGAACAAAGGAAGGCTTATATAAACTCAAGTCTT
TATTTAGAGAACTGGCAAGCTGTCAAAAACAAAAAGGCCTTACCACCAAA
TTAAGTGAATAGCCGCTATAGCCAGCAGGGCCAGCAGGAGGGATGGTGCA
5851 CTGCTGGCACTATGCCACGGCTGCTTGTGACTCTGAGAGCAACTGCTT
GGAAATGACAGCACTTGGTGCAATTTCTTTGTTTCAGAATGCGTAGAGC
GTGTGCTTGGCGACAGTTTTTCTAGTTAGGCCACTTCTTTTCTTCTC
6001 TCCTCATTCTCCTAAGCATGTCTCCATGCTGGTAATCCAGTCAAGTGAA
CGTTCAAACAATGAATCCATCACTGTAGGATTCTCGTGGTGATCAAATCT
TTGTGTGAGGTCTATAAAATATGGAAGCTTATTTATTTTTCGTTCTTCCA
6151 TATCAGTCTTCTATGACAATTCACATCCACCACAGCAAATTAAGGTG
AAGGAGGCTGGTGGGATGAAGAGGCTTCTAGCTTTACGTTCTTCTTG
CAAGGCCACAGGAAAATGCTGAGAGCTGTAGAATACAGCCTGGGGTAAGA
6301 AGTTCAGTCTCCTGCTGGGACAGCTAACCGCATCTTATAACCCCTTCTGA
GACTCATCTTAGGACCAAATAGGGTCTATCTGGGGTTTTGTTCTTGCTG
TTCCTCCTGGAAGGCTATCTCACTATTTCACTGCTCCCACGGTTACAAAC
6451 CAAAGATACAGCCTGAATTTTTCTAGGCCACATTACATAAATTTGACCT
GGTACCAATATTGTTCTCTATATAGTTATTTCTTCCCCTGTGTTAA
CCCCTTAAGGCATTGAGAACAACTAGAATCATAGAATGGTTTGGATTGGA
6601 AGGGGCCTTAAACATCATCCATTTCCAACCCTCTGCCATGGGCTGCTTGC
CACCACTGGCTCAGGCTGCCAGGGCCCCATCCAGCCTGGCCTTGAGCA
CCTCCAGGGATGGGGCACCCACAGCTTCTTGGGCAGCCTGTGCCAACAC
6751 CTCACCACTCTCTGGGTAAAGAATTCTCTTTTAACATCTAATCTAAATCT
CTTCTCTTTTAGTTTAAAGCCATTCTCTTTTCCGTTGCTATCTGTCC
AAGAAATGTGTATTGGTCTCCCTCCTGCTTATAAGCAGGAAGTACTGGAA
6901 GGCTGCAGTGAGGTCTCCCCACAGCCTTCTTCTCCAGGCTGAACAAGC

FIG. 6C

SUBSTITUTE SHEET (RULE 26)

19/43

CCAGCTCCTTCAGCCTGTCTTCGTAGGAGATCATCTTAGTGGCCCTCCTC
TGGACCCATTCCAACAGTTCCACGGCTTTCTTGTTGGAGCCCCAGGTCTGG
7051 ATGCAGTACTTCAGATGGGGCTTACAAAGGCAGAGCAGATGGGGACAAT
CGCTTACCCCTCCCTGCTGGCTGCCCTGTTTTGATGCAGCCAGGGTAC
TGTTGGCCTTTTCAGGCTCCAGACCCCTTGCTGATTTGTGTCAAGCTTTT
7201 CATCCACCAGAACCCACGCTTCCTGGTTAATACTTCTGCCCTCACTTCTG
TAAGCTTGTTTCAGGAGACTTCCATTCTTTAGGACAGACTGTGTTACACC
TACCTGCCCTATTCTTGATATATACATTTTCAGTTCATGTTTCCTGTAAC
7351 AGGACAGAATATGTATTCCTCTAACAAAAATACATGCAGAATTCCTAGTG
CCATCTCAGTAGGGTTTTTCATGGCAGTATTAGCACATAGTCAATTTGCTG
CAAGTACCTTCCAAGCTGCGGCCTCCCATAAATCCTGTATTTGGGATCAG
7501 TTACCTTTTGGGGTAAGCTTTTGTATCTGCAGAGACCCTGGGGGTCTGA
TGTGCTTCAGCTCTGCTCTGTTCTGACTGCACCATTTTCTAGATCACCCA
GTTGTTCCCTGTACAACCTCCTTGCTCCTCCATCCTTTCCAGCTTGATCT
7651 TTGACAAATACAGGCCTATTTTTGTGTTTGCTTCAGCAGCCATTTAATTC
TTCAGTGTCTCTGTTCTGTTGATGCCACTGGAACAGGATTTTCAGCAG
TCTTGCAAAGAACATCTAGCTGAAAACCTTCTGCCATTCAATATTCTTAC
7801 CAGTTCTTCTTGTTTGAGGTGAGCCATAAATTACTAGAACCTCGTCACTG
ACAAGTTTATGCATTTTATTACTTCTATTATGTACTTACTTTGACATAAC
ACAGACACGCACATATTTTGTGGGATTTCCACAGTGTCTCTGTGTCCTT
7951 CACATGGTTTTACTGTCATACTTCCGTTATAACCTTGGCAATCTGCCAG
CTGCCCATCACAAGAAAAGAGATTCTTTTTTATTACTTCTCTTCAGCCA
ATAAACAAAATGTGAGAAGCCCAACAAGAAGTTGTGGGGCAGGCTGCCA
8101 TCAAGGGAGAGACAGCTGAAGGGTTGTGTAGCTCAATAGAATTAAGAAAT
AATAAAGCTGTGTCAGACAGTTTTGCCTGATTTATACAGGCACGCCCAA
GCCAGAGAGGCTGTCTGCCAAGGCCACCTTGCACTCCTGGTTTGTAGA
8251 TTAAGTCATAGGTAACTTTTCTGGTGAATTGCGTGGAGAATCATGATGGCA
GTTCTTGCTGTTTACTATGGTAAGATGCTAAAATAGGAGACAGCAAAGTA
ACACTTGCTGCTGTAGGTGCTCTGCTATCCAGACAGCGATGGCACTCGCA
8401 CACCAAGATGAGGGATGCTCCAGCTGACGGATGCTGGGGCAGTAACAGT
GGGTCCCATGCTGCCTGCTCATTAGCATCACCTCAGCCCTCACCAGCCCA
TCAGAAGGATCATCCCAAGCTGAGGAAAGTTGCTCATCTTCTTCACATCA
8551 TCAAACCTTTGGCCTGACTGATGCCTCCGGATGCTTAAATGTGGTCACT
GACATCTTTATTTTTCTATGATTTCAAGTCAGAACCTCCGGATCAGGAGG
GAACACATAGTGGGAATGTACCCTCAGCTCCAAGGCCAGATCTTCCTTCA
8701 ATGATCATGCATGCTACTTAGGAAGGTGTGTGTGTGAATGTAGAATTG
CCTTTGTTATTTTTCTTCTGCTGTCAGGAACATTTTGAATACCAGAGA
AAAAGAAAAGTGCTCTTCTTGGCATGGGAGGAGTTGTCACACTTGCAAAA
8851 TAAAGGATGCAGTCCCAAATGTTCAATCTCAGGGTCTGAAGGAGGATC
AGAAACTGTGTATACAATTTAGGCTTCTCTGAATGCAGCTTTTGAAAGC
TGTTCTTGGCCGAGGCAGTACTAGTCAGAACCTCGGAAACAGGAACAAA
9001 TGTCTTCAAGGTGCAGCAGGAGGAAACACCTTGCCCATCATGAAAGTGAA
TAACCACTGCCGCTGAAGGAATCCAGCTCCTGTTTGAGCAGGTGCTGCAC
ACTCCACACTGAAACAACAGTTCATTTTTATAGGACTTCCAGGAAGGAT
9151 CTTCTTCTTAAGCTTCTTAATTATGGTACATCTCCAGTTGGCAGATGACT
ATGACTACTGACAGGAGAATGAGGAAGTCTGGGAATATTTCTGTTTGA
CCACCATGGAGTCACCCATTTCTTTACTGGTATTTGGAAATAATAATTCT

FIG.6D

SUBSTITUTE SHEET (RULE 26)

20/43

9301 GAATTGCAAAGCAGGAGTTAGCGAAGATCTTCATTTCTTCCATGTTGGTG
ACAGCACAGTTCTGGCTATGAAAGTCTGCTTACAAGGAAGAGGATAAAAA
9401 TCATAGGGATAATAAATCTAAGTTTGAAGACAATGAGGTTTATAGCTGCAT
TTGACATGAAGAAATTGAGACCTCTACTGGATAGCTATGGTATTTACGTG
TCTTTTGTAGTTACTTATTGACCCAGCTGAGGTCAAGTATGAAGTCT
9551 AGGTCTCTCGGGCTACTGGCATGGATTGATTACATACAACTGTAATTTA
GCAGTGATTTAGGGTTTATGAGTACTTTTGCAGTAAATCATAGGGTTAGT
AATGTTAATCTCAGGGAAAAAAAAAAAAAGCCAACCCTGACAGACATCCC
9701 AGCTCAGGTGGAATCAAGGATCACAGCTCAGTGCGGTCCAGAGAACAC
AGGGACTCTTCTCTTAGGACCTTTATGTACAGGGCCTCAAGATAACTGAT
GTTAGTCAGAAGACTTTCCATTCTGGCCACAGTTCAGCTGAGGCAATCCT
9851 GGAATTTTCTCTCCGCTGCACAGTTCAGTCATCCAGTTTGTACAGTTC
TGGCACTTTTGGGTGAGGCCGTGATCCAAGGAGCAGAAGTTCAGCTAT
GGTCAGGGAGTGCTGACCGTCCCAACTCACTGCACTCAAACAAAGGCGA
10001 AACCACAAGAGTGGCTTTTGTGAAATTGCAGTGTGGCCAGAGGGCTG
CACCAGTACTGGATTGACCACGAGGCAACATTAATCCTCAGCAAGTGCAA
TTTGCAGCCATTAAATTGAACTAACTGATACTACAATGCAATCAGTATCA
10151 ACAAGTGGTTTGGCTTGAAGATGGAGTCTAGGGGCTCTACAGGAGTAGC
TACTCTCTAATGGAGTTGCATTTTGAAGCAGGACACTGTGAAAAGCTGGC
CTCCTAAAGAGGCTGCTAAACATTAGGGTCAATTTTCCAGTGCATTTCT
10301 GAAGTGTCTGCAGTTCCTCATGCAAGCTGCCCAAACATAGCACTTCCAA
TTGAATACAATTATATGCAGGCGTACTGCTTCTTGCCAGCACTGTCTTCT
TCAAATGAACTCAACAAACAATTTCAAAGTCTAGTAGAAAGTAACAAGCT
10451 TTGAATGTCATTAATAAGTATATCTGCTTTCAGTAGTTCAGCTTATTTAT
GCCCCTAGAAACATCTTGTACAAGCTGAACACTGGGGCTCCAGATTAGT
GGTAAAACCTACTTTATACAATCATAGAATCATAGAATGGCCTGGGTTGG
10601 AAGGGACCCCAAGGATCATGAAGATCCAACACCCCGCCACAGGCAGGGC
CACCAACCTCCAGATCTGGTACTAGACCAGGCAGCCAGGGCTCCATCCA
ACCTGGCCATGAACACCTCCAGGGATGGAGCATCCACAACCTCTCTGGGC
10751 AGCCTGTGCCAGCACCTCACCACCTCTCTGTGAAGAACTTTTCCCTGAC
ATCCAATCTAAGCCTTCCCTCCTTGAGGTTAGATCCACTCCCCCTTGTGC
TATCACTGTCTACTCTTGTAATAAGTTGATTCTCCTCTTTTGAAGGT
10901 TGCAATGAGGTCTCCTTGACGCTTCTTCTTCTGCAAGGATGAACAAGC
CCAGTCCCTCAGCCTGTCTTTATAGGAGAGGTGCTCCAGCCCTCTGATC
ATCTTTGTGGCCCTCCTCTGGACCGCTCCAAGAGCTCCACATCTTCTCT
11051 GTAGTGGGGGCCCCAGGCCTGAATGCAGTACTCCAGATGGGGCTCAAAA
GAGCAGAGTAAAGAGGGACAATCACCTTCTCACCTGCTGGCCAGCCCT
CTTCTGATGGAGCCCTGGATACAACCTGGCTTTCTGAGCTGCAACTTCTCC
11201 TTATCAGTTCCACTATTAACACAGGAACAATACAACAGGTGCTGATGGCC
AGTGCAGAGTTTTTCACTTCTTCAATTCGGTAGATCTTAGATGAGGAA
CGTTGAAGTTGTGCTTCTGCGTGTGCTTCTTCTCCTCAAATACTCCTGC
11351 CTGATACCTACCCACCTGCCACTGAATGGCTCCATGGCCCCCTGCAGC
CAGGGCCCTGATGAACCCGGCACTGCTTCAGATGCTGTTTAATAGCACAG
TATGACCAAGTTGCACCTATGAATACACAAACAATGTGTTGCATCCTTCA
11501 GCACTTGAGAAGAAGAGCCAAATTTGCATTGTGAGGAAATGGTTTAGTAA
TTCTGCCAATTAACCTTGTATCTACCATGGCTGTTTTATGGCTGTT
AGTAGTGGTACACTGATGATGAACAATGGCTATGCAGTAAATCAAGACT

FIG. 6E

SUBSTITUTE SHEET (RULE 26)

21/43

11651 GTAGATATTGCAACAGACTATAAAATTCCTCTGTGGCTTAGCCAATGTGG
TACTTCCACATTGTATAAGAAATTTGGCAAGTTTAGAGCAATGTTTGAA
GTGTTGGGAAATTTCTGTATACTCAAGAGGGCGTTTTGACAACTGTAGA
11801 ACAGAGGAATCAAAGGGGGTGGGAGGAAGTTAAAGAAGAGGCAGGTGC
AAGAGAGCTTGCAGTCCCGCTGTGTGTACGACACTGGCAACATGAGGTCT
TTGCTAATCTTGGTGCTTTGCTTCTGCCCCTGGCTGCCTTAGGGTGCGA
11951 TCTGCCTCAGACCCACAGCCTGGGCAGCAGGAGGACCCTGATGCTGCTGG
CTCAGATGAGGAGAATCAGCCTGTTTAGCTGCCTGAAGGATAGGCACGAT
TTTGGCTTTCTCAAGAGGAGTTTGGCAACCAGTTTCAGAAGGCTGAGAC
12101 CATCCCTGTGCTGCACGAGATGATCCAGCAGATCTTAACTGTTTAGCA
CCAAGGATAGCAGCGCTGCTTGGGATGAGACCCTGCTGGATAAGTTTTAC
ACCGAGCTGTACCAGCAGCTGAACGATCTGGAGGCTTGCGTGATCCAGGG
12251 CGTGGGCGTGACCGAGACCCCTCTGATGAAGGAGGATAGCATCCTGGCTG
TGAGGAAGTACTTTCAAGGATCACCTGTACCTGAAGGAGAAGAAGTAC
AGCCCCTGCGCTTGGGAAGTCGTGAGGGCTGAGATCATGAGGAGCTTTAG
12401 CCTGAGCACCAACCTGCAAGAGAGCTTGAGGTCTAAGGAGTAAAAAGTCT
AGAGTCGGGGCGGCGCTGGTAGGTGGCGGGGGTTCCAGGAGAGCCCC
CAGCGCGGACGGCAGCGCGTCACTACCGCTCCGTCTCCCTCCGCCAG
12551 GGTGCGCTGGCGCAACCGCTGCAAGGGCACCGACGTCCAGGCGTGGATCA
GAGGCTGCCGGCTGTGAGGAGCTGCCGCGCCCGGCCGCCGCTGCACAG
CCGGCCGCTTTGCGAGCGGACGCTACCGCTTGGCAGTTTTAAACGCAT
12701 CCCTCATTAAACGACTATACGCAAACGCCCTCCCGTCGGTCCGCGTCTC
TTTCCGCCGCCAGGGCGACACTCGCGGGGAGGGCGGGAAGGGGGCCGGGC
GGGAGCCCGCGCCAACCGTCGCCCGGTGACGGCACCGCCCCGCCCGCT
12851 GACGCGGTGCGGGCGCCGGGGCGTGGGGCTGAGCGCTGCGGGCGGGCCG
GGCCGGGCGGGGCGGGAGCTGAGCGCGGCGCGCTGCGGGCGGCGCCCC
CTCCGGTGCAATATGTTCAAGAGAATGGCTGAGTTGCGGGCTGACTCCGG
13001 GGGCAGGGTGAAGGTGCGGCGCGGGCGGAGGACGGGGCGGGCGCGGGGC
CGCCCGGCGGGTGCCGGGGCCTCTGCCGGCCCGCCGGCTCGGGCTGCTG
CGGCGCTTACGGGCGCGCTTCTCGCCGCTGCCGCTTCTTCTCTCCCGC
13151 GCAAGGGCGTCACCATCGTGAAGCCGGTAGTGTACGGGAACGTGGCGCGG
TACTTCGGGAAGAAGAGGGAGGAGGACGGGCACACGCATCAGTGGACGGT
TTACGTGAAGCCCTACAGGAACGAGGTAGGGCCCGAGCGGTGCGCCGCC
13301 GTTCTCGGAGCGCCGGAGCCGTGAGCGCCGCGCCTGGGTGCGCTGTGGGA
CACAGCGAGCTTCTCTCGTAGGACATGTCCGCCTACGTGAAAAAATCCA
GTTCAAGCTGCACGAGAGCTACGGGAATCCTCTCCGAGGTGGGTGTTGCG
13451 TCGGGGGGTTTGCTCCGCTCGGTCCCGCTGAGGCTCGTCGCCCTCATCTT
TCTTTCGTCCGCGAGTCGTTACCAAACCGCCGTACGAGATACCGAAACG
13551 GGCTGGGGCGAATTTGAAATCATCATCAAGATATTTTCATTGATCCAAA
CGAGCGACCCGTAAGTACGCTCAGCTTCTCGTAGTGCTTCCCCGTCCTG
GCGGGCCGGGGCTGGGCTGCTCGCTGCTGCCGTCACAGTCCCGCCAGCC
13701 GCGGAGCTGACTGAGCTCCCTTTCCCGGGACGTGTGCTCTGTGTTGCGTC
AGCGAGGCTATCGGGAGGGCTTTGGCTGCATTTGGCTTCTCTGGCGCTTA
GCGCAGGAGCACGTTGTGCTACGCCTGAACCTACAGCTGTGAGAAGGCCGT
13851 GGAAACCGCTCTCAAACGATTTATTGGCGAAATGGCTCTAAACTAAATC
GTCTCCTCTTTGGAAATGCTTTAGAGAAGGTCTCTGTGGTAGTTCTTA
TGCATCTATCCTAAAGCACTTGGCCAGACAATTTAAAGACATCAAGCAGC

FIG.6F

SUBSTITUTE SHEET (RULE 26)

22/43

14001 ATTTATAGCAGGCACGTTTAAATAACGAATACTGAATTTAAGTAACTCTGC
TCACGTTGTATGACGTTTATTTTCGTATTCCTGAAAGCCATTAAAATCCT
GTGCAGTTGTTTAGTAAGAACAGCTGCCACTGTTTTGTATCTAGGAGATA
14151 ACTGGTGTTCCTACAGTTCCTCAAGCTGATAAACTCTGCTTTGTATC
TAGGTAACCTGTATCACTTGCTGAAGCTTTTTCAGTCTGACACCAATGC
AATCCTGGGAAAGAAAACCTGTAGTTTCTGAATCTATGATGAAATGGTAT
14301 GAAAATTTTAAATGTCAACCGAGCCTGACTTTATTTAAAAAAATTTATTGA
TGGTGTGTGTATTTTGGTCCTTCCTTAGATATTTCAAGATCCTACTGCC
ATGATGCAGCAACTGCTAACGACGTCCCGTCAGCTGACACTTGGTGCTTA
14451 CAAGCATGAAACAGAGTGTAAAGTGCAAAATGAGGATACCTTCGCCGACCG
TCATTCACTACTAATGTTTTCTGTGGGATGTGATCGTACAGTGAGTTTGG
CTGTGTGAAATTTGAATAGCTTGGTATTGGCAGTGATGACGTGATCGATG
14601 CCTTGCTTATCATGTTTGAATGAAGTAGAATAAATGCAGCCTGCTTTAT
TTGAGATAGTTTGGTTCATTTTATGGAATGCAAGCAAAGATTATACTTCC
TCACTGAATTGCACTGTCCAAAGGTGTGAAATGTGTGGGGATCTGGAGGA
14751 CCGTGACCGAGGGACATTGGATCGCTATCTCCCATTTCTTTTGTGTTAC
CAGTTCAGATTTTCTTTTACCTAGTCTTTAATTTCCAGGGTTTTGTITT
TTCCTTGGTCATAGTTTTGTTTTTCACTCTGGCAAATGATGTTGTGAAT
14901 TACACTGCTTCAGCCACAAAACCTGATGGACTGAATGAGGTATCAAAACAA
ACTTTTCTTCTCCGTATTTCTTTTTTCCCTTTTCCCTTTTCCCTTTTAC
TGCTGTTGTTGAGTCTGTAAGGCTAAAAGTAACTGTTTTGTGCTTTTTCA
15051 GGACGTGTGCTTTCCAAATTAAGTCCACATATATAAAGAAAGGTTGGAAT
TTTAAAGATAATTCATGTTTCTTCTTTTTTCCACCACAGTTGCAGA
TCTTGAAGTAAAACAGGGAAAAGCTGGAAGCTGCCAAAAGAAAACCA
15201 GTTTTGAATTTGCTGAGCTTAAAGAAAGGTTAAAAGCAAGTCGTGAAACC
ATCAACTGCTTAAAGAGTGAAATCAGAAAACCTGAAGAGGATGATCAGTC
TAAAGATATGTGATGAGTGTGACTTGGCAGGGAGCCTATAATGAGAATG
15351 AAAGGACTTCAGTCGTGGAGTTGTATGCGTTCTCTCCAATTCTGTAACGG
AGACTGTATGAATTTCAATTTGCAAATCACTGCAGTGTGTGACAACTGACT
TTTTATAAATGGCAGAAAACAAGAATGAATGTATCCTCATTTTATAGTTA
15501 AAATCTATGGGTATGTACTGGTTTATTTCAAGGAGAATGGATCGTAGAGA
CTTGGAGGCCAGATTGCTGCTTGTATTGACTGCATTTGAGTGGTGTAGGA
ACATTTTGTCTATGGTCCCGTGTAGTTTACAGAATGCCACTGTTCACTG
15651 TTTTGTGTTGTATTTTACTTTTTCTACTGCAACGTCAAGGTTTTAAAAGT
TGAAAATAAAACATGCAGGTTTTTTTTAAATATTTTTTGTCTCTATCCA
GTTTGGGCTTCAAGTATTATTGTTAACAGCAAGTCCTGATTTAAGTCAGA
15801 GGCTGAAGTGTAAATGGTATTCAAGATGCTTAAGTCTGTTGTGAGCAAAAC
AAAAGAGAAAACCTCATAAAATCAGGAAGTTGGCATTCTAATAACTTCT
TTATCAACAGATAAGAGTTTCTAGCCCTGCATCTACTTTCACTTATGTAG
15951 TTGATGCCTTTATATTTTGTGTGTTTGGATGCAGGAAGTGATTCCTACTC
TGTTATGTAGATATTCTATTTAACACTTGTACTCTGCTGTGCTTAGCCTT
16051 TCCCATGAAAATTCAGCGGCTGTAAATCCCCCTCTCTTTTGTAGCCTC
ATACAGATGGCAGACCCTCAGGCTTATAAAGGCTTGGGCATCTTCTTTAC
TGCTTTGAGATTCTGTGTTGCAGTAACCTCTGCCAGAGAGGAGAAAAGCC
16201 CCACAAACCTCATCCCTTCTTCTATAGCAATCAGTATTACTAATGCTTT
GAGAACAGAGCACTGGTTTGAACGTTTGATAATTAGCATTTAACATGGC
TTGGTAAAGATGCAGAACTGAAACAGCTGTGACAGTATGAACTCAGTATG

FIG.6G

SUBSTITUTE SHEET (RULE 26)

23/43

16351 GAGACTTCATTAAGACAAACAGCTGTTAAATCAGGCATGTTTCATTGAG
GAGGACGGGGCAACTTGCACCAAGTGGTGCCACACAAATCCTTCCTGGCG
CTGCAGACCAATTTTTCTGGCATTCTGACTGCCGTTGCTGCTGGTCACAG
16501 AGAGCAACTATTTTTATCAGCCACAGGCAATTTGCTTGTAGTATTTTCCA
AGTGTGTAGGTAAGTATAAATGCATCGGCTCCAGAGCACTTTGAGTATA
CTTATTA AAAACATAAATGAAAGACAAATTAGCTTTGCTTGGGTGCACAG
16651 AACATTTTTAGTTCAGCCTGCTTTTTGGTAGAAGCCCTCTTCTGAGGCT
AGAACTGACTTTGACAAGTAGAGAACTGGCAACGGAGCTATTGCTATCG
16751 AAGGATCCTTGTAAACAAAGTTAATCGTCTTTAAGGTTTGGTTTATTCA
TTAAATTTGCTTTAAGCTGTAGCTGAAAAAGAACGTGCTGTCTTCCATG
16851 CACCAGGTGGCAGCTCTGTGCAAAGTGCTCTCTGGTCTCACCAGCCTTTT
AATTGCCGGGATTCTGGCACGTCTGAGAGGGCTCAGACTGGCTTCGTTTG
TTTGAACAGCGTGTACTGCTTTCTGTAGACATGGCCGGTTTCTCTCCTGC
17001 AGCTTATGAACTGTTCACTGAACACACTGGAACAGGTTGCCAAGGA
GGCCGTGGATGCCCCATCCTGGAGGCATTCAAGGCCAGGCTGGATGTGG
CTCTGGGCAGCCTGGTCTGGTGGTGGCGATCCTGCACATAGCAGCGGGG
17151 TTGAACTCGATGATCACTGTGGTCTTTTCAACCCAGGCTATTCTATGA
TTCTATGATTCAACAGCAATCATATGTACTGAGAGAGGAAACAAACACA
AGTGCTACTGTTTGCAAGTTTTGTTCAATTTGGTAAAAGAGTCAGGTTTTA
17301 AAATTCAAAATCTGTCTGGTTTTGGTGTTTTTTTTTTTTATTTATTATT
TCTTTGGGGTTCTTTTGATGCTTTATCTTTCTGCCAGGACTGTGTGA
CAATGGGAACGAAAAAGAACATGCCAGGCACTGTCCTGGATTGCACACGC
17451 TGGTTGCACTCAGTAGCAGGCTCAGAACTGCCAGTCTTCCACAGTATTA
CTTTCTAAACCTAATTTTAATAGCGTTAGTAGACTTCCATCACTGGGCAG
TGCTTAGTGAATGCTCTGTGTGAACGTTTTACTTATAAGCATGTTGGAAG
17601 TTTTGATGTTCTGGATGCAGTAGGGAAGGACAGATTAGCTATGTGAAAA
GTAGATTCTGAGTATCGGGTTACAAAAAGTATAGAAACGATGAGAAATT
CTTGTTGTAACATAATTGGAATTTCTTTAAGCGTTCACTTATGCTACATTC
17751 ATAGTATTTCCATTTAAAAGTAGGAAAAGGTAAAACGTGAAATCGTGTGA
TTTTCGGATGGAACACCGCCTTCCTATGCACCTGACCAACTCCAGAGGA
AAAGCCTATTGAAAGCCGAGATTAAGCCACCAAAAGAACTCATTTGCATT
17901 GGAATATGTAGTATTTGCCCTCTTCCTCCCGGTAATTACTATACTTTAT
AGGGTGCTTATATGTTAAATGAGTGGCTGGCACTTTTTATTCTCACAGCT
GTGGGGAATTCTGTCTCTAGGACAGAAACAATTTAATCTGTTCCACTG
18051 GTGACTGCTTTGTGCACTTCCACCTGAAGAGATCAATACACTCTTCAA
TGTCTAGTTCTGCAACACTTGGCAAACCTCACATCTTATTTCACTCTC
TTCATGCCTATGCTTATTAAGCAATAATCTGGGTAATTTTGTTTTAAAT
18201 CACTGTCCTGACCCAGTGATGACCGTGTCCACCTAAAGCTCAATTCAG
GTCCTGAATCTTTCAACTCTCTATAGCTAACATGAAGAATCTTCAAAG
TTAGGTCTGAGGGACTTAAGGCTAACTGTAGATGTTGTTGCCTGGTTTCT
18351 GTGCTGAAGGCCGTGTAGTAGTTAGAGCATTCAACCTCTAGAAGAAGCTT
GGCCAGCTGGTCGACCTGCAGATCCGGCCCTCGAGGGGGGGCCGGTACC
CAGCTTTTGTTCCTTTAGTGAGGGTTAATTTGAGCTTGGCGTAATCAT
18501 GGTCAAGCTGTTTCTGTGTGAAATTGTTATCCGCTCACAATTCACAC
AACATACGAGCCGGAAGCATAAAGTGTAAGCCTGGGGTGCTTAATGAGT
GAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGG
18651 GAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGGGGAGA

FIG.6H

SUBSTITUTE SHEET (RULE 26)

24/43

GGCGGTTTGGGTATTGGGCGCTCTCCGCTTCCTCGCTCACTGACTCGCT
GCGCTCGGTCTGTTCCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG
18801 TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGA
GCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCTTGCTGGC
GTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCT
18951 CAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTT
CCCCCTGGAAGCTCCCTCGTGCGCTCTCTGTTCCGACCTGCCGCTTAC
CGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATA
19101 GCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGTTTCGCTCCAAGCTG
GGCTGTGTGCACGAACCCCCGTTACGCCGACCGCTGCGCCTTATCCGG
TAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGG
19251 CAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCT
ACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAAGGACAGT
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAGAGAGTTG
19401 GTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTT
GTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCC
TTTGATCTTTTCTACGGGGTCTGACGCTCAGTGAACGAAACTCACGTT
19551 AAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTACCTAGATCCTT
TTAAATTAATAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAAC
TTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGA
19701 TCTGTCTATTTTCTGTTTCATCCATAGTTGCCTGACTCCCGTCTGTAGATA
ACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACC
GCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAG
19851 CCGGAAGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCCTCCATC
CAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA
TAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGCT
20001 CGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGA
GTTACATGATCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCC
TCCGATCGTTGTCAGAAGTAAGTTGGCCGCAAGTGTATCACTCATGGTTA
20151 TGGCAGCACTGCATAATTCTTACTGTGTCATGCCATCCGTAAGATGCTTT
TCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCG
GCGACCGAGTTGCTCTTGCCCGCGTCAATACGGGATAATACCGCGCCAC
20301 ATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGA
AAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCAC
TCGTGCACCCAAGTATCTTCAGCATCTTTTACTTTACCGAGCGTTTCTG
20451 GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCG
ACACGGAAATGTTGAATACTCATACTCTTCCTTTTCAATATTATTGAAG
CATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTT
20601 AGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAGTGCCA
CCTAAATTGTAAGCGTTAATATTTTGTAAATTCGCGTTAAATTTTGT
TAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTA
20751 TAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTGTTCCAGTTTGA
ACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAAAGGGCGAAAA
ACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCTAATCAAG
20901 TTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCTAAAGGGA
GCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAG
GAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGC

FIG. 6I

SUBSTITUTE SHEET (RULE 26)

25/43

21051 GGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTAC
AGGGCGCGTCCCATTGCGCATTCAGGCTGCGCAACTGTTGGGAAGGGCGA
TCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGC
21201 TGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCAGTCACGACGTT
GTAAAACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGAATTG
21301 GAGCTCCACCGCGGTGGCGGCCGCTCTAG

FIG.6J

26/43




FIG.7

27/43




FIG.8

28/43





FIG.9

29/43



SUBSTITUTE SHEET (RULE 26)

30/43




FIG.11

31/43





FIG. 12

32/43




FIG.13

33/43

SEQ ID NO: 11

GTACCGGGCCCCCCTCGAGGTGAATATCCAAGAATGCAGAACTGCATGGAAAGCAGAGCTG
CAGGCACGATGGTGCTGAGCCTTAGCTGCTTCCTGCTGGGAGATGTGGATGCAGAGACGAAT
GAAGGACCTGTCCCTTACTCCCCTCAGCATTCTGTGCTATTTAGGGTTCTACCAGAGTCCTT
AAGAGGTTTTTTTTTTTTTTGGTCCAAAAGTCTGTTTGTGGTTTTGACCACTGAGAGCAT
GTGACACTTGTCTCAAGCTATTAACCAAGTGTCAGCCAAAATCGATGTCACAACTTGGGAA
TTTTCCATTTGAAGCCCCTTGCAAAAACAAAGAGCACCTTGCCTGCTCCAGCTCCTGGCTGT
GAAGGGTTTTGGTGCCAAAGAGTGAAAGGCTTCCTAAAAATGGGCTGAGCCGGGGAAGGGGG
GCAACTTGGGGGCTATTGAGAAACAAGGAAGGACAAACAGCGTTAGGTCATTGCTTCTGCAA
ACACAGCCAGGGCTGCTCCTCTATAAAAGGGGAAGAAAGAGGCTCCGCAGCCATCACAGACC
CAGAGGGGACGGTCTGTGAATCAAGCTT

FIG. 14

34/43

SEQ ID NO: 17

IFN -A

ATGGCTTTGACCTTTGCCTTACTGGTGGCTCTCCTGGTGCTGAGCTGCAAGAGCAGCTGCTCTGT
GGGCTGCGATCTGCCTCA

SEQ ID NO: 18

IFN-B

GACCCACAGCCTGGGCAGCAGGAGGACCCTGATGCTGCTGGCTCAGATGAGGAGAATCAGCCTGT
TTAGCTGCCTGAAGGATAGGCACGATTTTGGCTTT

SEQ ID NO: 19

IFN-C

CTCAAGAGGAGTTTGGCAACCAGTTTCAGAAGGCTGAGACCATCCCTGTGCTGCACGAGATG

SEQ ID NO: 20

IFN-D

TCCAGCAGATCTTTAACCTGTTTAGCACCAAGGATAGCAGCGCTGCTTGGGATGAGACCCTGCTG
GATAAGTTTACACCGAGCTGTACCAGCA

SEQ ID NO: 21

IFN-E

CTGAACGATCTGGAGGCTTGCCTGATCCAGGGCGTGGGCGTGACCGAGACCCCTCTGATGAAGGA
GGATAGCATCCT

SEQ ID NO: 22

IFN-F

GCTGTGAGGAAGTACTTTTCAGAGGATCACCTGTACCTGAAGGAGAAGAAGTACAGCCCTTGCGC
TTGGGAAGTCGTGAGGG

SEQ ID NO: 23

IFN-G

CTGAGATCATGAGGAGCTTTAGCCTGAGCACCAACCTGCAAGAGAGCTTGAGGTCTAAGGAGTAA

SEQ ID NO: 24

IFN-1

CCCAAGCTTTCACCATGGCTTTGACCTTTGCCTT

SEQ ID NO: 25

IFN-2b

ATCTGCCTCAGACCCACAG

FIG.15A

35/43

SEQ ID NO: 26
IFN-3c
GATTTTGGCTTTCCTCAAGAGGAGTT

SEQ ID NO: 27
IFN-4b
GCACGAGATGATCCAGCAGAT

SEQ ID NO: 28
IFN-5
ATCGTTCAGCTGCTGGTACA

SEQ ID NO: 29
IFN-6
CCTCACAGCCAGGATGCTAT

SEQ ID NO: 30
IFN-7
ATGATCTCAGCCCTCACGAC

SEQ ID NO: 31
IFN-2
CTGTGGGTCTGAGGCAGAT


SEQ ID NO: 32
IFN-3b
AACTCCTCTTGAGGAAAGCCAAAATC

SEQ ID NO: 33
IFN-4
ATCTGCTGGATCATCTCGTGC

SEQ ID NO: 34
IFN-8
TGCTCTAGACTTTTTACTCCTTAGACCTCAAGCTCT

FIG.15B

36/43



SUBSTITUTE SHEET (RULE 26)

37/43




FIG.17

38/43

Series 1




FIG.18

39/43




FIG.19

40/43




FIG.20

41/43




FIG.21

42/43

SEQ ID NO: 38
Oligo 1. TCACTCGAGGTGAATATCCAAGAAT

SEQ ID NO: 39
Oligo 2. GAGATCGATTITGGCTGGACACTTG

SEQ ID NO: 40
Oligo 3. CACATCGATGTCACAACTTGGGAAT

SEQ ID NO: 41
Oligo 4. TCTAAGCTTCGTCACAGACCGTCCC

FIG.22

43/43




FIG.23

SEQUENCE LISTING

<110> Avigenics, Inc.

<120> Production of a Transgenic Avian by
Cytoplasmic Injection

<130> 11106-014-228

<140> To be assigned

<141> 2002-09-18

<150> 60/351,550

<151> 2002-01-25

<150> 60/322,969

<151> 2001-09-18

<160> 41

<170> PatentIn version 3.1

<210> 1

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Primer 5pLMAR2

<400> 1

tgccgccttc tttgatattc

20

<210> 2

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Primer LE-6.1kbrev1

<400> 2

ttggtggtaa ggcctttttg

20

<210> 3

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> Primer lys-6.1

<400> 3

ctggcaagct gtcaaaaaca

20

<210> 4

<211> 20

<212> DNA

<213> Artificial sequence

<220>
 <223> Primer LysE1rev

<400> 4
 cagctcacat cgtccaaaga

20

<210> 5
 <211> 498
 <212> DNA
 <213> Artificial sequence

<220>
 <223> IFNMAGMAX

<220>
 <221> misc_feature
 <222> (1)..(498)
 <223>

<400> 5
 tgcgatctgc ctacagacca cagcctgggc agcaggagga ccctgatgct gctggctcag 60
 atgaggagaa tcagcctggt tagctgcctg aaggataggc acgattttgg ctttcctcaa 120
 gaggagtgtt gcaaccagtt tcagaaggct gagaccatcc ctgtgctgca cgagatgac 180
 cagcagatct ttaacctgtt tagcaccaag gatagcagcg ctgcttgga tgagaccctg 240
 ctggataagt ttacaccga gctgtaccag cagctgaacg atctggaggc ttgcgtgac 300
 cagggcgtgg gcgtgaccga gaccctctg atgaaggagg atagcatcct ggctgtgagg 360
 aagtactttc agaggatcac cctgtacctg aaggagaaga agtacagccc ctgcgcttgg 420
 gaagtcgtga gggctgagat catgaggagc tttagcctga gcaccaacct gcaagagagc 480
 ttgaggtcta aggagtaa 498

<210> 6
 <211> 12728
 <212> DNA
 <213> Gallus gallus

<220>
 <221> misc_feature
 <222> (1)..(237)
 <223> 5prime matrix (scaffold) attachment region (MAR)

<220>
 <221> misc_feature
 <222> (261)..(1564)
 <223> 5prime matrix (scaffold) attachment region (MAR)

<220>
 <221> misc_feature
 <222> (1565)..(1912)
 <223> 5prime matrix (scaffold) attachment region (MAR)

<220>
<221> misc_feature
<222> (1930)..(2012)
<223> 5prime matrix (scaffold) attachment region (MAR)

<220>
<221> misc_feature
<222> (2013)..(2671)
<223> Intrinsically curved DNA

<220>
<221> misc_feature
<222> (5848)..(5934)
<223> Transcription Enhancer

<220>
<221> misc_feature
<222> (9160)..(9325)
<223> Transcription Enhancer

<220>
<221> misc_feature
<222> (9326)..(9626)
<223> Negative Regulatory Element

<220>
<221> misc_feature
<222> (9621)..(9660)
<223> Hormone Response Element

<220>
<221> misc_feature
<222> (9680)..(10060)
<223> Hormone Response Element

<220>
<221> misc_feature
<222> (10576)..(10821)
<223> Chicken CR1 Repeat Sequence

<220>
<221> misc_feature
<222> (10926)..(11193)
<223> Chicken CR1 Repeat Sequence

<220>
<221> misc_feature
<222> (11424)..(11938)
<223> Lysozyme Proximal Promoter and Lysozyme Signal Peptide

<220>
<221> misc_feature

<222> (11946)..(12443)
 <223> Human Interferon alpha 2d encoding region codon optimized for expression in chicken cells (IFNMAGMAX)

<220>
 <221> polyA_signal
 <222> (12444)..(12728)
 <223>

<400> 6
 tgccgccttc tttgatattc actctgttgt atttcatctc ttcttgccga tgaaaggata 60
 taacagtctg tataacagtc tgtgaggaaa tacttggtat ttcttotgat cagtgttttt 120
 ataagtaatg ttgaatattg gataaggctg tgtgtccttt gtcttgggag acaaagccca 180
 cagcagggtg tggttggggg ggtggcagct cagtgcagag agaggttttt ttgcctgttt 240
 tttttttttt tttttttttt aagtaagggtg ttcttttttc ttagtaaatt ttctactgga 300
 ctgtatgttt tgacagggtca gaaacatttc ttcaaaagaa gaaccttttg gaaactgtac 360
 agcccttttc ttctattccc tttttgtctt ctgtgccaat gcctttgggt ctgattgcat 420
 tatgaaaac gttgatcgga acttgagggt tttatttata gtgtggcttg aaagcttgga 480
 tagctgttgt tacacgagat acctatttaa gtttaggcca gcttgatgct ttattttttc 540
 cctttgaagt agtgagcgtt ctctgggttt ttctcttga aactgggtgag gcttagattt 600
 ttctaattggg attttttacc tgatgatcta gttgcatacc caaatgcttg taaatgtttt 660
 cctagttaac atgttgataa cttcggattt acatgttgta tatacttgtc atctgtgttt 720
 ctagtaaaaa tatatggcat ttatagaaat acgtaattcc tgatttcctt tttttttatc 780
 tctatgctct gtgtgtacag gtcaaacaga cttcactcct atttttattt atagaatttt 840
 atatgcagtc tgcgttggt tcttgtgttg taaggataca gccttaaatt tcctagagcg 900
 atgctcagta aggcgggttg tcacatgggt tcaaatgtaa aacgggcacg tttggctgct 960
 gccttccoga gatccaggac actaaactgc ttctgcactg aggtataaat cgcttcagat 1020
 cccagggaag tgcagatcca cgtgcatatt cttaaagaag aatgaatact ttctaaaata 1080
 ttttggcata ggaagcaagc tgcattggatt tggttgggac ttaaattatt ttggtaacgg 1140
 agtgcattag ttttaaacac agttgcagca tgctaacgag tcacagcggt tatgcagaag 1200
 tgatgcctgg atgcctgttg cagctgttta cggcactgcc ttgcagtgag cattgcagat 1260
 aggggtgggg tgcttttgtt cgtgttccca cacgctgcca cacagccacc tcccgaaca 1320
 catctcacct gctgggtact tttcaaacca tcttagcagt agtagatgag ttactatgaa 1380
 acagagaagt tcctcagttg gatattctca tgggatgtct ttttcccat gttgggcaaa 1440
 gtatgataaa gcatctctat ttgtaaatta tgcacttggt agttcctgaa tcctttctat 1500
 agcaccactt attgcagcag gtgtaggctc tgggtgggcc tgtgtctgtg cttcaatctt 1560

ttaaagcttc tttggaaata cactgacttg attgaagtct cttgaagata gtaaacagta	1620
cttacctttg atcccaatga aatcgagcat ttcagttgta aaagaattcc gcctattcat	1680
accatgtaat gtaattttac acccccagtg ctgacacttt ggaatatatt caagtaatag	1740
actttggcct caccctcttg tgtactgtat tttgtaatag aaaatatttt aaactgtgca	1800
tatgattatt acattatgaa agagacattc tgctgatctt caaatgtaag aaaatgagga	1860
gtgctgtgca ttttataaat acaagtgatt gcaaattagt gcagggtgcc ttaaaaaaaa	1920
aaaaaaaaag taatataaaa aggaccaggt gttttacaag tgaaatacat tcctatttgg	1980
taaacagtta catTTTTatg aagattacca gcgctgtga ctttctaaac ataaggctgt	2040
attgtcttcc tgtaccattg catttcctca ttcccaattt gcacaaggat gtctgggtaa	2100
actattcaag aaatggcttt gaaatacagc atgggagctt gtctgagttg gaatgcagag	2160
ttgcactgca aaatgtcagg aaatggatgt ctctcagaat gcccaactcc aaaggatttt	2220
atatgtgtat atagtaagca gtttcctgat tccagcaggc caaagagtct gctgaatgtt	2280
gtgttgccgg agacctgtat ttctcaacaa ggtaagatgg taccctagca actgcggatt	2340
ttaatacatt ttcagcagaa gtacttagtt aatctctacc tttagggatc gtttcatcat	2400
ttttagatgt tatacttgaa atactgcata acttttagct ttcattgggt ctttttttc	2460
agcctttagg agactgttaa gcaatttgcg gtccaacttt tgtgttggtc ttaaactgca	2520
atagtagttt acctgttatt gaagaaataa agaccatttt tatattaaaa aatacttttg	2580
tctgtcttca ttttgacttg totgatatcc ttgcagtgcc cattatgtca gttctgtcag	2640
atattcagac atcaaaactt aacgtgagct cagtggagtt acagctgcgg ttttgatgct	2700
gttattattt ctgaaactag aaatgatgtt gtcttcatct gctcatcaaa cacttcatgc	2760
agagtgtgaa gctagtgaga aatgcataca ttatttgata cttttttaaa gtcaactttt	2820
tatcagattt ttttttcatt tggaaatata ttgttttcta gactgcatag cttctgaatc	2880
tgaaatgcag tctgattggc atgaagaagc acagcactct tcatcttact taaacttcat	2940
tttggaatga aggaagttaa gcaagggcac aggtccatga aatagagaca gtgcgctcag	3000
gagaaagtga acctggattt ctttggttag tgttctaaat ctgtagtgag gaaagtaaca	3060
cccgattcct tgaaagggct ccagctttta tgcttccaaa ttgaagggtg caggcaactt	3120
ggccactggt tatttactgc attatgtctc agtttgcag ctaacctggc ttctccacta	3180
ttgagcatgg actatagcct ggcttcagag gccaggtgaa gggtgggatg ggtggaagga	3240
gtgctgggct gtggctgggg ggactgtggg gactccaagc tgagcttggg gtgggcagca	3300
cagggaaaag tgtgggtaac tatttttaag tactgtgttg caaacgtctc atctgcaaat	3360
acgtagggtg tgtactctcg aagattaaca gtgtgggttc agtaatatat ggatgaattc	3420

acagtggaag cattcaagg tagatcatct aacgacacca gatcatcaag ctatgattgg 3480
 aagcggatc agaagagcga ggaaggttaag cagtcttcat atgttttccc tccacgtaaa 3540
 gcagtctggg aaagtagcac ccttgagca gagacaagga aataattcag gagcatgtgc 3600
 taggagaact ttcttgctga attctacttg caagagcttt gatgcctggc ttctggtgcc 3660
 ttctgcagca cctgcaaggc ccagagcctg tggtagctg gagggaaaga ttctgctcaa 3720
 gtccaagctt cagcaggta ttgtctttgc ttcttcccc agcactgtgc agcagagtgg 3780
 aactgatgtc gaagcctcct gtccactacc tgttgctgca ggcagactgc tctcagaaaa 3840
 agagagctaa ctctatgcca tagtctgaag gtaaatggg ttttaaaaa gaaaacacaa 3900
 aggcaaaacc ggctgcccc tgagaagaaa gcagtggtaa acatggtaga aaagggtgcag 3960
 aagccccag gcagtgtgac aggccctcc tgccacctag aggcgggaac aagcttccct 4020
 gcctagggct ctgccgcga agtgctgtt tctttggtg gttttgttg gcgtttggtt 4080
 ttgagattta gacacaaggg aagcctgaaa ggaggtgttg ggcactatct tggtttgtaa 4140
 agcctgtact tcaaatatat attttgtgag ggagtgtagc gaattggcca atttaaaata 4200
 aagttgcaag agattgaagg ctgagtagtt gagaggtaa cacgtttaat gagatcttct 4260
 gaaactactg cttctaaaca cttgtttgag tggtagacc ttggataggt gagtgtctct 4320
 gttacatgtc tgatgcactt gcttgtcctt ttccatccac atccatgcat tccacatcca 4380
 cgcatttgct acttatcca tatctgtcat atctgacata cctgtctctt cgtcacttgg 4440
 tcagaagaaa cagatgtgat aatccccagc cgccccagt ttgagaagat ggcagttgct 4500
 tctttccctt tttcctgcta agtaaggatt ttctcctggc tttgacacct cacgaaatag 4560
 tcttctgccc ttacattctg ggcattatct caaatatctt tggagtgcgc tgctctcaag 4620
 tttgtgtctt cctactctta gagtgaatgc tcttagagt aaagagaagg aagagaagat 4680
 gttggccgca gttctctgat gaacacacct ctgaataatg gccaaagggt ggtgggtttc 4740
 tctgaggaac gggcagcgtt tgcctctgaa agcaaggagc tctgcggagt tgcagttatt 4800
 ttgcaactga tgggtggaact ggtgcttaaa gcagattccc taggttccct gctacttctt 4860
 ttcttcttg gcagtcagtt tatttctgac agacaaacag ccacccccac tgcaggctta 4920
 gaaagtatgt ggctctgcct ggggtgtgta cagctctgcc ctggtgaaag gggattaaaa 4980
 cgggcaccat tcatcccaa caggatcctc attcatggat caagctgtaa ggaacttggg 5040
 ctccaacctc aaacattaa ttggagtacg aatgtaatta aaactgcatt ctgcattcc 5100
 taagtcatct agtctggact ctgcagcatg taggtcgga gctccactt tctcaaagac 5160
 cactgatgga ggagtagtaa aaatggagac cgattcagaa caaccaacgg agtggtgccg 5220
 aagaaactga tggaaataat gcatgaattg tgtggtggac atttttttta aatacataaa 5280

ctacttcaaa tgaggtcgga gaaggtcagt gttttattag cagccataaa accaggtgag	5340
cgagtacat tttctctac aagaaaaacg attctgagct ctgcgtaagt ataagttctc	5400
catagcggct gaagctcccc cctggctgcc tgccatctca gctggagtgc agtgccattt	5460
ccttgggggtt tctctcacag cagtaatggg acaatacttc aaaaaattc tttcttttcc	5520
tgtcatgtgg gatccctact gtgccctcct ggttttacgt taccocctga ctgttcatt	5580
cagcggtttg gaaagagaaa aagaatttgg aaataaaaca tgtctacgtt atcacctcct	5640
ccagcatttt ggtttttaat tatgtcaata actggccttag atttggaat gagaggggg	5700
tgggtgtatt accgaggaac aaaggaaggc ttatataaac tcaagtcttt tatttagaga	5760
actggcaagc tgtaaaaaac aaaaaggcct taccaccaa ttaagtgaat agccgctata	5820
gccagcaggg ccagcacgag ggatggtgca ctgctggcac tatgccacgg cctgcttggtg	5880
actctgagag caactgcttt ggaaatgaca gcacttggtg caatttcctt tgtttcagaa	5940
tgcgtagagc gtgtgcttgg cgacagtttt tctagttagg ccacttcctt tttccttctc	6000
tcctcattct cctaagcatg tctccatgct ggtaatccca gtcaagtga cgttcaaaca	6060
atgaatccat cactgtagga ttctcgtggt gatcaaatct ttgtgtgagg tctataaaat	6120
atggaagctt atttattttt cgttcttcca tatcagtcct ctctatgaca attcacatcc	6180
accacagcaa attaaagtg aaggaggctg gtgggatgaa gagggctctc tagctttacg	6240
ttcttccttg caaggccaca ggaaaatgct gagagctgta gaatacagcc tggggtaaga	6300
agttcagctc cctgctggga cagctaaccg catcttataa ccccttctga gactcatctt	6360
aggaccaa atagggtctatc tggggttttt gtctctgctg ttctcctgg aaggctatct	6420
cactatttca ctgctccac gggtacaaac caaagataca gcctgaattt tttctaggcc	6480
acattacata aatttgacct ggtaccaata ttgttctcta tatagttatt tccttcccca	6540
ctgtgtttaa ccccttaagg cattcagaac aactagaatc atagaatggt ttggattgga	6600
aggggcctta aacatcatcc atttccaacc ctctgccatg ggctgcttgc caccactgg	6660
ctcaggctgc ccagggcccc atccagcctg gccttgagca cctccaggga tggggcacc	6720
acagcttctc tgggcagcct gtgccaacac ctcaccactc tctgggtaaa gaattctctt	6780
ttaacatcta atctaaatct cttctctttt agtttaaagc cattcctctt tttccggtt	6840
ctatctgtcc aagaaatgtg tattggtctc cctcctgctt ataagcagga agtactggaa	6900
ggctgcagtg aggtctcccc acagccttct cttctccagg ctgaacaagc ccagctcctt	6960
cagcctgtct tcgtaggaga tcatcttagt ggccctctc tggaccatt ccaacagttc	7020
cacggcttct ttgtggagcc ccaggctggt atgcagtact tcagatgggg cttacaaag	7080
gcagagcaga tggggacaat cgcttaccct tccctgctgg ctgccctgt tttgatgcag	7140

cccagggtac tgttggcctt tcaggctccc agacccttg ctgatttgtg tcaagctttt	7200
catccaccag aaccacgct tcctggtaa tacttctgcc ctcaactctg taagcttggt	7260
tcaggagact tccattcttt aggacagact gtgttacacc tacctgccct attcttgcatt	7320
atatacattt cagttcatgt ttcctgtaac aggacagaa atgtattcct ctaacaaaaa	7380
tacatgcaga attcctagt ccatctcagt aggggttttca tggcagtatt agcacatagt	7440
caatttgctg caagtacctt ccaagctgcg gcctcccata aatcctgtat ttgggatcag	7500
ttaccttttg gggtaagctt ttgtatctgc agagaccctg ggggttctga tgtgcttcag	7560
ctctgctctg ttctgactgc accattttct agatcaccca gttgttctct tacaacttcc	7620
ttgtcctcca tcctttccca gcttgtatct ttgacaaata caggcctatt tttgtgttg	7680
cttcagcagc catttaattc ttcagtgtca tcttgttctg ttgatgccac tggaacagga	7740
ttttcagcag tcttgcaaag aacatctagc tgaaaacttt ctgccattca atattcttac	7800
cagttcttct tgtttgaggt gagccataaa ttactagaac ttcgtcactg acaagtttat	7860
gcattttatt acttctatta tgtacttact ttgacataac acagacacgc acatattttg	7920
ctgggatttc cacagtgtct ctgtgtcctt cacatgggtt tactgtcata cttccgttat	7980
aaccttgcca atctgccag ctgccatca caagaaaaga gattcctttt ttattacttc	8040
tcttcagcca ataaacaaaa tgtgagaagc ccaacaaga acttgtggg caggctgcc	8100
tcaagggaga gacagctgaa gggttgtgta gctcaataga attaagaaat aataaagctg	8160
tgtcagacag ttttgccctga tttatacagg cagccccaa gccagagagg ctgtctgcc	8220
aggccacott gcagtccttg gtttgaaga taagtcatag gtaacttttc tggatgaattg	8280
cgtggagaat catgatggca gttcttgctg tttactatgg taagatgcta aaataggaga	8340
cagcaaagta aacttgctg ctgtaggctc tctgtatcc agacagcgat ggactcgc	8400
caccaagatg agggatgctc ccagctgacg gatgctgggg cagtaacagt gggccccatg	8460
ctgcctgctc attagcatca cctcagccct caccagccca tcagaaggat catccaagc	8520
tgaggaaagt tgctcatctt cttcacatca tcaaacttt ggctgactg atgcctccc	8580
gatgcttaaa tgtggctact gacatcttta ttttctatg atttcaagtc agaactccg	8640
gatcaggagg gaacacatag tgggaatgta ccctcagctc caaggccaga tcttccttca	8700
atgatcatgc atgctactta ggaagggtg tgtgtgtgaa tgtagaattg cctttgttat	8760
ttttcttcc tgctgtcagg aacattttga ataccagaga aaaagaaaag tgctcttctt	8820
ggcatgggag gagttgtcac acttgcaaaa taaaggatgc agtcccaaat gttcataatc	8880
tcagggtctg aaggaggatc agaaactgtg tatacaattt caggcttctc tgaatgcagc	8940
ttttgaaagc tgttcctggc cgaggcagta ctagtcaaa ccctcgaaa caggaacaaa	9000

tgtcttcaag gtgcagcagg aggaaacacc ttgcccatca tgaaagtga taaccactgc	9060
cgtgaagga atccagctcc tgtttgagca ggtgctgcac actcccacac tgaaacaaca	9120
gttcattttt ataggacttc caggaaggat cttcttctta agcttcttaa ttatggtaca	9180
tctccagttg gcagatgact atgactactg acaggagaat gaggaactag ctgggaatat	9240
ttctgtttga ccaccatgga gtcacccatt tctttactgg tatttgga aaataattct	9300
gaattgcaa gcaggagtta gcgaagatct tcatttcttc catgttggtg acagcacagt	9360
tctggctatg aaagtctgct tacaaggaag aggataaaaa tcatagggat aataaatcta	9420
agtttgaaga caatgaggtt ttagctgcat ttgacatgaa gaaattgaga cctctactgg	9480
atagctatgg tatttacgtg tctttttgct tagttactta ttgaccccag ctgaggtcaa	9540
gtatgaactc aggtctctcg ggctactggc atggattgat tacatacaac tgtaatttta	9600
gcagtgattt agggtttatg agtacttttg cagtaaatca tagggtagt aatgttaatc	9660
tcaggga aaa aaaaaaag ccaaccctga cagacatccc agctcagggtg gaaatcaagg	9720
atcacagctc agtgcggtcc cagagaacac agggactctt ctcttaggac ctttatgtac	9780
agggcctcaa gataactgat gttagtcaga agactttcca ttctggccac agttcagctg	9840
aggcaatcct ggaattttct ctccgctgca cagtccagtt catcccagtt tgtacagttc	9900
tggcactttt tgggtcaggc cgtgatccaa ggagcagaag ttccagctat ggtcaggag	9960
tgcctgaccg tcccaactca ctgcactcaa acaaaggcga aaccacaaga gtggcttttg	10020
ttgaaattgc agtgtggccc agaggggctg caccagtact ggattgacca cgaggcaaca	10080
ttaatcctca gcaagtgcaa ttgacagcca ttaaatgaa ctaactgata ctacaatgca	10140
atcagtatca acaagtgggt tggcttgga gatggagtct aggggctcta caggagtagc	10200
tactctctaa tggagttgca ttttgaagca ggacactgtg aaaagctggc ctccctaaaga	10260
ggctgctaaa cattagggtc aattttccag tgcactttct gaagtgtctg cagttcccca	10320
tgcaaagctg cccaaacata gcacttccaa ttgaatacaa ttatatgcag gcgtactgct	10380
tcttgccagc actgtccttc tcaaatgaac tcaacaaaca atttcaaagt ctagtagaaa	10440
gtaacaagct ttgaatgtca ttaaaaagta tatctgcttt cagtagttca gcttatttat	10500
gccactaga aacatcttgt acaagctgaa cactggggct ccagattagt ggtaaaacct	10560
actttataca atcatagaat catagaatgg cctgggttgg aagggaacccc aaggatcatg	10620
aagatccaac acccccgcga caggcagggc caccaacctc cagatctggt actagaccag	10680
gcagcccagg gctccatcca acctggccat gaacacctcc agggatggag catccacaac	10740
ctctctgggc agcctgtgcc agcacctcac caccctctct gtgaagaact tttccctgac	10800
atccaatcta agccttcctt ccttgaggtt agatccactc ccccttgtgc tatcactgtc	10860

tactcttgta aaaagttgat tctcctcctt tttggaaggt tgcaatgagg tctccttgca 10920
 gccttcttct cttctgcagg atgaacaagc ccagctccct cagcctgtct ttataggaga 10980
 ggtgctccag ccctctgac atctttgtgg ccctcctctg gacccgctcc aagagctcca 11040
 catctttcct gtactggggg cccaggcct gaatgcagta ctccagatgg ggcctcaaaa 11100
 gagcagagta aagagggaca atcaccttcc tcacctgtct ggcagccct cttctgatgg 11160
 agccctggat acaactggct ttctgagctg caacttctcc ttatcagttc cactattaaa 11220
 acaggaacaa tacaacaggt gctgatggcc agtgcagagt tttcacact tottcatttc 11280
 ggtagatctt agatgaggaa cgttgaagtt gtgcttctgc gtgtgcttct tcctcctcaa 11340
 atactcctgc ctgatactc accccacctg ccactgaatg gctccatggc cccctgcagc 11400
 cagggccctg atgaaccgg cactgcttca gatgctgttt aatagcacag tatgaccaag 11460
 ttgcacctat gaatacacia acaatgtgtt gcaccttca gcacttgaga agaagagcca 11520
 aatttgcatt gtcaggaaat ggtttagtaa ttctgccaat taaaacttgt ttatctacca 11580
 tggctgtttt tatggctgtt agtagtggtta cactgatgat gaacaatggc tatgcagtaa 11640
 aatcaagact gtagatattg caacagacta taaaattcct ctgtggctta gccaatgtgg 11700
 tacttccac attgtataag aaatttggca agtttagagc aatgtttgaa gtgttgggaa 11760
 atttctgtat actcaagagg gcgtttttga caactgtaga acagaggaat caaaaggggg 11820
 tgggaggaag taaaagaag aggcaggtgc aagagagctt gcagtcccgc tgtgtgtacg 11880
 acactggcaa catgaggtct ttgctaactt tgggtctttg cttcctgccc ctggctgcct 11940
 taggggtcga tctgcctcag acccacagcc tgggcagcag gaggaccctg atgctgctgg 12000
 ctgagatgag gagaatcagc ctgttttagct gcctgaagga taggcacgat tttggctttc 12060
 ctcaagagga gtttggcaac cagtttcaga aggctgagac catccctgtg ctgcacgaga 12120
 tgatccagca gatctttaac ctgttttagca ccaaggatag cagcgtgct tgggatgaga 12180
 ccctgctgga taagttttac accgagctgt accagcagct gaacgatctg gaggcttgcg 12240
 tgatccaggg cgtgggcgtg accgagacc ctctgatgaa ggaggatagc atcctggctg 12300
 tgaggaagta ctttcagagg atcaccctgt acctgaagga gaagaagtac agcccctgcg 12360
 cttgggaagt cgtgagggct gagatcatga ggagctttag cctgagcacc aacctgcaag 12420
 agagcttgag gtctaaggag taaaaagtct agagtcgggg cggccggccg cttcgagcag 12480
 acatgataag atacattgat gagtttggac aaaccacaac tagaatgcag tgaaaaaat 12540
 gctttatttg tgaaatttgt gatgctattg ctttatttgt aaccattata agctgcaata 12600
 aacaagttaa caacaacaat tgcattcatt ttatgtttca gggtcagggg gaggtgtggg 12660
 aggtttttta aagcaagtaa aacctctaca aatgtggtta aatcgataag gatccgtcga 12720

12728

gcggccgc

<210> 7
<211> 11945
<212> DNA
<213> Gallus gallus

<220>
<221> misc_feature
<222> (1)..(237)
<223> 5prime matrix attachment region (MAR)

<220>
<221> misc_feature
<222> (261)..(1564)
<223> 5prime matrix attachment region (MAR)

<220>
<221> misc_feature
<222> (1565)..(1912)
<223> 5prime matrix attachment region (MAR)

<220>
<221> misc_feature
<222> (1930)..(2012)
<223> 5prime matrix attachment region (MAR)

<220>
<221> misc_feature
<222> (2013)..(2671)
<223> Intrinsically Curved DNA

<220>
<221> misc_feature
<222> (5848)..(5934)
<223> Transcription Enhancer

<220>
<221> misc_feature
<222> (9160)..(9325)
<223> Transcription Enhancer

<220>
<221> misc_feature
<222> (9326)..(9626)
<223> Negative Regulatory Element

<220>
<221> misc_feature
<222> (9627)..(9660)
<223> Hormone Response Element

<220>
 <221> misc feature
 <222> (9680)..(10060)
 <223> Hormone Response Element

<220>
 <221> misc feature
 <222> (10576)..(10821)
 <223> Chicken CR1 Repeat

<220>
 <221> misc feature
 <222> (10926)..(11193)
 <223> Chicken CR1 Repeat

<220>
 <221> misc feature
 <222> (11424)..(11938)
 <223> Proximal promoter and lysozyme signal peptide

```

<400> 7
tgccgccttc tttgatattc actctgttgt atttcatctc ttcttgccga tgaaaggata      60
taacagtctg tataacagtc tgtgaggaaa tacttggtat ttcttctgat cagtgttttt      120
ataagtaatg ttgaatattg gataaggctg tgtgtccttt gtcttgggag acaaagccca      180
cagcaggttg tggttggggt ggtggcagct cagtgcagg agaggttttt ttgcctgttt      240
tttttttttt tttttttttt aagtaagggtg ttcttttttc ttagtaaatt ttctactgga      300
ctgtatgttt tgacaggtca gaaacatttc ttcaaaagaa gaaccttttg gaaactgtac      360
agcccttttc tttcattccc tttttgcttt ctgtgccaat gcctttgggt ctgattgcat      420
tatggaaaac gttgatcgga acttgagggt tttatttata gtgtggcttg aaagcttgga      480
tagctgttgt tacacgagat accttattaa gtttaggcca gcttgatgct ttattttttc      540
cctttgaagt agtgagcgtt ctctggtttt ttctcttga aactggtgag gcttagattt      600
ttctaattggg attttttacc tgatgatcta gttgcatacc caaatgcttg taaatgtttt      660
cctagttaac atgttgataa cttcggattt acatgttgta tatacttgtc atctgtgttt      720
ctagtaaaaa tatatggcat ttatagaaat acgtaattcc tgatttcctt tttttttatc      780
tctatgctct gtgtgtacag gtcaaacaga cttcactcct atttttatatt atagaatttt      840
atatgcagtc tgtcgttggt tcttgtgttg taaggataca gccttaaatt tcctagagcg      900
atgctcagta aggcgggttg tcacatgggt tcaaatgtaa aacgggcacg tttggctgct      960
gccttcccgat gatccaggac actaaactgc ttctgcactg aggtataaat cgcttcagat     1020
cccaggaag tgcagatcca cgtgcatatt cttaaagaag aatgaatact ttctaaaata     1080
ttttggcata ggaagcaagc tgcattggatt tgtttgggac ttaaattatt ttggtaacgg     1140

```


agtgcataagg ttttaaacac agttgcagca tgctaacgag tcacagcgtt tatgcagaag	1200
tgatgcctgg atgcctgttg cagctgttta cggcactgcc ttgcagtga cattgcagat	1260
aggggtgggg tgctttgtgt cgtgttccca cacgctgcc cacagccacc tcccggaaca	1320
catctcacct gctgggtact tttcaaacca tcttagcagt agtagatgag ttactatgaa	1380
acagagaagt tctcagttg gatattctca tgggatgtct tttttcccat gttgggcaaa	1440
gtatgataaa gcatctctat ttgtaaatta tgcacttggt agttcctgaa tcctttctat	1500
agcaccactt attgcagcag gtgtaggctc tgggtgggcc tgtgtctgtg cttcaatctt	1560
ttaaagcttc tttggaaata cactgacttg attgaagtct cttgaagata gtaaacagta	1620
cttacctttg atcccaatga aatcgagcat ttcagttgta aaagaattcc gcctattcat	1680
accatgtaat gtaattttac accccagtg ctgacacttt ggaatatatt caagtaatag	1740
actttggcct caccctcttg tgtactgtat tttgtaatag aaaatatatt aaactgtgca	1800
tatgattatt acattatgaa agagacattc tgctgatctt caaatgtaag aaaatgagga	1860
gtgcgtgtgc ttttataaat acaagtgtt gcaaattagt gcaggtgtcc ttaaaaaaaaa	1920
aaaaaaaaag taatataaaa aggaccaggt gttttacaag tgaaatacat tcctatttgg	1980
taaacagtta catttttatg aagattacca gcgtgtgtga ctttctaaac ataaggctgt	2040
attgtcttcc tgtaccattg catttcctca tttccaattt gcacaaggat gtctgggtaa	2100
actattcaag aaatggcttt gaaatacagc atgggagctt gtctgagttg gaatgcagag	2160
ttgcactgca aaatgacag aaatggatgt ctctcagaat gcccaactcc aaaggatttt	2220
atatgtgtat atagtaagca gtttcctgat tccagcaggc caaagagtct gctgaatgtt	2280
gtgttgccgg agacctgtat ttotcaacaa ggtaagatgg taccctagca actgcggatt	2340
ttaatacatt ttcagcagaa gtacttagtt aatctctacc tttagggatc gtttcatcat	2400
ttttagatgt tatacttgaa atactgcata acttttagct ttcatgggtt cctttttttc	2460
agccttttag agactgttaa gcaatttgct gtccaacttt tgtgttggtc ttaaactgca	2520
atagtagttt acctgtatt gaagaaataa agaccatttt tatattaaaa aatacttttg	2580
tctgtottca ttttgacttg tctgatatcc ttgcagtgcc cattatgtca gttctgtcag	2640
atattcagac atcaaaactt aacgtgagct cagtggagtt acagctgcgg ttttgatgct	2700
gttattattt ctgaaactag aaatgatgtt gtcttcatct gctcatcaaa cacttcatgc	2760
agagtgtgag gctagtgaga aatgcataca tttattgata cttttttaaa gtcaactttt	2820
tatcagattt ttttttcatt tggaaatata ttgttttcta gactgcatag cttctgaatc	2880
tgaaatgcag tctgattggc atgaagaagc acagcactct tcatcttact taaacttcat	2940
tttggaatga aggaagttaa gcaagggcac aggtccatga aatagagaca gtgcgctcag	3000

gagaaagtga acctggattt ctttggctag tgttctaaat ctgtagtgag gaaagtaaca	3060
cccgattcct tgaaagggtt ccagctttaa tgcttccaaa ttgaagggtg caggcaactt	3120
ggccactggt tatttactgc attatgtctc agtttcgcag ctaacctggc ttctccacta	3180
ttgagcatgg actatagcct ggcttcagag gccaggtgaa ggttgggatg ggtggaagga	3240
gtgctgggct gtggctgggg ggactgtggg gactccaagc tgagcttggg gtgggcagca	3300
cagggaaaaag tgtgggtaac tatttttaag tactgtgttg caaacgtctc atctgcaaat	3360
acgtagggtg tgtactctcg aagattaaca gtgtgggttc agtaatatat ggatgaattc	3420
acagtggaag cattcaaggg tagatcatct aacgacacca gatcatcaag ctatgattgg	3480
aagcggatc agaagagcga ggaaggtaag cagtcttcat atgttttccc tccacgtaaa	3540
gcagtctggg aaagtagcac cccttgagca gagacaagga aataattcag gagcatgtgc	3600
taggagaact ttcttgctga attctacttg caagagcttt gatgcctggc ttctggtgcc	3660
ttctgcagca cctgcaaggc ccagagcctg tggtagctg gagggaaaga ttctgctcaa	3720
gtccaagctt cagcagggtca ttgtctttgc ttcttcccc agcactgtgc agcagagtgg	3780
aactgatgtc gaagcctcct gtccactacc tgttgctgca ggcagactgc tctcagaaaa	3840
agagagctaa ctctatgccca tagtctgaag gtaaaatggg ttttaaaaaa gaaaacacaa	3900
aggcaaaacc ggctgccccca tgagaagaaa gcagtggtaa acatggtaga aaagggtcag	3960
aagccccag gcagtgtgac agggccctcc tgccacctag aggcgggaac aagcttcctt	4020
gcctagggct ctgcccgcga agtgcggtgtt tctttgggtg gttttgtttg gcgtttggtt	4080
ttgagattta gacacaaggg aagcctgaaa ggaggtgttg ggcactattt tggtttgtaa	4140
agcctgtact tcaaataat attttgtgag ggagtgtagc gaattggcca atttaaaata	4200
aagttgcaag agattgaagg ctgagtagtt gagagggtaa cacgtttaat gagatcttct	4260
gaaactactg cttctaaaca cttgtttgag tggtagagacc ttggataggt gagtgctctt	4320
gttacatgtc tgatgcactt gottgtcctt ttccatccac atccatgcat tccacatcca	4380
cgcatttgtc acttatccca tatctgtcat atctgacata cctgtctctt cgtcacttgg	4440
tcagaagaaa cagatgtgat aatccccagc cgccccaaagt ttgagaagat ggcagttgct	4500
tctttccctt tttctgcta agtaaggatt ttctcctggc tttagacacct cacgaaatag	4560
tcttctgcc ttacattctg ggcattatit caaatatctt tggagtgcgc tgctctcaag	4620
tttgtgtctt cctactctta gagtgaatgc tcttagagtg aaagagaagg aagagaagat	4680
gttgccgcga gttctctgat gaacacacct ctgaataatg gccaaagggtg ggtgggtttc	4740
tctgaggaac gggcagcgtt tgcctctgaa agcaaggagc tctgcggagt tgcagttatt	4800
ttgcaactga tgggtggaact ggtgcttaaa gcagattccc taggttccct gctacttctt	4860

ttccttcttg gcagtcagtt tatttctgac agacaaacag ccacccccac tgcaggctta	4920
gaaagtatgt ggctctgcct ggggtgtgta cagctctgcc ctggtgaaag gggattaaaa	4980
cgggcaccat tcatccaaa caggatcctc attcatggat caagctgtaa ggaacttggg	5040
ctccaacctc aaaacattaa ttggagtacg aatgtaatta aaactgcatt ctcgcatcc	5100
taagtcattt agtctggact ctgcagcatg taggtcggca gctccactt tctcaaagac	5160
cactgatgga ggagtagtaa aaatggagac cgattcagaa caaccaacgg agtggtgccg	5220
aagaaactga tggaaataat gcatgaattg tgtggtggac atttttttta aatacataaa	5280
ctacttcaaa tgaggtcgga gaaggtcagt gttttattag cagccataaa accaggtag	5340
cgagtacat ttttctctac aagaaaaacg attctgagct ctgcgtaagt ataagtctc	5400
catagcggct gaagctcccc cctggctgcc tgccatctca gctggagtgc agtgccattt	5460
ccttgggggt tctctcacag cagtaatggg acaatacttc acaaaaattc tttcttttcc	5520
tgtcatgtgg gatccctact gtgccctcct ggttttacgt taccctctga ctgttcatt	5580
cagcggtttg gaaagagaaa aagaatttgg aaataaaaca tgtctacgtt atcacctct	5640
ccagcatttt ggtttttaat tatgtcaata actggcttag atttggaat gagaggggt	5700
tgggtgtatt accgaggaac aaaggaaggc ttatataaac tcaagtcttt tatttagaga	5760
actggcaagc tgtcaaaaac aaaaaggcct taccaccaa ttaagtgaat agccgctata	5820
gccagcaggg ccagcacgag ggatggtgca ctgctggcac tatgccacgg cctgcttgtg	5880
actctgagag caactgcttt ggaatgaca gcacttgggt caatttcctt tgtttcagaa	5940
tgcgtagagc gtgtgcttgg cgacagtttt tctagttagg ccacttcttt tttccttctc	6000
tcctcattct cctaagcatg tctccatgct ggtaatccca gtcaagtga cgttcaaaca	6060
atgaatccat cactgtagga ttctogtggg gatcaaatct ttgtgtgagg tctataaaat	6120
atggaagctt atttattttt cgttcttcca tatcagctct ctctatgaca attcacatcc	6180
accacagcaa attaaagggt aaggaggctg gtgggatgaa gagggctctc tagctttacg	6240
ttcttccttg caaggccaca ggaaaatgct gagagctgta gaatacagcc tggggtgaaga	6300
agttcagtct cctgctggga cagctaaccg catcttataa ccccttctga gactcatctt	6360
aggaccaa atagggtctatc tgggggtttt gtctctgctg ttctcctggt aaggctatct	6420
cactatttca ctgctccac ggttacaac caaagataca gcctgaattt tttctaggcc	6480
acattacata aatttgacct ggtaccaata ttgttctcta tatagttatt tccttcccc	6540
ctgtgttttaa ccccttaagg cattcagaac aactagaatc atagaatggt ttggattgga	6600
aggggcctta aacatcatcc atttccaacc ctctgccatg ggctgcttgc caccactgg	6660
ctcaggctgc ccagggcccc atccagcctg gccttgagca cctccaggga tggggcaccc	6720

acagcttctc tgggcagcct gtgccaacac ctcaccactc tctgggtaaa gaattctctt	6780
ttaacatcta atctaaatct cttctctttt agtttaaagc cattcctctt tttcccgttg	6840
ctatctgtcc aagaaatgtg tattggtctc cctcctgctt ataagcagga agtactggaa	6900
ggctgcagtg aggtctcccc acagccttct cttctccagg ctgaacaagc ccagctcctt	6960
cagcctgtct tcgtaggaga tcctcttagt ggccctcctc tggaccatt ccaacagttc	7020
cacggctttt ttgtggagcc ccaggtctgg atgcagtact tcagatgggg ccttacaaag	7080
gcagagcaga tggggacaat cgcttaccct tccctgctgg ctgcccctgt tttgatgcag	7140
cccagggtag tgttggcctt tcaggctccc agacccttg ctgatttggt tcaagctttt	7200
catccaccag aaccacgct tcctgggtaa tactctgcc ctccattctg taagcttggt	7260
tcaggagact tccattcttt aggacagact gtgttacacc tacctgccct attcttgcct	7320
atatacatit cagttcatgt ttcctgtaac aggacagaat atgtattcct ctaacaaaaa	7380
tacatgcaga attcctagt ccatctcagt agggttttca tggcagtatt agcacatagt	7440
caatttgctg caagtacctt ccaagctgcg gcctccata aatcctgtat ttgggatcag	7500
ttaccttttg gggtaagctt ttgtatctgc agagaccctg ggggttctga tgtgcttcag	7560
ctctgctctg ttctgactgc accattttct agatcaccca gttgttctg tacaacttcc	7620
ttgtcctcca tcctttccca gcttgatctt ttgacaaata caggcctatt tttgtgttg	7680
cttcagcagc ctttaattc ttcagtgtca tctgttctg ttgatgccac tggaacagga	7740
ttttcagcag tcttgcaaag aacatctagc tgaaaacttt ctgccattca atattcttac	7800
cagttcttct tgtttgaggt gagccataaa ttactagaac ttcgtcactg acaagtttat	7860
gcattttatt acttctatta tgtacttact ttgacataac acagacagc acatattttg	7920
ctgggatttc cacagtgtct ctgtgtcctt cacatggttt tactgtcata cttccgttat	7980
aaccttggca atctgccag ctgcccata caagaaaaga gattcctttt ttattacttc	8040
tcttcagcca ataaacaaaa tgtgagaagc ccaaacaaga acttgtgggg caggctgcc	8100
tcaagggaga gacagctgaa gggttgtgta gctcaataga attaagaaat aataaagctg	8160
tgtcagacag ttttgctga tttatacagg cagcccca gccagagagg ctgtctgcc	8220
aggccacctt gcagtccttg gtttgtaaga taagtcata gtaacttttc tggatgaattg	8280
cggtggagaat catgatggca gttcttgctg tttactatgg taagatgcta aaataggaga	8340
cagcaaagta acacttgctg ctgtaggtgc tctgctatcc agacagcgat ggactcgc	8400
caccaagatg agggatgctc ccagctgacg gatgctgggg cagtaacagt gggtoecatg	8460
ctgcctgctc attagcatca cctcagccct caccagccca tcagaaggat catcccaagc	8520
tgaggaaagt tgctcatctt cttcacatca tcaaactttt ggctgactg atgcctccc	8580

gatgcttaaa tgtggctact gacatcttta tttttctatg atttcaagtc agaacctccg 8640
gatcaggagg gaacacatag tgggaatgta ccttcagctc caaggccaga tcttccttca 8700
atgatcatgc atgctactta ggaagggtg tgtgtgtgaa tgtagaattg cctttgttat 8760
tttttcttcc tgctgtcagg aacattttga ataccagaga aaaagaaaag tgctcttctt 8820
ggcatgggag gagttgtcac acttgcaaaa taaaggatgc agtcccaa atgttcataatc 8880
tcagggtctg aaggaggatc agaaactgtg tatacaattt caggcttctc tgaatgcagc 8940
ttttgaaagc tgttcctggc cgaggcagta ctagtacaga ccttcggaaa caggaacaaa 9000
tgtcttcaag gtgcagcagg aggaacacc ttgccatca tgaaagtga taaccactgc 9060
cgctgaagga atccagctcc tgtttgagca ggtgctgcac actccacac tgaaacaaca 9120
gttcattttt ataggacttc caggaaggat cttcttctta agcttcttaa ttatggtaca 9180
tctccagttg gcagatgact atgactactg acaggagaat gaggaactag ctgggaatat 9240
ttctgtttga ccaccatgga gtcacccatt tctttactgg tatttgga taataattct 9300
gaattgcaaa gcaggagtta gcgaagatct tcatttcttc catgttggtg acagcacagt 9360
tctggctatg aaagtctgct tacaaggaag aggataaaaa tcatagggat aataaatcta 9420
agtttgaaga caatgaggtt ttagctgcat ttgacatgaa gaaattgaga cctctactgg 9480
atagctatgg tatttacgtg tctttttgct tagttactta ttgacccag ctgaggtcaa 9540
gtatgaactc aggtctctcg ggctactggc atggattgat tacatacaac tgtaatttta 9600
gcagtgattt aggggtttatg agtacttttg cagtaaatca tagggtagt aatgttaatc 9660
tcagggaaaa aaaaaaaaaag ccaacctga cagacatccc agctcaggtg gaaatcaagg 9720
atcacagctc agtgcggtcc cagagaacac agggactctt ctcttaggac ctttatgtac 9780
agggcctcaa gataactgat gttagtcaga agactttcca ttctggccac agttcagctg 9840
aggcaatcct ggaattttct ctccgtgca cagttccagt catcccagtt tgtacagttc 9900
tggcactttt tgggtcaggc cgtgatccaa ggagcagaag ttccagctat ggtcagggag 9960
tgccgtgaccg tccaactca ctgcactcaa acaaaggcga aaccacaaga gtggcttttg 10020
ttgaaattgc agtgtggccc agaggggctg caccagtact ggattgacca cgaggcaaca 10080
ttaatcctca gcaagtgcaa tttgcagcca ttaaattgaa ctaactgata ctacaatgca 10140
atcagtatca acaagtgggt tggcttgga gatggagtct aggggctcta caggagtagc 10200
tactctctaa tggagttgca ttttgaagca ggacactgtg aaaagctggc ctctaaaaga 10260
ggctgctaaa cattagggtc aattttccag tgcaacttct gaagtgtctg cagttcccca 10320
tgcaaagctg cccaaacata gcacttcaa ttgaatacaa ttatatgcag gcgtactgct 10380
tcttgccagc actgtccttc tcaaatgaac tcaacaaaca atttcaaagt ctagtagaaa 10440

```

gtaacaagct ttgaatgtca ttaaaaagta tatctgcttt cagtagttca gcttatttat 10500
gccactaga aacatcttgt acaagctgaa cactggggct ccagattagt ggtaaacct 10560
actttataca atcatagaat catagaatgg cctgggttgg aagggacccc aaggatcatg 10620
aagatccaac acccccgcca caggcagggc caccaacctc cagatctggt actagaccag 10680
gcagcccagg gctccatcca acctggccat gaacacctcc agggatggag catccacaac 10740
ctctctgggc agcctgtgcc agcacctcac caccctctct gtgaagaact ttccctgac 10800
atccaatcta agccttcctt ccttgaggtt agatccactc ccccttgtc tatcactgtc 10860
tactcttgta aaaagttgat tctctcctt tttggaagg tgcattgagg tctccttgca 10920
gccttcttct cttctgcagg atgaacaagc ccagctccct cagcctgtct ttataggaga 10980
gggtgctccag ccctctgac atctttgtgg ccctcctctg gaccgctcc aagagctcca 11040
catctttcct gtactggggg cccagggcct gaatgcagta ctccagatgg ggcctcaaaa 11100
gagcagagta aagagggaca atcaccttc tcacctgtt gccagccct cttctgatgg 11160
agccctggat acaactggct ttctgagctg caacttctcc ttatcagttc cactattaaa 11220
acaggaacaa tacaacaggt gctgatggcc agtgcagagt tttcacact tcttcatttc 11280
ggtagatctt agatgaggaa cggtgaagtt gtgcttctgc gtgtgcttct tctcctcaa 11340
atactcctgc ctgatactc accccacctg ccaactgaatg gctccatggc cccctgcagc 11400
cagggccctg atgaaccgg cactgcttca gatgctgtt aatagcacag tatgaccaag 11460
ttgcacctat gaatacacia acaatgtgtt gcaccttca gcacttgaga agaagagcca 11520
aatttgcat gtcaggaaat ggtttagtaa ttctgccaat taaaacttgt ttatctacca 11580
tggctgtttt tatgctgtt agtagtggt cactgatgat gaacaatggc tatgcagtaa 11640
aatcaagact gtagatattg caacagacta taaaattcct ctgtggctta gccaatgtgg 11700
tacttccac attgtataag aaatttgga agtttagagc aatgtttgaa gtgttgggaa 11760
atttctgtat actcaagagg gcgttttga caactgtaga acagaggaat caaaagggg 11820
tgggaggaag ttaaaagaag aggcaggtgc aagagagctt gcagtcccg tggtgtgtacg 11880
acactggcaa catgaggtct ttgctaactc tgggtgcttg cttcctgccc ctggctgcct 11940
taggg 11945

```

```

<210> 8
<211> 285
<212> DNA
<213> SV40

```

```

<220>
<221> misc_feature
<222> (1)..(285)
<223> SV40 Polyadenylation Sequence

```

<400> 8
aaagtctaga gtcggggcgg ccggccgctt cgagcagaca tgataagata cattgatgag 60
tttgacaaa ccacaactag aatgcagtga aaaaaatgct ttatttgtga aatttgtgat 120
gctattgctt tatttgaac cattataagc tgcaataaac aagttaacaa caacaattgc 180
attcatttta tgtttcaggt tcagggggag gtgtgggagg ttttttaaag caagtaaaac 240
ctctacaaat gtggtaaaaat cgataaggat ccgtcgagcg gccgc 285

<210> 9
<211> 5972
<212> DNA
<213> Gallus gallus

<220>
<221> misc_feature
<222> (1)..(5972)
<223> Lysozyme 3prime domain

<400> 9
cgcgtagtag gtggcggggg gttcccagga gagccccag cgcgacggc agcgccgtca 60
ctcaccgctc cgtctccctc cgcccagggt cgctggcg caccgctgca agggcaccga 120
cgtccaggcg tggatcagag gctgccggt gtgaggagct gccgcgccg gcccgcccgc 180
tgcacagccg gccgctttgc gagcgcgacg ctaccgctt ggagtttta aacgcatccc 240
tcattaaaaac gactatacgc aaacgccttc ccgtcggtcc gcgtctctt cgcgcccgag 300
ggcgacactc gcggggaggg cggaagggg gccgggcggg agcccgcggc caaccgtcgc 360
cccgtgacgg caccgccccg ccccggtgac gcggtgcgg cgccggggcc gtggggctga 420
gcgctgcggc ggggccgggc cgggccggg cgggagctga gcgcggcgcg gctgcggcg 480
gcgccccctc cgggtgaata tgttcaagag aatggctgag ttccggcctg actccggggg 540
caggggtgaag gtgcggcgcg ggccggagga cggggcgggc gcggggccgc ccggcggggtg 600
ccggggcctc tgccggccc cccggctcgg gctgctgcgg cgttacggg cgcgcttctc 660
gccgctgccg cttctcttct ctcccgca agggcgctac catcgtgaag ccggtagtgt 720
acgggaacgt ggcgcggtac ttcgggaaga agaggagga ggacgggcac acgcatcagt 780
ggacgggttta cgtgaagccc tacaggaacg aggtagggcc cgagcgcgtc ggccgccgtt 840
ctcggagcgc cggagccgtc agcgcgcgc ctgggtgcgc tgtgggacac agcgagcttc 900
tctcgtagga catgtccgcc tacgtgaaaa aaatccagtt caagctgcac gagagctacg 960
ggaatcctct ccgaggtggg tgttgcgtcg gggggtttgc tccgctcggt cccgctgagg 1020
ctcgtcgccc tcatctttct ttcgtgcgc agtcgttacc aaaccgccgt acgagatcac 1080
cgaaacgggc tggggcgaat ttgaaatcat catcaagata tttttcattg atccaaacga 1140

gcgacccgta agtacgctca gcttctcgta gtgcttcccc cgtcctggcg gcccggggct 1200
 gggtgctcg ctgctgccg tcacagtccc gccagcccg gagctgactg agctcccttt 1260
 cccgggacgt gtgctctgtg ttcggtcagc gaggctatcg ggagggcttt ggctgcattt 1320
 ggcttctctg gcgcttagcg caggagcacg ttgtgctacg cctgaactac agctgtgaga 1380
 aggccgtgga aaccgctctc aaactgattt attggcgaaa tggctctaaa ctaaactcgtc 1440
 tcctctcttt ggaaatgctt tagagaaggt ctctgtggtg gttcttatgc atctatccta 1500
 aagcacttgg ccagacaatt taaagacatc aagcagcatt tatagcaggc acgtttaata 1560
 acgaatactg aatttaagta actctgctca cgttgatga cgtttatttt cgtattcctg 1620
 aaagccatta aaatcctgtg cagttgttta gtaagaacag ctgccactgt tttgtatcta 1680
 ggagataact ggtgtttccc tacagtcttc aagctgataa aactctgtct ttgtatctag 1740
 gtaaccctgt atcacttgct gaagcttttt cagtctgaca ccaatgcaat cctgggaaag 1800
 aaaactgtag tttctgaatt ctatgatgaa atgggatgaa aattttaatg tcaaccgagc 1860
 ctgactttat ttaaaaaaaaa ttattgatgg tgctgtgtat tttggctcct ccttagatat 1920
 ttcaagatcc tactgccatg atgcagcaac tgctaacgac gtcccgtcag ctgacacttg 1980
 gtgcttacia gcatgaaaca gagtgtaagt gcaaaatgag gataccttcg ccgaccgtca 2040
 ttcactacta atgttttctg tgggatgtga tcgtacagtg agtttggtg tgtgaaattt 2100
 gaatagcttg gtattggcag tgatgacgtg atcgatgcct tgcttatcat gtttgaaatg 2160
 aagtagaataaatgcagcct gctttatttg agatagtgtt gttcatttta tggaatgcaa 2220
 gcaaagatta tacttctca ctgaattgca ctgtccaaag gtgtgaaatg tgtggggatc 2280
 tggaggaccg tgaccgaggg acattggatc gctatctccc atttcttttg ctgttaccag 2340
 ttcagatttt cttttcacct agtctttaat tcccagggtt ttgttttttc cttggtcata 2400
 gtttttgttt ttcactctgg caaatgatgt tgtgaattac actgcttcag ccacaaaact 2460
 gatggactga atgaggtcat caaacaaaact tttcttctc cgtatttctt ttttttccc 2520
 ccacttatca tttttactgc tgttggtgag tctgtaaggc taaaagtaac tgttttgtgc 2580
 tttttcagga cgtgtgcttt ccaaattact gccacatata taaagaaagg ttggaatttt 2640
 aaagataatt catgtttctt cttctttttt gccaccacag ttgcagatct tgaagtaaaa 2700
 accagggaaa agctggaagc tgccaaaaag aaaaccagtt ttgaaattgc tgagcttaaa 2760
 gaaagggttaa aagcaagtcg tgaaccatc aactgcttaa agagtgaat cagaaaactc 2820
 gaagaggatg atcagtctaa agatatgtga tgagtgtga cttggcaggg agcctataat 2880
 gagaatgaaa ggacttcagt cgtggagttg tatgcgttct ctccaattct gtaacggaga 2940
 ctgtatgaat ttcatttgca aatcactgca gtgtgtgaca actgactttt tataaatggc 3000

agaaaacaag aatgaatgta tcctcatttt atagttaaaa tctatgggta tgtactgggt	3060
tatttcaagg agaatggatc gtagagactt ggaggccaga ttgctgcttg tattgactgc	3120
atttgagtgg tgtaggaaca ttttgtctat ggtcccgtgt tagtttacag aatgccactg	3180
ttcactgttt tgttttgtat ttacttttt ctactgcaac gtcaaggttt taaaagttga	3240
aaataaaaca tgcaggtttt ttttaaata tttttgtct ctatccagtt tgggcttcaa	3300
gtattattgt taacagcaag tcctgattta agtcagaggc tgaagtgtaa tggatttcaa	3360
gatgcttaag tctgttgta gcaaaacaaa agagaaaact tcataaaatc aggaagttgg	3420
catttcta atcttcttta tcaacagata agagtttcta gccctgcac tactttcact	3480
tatgtagttg atgcctttat attttgtgtg tttggatgca ggaagtgtt cctactctgt	3540
tatgtagata ttctatttaa cacttgtact ctgctgtgct tagcctttcc ccatgaaaat	3600
tcagcggctg taaatcccc tcttcttttg tagcctcata cagatggcag accctcaggc	3660
ttataaaggc ttgggcatct tctttactgc tttgagattc tgtgttgca taacctctgc	3720
cagagaggag aaaagcccca caaacctcat ccccttcttc tatagcaatc agtattacta	3780
atgctttgag aacagagcac tggtttgaaa cgtttgataa ttagcattta acatggcttg	3840
gtaaagatgc agaactgaaa cagctgtgac agtatgaact cagtatggag acttcattaa	3900
gacaaacagc tgttaaaatc aggcattgtt cattgaggag gacggggcaa cttgcaccag	3960
tggtgccac acaaatcctt cctggcgtg cagaccaatt tttctggcat tctgactgcc	4020
gttgctgctg gtcacagaga gcaactattt ttatcagcca caggcaattt gctttagta	4080
ttttccaagt gttgtaggta agtataaatg catcggtccc agagcacttt gagtatactt	4140
attaaaaaca taaatgaaag acaaattagc tttgcttggg tgcacagaac atttttagtt	4200
ccagcctgct ttttggtaga agcctcttc tgaggctaga actgactttg acaagtagag	4260
aaactggcaa cggagctatt gctatcgaag gatccttgtt aacaaagtt atcgtctttt	4320
aaggtttgg tttattcatta aatttgcttt taagctgtag ctgaaaaaga acgtgctgtc	4380
ttccatgcac cagggtggcag ctctgtgcaa agtgcctct ggtctcacca gccttttaat	4440
tgccgggatt ctggcacgtc tgagagggct cagactggct tcgtttgttt gaacagcgtg	4500
tactgctttc tgtagacatg gccggtttct ctctgcagc ttatgaaact gttcacactg	4560
aacacactgg aacaggttgc ccaaggaggc cgtggatgcc ccatccctgg aggcattcaa	4620
ggccaggctg gatgtggctc tgggcagcct ggtctggtgg ttggcgatcc tgcacatagc	4680
agcggggttg aaactcgatg atcactgtgg tccttttcaa ccaggctat tctatgattc	4740
tatgattcaa cagcaaatca tatgtactga gagaggaaac aaacacaagt gctactgttt	4800
gcaagttttg ttcatttggg aaaagagtca ggttttaaaa ttcaaaatct gtctggtttt	4860

```

gggtgtttttt tttttttatt tattatttct ttgggggttct ttttgatgct ttatctttct 4920
ctgccaggac tgtgtgacaa tgggaacgaa aaagaacatg ccaggcactg tcctggattg 4980
cacacgctgg ttgcactcag tagcaggctc agaactgcc agtctttccac agtattactt 5040
tctaaacctta attttaatat cggttagtaga cttccatcac tgggcagtgc ttagtgaaatg 5100
ctctgtgtga acgttttact tataagcatg ttggaagttt tgatgttcct ggatgcagta 5160
gggaaggaca gattagctat gtgaaaagta gattctgagt atcgggggta caaaaagtat 5220
agaaacgatg agaaattctt gttgtaacta attggaattt ctttaagcgt tcacttatgc 5280
tacattcata gtatttccat ttaaaagtag gaaaaggtaa aacgtgaaat cgtgtgattt 5340
tcggatggaa caccgccttc ctatgcacct gaccaacttc cagaggaaaa gcctattgaa 5400
agccgagatt aagccaccaa aagaactcat ttgcattgga atatgtagta tttgcctct 5460
tcctcccggt taattactat actttatagg gtgcttatat gttaaagag tggctggcac 5520
tttttattct cacagctgtg gggaattctg tcctctagga cagaaacaat ttaaatctgt 5580
tcactgggtg actgctttgt cagcacttcc acctgaagag atcaatacac tcttcaatgt 5640
ctagtctctgc aacacttggc aaacctcaca tcttatttca tactctcttc atgcctatgc 5700
ttattaaagc aataatctgg gtaatttttg ttttaatcac tgcctgacc ccagtgatga 5760
ccgtgtccca cctaaagctc aattcaggct ctgaatctct tcaactctct atagctaaca 5820
tgaagaatct tcaaaagtta ggtctgaggg acttaaggct aactgtagat gttgttgct 5880
ggtttctgtg ctgaaggccg tgtagtagtt agagcattca acctctagaa gaagcttgcc 5940
cagctggtcg acctgcagat ccggccctcg ag 5972

```

```

<210> 10
<211> 18391
<212> DNA
<213> Gallus gallus

```

```

<220>
<221> misc_feature
<222> (1)..(237)
<223> 5prime matrix (scaffold) attachment region (MAR)

```

```

<220>
<221> misc_feature
<222> (261)..(1564)
<223> 5prime matrix (scaffold) attachment region (MAR)

```

```

<220>
<221> misc_feature
<222> (1565)..(1912)
<223> 5prime matrix (scaffold) attachment region (MAR)

```

<220>
<221> misc_feature
<222> (1930)..(2012)
<223> Sprime matrix (scaffold) attachment region (MAR)

<220>
<221> misc_feature
<222> (2013)..(2671)
<223> Intrinsically curved DNA

<220>
<221> misc_feature
<222> (5848)..(5934)
<223> Transcription enhancer

<220>
<221> misc_feature
<222> (9160)..(9325)
<223> Transcription enhancer

<220>
<221> misc_feature
<222> (9326)..(9626)
<223> Negative regulatory element

<220>
<221> misc_feature
<222> (9621)..(9660)
<223> Hormone response element

<220>
<221> misc_feature
<222> (9680)..(10060)
<223> Hormone response element

<220>
<221> misc_feature
<222> (10576)..(10821)
<223> Chicken CR1 Repeat Sequence

<220>
<221> misc_feature
<222> (10926)..(11193)
<223> Chicken CR1 Repeat Sequence

<220>
<221> misc_feature
<222> (11424)..(11938)
<223> Lysozyme Proximal Promoter and Lysozyme Signal Peptide

<220>
<221> misc_feature

<222> (11946)..(12443)
 <223> human interferon alpha 2b codon-optimized for expression in chick
 ens

<220>
 <221> misc_feature
 <222> (12464)..(18391)
 <223> Chicken Lysozyme 3prime domain

```

<400> 10
tgccgccttc tttgatattc actctgttgt atttcatctc ttcttgccga tgaaaggata    60
taacagtctg tataacagtc tgtgaggaaa tacttggtat ttctttctgat cagtgttttt    120
ataagtaatg ttgaatattg gataaggctg tgtgtccttt gtcttgggag acaaagccca    180
cagcaggtgg tggttggggg ggtggcagct cagtgcagag agaggttttt ttgcctgttt    240
tttttttttt tttttttttt aagtaagggtg ttcttttttc ttagtaaatt ttctactgga    300
ctgtatgttt tgacagggtca gaaacatttc ttcaaaagaa gaaccttttg gaaactgtac    360
agcccttttc tttcattccc tttttgcttt ctgtgccaat gcctttgggt ctgattgcat    420
tatggaaaac gttgatcgga acttgaggtt tttatttata gtgtggcttg aaagcttgga    480
tagctgttgt tacacgagat acctatttaa gtttaggcca gcttgatgct ttattttttc    540
cctttgaagt agtgagcgtt ctctggtttt tttcctttga aactggtgag gcttagattt    600
ttctaattggg attttttacc tgatgatcta gttgcatacc caaatgcttg taaatgtttt    660
cctagttaac atgttgataa cttcggtatt acatgttgta tatacttgct atctgtgttt    720
ctagtaaaaa tatatggcat ttatagaaat acgtaattcc tgatttcctt tttttttatc    780
tctatgctct gtgtgtacag gtcaaacaga cttcactcct atttttattt atagaatttt    840
atatgcagtc tgtcgttggt tcttgtgttg taaggatata gccttaaatt tcctagagcg    900
atgctcagta aggcgggttg tcacatgggt tcaaatgtaa aacgggcacg tttggctgct    960
gccttcccga gatccaggac actaaactgc ttctgcactg aggtataaat cgcttcagat   1020
cccaggaag tgcagatcca cgtgcatatt cttaaagaag aatgaatact ttctaaaata   1080
ttttggcata ggaagcaagc tgcattggatt tgtttgggac ttaaattatt ttggtaacgg   1140
agtgcattag ttttaaacac agttgcagca tgctaacgag tcacagcggt tatgcagaag   1200
tgatgcctgg atgcctgttg cagctgttta cggcactgcc ttgcagtgag cattgcagat   1260
aggggtgggg tgcttttgtg cgtgttccca cacgtgccca cacagccacc tcccgaaca   1320
catctcacct gctgggtact tttcaaacca tcttagcagt agtagatgag ttactatgaa   1380
acagagaagt tcctcagttg gatattctca tgggatgtct tttttcccat gttgggcaaa   1440
gtatgataaa gcatctctat ttgtaaatta tgcacttggt agttcctgaa tcctttctat   1500

```

agcaccactt attgcagcag gtgtaggctc tgggtgtggcc tgtgtctgtg cttcaatctt 1560
 ttaaagcttc tttggaaata cactgacttg attgaagtct cttgaagata gtaaacagta 1620
 cttacctttg atcccaatga aatcgagcat ttcagttgta aaagaattcc goctattcat 1680
 accatgtaat gtaattttac acccccagtg ctgacacttt ggaatatatt caagtaatag 1740
 actttggcct caccctcttg tgtactgtat tttgtaatag aaaatatttt aaactgtgca 1800
 tatgattatt acattatgaa agagacattc tgctgatctt caaatgtaag aaaatgagga 1860
 gtgogtgtgc ttttataaat acaagtgatt gcaaattagt gcaggtgtcc ttaaaaaaaa 1920
 aaaaaaaaaag taatataaaa aggaccaggt gttttacaag tgaaatacat tcctatttgg 1980
 taaacagtta cttttttatg aagattacca gcgctgctga ctttctaaac ataaggctgt 2040
 attgtcttcc tgtaccattg catttctca ttccaattt gcacaaggat gtctgggtaa 2100
 actattcaag aaatggcttt gaaatacagc atgggagctt gtctgagttg gaatgcagag 2160
 ttgcaactgca aaatgtcagg aaatggatgt ctctcagaat gcccactcc aaaggatttt 2220
 atatgtgtat atagtaagca gtttctgtat tccagcaggc caaagagtct gctgaatgtt 2280
 gtgttgccgg agacctgtat ttctcaacaa ggtaagatgg taccctagca actgcggatt 2340
 ttaatacatt ttcagcagaa gtacttagtt aatctctacc tttagggatc gtttcatcat 2400
 ttttagatgt tatacttgaa atactgcata acttttagct ttcattgggtt ctttttttc 2460
 agcctttagg agactgttaa gcaatttgcg gtccaacttt tgtgttggtc ttaactgca 2520
 atagtagttt acctgtatt gaagaaataa agaccatttt tatattaaaa aatacttttg 2580
 tctgtcttca ttttgacttg tctgatatcc ttgcagtgcc cattatgtca gttctgtcag 2640
 atattcagac atcaaaactt aacgtgagct cagtggagtt acagctgcgg ttttgatgct 2700
 gttattatct ctgaaactag aaatgatgtt gtcttcatct gctcatcaaa cacttcatgc 2760
 agagtgtgag gctagtgaga aatgcataca tttattgata ctttttttaa gtcaactttt 2820
 tatcagattt ttttttcatt tggaaatata ttgttttcta gactgcatag cttctgaatc 2880
 tgaaatgcag tctgattggc atgaagaagc acagcactct tcatcttact taaacttcat 2940
 tttggaatga aggaagttaa gcaagggcac aggtccatga aatagagaca gtgcgctcag 3000
 gagaaagtga acctggattt ctttggctag tgttctaaat ctgtagtgag gaaagtaaca 3060
 cccgattcct tgaaagggtc ccagctttta tgcttccaaa ttgaagggtg caggcaactt 3120
 ggccactggt tatttactgc attatgtctc agtttgcag ctaacctggc ttctccacta 3180
 ttgagcatgg actatagcct ggcttcagag gccaggtgaa gggtgggatg ggtggaagga 3240
 gtgctgggct gtggctgggg ggactgtggg gactccaagc tgagcttggg gtgggcagca 3300
 cagggaaaag tgtgggtaac tatttttaag tactgtgttg caaacgtctc atctgcaaat 3360

acgtagggtg tgtactctcg aagattaaca gtgtgggttc agtaatatat ggatgaattc	3420
acagtgggaag cattcaaggg tagatcatct aacgacacca gatcatcaag ctatgattgg	3480
aagcgggtatc agaagagcga ggaaggtaag cagtcttcat atgttttccc tccacgtaaa	3540
gcagtctggg aaagtagcac cccttgagca gagacaagga aataattcag gagcatgtgc	3600
taggagaact ttcttgctga attctacttg caagagcttt gatgcctggc ttctgggtgcc	3660
ttctgcagca cctgcaaggc ccagagcctg tggtagctg gagggaaaga ttctgctcaa	3720
gtccaagctt cagcaggcca ttgtctttgc ttcttcccc agcactgtgc agcagagtgg	3780
aactgatgtc gaagcctcct gtccactacc tgttgctgca ggcagactgc tctcagaaaa	3840
agagagctaa ctctatgcca tagtctgaag gtaaaatggg ttttaaaaaa gaaaacacaa	3900
aggcaaaacc ggctgcccc tgagaagaaa gcagtggtaa acatggtaga aaaggtgcag	3960
aagccccag gcagtgtgac agggccctcc tgccacctag aggcgggaac aagcttccct	4020
gcctagggct ctgcccgcga agtgcgtgtt tctttggtgg gttttgtttg gcgtttggtt	4080
ttgagattta gacacaaggg aagcctgaaa ggagggtgtg ggcactattt tggtttgtaa	4140
agcctgtact tcaaatatat attttgtgag ggagtgtagc gaattggcca attttaaata	4200
aagttgcaag agattgaagg ctgagtagtt gagagggtaa cacgtttaat gagatcttct	4260
gaaactactg cttctaaaca cttgtttgag tggtagacc ttggataggt gagtgtctct	4320
gttacatgtc tgatgcactt gcttgtcctt ttccatccac atccatgcat tccacatcca	4380
cgcatttgtc acttatccca tatctgtcat atctgacata cctgtctctt cgtcacttgg	4440
tcagaagaaa cagatgtgat aatccccagc cgcaccaagt ttgagaagat ggcagttgct	4500
tctttccctt ttctctgcta agtaaggatt ttctcctggc ttgacacct cacgaaatag	4560
tcttctgcc ttacattctg ggcattattt caaatatctt tggagtgcgc tgctctcaag	4620
tttgtgtctt cctactctta gagtgaatgc tcttagagtg aaagagaagg aagagaagat	4680
gttgccgca gttctctgat gaacacacct ctgaataatg gccaaagggt ggtgggtttc	4740
tctgaggaac gggcagcgtt tgcctctgaa agcaaggagc tctgcggagt tgcagttatt	4800
ttgcaactga tgggtggaact ggtgcttaaa gcagattccc taggttccct gctacttctt	4860
ttcttcttgg gcagtcagtt tatttctgac agacaaacag ccacccccac tgcaggctta	4920
gaaagtatgt ggctctgcct ggggtgtgta cagctctgcc ctggtgaaag gggattaaaa	4980
cgggcaccat tcatcccaa caggatcctc attcatggat caagctgtaa ggaacttggg	5040
ctccaaacct aaacatttaa ttggagtacg aatgtaatta aaactgcatt ctgcattcc	5100
taagtcattt agtctggact ctgcagcatg taggtcggca gctccactt tctcaaagac	5160
cactgatgga ggagtagtaa aaatggagac cgattcagaa caaccaacgg agtgttgccg	5220

aagaaactga tggaaataat gcatgaattg tgtggtggac atttttttta aatacataaa	5280
ctacttcaaa tgaggtcgga gaaggtcagt gttttattag cagccataaa accaggtgag	5340
cgagtaccat ttttctctac aagaaaaacg attctgagct ctgcgtaagt ataagttctc	5400
catagcggtt gaagctcccc cctggctgcc tgccatctca gctggagtgc agtgccattt	5460
ccttgggggtt tctctcacag cagtaatggg acaatacttc acaaaaattc tttcttttcc	5520
tgtcatgtgg gatccctact gtgccctcct ggttttacgt taccctctga ctgttccatt	5580
cagcggtttg gaaagagaaa aagaatttgg aaataaaaca tgtctacgtt atcacctcct	5640
ccagcatttt ggtttttaat tatgtcaata actggcttag atttggaat gagagggggt	5700
tgggtgtatt accgaggaac aaaggaaggc ttatataaac tcaagtcttt tatttagaga	5760
actggcaagc tgtcaaaaac aaaaaggcct taccaccaa ttaagtgaat agccgctata	5820
gccagcaggg ccagcacgag ggatggtgca ctgctggcac tatgccacgg cctgcttggt	5880
actctgagag caactgcttt ggaaatgaca gcacttggtg caatttcctt tgtttcagaa	5940
tgcgtagagc gtgtgcttgg cgacagtttt tctagttagg ccacttcttt tttccttctc	6000
tcctcattct cctaagcatg tctccatgct ggtaatccca gtcaagtga cgttcaaaca	6060
atgaatccat cactgtagga ttctcgtggt gatcaaatct ttgtgtgagg tctataaaat	6120
atggaagctt atttattttt cgttcttcca tatcagtctt ctctatgaca attcacatcc	6180
accacagcaa attaaagggt aaggaggctg gtgggatgaa gagggctctc tagctttacg	6240
ttcttccttg caaggccaca ggaaaatgct gagagctgta gaatacagcc tggggtaaga	6300
agttcagtct cctgctggga cagctaaccg catcttataa ccccttctga gactcatctt	6360
aggaccaa atagggtctatc tgggggtttt gttcctgctg ttccctcctg aaggctatct	6420
cactatttca ctgctccac gggtacaaac caaagataca gcctgaattt tttctaggcc	6480
acattacata aatttgacct ggtaccaata ttgttctcta tatagttatt tccttcccca	6540
ctgtgtttaa ccccttaagg cattcagaac aactagaatc atagaatggt ttggattgga	6600
aggggcctta aacatcatcc atttccaacc ctctgccatg ggctgcttgc caccactgg	6660
ctcaggctgc ccaggggccc atccagcctg gccttgagca cctccaggga tggggcaccc	6720
acagcttctc tgggcagcct gtgccaacac ctcaccactc tctgggtaaa gaattctctt	6780
ttaacatcta atctaaatct cttctctttt agtttaaagc cattcctctt tttccggtg	6840
ctatctgtcc aagaaatgtg tattggtctc cctcctgctt ataagcagga agtactggaa	6900
ggctgcagtg aggtctcccc acagccttct cttctccagg ctgaacaagc ccagctcctt	6960
cagcctgtct tcgtaggaga tcatcttagt ggccctctc tggaccatt ccaacagttc	7020
cacggctttc ttgtggagcc ccaggctctg atgcagtact tcagatgggg ccttacaag	7080

gcagagcaga tggggacaat cgcttaccoc tccctgctgg ctgcccctgt tttgatgcag	7140
cccaggggtac tgttggcctt tcaggctccc agacccttg ctgatttgty tcaagctttt	7200
catccaccag aacccacgct tcctggtaa tacttctgcc ctcaactctg taagcttggt	7260
tcaggagact tccattcttt aggacagact gtgttacacc tacctgccct attcttgcac	7320
atatacatctt cagttcatgt ttcctgtaac aggacagaa atgtattcct ctaacaaaaa	7380
tacatgcaga attcctagtgc ccatctcagt agggttttca tggcagtatt agcacatagt	7440
caatttgctg caagtacctt ccaagctgag gcctcccata aatcctgtat ttgggatcag	7500
ttaccttttg gggtaagctt ttgtatctgc agagaccctg ggggttctga tgtgcttcag	7560
ctctgctctg ttctgactgc accattttct agatcaccca gttgttctg tacaacttcc	7620
ttgtcctcca tccctttcca gcttgtatct ttgacaaata caggcctatt tttgtgttg	7680
cttcagcagc cttttaattc ttcagtgtca tcttgttctg ttgatgccac tggacagga	7740
ttttcagcag tcttgcaaaag aacatctagc tgaaaacttt ctgccattca atattcttac	7800
cagttcttct tgtttgaggt gagccataaa ttactagaac ttcgtcactg acaagttat	7860
gcattttatt acttctatta tgtacttact ttgacataac acagacacgc acatattttg	7920
ctgggatttc cacagtgtct ctgtgtcctt cacatggttt tactgtcata cttccgttat	7980
aaccttgcca atctgcccag ctgcccata caagaaaaga gattcctttt ttattacttc	8040
tcttcagcca ataaacaaaa tgtgagaagc ccaaacaaga acttgtgggg caggctgcca	8100
tcaagggaga gacagctgaa gggttgtgta gctcaataga attaagaaat aataaagctg	8160
tgtcagacag ttttgccctga tttatacagg cagcccccaa gccagagagg ctgtctgcca	8220
aggccacctt gcagtccttg gtttgaaga taagtcatag gtaacttttc tggatgaattg	8280
cggtggagaat catgatggca gttcttgctg tttactatgg taagatgcta aaataggaga	8340
cagcaaaagta aacttgctg ctgtaggtgc tctgctatcc agacagcgat ggcactcgca	8400
caccaagatg agggatgctc ccagctgacg gatgctgggg cagtaacagt gggccccatg	8460
ctgctgctc attagcatca cctcagccct caccagccca tcagaaggat catccaagc	8520
tgaggaaagt tgctcatctt cttcacatca tcaaaccctt ggctgactg atgcctccc	8580
gatgcttaaa tgtggtcact gacatcttta ttttctatg atttcaagtc agaacctccg	8640
gatcaggagg gaacacatag tgggaatgta cctcagctc caaggccaga tcttcttca	8700
atgatcatgc atgctactta ggaaggtgtg tgtgtgtgaa tgtagaattg ctttgttat	8760
ttttcttcc tgctgtcagg aacattttga ataccagaga aaaagaaaag tgctcttctt	8820
ggcatgggag gagttgtcac acttgcaaaa taaaggatgc agtcccaaat gttcataatc	8880
tcagggtctg aaggaggatc agaaactgtg tatacaattt caggcttctc tgaatgcagc	8940

ttttgaaagc tgttcctggc cgaggcagta ctagtcagaa ccctcggaaa caggaacaaa	9000
tgtcttcaag gtgcagcagg aggaacacc ttgcccatca tgaaagtga taaccactgc	9060
cgctgaagga atccagctcc tgtttgagca ggtgctgcac actcccacac tgaaacaaca	9120
gttcattttt ataggacttc caggaaggat ctctcttta agcttcttaa ttatggtaca	9180
tctccagttg gcagatgact atgactactg acaggagaat gaggaactag ctgggaatat	9240
ttctgtttga ccaccatgga gtcaccatt tctttactgg tatttgga taataattct	9300
gaattgcaaa gcaggagtta gcgaagatct tcatttcttc catgttggtg acagcacagt	9360
tctggtatg aaagtctgct tacaaggaag aggataaaaa tcatagggat aataaatcta	9420
agtttgaaga caatgaggtt ttagctgcat ttgacatgaa gaaattgaga cctctactgg	9480
atagctatgg tattttacgtg tctttttgct tagttactta ttgaccccag ctgaggtcaa	9540
gtatgaactc aggtctctcg ggctactggc atggattgat tacatacaac tgtaatttta	9600
gcagtgattt agggtttatg agtacttttg cagtaaatca tagggtagt aatgttaatc	9660
tcaggga aaaaaaaaag ccaaccctga cagacatccc agctcagggtg gaaatcaagg	9720
atcacagctc agtgcggtcc cagagaacac agggactctt ctcttaggac ctttatgtac	9780
agggcctcaa gataactgat gtagtcaga agactttcca ttctggccac agttcagctg	9840
aggcaatcct ggaattttct ctccgctgca cagttccagt catcccagtt tgtacagttc	9900
tggcactttt tgggtcaggc cgtgatccaa ggagcagaag ttccagctat ggtcaggagg	9960
tgcctgaccg tcccaactca ctgcactcaa acaaaggcga aaccacaaga gtggcttttg	10020
ttgaaattgc agtgtggccc agaggggctg caccagtact ggattgacca cgaggcaaca	10080
ttaatcctca gcaagtgcaa ttgcagcca ttaattgaa ctaactgata ctacaatgca	10140
atcagtatca acaagtgtt tggcttgaa gatggagtct aggggctcta caggagtagc	10200
tactctctaa tggagttgca ttttgaagca ggacactgtg aaaagctggc ctctaaaga	10260
ggctgctaaa cattagggtc aattttccag tgcactttct gaagtgtctg cagttcccca	10320
tgcaaagctg ccaaacata gcacttccaa ttgaatacaa ttatatgcag gcgtactgct	10380
tcttgccagc actgtccttc tcaaatgaac tcaacaaca atttcaaagt ctagtagaaa	10440
gtaacaagct ttgaatgtca ttaaaaagta tatctgctt cagtagttca gcttatttat	10500
gccactaga aacatcttgt acaagctgaa cactggggct ccagattagt ggtaaacct	10560
actttataca atcatagaat catagaatgg cctgggttgg aagggacccc aaggatcatg	10620
aagatccaac acccccgcca caggcagggc caccaacctc cagatctggt actagaccag	10680
gcagcccagg gctccatcca acctggccat gaacacctc agggatggag catccacaac	10740
ctctctgggc agcctgtgcc agcacctcac caccctctct gtgaagaact ttccctgac	10800

atccaatcta agccttccct ccttgagggt agatccactc ccccttggtc tatcactgtc 10860
tactcttgta aaaagttgat tctcctcctt tttggaaggt tgcaatgagg tctccttgca 10920
gccttcttct cttctgcagg atgaacaagc ccagctccct cagcctgtct ttataggaga 10980
ggtgctccag cctctgatac atctttgttg cctcctcttg gacccgtcc aagagctcca 11040
catctttcct gtactggggg cccaggcct gaatgcagta ctccagatgg ggcctcaaaa 11100
gagcagagta aagagggaca atcaccttcc tcaccctgct gccagccct cttctgatgg 11160
agccctggat acaactggct ttctgagctg caacttctcc ttatcagttc cactattaaa 11220
acaggaacaa tacaacaggt gctgatggcc agtcagaggt tttcacact tcttcatttc 11280
ggtagatctt agatgaggaa cgttgaaggt gtgcttctgc gtgtgcttct tctcctcaa 11340
atactcctgc ctgatacctc acccacctg ccactgaatg gctccatggc cccctgcagc 11400
cagggccctg atgaaccgg cactgcttca gatgctgttt aatagcacag tatgaccaag 11460
ttgcacctat gaatacacia acaatgtgtt gcctccttca gcacttgaga agaagagcca 11520
aatttgcat gtcaggaaat ggtttagtaa ttctgccaat taaaacttgt ttatctacca 11580
tggtgtttt tatggctgtt agtagtggt cactgatgat gaacaatggc tatgcagtaa 11640
aatcaagact gtagatattg caacagacta taaaattcct ctgtggctta gccaatgtgg 11700
tacttccac attgtataag aaatttgga agtttagagc aatgtttgaa gtgttggaa 11760
atttctgtat actcaagagg gcgtttttga caactgtaga acagaggaat caaaagggg 11820
tgaggaggaag ttaaagaag aggcaggtgc aagagagctt gcagtcctgc tgtgtgtacg 11880
acactggcaa catgaggtct ttgctaactc tgggtgtttg cttcctgccc ctggctgcct 11940
tagggtgcga tctgcctcag acccacagcc tgggcagcag gaggaccctg atgctgctgg 12000
ctcagatgag gagaatcagc ctgtttagct gcctgaagga taggcacgat tttggctttc 12060
ctcaagagga gtttggcaac cagtttcaga aggtgagac catccctgtg ctgcacgaga 12120
tgatccagca gatctttaac ctgtttagca ccaaggatag cagcgtgct tgggatgaga 12180
ccctgctgga taagttttac accgagctgt accagcagct gaacgatctg gaggcttgcg 12240
tgatccaggg cgtgggcgtg accgagacc ctctgatgaa ggaggatagc atcctggctg 12300
tgaggaagta ctttcagagg atcacctgt acctgaagga gaagaagtac agccctgcg 12360
cttggaagt cgtgagggt gagatcatga ggagctttag cctgagcacc aacctgcaag 12420
agagcttgag gtctaaggag taaaagtct agagtcgggg cggcgcgtgg taggtggcg 12480
ggggttccca ggagagcccc cagcgcggac ggcagcgcg tcaactaccg ctccgtctcc 12540
ctccgccag ggtcgcctgg cgcaaccgt gcaagggcac cgacgtccag gcgtggatca 12600
gaggctgccg gctgtgagga gctgccgcgc ccggcccgcc cgctgcacag ccggccgctt 12660

tgcgagcgcg acgctacccg cttggcagtt ttaaacgcat ccctcattaa aacgactata 12720
 cgcaaacgcc ttcccgtcgg tcgcgtctc tttccgcgc cagggcgaca ctccggggga 12780
 gggcggaag ggggcccggc gggagcccgc ggccaaccgt cgcccgtga cggcaccgcc 12840
 ccgccccgt gacgcggtgc gggcgccggg gccgtggggc tgagcgctgc ggcggggccg 12900
 ggcggggccg gggcgggagc tgagcgcggc gcggctgcgg gcggcgcccc ctccggtgca 12960
 atatgttcaa gagaatggct gagtccgggc ctgactccgg gggcagggtg aaggtgcggc 13020
 gcgggcggag ggacggggcg ggcgcggggc cggccggcgg gtgccggggc ctctgccggc 13080
 ccgccccgt cgggctgctg cggcgcttac gggcgcgctt ctgcgcgtg ccgcttctct 13140
 tctctccgc gcaagggcgt caccatcgtg aagccggtag tgtacggga cgtggcgcg 13200
 tacttcggga agaagagga ggagacggg cacacgcac agtggacgt ttacgtgaag 13260
 ccctacagga acgaggtagg gcccgagcgc gtcggccgcc gttctcggag cgccggagcc 13320
 gtcagcgccg cgcctgggtg cgctgtggga cacagcgagc ttctctcgta ggacatgtcc 13380
 gcctacgtga aaaaaatcca gttcaagctg cagcagagct acgggaatcc tctccgaggt 13440
 ggggtgtgcg tcgggggggt tgcctccgctc ggtcccgtg aggcctcgtc ccctcatctt 13500
 tctttcgtgc cgcagtcgtt accaaaccgc cgtacgagat caccgaaacg ggctggggcg 13560
 aatttgaaat catcatcaag atatttttca ttgatccaaa cgagcgaccc gtaagtacgc 13620
 tcagcttctc gtagtgcttc ccccgtcctg gcggcccggg gctgggctgc tcgctgctgc 13680
 cggtcacagt cccgccagcc gcggagctga ctgagctccc tttcccgga cgtgtgctct 13740
 gtgttcggtc agcgaggcta tcgggagggc tttggctgca tttggcttct ctggcgctta 13800
 gcgcaggagc acgttgtgt acgcctgaac tacagctgtg agaaggccgt ggaaaccgct 13860
 ctcaaactga tttattggcg aaatggctct aaactaaac gtctcctctc tttggaaatg 13920
 ctttagagaa ggtctctgtg gtagttotta tgcactatc ctaaagcact tggccagaca 13980
 atttaaagac atcaagcagc atttatagca ggcacgttta ataacgaata ctgaatttaa 14040
 gtaactctgc tcacgttgta tgacgtttat tttcgtatc ctgaaagcca ttaaaatcct 14100
 gtgcagttgt ttagtaagaa cagctgccac tgttttgtat ctaggagata actggtgttt 14160
 ccctacagtt ctcaagctga taaaactctg tctttgtatc taggtaaccc tgtatcactt 14220
 gctgaagctt tttcagctgc acaccaatgc aatcctggga aagaaaactg tagtttctga 14280
 attctatgat gaaatgggtat gaaaatttta atgtcaaccg agcctgactt tatttaaaaa 14340
 aaattattga tgggtgctgtg tttttggtc cttccttaga tatttcaaga tcctactgcc 14400
 atgatgcagc aactgctaac gacgtcccgt cagctgacac ttgggtgctta caagcatgaa 14460
 acagagtgtg agtgcaaaat gaggatacct tcgccgaccg tcattcacta ctaatgtttt 14520

ctgtgggatg tgatcgtaca gtgagtttgg ctgtgtgaaa ttggaatagc ttggtattgg 14580
cagtgatgac gtgatcgatg ccttgcttat catgtttgaa atgaagtaga ataaatgcag 14640
cctgctttat ttgagatagt ttggttcatt ttatggaatg caagcaaaga ttatacttcc 14700
tcaactgaatt gcaactgtcca aaggtgtgaa atgtgtgggg atctggagga ccgtgaccga 14760
gggacattgg atcgctatct cccatttctt ttgctgttac cagttcagat ttctttttca 14820
cctagtcttt aattcccagg gttttgtttt ttccttggtc atagtttttg ttttctactc 14880
tggcaaatga tgttgtgaat tcaactgctt cagccacaaa actgatggac tgaatgaggt 14940
catcaaacia acttttcttc ttccgtattt cctttttttt ccccccacta tcatttttac 15000
tgctgttggt gagtctgtaa ggctaaaagt aactgttttg tgctttttca ggacgtgtgc 15060
tttccaaatt actgccacat atataaagaa aggttggaat tttaaagata attcatgttt 15120
cttcttcttt ttgtccacca cagttgcaga tcttgaagta aaaaccaggg aaaagctgga 15180
agctgccaaa aagaaaacca gttttgaaat tgctgagctt aaagaaaggt taaaagcaag 15240
tcgtgaaacc atcaactgct taaagagtga aatcagaaaa ctcgaagagg atgatcagtc 15300
taaagatatg tgatgagtgt tgacttgga gggagcctat aatgagaatg aaaggacttc 15360
agtcgtggag ttgtatgct tctctccaat tctgtaacgg agactgtatg aatttcattt 15420
gcaaatcact gcagtgtgtg acaactgact tttataaat ggcagaaaac aagaatgaat 15480
gtatcctcat tttatagtta aaatctatgg gtatgtactg gtttatttca aggagaatgg 15540
atcgtagaga cttggaggcc agattgctgc ttgtattgac tgcatttgag tgggttagga 15600
acattttgtc tatgggtccg tgttagttta cagaatgcca ctgttactg ttttgttttg 15660
tattttactt tttctactgc aacgtcaagg ttttaaaagt tgaaaataaa acatgcaggt 15720
tttttttaaa tatttttttg tctctatcca gtttgggctt caagtattat tgtaacagc 15780
aagtcctgat ttaagtcaga ggctgaagt taatggtatt caagatgctt aagtctgttg 15840
tcagcaaaac aaaagagaaa acttcataaa atcaggaagt tggcatttct aataacttct 15900
ttatcaacag ataagagttt ctagecctgc atctacttct acttatgtag ttgatgcctt 15960
tatattttgt gtgtttggat gcaggaagt attcctactc tgttatgtag atattctatt 16020
taacacttgt actctgctgt gcttagcctt tccccatgaa aattcagcgg ctgtaaatcc 16080
ccctcttctt ttgtagctc atacagatgg cagaccctca ggcttataaa ggcttgggca 16140
tcttctttac tgctttgaga ttctgtgttg cagtaacctc tgccagagag gaaaaagcc 16200
ccacaaacct catccccctt ttctatagca atcagtatta ctaatgcttt gagaacagag 16260
cactggtttg aaacgtttga taattagcat ttaacatggc ttggtaaaga tgcagaactg 16320
aaacagctgt gacagtatga actcagtatg gagacttcat taagacaaac agctgttaaa 16380

atcaggcatg ttctattgag gaggacgggg caacttgac cagtgggtgcc cacacaaatc 16440
 cttcctggcg ctgcagacca atttttctgg cattctgact gccgttgctg ctggtcacag 16500
 agagcaacta tttttatcag ccacaggcaa ttgtcttgta gtattttcca agtgttgtag 16560
 gtaagtataa atgcatcggc tccagagcac tttaggtata cttattaaaa acataaatga 16620
 aagacaaatt agctttgctt ggggtgcacag aacattttta gttccagcct gctttttggt 16680
 agaagccctc ttctgaggct agaactgact ttgacaagta gagaaactgg caacggagct 16740
 attgctatcg aaggatcctt gttaacaaag ttaatcgtct tttaagggtt ggttttattca 16800
 ttaaatttgc ttttaagctg tagctgaaaa agaactgct gtcttccatg caccagggtg 16860
 cagctctgtg caaagtgtc tctggctc caagcctttt aattgccggg attctggcac 16920
 gtctgagagg gctcagactg gcttcgtttg ttgaaacagc gtgtactgct ttctgtagac 16980
 atggccggtt tctctcctgc agcttatgaa actgttcaca ctgaacacac tggaacaggt 17040
 tgcacaagga ggccgtggat gcccatccc tggaggcatt caaggccagg ctggatgtgg 17100
 ctctgggcag cctgggtctg tggttggcga tctgcacat agcagcgggg ttgaaactcg 17160
 atgatcactg tggctccttt caaccaggc tattctatga ttctatgatt caacagcaaa 17220
 tcatatgtac tgagagagga aacaaacaca agtgtactg tttgcaagtt ttgttcattt 17280
 ggtaaaagag tcaggtttta aaattcaaaa tctgtctggt tttgggtgtt tttttttttt 17340
 atttattatt tctttggggt tctttttgat gctttatctt tctctgccag gactgtgtga 17400
 caatgggaac gaaaaagaac atgccaggca ctgtcctgga ttgcacacgc tggttgcact 17460
 cagtagcagg ctcaagaact ccagtctttc cacagtatta ctttctaaac ctaattttta 17520
 tagcgttagt agacttccat cactgggcag tgcttagtga atgctctgtg tgaacgtttt 17580
 acttataagc atgttggaag ttttgatgtt cctggatgca gtagggaagg acagattagc 17640
 tatgtgaaaa gtagattctg agtatcgggg ttacaaaaag tatagaaacg atgagaaatt 17700
 cttgttgtaa ctaattggaa tttctttaag cgttcactta tgctacattc atagtatttc 17760
 catttaaaag taggaaaagg taaaacgtga aatcgtgtga ttttcggatg gaacaccgcc 17820
 ttctatgca cctgaccaac ttccagagga aaagcctatt gaaagccgag attaagccac 17880
 caaaagaact catttgcatt ggaatatgta gtatttggcc tcttctccc gggtaattac 17940
 tatactttat aggggtgctta tatgttaaat gagtggctgg cactttttat tctcacagct 18000
 gtggggaatt ctgtcctcta ggacagaaac aattttaatc tgttccactg gtgactgctt 18060
 tgtcagcact tccacctgaa gagatcaata cactcttcaa tgtctagttc tgcaacactt 18120
 ggcaaacctc acatcttatt tcatactctc ttcatgccta tgcttattaa agcaataatc 18180
 tgggtaattt ttgttttaat cactgtcctg accccagtga tgaccgtgtc ccacctaaag 18240

ctcaattcag gtcctgaatc tcttcaactc tctatagcta acatgaagaa tcttcaaaag 18300
 ttaggtctga gggacttaag gctaactgta gatgttggtg cctgggttct gtgctgaagg 18360
 ccgtgtagta gttagagcat tcaacctcta g 18391

<210> 11
 <211> 586
 <212> DNA
 <213> Artificial sequence

<220>
 <223> MDOT artificial promoter

<400> 11
 gtaccgggcc cccctcgag gtgaatatcc aagaatgcag aactgcatgg aaagcagagc 60
 tgcaggcacg atggtgctga gccttagctg cttcctgctg ggagatgtgg atgcagagac 120
 gaatgaagga cctgtccctt actcccctca gcattctgtg ctatttaggg ttctaccaga 180
 gtccttaaga ggtttttttt ttttttggtc caaaagtctg tttgtttggt ttgaccact 240
 gagagcatgt gacacttgct tcaagctatt aaccaagtgt ccagccaaaa tcgatgtcac 300
 aacttgggaa ttttccattt gaagcccctt gcaaaaacaa agagcacctt gcctgctcca 360
 gtcctggct gtgaagggtt ttggtgccaa agagtgaag gcttcctaaa aatgggctga 420
 gccgggaag gggggcaact tgggggctat tgagaaacaa ggaaggacaa acagcgtag 480
 gtcattgctt ctgcaaacac agccagggt gtcctctat aaaaggggaa gaaagaggct 540
 ccgcagccat cacagacca gaggggacgg tctgtgaatc aagctt 586

<210> 12
 <211> 11
 <212> PRT
 <213> Artificial sequence

<220>
 <223> SV40 terminator

<400> 12

Cys Gly Gly Pro Lys Lys Lys Arg Lys Val Gly
 1 5 10

<210> 13
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Lys051

<400> 13
 tgcaccttc agcacttgag

20

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer IFN-3rev

<400> 14
 aactcctctt gaggaagcc

20

<210> 15
 <211> 34
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer LYSBSU

<400> 15
 ccccccccta aggcagccag gggcaggaag caaa

34

<210> 16
 <211> 12
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Primer SaltoNotI

<400> 16
 tcgagcggcc gc

12

<210> 17
 <211> 83
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer used in the formation
 of the chicken codon optimized human interferon
 2b-encoding nucleic acid

<400> 17
 atggccttga cctttgcctt actggtggct ctctgtgtgc tgagctgcaa gagcagctgc 60
 tctgtgggct gcgatctgcc tca 83

<210> 18
 <211> 100
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer used in the formation
 of the chicken codon optimized human interferon
 2b-encoding nucleic acid

<400> 18
 gaccacagc ctgggcagca ggaggaccct gatgctgctg gctcagatga ggagaatcag 60

cctgttttagc tgcctgaagg ataggcacga ttttggcttt

100

<210> 19
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 19
ctcaagagga gtttggcaac cagtttcaga aggctgagac catccctgtg ctgcacgaga 60
tg 62

<210> 20
<211> 94
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 20
tccagcagat ctttaacctg ttttagcacca aggatagcag cgctgcttgg gatgagaccc 60
tgctggataa gttttacacc gagctgtacc agca 94

<210> 21
<211> 77
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 21
ctgaacgatac tggaggcttg cgtgatccag ggcgtgggag tgaccgagac ccctctgatg 60
aaggaggata gcatcct 77

<210> 22
<211> 82
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 22
gctgtgagga agtactttca gaggatcacc ctgtacctga aggagaagaa gtacagccct 60
tgcgcttggg aagtcgtgag gg 82

<210> 23
<211> 65
<212> DNA

<213> Artificial Sequence

<220>

<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 23
ctgagatcat gaggagcttt agcctgagca ccaacctgca agagagcttg aggtctaagg 60
agtaa 65

<210> 24

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 24
cccaagcttt caccatggct ttgacctttg cctt 34

<210> 25

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 25
atctgcctca gaccacag 19

<210> 26

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 26
gattttggct ttcctcaaga ggagtt 26

<210> 27

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 27

gcacgagatg atccagcaga t

21

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 28
atcggtcagc tgctgtaca

20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 29
cctcacagcc aggatgctat

20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 30
atgatctcag ccctcacgac

20

<210> 31
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 31
ctgtgggtct gaggcagat

19

<210> 32
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon

2b-encoding nucleic acid

<400> 32
aactcctctt gaggaaagcc aaaatc 26

<210> 33
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 33
atctgctgga tcatctcgtg c 21

<210> 34
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the formation
of the chicken codon optimized human interferon
2b-encoding nucleic acid

<400> 34
tgctctagac tttttactcc ttagacctca agctct 36

<210> 35
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> neo for-1 primer for detecting the interferon transgene

<400> 35
tggtattgcac gcaggttct 19

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> neo rev-1 primer for detecting the interferon transgene

<400> 36
gtgcccagtc atagccgaat 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> FAM labeled NEO-PROBE1 for detecting the interferon transgene

<400> 37
cctctccacc caagcggccg 20

<210> 38
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the synthesis of the MDOT promoter

<400> 38
tcactcgagg tgaatatcca agaat 25

<210> 39
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the synthesis of the MDOT promoter

<400> 39
gagatcgatt ttggctggac acttg 25

<210> 40
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the synthesis of the MDOT promoter

<400> 40
cacatcgatg tcacaacttg ggaat 25

<210> 41
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer used in the synthesis of the MDOT promoter

<400> 41
tctaagcttc gtcacagacc gtccc 25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
27 March 2003 (27.03.2003)

PCT

(10) International Publication Number
WO 03/025146 A3

- (51) International Patent Classification⁷: C12N 15/00
- (21) International Application Number: PCT/US02/29878
- (22) International Filing Date:
18 September 2002 (18.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/322,969 18 September 2001 (18.09.2001) US
60/351,550 25 January 2002 (25.01.2002) US
- (71) Applicant (for all designated States except US): AVIGEN-ICS, INC. [US/US]; 111 Riverbend Road, Athens, GA 30605 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): RAPP, Jeffrey, C. [US/US]; 265 Pinewood Circle, Athens, GA 30606 (US). CHRISTMANN, Leandro [BR/US]; 1311 Victoria Road, Watkinsville, GA 30677 (US).
- (74) Agents: ANTLER, Adriane, M. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
18 December 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/025146 A3

(54) Title: PRODUCTION OF A TRANSGENIC AVIAN BY CYTOPLASMIC INJECTION

(57) Abstract: This invention provides methods for the stable introduction of heterologous coding sequences into the genome of a bird and expressing the coding sequences to produce desired proteins or to alter the phenotype of the bird. The present invention provides preferred methods for introducing a transgene into the cytoplasm of avian embryonic cells by cytoplasmic microinjection. The embryo then develops into a transgenic adult capable of expressing a heterologous protein and/or capable of generating a line of transgenic birds through breeding. Synthetic vectors and gene promoters useful in the methods are also provided by the present invention, as are transgenic birds that express heterologous protein and avian eggs containing heterologous protein.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/29878

A. CLASSIFICATION OF SUBJECT MATTER												
IPC(7) : C12N 15/00 US CL : 800/21												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols) U.S. : 800/21												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST medline biosis caplus												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
A	IVARIE et al. Avian transgenesis: progress towards the promise. Trends in Biotechnology. January 2003. Vol. 21. No. 1. Pg 14-19. See entire article.	1-39										
A	PARK et al. Birth of germline chimeras by transfer of chicken embryonic germ (EG) cells into recipient embryos. Molecular Reproduction and Development. August 2003. Vol. 65. No. 4. pg. 389-395. See entire article.	1-39										
A	HARVEY et al. Validating the hen as a bioreactor for the production of exogenous proteins in egg white. Poultry Science. June 2003. Vol. 82. No. 6. pg 927-930. See entire article.	1-39										
A	LAMPARD et al. Secretion of foreign proteins mediated by chicken lysozyme gene regulatory sequences. Biochem. Cell Biol. 2002. Vol. 80. No. 6. pg 777-788. See entire article.	1-39										
A	JEONG et al. Migration activity of chicken gonadal primordial germ cells (gPGCs) and post-transfer localization of LacZ-transfected gPGCs in the embryonic gonads. Asian-Australasian Journal Animal Sciences. September 2002. Vol. 15. No. 9. Pg 1227-1231. See entire article.	1-39										
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.												
* Special categories of cited documents: <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"B" earlier application or patent published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"A" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"A" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"A" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 28 July 2003 (28.07.2003)		Date of mailing of the international search report 27 AUG 2003										
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230		Authorized officer <i>Valerie Bell-Harris for Deborah Reynolds</i> Telephone No. 703-308-1235										

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/29878

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-39

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/29878

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-39, drawn to a method of making a transgenic avian.

Group II, claim(s) 40-49, drawn to a transgenic avian.

Group III, claim(s) 50-53, drawn to proteins.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups I-III share the special technical feature of a transgenic avian producing an exogenous protein in the white of an egg laid by the avian. The special technical feature is not a contribution over the prior art because MacArthur (WO 9747739) taught such an avian.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.